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Abstract 
Duchenne muscular dystrophy (DMD) is a progressive muscle wasting disease resulting from a 
mutation in the X-linked gene encoding the protein dystrophin. DMD is characterized by profound 
muscle weakness as degenerating muscle is replaced by fat and connective tissue. Early loss of 
ambulation followed by premature death due to cardiac and/or respiratory failure characterize the 
most debilitating aspects of DMD, a disease for which there is currently no cure. Limited success 
has been reported when treating DMD with gene based therapies. Current standard of care involves 
glucocorticoids, which target a secondary cellular myopathy; inflammation. While this line of 
treatment has provided promising benefits, these drugs present a variety of negative side effects 
for patients. As such, extensive research has been focused on identifying both therapeutic targets 
and corresponding novel therapies for the treatment of the DMD myopathy.  
The focus of this dissertation was to first determine the degree and precise mechanism of 
mitochondrial dysfunction in DMD followed by the evaluation of SBT-20, a mitochondrial-
targeted peptide, as a therapeutic candidate for the treatment and prevention of DMD 
pathophysiology. In order to address these questions, we first comprehensively evaluated 
mitochondrial bioenergetics across a spectrum of oxidative and glycolytic muscles in the D2.B10-
DMDmdx/2J mouse (D2.mdx) in early and late stages of disease progression. We then tested the 
efficacy of SBT-20 in improving both DMD myopathy in respiratory and skeletal muscles, as well 
as the underlying mechanism of mitochondrial dysfunction in dystrophic muscle.   
Our findings reveal that the mitochondrial H2O2 emission is elevated during impaired oxidative 
phosphorylation in cardiac, respiratory, oxidative and glycolytic muscle in young (4-week) and 
aged (52-week) D2.mdx mice and furthermore, that there is a specific defect in mtCK functionality 
in oxidative muscle. SBT-20 was effective in improving mitochondrial bioenergetics following 
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short (4 weeks) and long (12 weeks) term treatment. This was associated with improved 
pathophysiology following short-term treatment. Taken together, this thesis identifies impairments 
in mitochondrial bioenergetics as a contributing factor to the pathophysiology in dystrophic muscle 
and further highlights SBT-20 as a promising therapy for the improvement of myopathy in DMD.  
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1 Introduction 
Duchenne muscular dystrophy (DMD) is a progressive muscle wasting disease affecting 1 in 3500 
boys. Resulting from a mutation in the X-linked gene encoding the protein dystrophin, DMD is 
characterized by profound muscle weakness and exercise intolerance as degenerating muscle is 
gradually replaced by fat and connective tissue [1-3]. This debilitating disease results in boys being 
wheelchair bound by the age of 10-12 and eventual death due to cardiac and/or respiratory failure 
in their early 20s [4, 5]. There is currently no cure for DMD.  
A lack of dystrophin presents a myriad of problems within the muscle as this protein is the anchor 
between the cell membrane and the cytoskeleton [1, 2]. Dystrophin, a 427 KDa rod-shaped protein, 
establishes structural integrity and cytoskeletal organization within muscle fibres. Without this 
anchor, muscle fibres become more susceptible to damage, particularly through tearing of cell 
membranes, leading to impairments in a variety of cell functions and the subsequent activation of 
cell death pathways [6, 2].   Current therapies are glucocorticoid based and have successfully 
extended lifespan while helping to maintain some muscle function. However, given the long-term 
requirement for treatment, these drugs present a variety of negative side effects for patients and 
ultimately do not provide a cure [7]. As such, extensive research to date has focused on gene-based 
therapies, given the genetic origin of this disease. Unfortunately, limited success has been reported 
[8]. This highlights the importance of the search for other therapeutic targets to alleviate the 
multitude of cellular impairments associated with DMD. 
Formulated several years prior to the discovery of the genetic defect underlying this disease [9], 
the calcium (Ca2+) hypothesis of DMD identified increases in cytosolic Ca2+ as the link between 
increased sarcolemmal tearing and muscle fibre degeneration in dystrophic muscle [10]. Since 
such time, the cellular implications of elevated cytosolic Ca2+ in DMD have been studied 
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extensively, yet the exact mechanisms that render the muscle more susceptible to elevated cell 
death are not well understood [11].    Cellular oxidative stress has long been considered a 
contributing factor to the pathogenesis of DMD, dating back to a time before dystrophin had been 
discovered. Early researchers established similarities between muscle pathology in DMD and the 
pathology associated with Vitamin E deficiency as well as ischemia reperfusion, two conditions 
in which oxidative damage is an established contributor to the pathogenesis [12, 13]. Later work 
revealed that cellular oxidative stress is indeed altered in patients with DMD as indicated through 
elevated lipid peroxidation [14-16] and protein carbonylation [17, 18], as well as increased activity 
of glutathione peroxidase [14, 19, 20] and increased levels of total glutathione [17, 20, 21]. While 
it is generally accepted that elevated oxidative stress is present within DMD, the source of 
oxidative stress remains controversial. 
The mitochondria are a key source of reactive oxygen species production (ROS) and have often 
been hypothesized to play a role in DMD pathology given the well-documented reduction in ATP 
content in both human and animal models of DMD [20, 22-24].  This energy-producing organelle 
also acts as a “sink” for Ca2+ during times of cytosolic Ca2+ overload [25, 26] and has the ability to 
induce mitochondrial derived apoptosis and necrosis [27]. Seemingly, it is possible that dystrophic 
muscle contain dysfunctional mitochondria that buffer cytosolic Ca2+, have limited ATP supply 
and produce elevated levels of ROS, consequentially activating cell death, the primary pathologic 
process in DMD [6]. This concept, while theoretically plausible, remains controversial as studies 
investigating mitochondrial oxidative phosphorylation reveal divergent findings [23, 28-34] and 
to our knowledge, only one study to date has measured mitochondrial ROS production, revealing 
decreased mitochondria H2O2 (mH2O2) release but increased rates of mH2O2 scavenging, 
indicative of compensation [33]. Furthermore, measurement of mitochondrial calcium retention 
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capacity (CRC), an index of susceptibility to permeability transition pore (PTP) opening and 
subsequent cell death, has also provided conflicting results. While some studies demonstrate a 
decrease in time to PTP opening [33, 35], studies quantifying the concentration of calcium required 
to induce PTP opening have found no differences between DMD and WT animals [33, 36]. Given 
mitochondrial oxidative phosphorylation, ROS generation and Ca2+-induced PTP opening form a 
triad whereby each bioenergetic pillar concurrently influences, and is influenced, by the other two 
parameters, the evaluation of all three components of mitochondrial bioenergetics in tandem is 
necessary to comprehensively evaluate mitochondrial function. Therefore, the purpose of this 
thesis is to 1. Determine the degree and specific source of altered mitochondrial bioenergetics in 
DMD and 2. Determine the contribution of the mitochondria to DMD disease pathology through 
the use of a mitochondrial-targeted therapeutic.  
  
 
 
4 
2 Literature Review 
 
2.1 Overview and Introduction to Duchenne muscular dystrophy 
2.1.1 Overview of Duchenne muscular dystrophy 
Duchenne muscular dystrophy (DMD) is the most common form of childhood muscular dystrophy 
and results from a mutation in the gene encoding for the protein dystrophin; a sub-sarcolemmal 
protein that plays a role in cell membrane integrity and in linking the extracellular matrix to the 
cytoskeleton (Figure 2.1) [37]. This condition is genetic in nature due to its X-linked pattern of 
inheritance, although about 25% of cases are due to de novo gene mutations [38]. Approximately 
1 in 3500 boys are affected and there is currently no cure. 
Dystrophin is associated with the cell membranes of skeletal, cardiac and smooth muscle cells yet 
individual muscles are affected in a heterogenic manner. Disease progression can be divided into 
stages and are summarized in Table 2.1. 
2.1.2 Genetic Nature of DMD 
The full-length dystrophin gene is predominately expressed in skeletal and cardiac muscle with 
smaller proportions found in the smooth muscle of the brain. This gene is located at Xp21.2 and 
contains 79 exons [39] with mutations occurring as deletions in ~60% of patients, duplications 
in ~10% of patients and small mutations in ~30% of patients, including small insertions or 
deletions within an exon (~7%) and nonsense mutations (~15%) [40-42]. Within patients in 
Canada between 2000 and 2009, 43% of mutations involved exons 45 to 53. The top ten deletions, 
which encompassed 26% of occurrences, were exons 45-47, 45-48, 45, 45-50, 45-55, 51, 45-49, 
45-52, 49-50, and 46-47. 29% of mutations involved exons 2 to 20. In cases involving  
duplications, exons 2, 2-7, 2-17, 3-7, 8-11, 10, 10-11, and 12 are most commonly duplicated [41]. 
It is the size of the gene and the wide range of specific mutations that make gene based therapy so 
difficult to implement as a treatment option for patients with DMD.  
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Figure 2-1: Schematic representation of the integral components of the dystroglycan 
complex. The dystroglycan complex is comprised of b-dystroglycan (b-DG), a-dystroglycan (a-
DG) and the sarcoglycan complex including subunits a, b, g and d which together with functional 
dystrophin provides structural support by anchoring actin in the cytoplasm and laminin in the 
extracellular matrix.  
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Table 2-1: Disease progression in DMD. Adapted from [43-45].   
Stage of Disease Key Characteristics 
Early Ambulatory 
(0-7 years) 
Skeletal: 
- Delays in developmental milestones such as sitting and walking 
- Move slower than peers 
- Balance Issues 
Cardiac/Respiratory: N/A 
Cognitive:  
- Delays in talking 
Late Ambulatory 
(7-10 years) 
Skeletal: 
- Severe difficulty walking; may require braces 
- Use of Gower’s maneuver to stand from sitting 
- Early onset of fatigue when walking 
- Difficulty lifting and carrying items despite full use of hands and 
fingers 
Cardiac/Respiratory:  
ECG abnormalities begin to appear 
Cognitive:  
- Evident delays in cognitive development 
Early Non-Ambulatory 
(10-14 years) 
Skeletal: 
- Become wheelchair dependent 
- Weakness in arms make daily activities difficult 
- Development of scoliosis due to weak back muscles and chronic 
sitting 
Cardiac/Respiratory:  
- Cardiomyopathy onset – early stages of heart failure 
Cognitive:  
- Evident delays in cognitive development 
Late Non-Ambulatory 
(15+) 
Skeletal: 
- Function is similar to Early Non-Ambulatory phase 
Cardiac/Respiratory:  
- Heart and respiratory issues become more prevalent and life-
threatening 
- Ultimate cause of death is due to cardiac and pulmonary 
complications 
Cognitive:  
- Function is similar to Early Non-Ambulatory phase 
2.1.3 Current Therapeutic Strategies 
Current therapeutic strategies for DMD can be categorized into two groups: 1. Strategies targeting 
the primary defect – a lack of dystrophin and 2. approaches to mitigate secondary and downstream 
pathological mechanisms – the cellular defects that result from a lack of dystrophin. Therapies 
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designed to restore dystrophin expression are complex in nature and involve either the read-
through of the premature termination codon, exon skipping or vector mediated gene therapy. In 
recent years, great advancements in gene based therapies have been made such that there are 
currently twelve different compounds in various stages of clinical trials (for comprehensive 
reviews see [8, 46]). Of these approaches, read-through and exon skipping therapies have been in 
the forefront of development in recent years. Specifically, Ataluren, involving read-through 
technology is involved in four separate phase 3 clinical trials and has conditional approval in 
Europe while Eteplirsen, which skips exon 51, is in phase 2/3 clinical trials and has conditional 
approval for use in the United States [8].  In general, despite promising results in rodents, most 
compounds targeting the lack of dystrophin have demonstrated non-significant improvements in 
functional parameters when administered to patients in clinical trials [46, 8]. Furthermore, given 
the wide range of sites and types of mutations that exist amongst patients, each compound targets 
a very limited population of patients in terms of the genetic defect it addresses. Indeed, while 
Eteplirsen has provided positive results, it’s therapeutic target is only beneficial in approximately 
13% of patients [47]. As such, while targeting the primary defect will ultimately be the cure for 
DMD, current administered therapies target the downstream cellular defects that result from a lack 
of dystrophin.  
The current standard of care for patients with DMD is the chronic administration of 
glucocorticoids, which target inflammation, a secondary pathology in DMD [48]. The first noted 
benefits of short-term glucocorticoid administration dates back to 1989 where a randomized 
clinical trial demonstrated improved strength, timed functional tests (time to stand, time to walk 
9m, time to climb 4 stairs) and forced vital capacity following treatment with prednisone [49]. A 
more recent Cochrane Review concluded that there is evidence to support improvements in muscle 
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strength or function, or both, through the use of glucocorticoids for up to two years [7]. 
Furthermore, chronic administration of glucocorticoids (1 year or longer) resulted in an increased 
median age of loss of mobility as well as extended life span relative to those who were treated for 
one month of less [48]. Despite these positive results, use of glucocorticoids in treatment plans 
remain variable amongst physicians, likely due to the myriad of negative side effects that occur, 
particularly as a result of long term administration [50]. Indeed, clinically adverse effects include 
weight gain, cushingoid symptoms, insulin resistance or diabetes, osteopenia and risk of bone 
fractures, cataracts as well as behavioral side effects [48, 7]. Despite these negative side effects, to 
date, glucocorticoid treatment is the best option as limited success has been found when targeting 
the primary defect. 
2.1.4 Animal Models of DMD 
Both naturally occurring and laboratory-generated animal models exist to study the 
pathophysiology of DMD. Please see Table 2.2 for a comparison of the most commonly used 
rodent models.  
2.1.4.1 Rodent Models of DMD 
As of 2015, there were over 60 animal models of DMD available for study yet the most commonly 
used remains the mdx mouse. Discovered in 1984, when a colony of C57BL/10ScSn mice showed 
severely elevated levels of serum creatine kinase, a hallmark phenotype of DMD, these animals 
were found to have a nonsense point mutation in exon 23 resulting in full deletion of the dystrophin 
gene [51]. Despite being dystrophin deficient, this rodent model displays minimal clinical 
symptoms and lifespan is only reduced by about 25%, contrary to the 75% reduction experienced 
in patients with DMD (Table 2.2) [52].  Disease progression in mdx mice occurs in several distinct 
phases; in the first 2 weeks, muscle is undistinguishable from that of healthy mice yet from weeks 
2-4, muscle undergoes a high degree of necrosis, triggering the start of a highly active regenerative 
 
 
9 
phase. During this regenerative phase, mdx limb muscles often become hypertrophic and muscle 
function actually improves, while the diaphragm shows progressive degeneration as seen in 
patients with DMD [53]. The severe dystrophic phenotype does not present until mice are 15 
months or older [52, 54, 55]. As such, the mdx mouse has been crossed with several different 
genetic backgrounds in an attempt to eliminate the compensatory mechanisms that prevent this 
model from developing clinical symptoms of DMD. While there are countless models being 
reported (for a complete review see [52], Supplementary Table 1), the majority arise from the 
crossing of the mdx mouse with another model designed to worsen the DMD myopathy, with two 
models of note in recent years, the Utrophin-Dystrophin double knockout (dko) and the DBA/2-
mdx (D2.mdx).  
The dko mouse lacks utrophin, which is shown to be upregulated in mdx mice as a compensatory 
response to a lack of dystrophin. Indeed, within the mdx model, muscles with the greatest 
upregulation of utrophin demonstrate the least pathological changes [56]. Dko mice have a 
markedly reduced life span (4-20 weeks), pronounced muscle weakness and impaired growth 
beginning at weaning. Muscle damage is similar to that of the mdx mouse from 2-6 weeks but 
remains severe throughout lifespan in contrast to the improvements seen in the mdx model [57]. 
This rodent model resembles disease progression and phenotype of patients with DMD and offers 
an alternative model to the mdx mouse. However, these animals often die prematurely and 
importantly, unlike in patients with DMD, carry an extra mutation that is not affected in humans. 
In fact, utrophin overexpression is currently being explored as a potential therapeutic target in 
DMD and as such, makes findings from this model difficult to interpret in the context of human 
disease [58].  
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The D2.mdx mouse model is a relatively new strain of mouse used to study DMD. These animals 
are a cross between the classic mdx mouse and the DBA/2J background, which, due to the deletion 
of latent TGF-B-binding protein 4 gene, demonstrates increased proteolysis, fibrosis, and 
inflammation as well as decreased self-renewal efficacy of satellite cells, preventing the robust 
regeneration seen in the classic mdx model [59]. D2.mdx mice demonstrate significantly decreased 
body mass and individual muscle mass relative to both wildtype and mdx counterparts. These 
animals also display elevated fibrosis, fat accumulation and loss of individual myofibers relative 
to mdx mice. Finally, this model exhibits impaired muscle function relative to WT controls at a 
time point where mdx mice show no decrements to function [60, 59].  Despite mimicking human 
disease progression more accurately, to date, there are limited studies published using this new 
model of DMD. 
2.1.4.2 Canine Models of DMD 
Dystrophin deficiency has been reported in approximately 20 different dog breeds and generally, 
the clinical phenotype of canine DMD (cDMD) is considered the best match to human disease. 
Additionally, given the size of this species, cDMD models are viewed as a way to bridge the gap 
between rodent research and application of therapies in humans particularly in the context of gene 
therapy [52]. Golden retriever muscular dystrophy dogs, which have a point mutation at intron 6 
resulting in the skipping of exon 7, are the most commonly used model with colonies existing 
across the USA, France, Brazil and Australia. These dogs share a very similar time course of 
disease progression to that of boys with DMD including muscle weakness and exercise intolerance 
occurring around 2-3 months of age (equivalent to three years in humans) as well as muscle 
atrophy, limb fibrosis, abnormal gait and cardiomyopathy by six months of age [61]. However, 
despite the early onset of clinical symptoms, cDMD animals never fully lose ambulation, unlike 
boys with DMD but do on average, also see a 75% reduction in life span. It should be noted that 
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disease manifestation is not heterogenic amongst dogs, though this is similar to disease in boys 
wherein there is variation in clinical symptoms despite all patients lacking dystrophin [61, 57].  
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Table 2-2: Comparison of commonly used animal models of DMD. Adapted from [52, 57, 59, 
60, 62].  
 Rodent Models   
mdx utr/mdx-/- D2.mdx cDMD Human 
General 
Genetic Defect Nonsense point 
mutation in exon 
23 
Nonsense 
point 
mutation in 
exon 23 
Nonsense 
point 
mutation in 
exon 23 
Point 
mutation at 
exon 7 
See section 
2.1.2 
Lifespan Reduced by 20-25% 
Reduced by 
95% 
No Data Reduced by 
75% 
Reduced by 
75% 
Body Weight 
Increases after 8 
weeks; reduced 
by 25% after 6 
months 
Reduced at 
time points ³ 
4 weeks of 
age 
Reduced at 
time points ³ 
4 weeks of 
age 
Reduced at 
all ages 
Reduced at 
all ages past 
birth 
Manifestation 
of Clinical 
Symptoms 
2-4 weeks; 
followed by a 
stable phase due 
to robust 
regeneration; 
severe muscle 
wasting and loss 
of function 
become evident 
at ³ 15 months 
At birth 4 weeks (no 
data prior to 
this time 
point) 
Birth-3 
months 
2-4 years 
Loss of 
Ambulation 
Rarely occurs Rarely 
occurs 
Rarely 
occurs 
Rarely 
occurs 
Common by 
early teens 
First evidence 
of 
cardiomyopathy 
10 - 20 months. 
10 months = 
abnormalities in 
echocardiography  
15-20 months = 
cardiac fibrosis  
8 weeks 28 weeks 6 months Mid-teens 
Creatine Kinase 
Levels 
Elevated Elevated Elevated Elevated Elevated 
Histopathology 
Acute Necrosis 3-4 weeks As early as 2 weeks 
No Data none none 
Limb Muscle 
Fibrosis 
Minimal in adult 
mice 
Extensive 
throughout 
lifespan 
Extensive in 
adult mice, 
earlier time 
points 
unknown 
Extensive 
throughout 
lifespan 
Extensive 
throughout 
lifespan 
Muscle 
Regeneration 
Robust Robust  Poor  Poor Poor 
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2.2 Primary Pathologic Outcomes in DMD 
2.2.1 Skeletal Muscle Wasting 
Duchenne muscular dystrophy is characterized by severe muscle wasting with limb skeletal muscle 
being the earliest target of the disease. In patients with DMD, muscle biopsies reveal necrotic 
muscle fibres, often in clusters, surrounded by macrophages and lymphocytes, indicative of muscle 
degeneration and an inflammatory response. At the early stages of this disease, necrotic fibres are 
accompanied by centrally located nuclei, indicative of regeneration that matches the degree of 
degeneration [54]. However, the stem cell pool in humans is limited and within a short period of 
time, regenerative capabilities within the muscle become exhausted, resulting in the infiltration of 
fibrotic and adipose tissue.  
Despite a homogenous absence of dystrophin within patients with DMD, disease progression is 
heterogeneous across skeletal muscles. Firstly, it has been demonstrated that fast twitch fibres, 
particularly IIB, are the earliest target of muscle degeneration with type I fibres being affected at 
later stages of the disease [63].  Indeed, by 5 years of age, IIB fibres are virtually absent in biopsy 
samples from patients with DMD [64].While the exact reason for this preferential degradation of 
fast twitch fibres is unknown, it has been hypothesized that the faster contraction of IIB fibres 
results in greater mechanical stress. Furthermore, as muscle wasting occurs, the remaining muscle 
fibres must compensate and as such, the shift to a greater proportion of type I fibres could be 
viewed as an adaptation to the increased load, similar to the adaptions that occur in response to 
endurance training in healthy individuals [63, 64]. Secondly, and perhaps most interesting, specific 
muscles within the body are completely spared of muscle wasting. Extraocular muscles, which are 
responsible for the most rapid eye movements known as saccades, are believed to closely mimic 
fibre type and function of type IIB fibres in the extremities, yet are found to function within 95% 
of the range of healthy individuals, even in the late stages of DMD disease progression [65]. This 
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suggests that extraocular muscles possess features that allow these fibres to resist degeneration. 
Karpati and colleagues proposed the small diameter of these fibres protects against mechanical 
stress due to the high surface to volume ratio that exists in these muscles [66]. While the exact 
mechanism of this protection remains to be elucidated, understanding how these fibres are spared 
could provide a potential treatment option for patients with DMD. 
 Patients with DMD also undergo selective muscle hypertrophy, which is somewhat 
counterintuitive given the severity of muscle wasting that occurs in the disease.  Indeed, calf 
hypertrophy is seen as a hallmark phenotype of patients with DMD. Additionally, at early stages 
of this disease, multiple reports of quadriceps hypertrophy exist within the literature yet this 
increase in fibre diameter occurs at a young age only, as atrophy of the vastus lateralis develops 
by the age of 7 or 8 [67, 68]. At this same young age, calf hypertrophy is at its peak with diameter 
values reaching twice the normal range, however the degree of hypertrophy decreases with age, 
despite values always exceeding normal. It has been proposed that this calf hypertrophy is due to 
postural abnormalities while patients with DMD are ambulatory. Patients with DMD are known 
to walk on their toes, which increases the power required from the calf. This increase in workload 
is likely the cause of fibre hypertrophy which explains the plateau of fibre diameter increases as 
patients age and become wheelchair bound [68, 67]. True hypertrophy is defined as an increase in 
the number/or size of individual muscle fibres within a given muscle, without the concomitant 
increase of connective tissue. Alternatively, psuedohypertrophy is defined as the infiltration of a 
muscle with collagen, fat, tumour, inflammatory cells and/or amyloidosis [67]. Early work by Cros 
and colleagues revealed that while the gastrocnemius-soleus complex appears to be unanimously 
hypertrophied in patients with DMD, this is a case of psuedohypertrophy. Indeed, despite increased 
fibre diameter relative to normal values, 18-38% of the gastrocnemius contained fat and connective 
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tissue, a significantly higher contribution compared to the 8% average found in healthy muscle 
[67]. Therefore, while compensatory hypertrophy within the calf is occurring, there is also a 
significant degree of muscle wasting exhibited as well. 
Ultimately, skeletal muscle wasting results in the loss of ambulation by the mid teenage years. 
This includes an inability to walk or lift/carry items.   While quality of life is significantly impacted 
by the loss of skeletal muscle function the ultimate cause of death for patients with DMD is due to 
cardiac and/or respiratory failure. 
2.2.2 Respiratory Failure 
In patients with DMD, respiratory weakness does not manifest until the second decade of life [69] 
despite the early onset of degeneration of the diaphragm [53].  However, once this weakness 
manifests, a progressive loss in respiratory capacity is evident. In the mdx mouse, diaphragm 
strength is reduced to 13.5% and the proportion of type I fibres has doubled in relation to age 
matched controls by the late stages of disease [53]. Within patients with DMD, as pulmonary 
function declines, the risk for bronchopulmonary illness as well as hypoventilation and dependence 
on ventilatory support increases.  The greatest decline in respiratory function occurs between the 
ages of 10 and 18 (Figure 2.2), beginning with increases in residual volume (RV) and decreases 
in expiratory reserve volume (ERV), the amount of air that remains in the lungs after fully exhaling 
and the additional amount of air that can be expired from the lungs by determined effort after 
normal expiration respectively. This ultimately leads to a decline in total lung capacity (TLC) by 
the age of 17 [70, 69, 5]. 
While respiratory failure remains a leading cause of death in patients with DMD, recent advances 
in treatment options including nocturnal noninvasive home ventilation have improved survival 
rates of patients with DMD. A meta-analysis from the UK revealed 53% of patients survive past 
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the age of 25 when provided with home ventilation options whereas this number drops to 12% 
when patients were non-ventilated with a mean age of survival of just 19.3 years [71]. Despite 
these clear benefits, home nocturnal ventilation is not routinely offered given the remaining ethical 
uncertainties surrounding this treatment, particularly in the context of quality of life.  
 
Figure 2-2: Time course of decline in respiratory capacity in patients with DMD. Schematic 
representation summarizing the decline in respiratory capacity based on numerous pulmonary 
functional measurements. ­represents an increase in measurement, ¯ represents a decrease in 
measurement. ERV: expiratory reserve volume; Cough PGA: abdominal gastric pressure during 
cough; RV: residual volume; FVC%; forced vital capacity; MIP; maximal static inspiratory 
pressure; SNIFF PDI: trans diaphragmatic pressure during a sniff; SNIFF POES: esophageal 
pressure during a sniff; IRV: inspiratory reserve volume; TLC: total lung capacity. Adapted from 
[70]. 
Given that respiratory muscles are considered skeletal muscles, muscle training in an attempt to 
improve strength and endurance is also considered as a form of therapy. Specifically, inspiratory 
muscle training though resistive breathing targets the diaphragm and improves endurance and 
strength within this muscle which coincides with improvements in Sniff PDI and Sniff POES. 
However, once patients with DMD reach a certain threshold of disease progression, muscle 
training no longer becomes effective and may in fact exacerbate the muscle wasting process [70]. 
At the pharmacological level, there is currently no form of treatment aimed specifically at 
Age (years)
8 9 10 11 12 13 14 15 16 17 >17
↓ ERV, ↓ Cough PGA, ↑RV
↓ FVC%, ↓ MIP, ↓ SNIFF PDI, ↓ SNIFF POES
↓ Nasal Inspiratory Pressure
↓ IRV, ↓ TLC
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preserving respiratory function. The previously mentioned glucocorticoids (see section 2.1.3 
Current Therapeutic Strategies), whose predominant role is to slow down skeletal muscle 
weakness by targeting inflammation, have been suggested to also affect respiratory function. In 
recent years, treatment with glucocorticoids has continued in patients past the point of loss of 
ambulation although results have been divergent. Some studies have reported no benefit of steroid 
use on respiratory function [72, 73] while others have reported improvements in parameters such 
as forced vital capacity (FVC) [74], maximal expiratory pressure (MEP) and spirometry [75, 76]. 
Given the myriad of negative side effects associated with long term administration of 
glucocorticoids, current clinical standard of care does not involve the use of these steroids past 
loss of ambulation. As such, respiratory function remains a primary concern for patients with 
DMD.  
2.2.3 Cardiomyopathy 
While cardiomyopathy develops in 98% of patients with DMD, the age of onset varies 
considerably. As such, clinical guidelines recommend ECG evaluations every two years up to the 
age of ten followed by yearly assessments as boys age with the goal of preventing the onset of 
fatal heart failure [77]. During the preclinical stage (0-10 years) patients present with no classic 
signs of heart failure, yet cardiomyocyte hypertrophy as well as ECG abnormalities (diastolic 
dysfunction, sinus tachycardia) can be identified. During the clinical stage of the disease (10-18 
years) while heart failure will still not be present in the majority of patients, cardiomyocyte 
atrophy, endocardial fibrosis and the progressive dilation of heart chambers is evident. Finally, 
during late stages of life (18+ years), 60% of patients will exhibit symptoms of heart failure while 
almost all patients will demonstrate diastolic dysfunction, dilated cardiomyopathy and arrhythmic 
complications [4, 78, 77]. This heart failure will be the ultimate cause of death in 40% of patients 
[37, 43]. Unfortunately, the mechanisms underlying heart failure in DMD remain poorly 
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understood and as such, current therapeutic approaches aim to treat the cardiomyopathy itself, 
rather than the cause of the myopathy within these patients [4].  
2.3 Secondary Pathophysiologic Responses in DMD 
2.3.1 Impaired Calcium Handling 
Dating back to 1978, the calcium (Ca2+) hypothesis of DMD suggests that chronic Ca2+ overload 
may play a role in muscle fibre degeneration as a result of the disruption to the cytoskeletal 
network that occurs in the absence of dystrophin [10]. Specifically, a lack of dystrophin results in 
the destabilization of the linkage between actin of the cytoskeleton and laminin of the 
extracellular matrix (Figure 2.1) resulting in a loss of integrity of the sarcolemma [11]. During 
stretch contraction, dystrophic fibres undergo micro tearing of the sarcolemma, requiring a Ca2+ 
dependent resealing process at the site of the tears. The influx of extracellular Ca2+ initiates a 
cytotoxic event that produces patches to seal the leaky cell membrane. These newly formed 
patches contain Ca2+ channels, which promote the influx of Ca2+ into the cytoplasm of the fibre 
[79].  
There are several pathological consequences resulting from the increase in [Ca2+] within the 
cytoplasm. Firstly, Ca2+-dependent proteases, known as calpains are activated which promote the 
degradation of proteins within the muscle fibre, leading to necrosis (Figure 2.4) [80, 81]. 
Additionally, this proteolytic activity further activates Ca2+ leak channels, which promotes more 
protease activity, thereby forming a damaging cycle of continuous protein degradation [79]. 
Indeed, increased calpain activity in mdx mice has been reported during both periods of muscle 
degeneration and regeneration and furthermore, the use of a calpain inhibitor reduced degeneration 
and necrosis by up to 50% [82].  
Secondly, cytosolic Ca2+ overload requires redistribution into other organelles, mainly the 
sarcoplasmic reticulum (SR) and the mitochondria [83]. Unfortunately, issues with Ca2+ buffering 
 
 
19 
by the SR have consistently been reported [84-86]. SR Ca2+ ATPase (SERCA) is responsible for 
the uptake of Ca2+ during relaxation as well as the release of Ca2+ for muscle contraction and is 
believed to account for about 70% of Ca2+ removal from the cytoplasm [87]. Decreased SERCA 
activity [84-86, 88] as well as a decrease in the binding capacity of calsequestrin [89], the protein 
responsible for Ca2+ sequestering within the lumen of the SR,  have been reported in DMD. 
Furthermore, overexpression of SERCA or the stabilization of SERCA activity [90-92] have 
improved the DMD pathology, further indicating impairments in the function of SERCA as a Ca2+ 
buffer within dystrophic muscle.  This leaves the mitochondria to act as the predominant Ca2+ sink 
(see 2.4.3.1 Mitochondrial Ca2+ Handling) which can result in further decrements to cell function 
(see 2.4.3 Mitochondrial Induced Cell Death). Finally, this increase in cytosolic Ca2+ can stimulate 
the production of ROS from both mitochondrial and non-mitochondrial sources which results in 
whole cell oxidative stress, another potential trigger of cell death (Figure 2.4) [93, 82, 94].  
2.3.2 Oxidative Stress 
2.3.2.1 Oxidative Stress Overview 
Oxidative stress occurs when the production of oxidants results in either macromolecular damage 
(protein carbonylation, lipid peroxidation, DNA oxidation) or the disruption of thiol redox circuits 
leading to dysfunctional cell signaling [95]. Oxidants are produced in the form of free radicals and 
non-radical oxidants, namely reactive oxygen species (ROS) and reactive nitrogen species (RNS) 
with the predominant initial forms being superoxide (O2•-) and nitric oxide (NO) respectively [96]. 
Superoxide is generated through either the incomplete reduction of oxygen in the electron transport 
chain (see 2.4.2 mitochondrial reactive oxygen species production) or as a specific product of 
enzymatic systems (NADPH Oxidase, Xanthine Oxidase), whereas NO is generated through 
enzymatic reactions. Both O2•- and NO can react to form a series of other ROS and RNS which 
act as the primary signaling molecules within the cell [97]. While NO is an important signaling 
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molecule in skeletal muscle, for simplicity sake, this literature review will focus solely on ROS 
signaling in DMD given the specific relevance to the presented data.  
Catalyzed by superoxide dismutase, O2•- reacts with itself and two protons (H+) to form hydrogen 
peroxide (H2O2) and oxygen (Figure 2.3). H2O2 is a nonradical oxidant that plays an important 
role in redox signaling [95]. While the fate of most O2•- is the dismutation into H2O2, O2•- itself 
an also act as a redox signal and is the primary driver of the aforementioned macromolecular 
damage [98]. O2•- is highly reactive with iron containing proteins and is known to partake in chain 
reactions whereby the initiation of a reaction with a single O2•- molecule can cause a chain reaction 
resulting in damage to multiple molecules [95]. This is the case in lipid peroxidation, a well 
characterized component of disease pathology in the late stages of DMD [14], wherein 
polyunsaturated fatty acids found in the cell membrane are oxidized through O2•- chain reactions 
in the presence of O2 and trace metal ions [95]. This results in further damage to an already fragile 
cell membrane in DMD. However, the network of intercellular antioxidant enzymes, including 
superoxide dismutase (SOD), catalase (CAT), glutathione (GSH), glutathione peroxidase (GPX), 
glutathione reductase (GR) and thioredoxin reductase (TRX) (Figure 2.3) are in high abundance 
in biological systems and can largely prevent these chain reactions from occurring. As such, any 
macromolecular damage is usually a result of single initiation events by O2•- and even then, free 
radical intermediates quantitatively play a very small role in overall cellular oxidative stress given 
their high reactivity and short half-life [95, 98]. As such, nonradical oxidants are the predominant 
contributors to oxidative stress through their ability to alter redox signaling.  
H2O2 is believed to be produced at 1-4% of the rate of O2 consumption and therefore represents a 
major source of oxidants within the cell [95]. This nonradical oxidant signals through the reversible 
modification of proteins, predominately thiols on exposed cysteines, thereby altering their function 
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[98]. Furthermore, H2O2 can act as a redox signal indirectly through redox couples within the 
antioxidant system including glutathione and thioredoxin. H2O2, like free radicals, is toxic to cells 
and therefore it’s concentration is tightly regulated in vivo (Figure 2.3) [98]. In the context of 
DMD, macromolecular damage is well quantified while the influence of non-radical oxidants on 
redox signaling within dystrophic tissue has garnered far less attention. Given the need for 
identifying novel therapeutic targets, understanding the sources of oxidants and their cellular 
targets is of great necessity.    
 
 
 
 
 
Figure 2-3: Schematic of the glutathione antioxidant defense system. When oxygen combines 
with a free electron, a superoxide radical is formed. Superoxide is then dismutated by superoxide 
dismutase into hydrogen peroxide (H2O2). H2O2 can be degraded to water and oxygen by the enzyme 
catalase or through the coupled oxidation of glutathione (GSH->GSSG) catalyzed by glutathione 
peroxidase (GPX). The oxidized glutathione (GSSG) must then be reduced by glutathione 
reductase to reform GSH. 
2.3.2.2 Evidence of ROS-induced Damage in DMD 
 
Throughout decades of research, excessive ROS production has been proposed as a possible 
mediator of muscle damage in dystrophic tissue. DMD was actually recognized as a disease of 
elevated oxidative stress before the cause of this condition (dystrophin, or lack thereof) was even 
discovered. Indeed, early researchers established similarities between muscle pathology in DMD 
and the pathology associated with Vitamin E deficiency as well as ischemia reperfusion, two 
conditions in which oxidative damage is an established contributor to the pathogenesis [12, 13]. 
Analysis of biopsies from patients with DMD show evidence of oxidative stress through the 
presence of a two-fold increase in protein carbonylation [18] as well as lipid peroxidation [99] two 
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previously mentioned forms of irreversible oxidative damage. These findings have been replicated 
in rodent models of DMD [14-17] along with reports of increased glutathione peroxidase activity 
[14, 19, 20] and increased levels of total glutathione [17, 20, 21]. At a functional level, work by 
Rando et al. revealed that dystrophic muscle is more susceptible to ROS-induced damage, in that 
myotubes from mdx mice underwent cell death in the presence of much lower concentrations of 
ROS relative to WT myotubes [100]. A second separate study showed that mdx mice were more 
susceptible to oxidative stress-induced cell death than myotubes expressing a truncated version of 
dystrophin (mimicking Becker’s MD), which in turn, were more susceptible to cell death than 
myotubes expressing full length dystrophin [16]. These findings collectively demonstrate that the 
susceptibility to ROS-induced cell death is positively correlated with dystrophic severity and 
furthermore, that there is a direct link between dystrophin and sensitivity to oxidative damage. In 
addition, evidence of increased ROS production causing lipid peroxidation and a compensatory 
increase in antioxidant enzymes was found in young mdx mice (19 days of age) prior to the 
presence of any necrosis, indicating that ROS may be a primary cause of muscle degeneration as 
opposed to a secondary response to muscle breakdown [16]. This is further supported by the notion 
that muscles that are spared in DMD (see section 2.2.1 Skeletal Muscle Wasting) have higher 
concentrations of antioxidant enzymes than the most susceptible muscles (type IIB fibres) [101] 
and that type IIB fibres have lower levels of glutathione peroxidase than all other fibre types [20] 
rendering them more susceptible to ROS-induced damage given their less robust antioxidant 
defense system.   
2.3.2.3 Antioxidant Clinical Trials in DMD 
A myriad of antioxidants have been tested in rodent models of DMD. Early work in an avian model 
of DMD tested both Penicillamine, a sulfhydryl compound with antioxidant properties and vitamin 
E, reporting modest benefits including the slowing of degeneration in avian skeletal muscle [102, 
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103]. Additionally, a low-iron diet, which reduces the production of hydroxyl radicals resulted in 
a decrease in necrosis in the mdx mouse [104]. More recently, several membrane permeable 
antioxidants have been tested in young mdx mice with varied success. While most antioxidants 
provided benefit at the histopathologic level, in most cases, minimal changes in muscle function 
were reported [105-110]. For example, the most widely used and potentially most promising 
antioxidant to date, n-acetylcysteine (NAC), has been shown to improve the dystrophic pathology 
in terms of markers of necrosis, muscle degeneration and inflammation following oral 
administration [111-114].  Only one study to date has assessed muscle strength following the oral 
administration of NAC and found that while force production was increased in mdx mice, NAC 
significantly reduced body weight gain and muscle weight gain in both healthy and dystrophic 
animals and therefore should be used with caution in the context of patients with DMD [115].        
Based on the early findings of elevated oxidative stress, several clinical trials using various 
antioxidants were also carried but ended with overall disappointing results. The use of superoxide 
dismutase, Vitamin E, penicillamine, and ascorbate (vitamin C) all resulted in minimal clinical 
benefits [116-119, 96, 120]. In retrospect, these early clinical studies (1954-1988) involved 
patients with advanced muscle degeneration (average age ³ 10 years). Based on the theory that 
oxidative stress is a primary cause of cell death and the use of antioxidants would prevent this cell 
death from occurring, clinical trials need to be initiated early in disease progression with the 
ultimate goal of this therapeutic target being to slow the progression of muscle degeneration not 
reverse the loss of muscle [96, 82, 121]. Additionally, all antioxidants tested to date are classified 
as non-specific scavengers, meaning they are 1. untargeted within the cell and 2. their mechanism 
of action involves scavenging already produced ROS as opposed to targeting the source of the 
elevated ROS production. In recent years it has been proposed that the specificity of ROS, the 
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spatial source of the oxidants and the timing of treatment should all be controlled when assessing 
the efficacy of antioxidants in the prevention of disease progression in DMD and more specifically, 
antioxidant treatments should be targeted to a specific source and initiated very early in disease 
progression [122].  
2.3.2.4 Mechanisms of elevated ROS in DMD 
While there is extensive evidence supporting the presence of elevated oxidative stress in DMD in 
both human and animal models as well as an established contribution of oxidative stress to disease 
pathology in animals, the specific source(s) of the elevated oxidative stress remain somewhat 
controversial.  
As previously mentioned, DMD is a disease of membrane fragility and impaired Ca2+ handling, 
two distinct pathological features that can both be caused by, and result in, elevated ROS 
production (Figure 2-4). Firstly, ROS have been shown to play an important role in the increased 
membrane permeability in DMD. Following eccentric contractions in the EDL of mdx mice, 
Evan’s Blue Dye (EBD) uptake, which signifies membrane damage, was significantly increased 
relative to WT controls while treatment with the antioxidant NAC prevented this dye uptake [111]. 
Similarly, treatment with ascorbic acid, another free radical scavenger, reduced EBD uptake and 
serum creatine kinase levels [123]. Additionally, ROS have been shown to directly stimulate Ca2+ 
entry into the cell both basally and following a stretch contraction [124]. Taken together, these 
results suggest that elevated ROS production plays a role in increased membrane permeability 
which subsequently leads to Ca2+ overload within the cell. In turn, Ca2+ overload within the cell 
can lead to ROS production, further amplifying the production of ROS, thus establishing another 
intracellular positive feedback loop for damaging Ca2+ and ROS signals [93]. Work by Shrykl et 
al., demonstrated this reciprocal amplification of ROS and Ca2+ signals and interestingly, 
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identified divergent sources of ROS responsible for different oxidative events. Specifically, in 
flexor digitorium brevis (FDB) fibres from mdx mice, basal levels of ROS were higher relative 
to WT, and following osmotic shock, which simulates mechanical stress, Ca2+ influx was 
significantly increased, along with an increase in ROS production in mdx muscle [121]. Basal 
levels of ROS appeared to be NOX specific, while post osmotic stress, mitochondrial 
accumulation of Ca2+ was significantly increased and was accompanied by an increase in 
mitochondrial ROS production. This signifies the potential of source specific increases in ROS 
production, dependent upon the activity level of the muscle [125].  
NADPH Oxidase, and specifically the isoform NOX2, has garnered particular interest in recent 
years as being a predominant source of ROS in DMD. NOX was first identified in inflammatory 
cells and more recently, subunits were found in close proximity to the sarcolemma of muscle 
fibres [126]. In dystrophic tissue, increased NOX activity as well as increased expression of 
NOX subunits has been reported [127-129]. Furthermore, blocking NOX2 activity using various 
NOX inhibitors results in a decrease in Ca2+ influx and improved force production in mdx muscle 
following a stretch contraction [121, 130]. Therefore, it is believed that elevated NOX activity 
results in an increase in ROS production that increases membrane permeability causing Ca2+ 
influx. However, the source of the subsequent burst of ROS that occurs in response to this Ca2+ 
influx remains unknown.  
It is well established that abnormal uptake of Ca2+ by the mitochondria results in an increase in 
ROS production via the electron transport chain. Therefore, it is plausible to believe that the 
mitochondria are a source of elevated ROS in DMD given the known impairments in Ca2+ 
associated with this disease. The mitochondria as a source of ROS will be discussed in greater 
detail in section 2.5.2 Mitochondrial ROS Production.  
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2.3.3 Inflammation 
Completing the triad of cellular pathologies contributing to muscle wasting in DMD is 
inflammation. In fact, inflammation is the therapeutic target of corticosteroids, the current standard 
of care for patients with DMD (see 2.1.3 Current Therapeutic Strategies). Inflammation is an early 
event in the pathological process of DMD with the first signs of inflammation and cell death 
occurring at 3-4 weeks of age in mdx mice and is believed to a be a key contributor to muscle cell 
death in dystrophic tissue [131]. The inflammatory process in dystrophic muscle involves the 
invasion of innate immune cells into sites of muscle damage, characteristic of chronic damage and 
repair cycles [122]. However, due to the chronic nature of muscle damage in DMD, repair cycles 
inevitably become exhausted, resulting in the infiltration of fibrotic tissue. Identified through 
histological observations, the predominant immune cells infiltrating dystrophic muscle include 
macrophages, t-cells and eosinophils and are believed to play an important role in the accumulation 
of fibrotic tissue in dystrophic muscle through their role in degeneration, necrosis and apoptosis 
[131]. Specifically, when knocking out T-cells from mdx mice, the degree of apoptosis and 
necrosis was decreased [132] while the onset of fibrosis was significantly delayed [133]. 
Furthermore, the depletion of macrophages, CD4+ and CD8+ cells ameliorated muscle 
histopathology and increased regeneration in young (3-4 week) mdx mice [132, 134, 135].  
While the exact mechanisms remain unknown, it is proposed that these immune cells mediate the 
progression of DMD through the stimulation of the translocation of NF-kB to the nucleus, which 
regulates the expression of pro-inflammatory cytokines including TNFa and Il-1b [136]. In 15-
day old mdx mice, there is evidence of elevated NF-kB DNA binding activity as well as elevated 
expression of TNFa and Il-1b at a time point that precedes the onset of muscle wasting [137]. 
Furthermore, genetic manipulation or pharmacological blockade of NF-kB improves the 
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dystrophic phenotype in mdx skeletal muscle [107, 138, 139]. Finally, glucocorticoids, which are 
known to improve muscle strength and function, also decrease the expression of NF-kB. 
NF-kB acting as the master regulator of inflammatory-mediated disease progression is an 
intriguing possibility, particularly given the finding that ROS are implicated in the activation of 
NF-kB in mdx muscle, as evidenced by the fact that NF-kB activation could be prevented by NAC 
[137]. As previously mentioned, NF-kB activation increases the expression of pro-inflammatory 
cytokines including TNFa, which is known to stimulate the production of mitochondrial ROS in 
a calcium-independent manner [140]. This could, once again, create a positive feedback loop 
whereby the increased ROS production via TNFa causes further activation of NF-kB with the end 
result being a chronic state of inflammation and subsequent muscle degeneration [82]. This idea 
is supported by reports of improvements in muscle necrosis and reduced inflammation in mdx mice 
injected with Remicade, an anti-TNFa antibody, although ROS levels were not evaluated in that 
work [141].  
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Figure 2-4: Overview of the pathophysiological consequences of dystrophin deficiency. A loss 
of dystrophin results in membrane fragility and subsequent tearing. Sarcolemmal tearing causes 
an influx of Ca2+ into the cytosol of dystrophic muscle fibres. This Ca2+ overload triggers oxidative 
stress via cytosolic sources as well as the uptake of Ca2+ by the mitochondria. Excessive Ca2+ uptake 
by the mitochondria can trigger both ROS production as well as the activation of cell death 
pathways which contribute to muscle wasting. Adapted from [46].  
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2.4 Introduction to Mitochondrial Bioenergetics 
2.4.1 Oxidative Phosphorylation 
Mitochondria are a double membrane structure, consisting of an ion permeant outer membrane 
(OMM), an intermembrane space rich with key physiological proteins and an inner mitochondrial 
membrane (IMM) that separates the mitochondrial matrix from the intermembrane space. 
Embedded within this IMM are proteins comprising the electron transport chain (ETC), a key 
component in mitochondrial energy transduction (Figure 2.5a). The ETC is made up of five 
protein complexes (I-V) and two mobile electron carriers, which together catalyze the ‘downhill’ 
transfer of electrons through a series of redox reactions that produce free energy [142]. The use of 
free energy in the production of ATP is based on a hypothesis proposed by eventual Nobel Prize 
winner Peter Mitchell in 1961 [143]. Known as the chemiosmotic theory of oxidative 
phosphorylation, it is used to explain how the energy produced from redox reactions can be 
coupled to ATP synthesis through the use of proton pumps in an energy transducing membrane, 
such as the IMM. Within the mitochondria, this energy is used to generate an electrochemical 
gradient by pumping protons from the negative side (matrix) to the positive side (intermembrane 
space), producing Dp (proton motive force). This Dp is sufficient to force the secondary pump, 
known as the ATP synthase, to reverse and synthesize ATP from ADP and Pi, powered by the flow 
of protons against the chemical gradient back into the matrix through complex V [144]. The 
coupling of the energy produced through oxidation of reducing equivalents and phosphorylation 
of ADP is known as oxidative phosphorylation (OXPHOS) and contributes 95% of the ATP 
produced within the cell under normal conditions [142].  
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Figure 2-5: Schematic of the pillars of mitochondrial bioenergetics. The primary function of 
the mitochondria is to produce ATP through A. Oxidative phosphorylation. Embedded within the 
IMM, the ETC consists of five protein complexes (I-V) and two mobile electron carriers which 
catalyze the transfer of electrons downhill through redox reactions that release free energy. This 
free energy is used to pump protons from the mitochondrial matrix to intermembrane space, 
establishing an electrochemical gradient that can be used to power the phosphorylation of ADP to 
produce ATP at complex V. A natural by-product of oxidative phosphorylation is B. Reactive 
Oxygen Species Production. When the electrochemical gradient is established in the absence of 
ATP production, membrane potential rises. A high membrane potential promotes the slipping of 
electrons prior to complex IV where they combine with oxygen to form free radicals.  
 
2.4.2 Mitochondrial Creatine Kinase 
Creatine kinase (CK), an important enzyme in cellular energetics, is comprised of a system of 
isoenzymes strategically located at sites of oxidative phosphorylation (mitochondria, mtCK) and 
utilization (cytosolic, cCK) within the cell [145, 146]. CK catalyzes the reversible transfer of the 
phosphoryl group between PCr and ATP through the reaction: MgADP- + PCr2- + H+ ßà 
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MgATP2- + Cr. The most common and well accepted function of the CK system is to act as a 
“temporal energy buffer” maintaining high intracellular ATP/ADP ratios at the expense of PCr 
[147]. cCK has been found to be bound to myofibrils and functionally coupled to myosin ATPase 
as well as Sarcoendoplasmic Ca2+ ATPase  and Na,K-ATPase where it’s main role is to maintain 
a high ATP/ADP ratio during periods of elevated activity [148]. More recently, the importance of 
mtCK in the movement of ADP and ATP between the cytosol and matrix has been established 
[149, 150, 146]. mtCK has a strong affinity for acidic phospholipids, much like those comprising 
the IMM and OMM. In fact, mtCK directly binds to VDAC on the OMM and to cardiolipin of the 
IMM. Given the high abundance of ANT on the IMM, this affinity for cardiolipin results in contact 
sites between mtCK and ANT and a direct binding to VDAC [151-153]. These three proteins create 
a functional substrate channel within the mitochondria that allows for the efficient transport of 
energy into and out of the mitochondria (Figure 2-6). This channel is the key component in what 
is known as the creatine-dependent model of energy exchange. Specifically, as ATP is produced 
through OXPHOS, ANT shuttles this ATP into the intermembrane space. mtCK can trans-
phosphorylate the phosphate group on ATP to Cr, producing ADP and PCr. This ADP can be 
shuttled back into the matrix through ANT to be used, once again, for the production of ATP 
through OXPHOS while PCr is shuttled out of the intermembrane space through VDAC until it 
comes in contact with cCK. cCK phosphorylates cytosolic ADP to produce ATP for the working 
muscle [147, 152, 154]. The high reliance on CK to facilitate the transfer of these high energy 
phosphates makes this model creatine-dependent and it is estimated that 80% of energy transfer 
occurs through this model of phosphate shuttling in cardiac muscle [146, 150]. Indeed, using 
spermatozoa, a species with a vast distance between the site of oxidative phosphorylation and site 
of energy utilization, it was established that PCr/Cr can overcome diffusion limitations 
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experienced by ATP/ADP, better meeting the demands of the working muscle [155, 147]. 
Specifically, PCr can diffuse at a rate seven times faster than ATP and Cr can diffuse at a rate 2000 
times faster than ADP, further demonstrating the improved capability of energy transfer when 
mtCK plays an active role [147]. While this is the main pathway for energy exchange, it is 
important to note, ADP and ATP can also freely diffuse through ANT and VDAC (Figure 2-6), a 
model of energy exchange, which is creatine-independent in nature as mtCK is not involved in this 
transfer of energy.  
Figure 2-6: Schematic representation of energy transfer between mitochondria and cytosol. 
The leading model for energy exchange involves a creatine-independent (-Cr) and creatine- 
dependent (+Cr) pathway. The left side depicts the –Cr pathway whereby ADP/ATP transfer 
occurs solely through diffusion across voltage dependent anion carrier (VDAC) on the outer 
mitochondrial membrane and adenosine nucleotide translocase (ANT) on the inner mitochondrial 
membrane. The right side depicts the +Cr pathway where, in the presence of Cr, energy transfer is 
facilitated by mitochondrial creatine kinase (mtCK) through the transfer of the phosphate group 
from ATP to Cr, producing phosphocreatine (PCr) and ADP in the inner membrane space. The 
PCr is exported via VDAC into the cytosol while the ADP is directly recycled back via ANT into 
the mitochondrial matrix. This schematic is published as part of Chapter 4 – Early myopathy in 
Duchenne muscular dystrophy is associated with elevated mitochondrial H2O2 emission 
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during impaired oxidative phosphorylation [156]. Figure adapted from Aliev et al., 2011, 
Guzun et al., 2012, Myer et al., 1984 and Wallimann et al., 2011 [146, 150, 147, 157]. 
2.4.3  Mitochondrial Reactive Oxygen Species Production 
A natural by-product of OXPHOS is the production of reactive oxygen species (ROS), specifically 
in the form of superoxide (O2•-). When electrons are transferred in groups of four, they harmlessly 
form water at complex IV, which drives OXPHOS. If electrons leak prior to complex IV they form 
O2•- through the one-electron reduction of O2 (Figure 2.5b) [158]. As previously mentioned, the 
energy released when electrons flow through the electron transport chain is converted into a proton 
gradient, Dp, which powers the phosphorylation of ADP into ATP. During this process, known as 
state III respiration, the concentration of O2•- produced is minimal as the majority of electrons 
effectively get transferred at complex IV (CIV) to produce water with a small amount of O2•- 
being concomitantly produced. However, in the absence of ADP and inorganic phosphate (Pi), 
ATP synthesis does not occur. Yet, if reducing equivalents are present, their oxidation without 
subsequent ATP production results in a buildup of Dp, causing electron flow to slow and coenzyme 
Q to become highly reduced. This results in the favoring of premature electron slip and a 
subsequent increase in the concentration of O2•- produced [159, 160]. To date, there are eleven 
identified sites of mitochondrial O2•- production in mammalian mitochondria that are located 
within the mitochondrial matrix and IMM (Table 2.3 and associated Figure 2.7). In addition, 
there are a class of enzymes termed monoamine oxidases (MAO) which are located in the OMM 
that are known to produce ROS [161].  
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Table 2-3: Sites of Mitochondrial Superoxide Production. Adapted from [158, 162]. See 
Figure 2.6 for schematic representation. The maximal capacity for ROS production is ranked 
from 1-11 with the site ranked 1 producing the most ROS. 
Site Localization of ROS Method of ROS production 
Maximal 
Capacity 
for ROS 
production 
Sites 1-4: 2-Oxoacid Dehydrogenase Complex  
2-oxoglutarate (OF) Matrix The dihydrolipoamide 
dehydrogenase component of all sites 
catalyzes the transfer of reducing 
equivalents and can generate ROS at 
the Flavin. 
4 
Branched Chain 2-
oxoacid (BF) 
Matrix 7 
2-oxoadipate (AF) Matrix 8 
Pyruvate 
Dehydrogenase (PF) 
Matrix 5 
Sites 5 and 6: Complex I 
IF Matrix Oxidizes NADH to NAD+ and 
reduces Q to QH2. Produces ROS 
when electrons leak from the fully 
reduced Flavin. 
10 
IQ Matrix When QH2/Q is highly reduced and 
Dp is high, QH2 is oxidized to drive 
the reduction of NAD+ during reverse 
electron transport. ROS is produced 
during this process 
2 
Site 7: Complex II 
IIF Matrix Q is reduced to QH2 by complex II 
through the oxidation of succinate to 
fumarate. ROS can be produced in 
both the forward (succinate) and 
reverse (QH2) direction. 
3 
Site 8: Glycerol-3-Phosphate Dehydrogenase  
GQ Matrix and 
Inner 
Membrane 
Space 
Reducing equivalents from 
carbohydrate and fat metabolism are 
transferred to Q with ROS as a by-
product of this reaction. 
6 
 
Site 9: Electron-transferring Flavoprotein-ubiquinone oxidoreductase  
EF Matrix This system transfers reducing 
equivalents from b-oxidation to the Q 
9 
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pool with ROS as a by-product of this 
reaction. 
Site 10: Dihydroorotate Dehydrogenase  
DQ Matrix This enzyme supports de novo 
pyrimidine biosynthesis and through 
the oxidation of dihydroorotate to 
orotate to reduce Q, ROS is 
produced. 
11 
Site 11: Complex III 
IIIQo Matrix and 
Inner 
Membrane 
Space 
In the presence of Q site inhibitors 
that block the oxidation of 
cytochrome b heme, reduced 
cytochrome b heme accumulates 
which limits the oxidation of the 
semiquinone at Q and allows for the 
interaction with O2 to form ROS 
1 
 
Figure 2-7: Mitochondrial Sites of ROS Production. Adapted from Wong et al. [162]. Eleven 
sites within the mitochondria that leak electrons to oxygen to produce ROS have been identified 
to date. All sites of ROS production are associated with substrate oxidation and the ETC. 
Electrons are passed from metabolites to the main ETC by dehydrogenases and all sites have the 
ability to produce ROS at either flavin groups (Sites 1-4: OF, BF, AF, PF; Site 5: IF; Site 7: IIF and 
Site 9: EF) or quinone binding sites (Site 6: IQ; Site 8: GQ; Site 10: DQ and Site 11: IIIQo).  
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A central theme of this thesis surrounds ADP’s governance of mitochondrial bioenergetics (see 
section 2.5.2.1 ADP as a Central Governor of Bioenergetics). As such, the remaining work focuses 
on sites of ROS production that are membrane potential dependent (specifically complex I and II) 
wherein the role of ADP in the attenuation of ROS production can be evaluated.  
Regular levels of ROS production that occur during state III respiration are necessary for cellular 
signaling and for the maintenance of homeostasis. However, an increase in O2•-  production can 
become pathological in nature due to an increase in oxidative stress and subsequent pathology (see 
2.3.2.1 Overview of Oxidative Stress). Indeed, the discovery that mitochondria have their own 
source of superoxide dismutase (MnSOD) confirmed the importance of mitochondrial O2•-  
contribution to cellular oxidative stress [163]. O2•- is a highly reactive form of ROS that not only 
has an incredibly short half-life but is impermeable to lipid membranes [164, 165]. High 
concentrations of MnSOD within the mitochondrial matrix catalyze the dismutation of O2•- to 
H2O2. As previously discussed, the production of H2O2 is tightly coupled with its removal through 
endogenous cellular antioxidant systems including glutathione (Figure 2.3) and thioredoxin 
systems [166]. During healthy conditions, the majority of H2O2 is scavenged before being emitted 
from the mitochondria. However, under pathological conditions, if H2O2 emission is excessive, it 
will either act as a redox stressor within the mitochondria or be emitted from the mitochondria at 
elevated rates that disrupts cellular homeostatic mechanisms through excessive redox pressure on 
a variety of regulatory pathways, thereby creating a functional oxidative stress. Indeed, there are 
several signaling pathways in which mitochondrial ROS production has been implicated including 
apoptosis, autophagy, endoplasmic reticulum stress and hypoxia [158]. Additionally, and perhaps 
most importantly, elevated levels of mitochondrial ROS production can contribute to the activation 
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of cell death pathways from within the mitochondria itself through the sensitization of the 
mitochondrial permeability transition pore (PTP)  [167].  
2.4.4 Mitochondrial Induced Cell Death 
2.4.4.1 Mitochondrial Ca2+ Handling 
Ca2+ is an ion required for most physiological processes within a cell. Changes in [Ca2+] within 
the cytosol is a tightly regulated process used to modify the activity of target molecules. This 
control over cytosolic [Ca2+] is achieved predominately through the sarcoplasmic reticulum, the 
main intracellular storage site of Ca2+. However, during times of cytosolic Ca2+ overload, the 
mitochondria has been identified as a key regulator of Ca2+ homeostasis within the muscle due to 
their capacity to uptake high concentrations of the ion at rapid rates [26]. In respiring mitochondria, 
the Dp (which results in a negatively charged matrix) drives the uptake of Ca2+ into the 
mitochondrial matrix through the mitochondrial calcium uniporter (MCU) [25]. Under healthy 
conditions, the Na+- Ca2+ exchanger (NCLX) acts as an efflux pathway to counteract this uptake 
and prevent the build-up of matrix Ca2+ [168]. However, when cytosolic [Ca2+] is increased, the 
mitochondria become a sink for Ca2+ as there is a kinetic imbalance between Ca2+ import and 
efflux. The MCU can facilitate Ca2+ accumulation at a rate of 1400 nmol Ca2+ •mg mitochondrial 
proteion-1•min-1 while the combined rate of efflux from all pathways is approximately 20 nmol 
Ca2+ •mg mitochondrial proteion-1•min-1  which can quickly result in Ca2+ overload within the 
mitochondria [168]. Ca2+ overload can trigger the opening of the PTP and the subsequent activation 
of mitochondrial derived cell death pathways which are described in detail below.  
2.4.4.2 Mitochondrial Permeability Transition Pore 
While the predominant role of the mitochondria is to produce ATP to meet the energetic demands 
of the cell, the mitochondria also maintain an intrinsic ability to induce cell death through apoptosis 
and necrosis. This switch in roles from life support of the cell to programmed cell death is mediated 
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by the opening of a pore located on the IMM known as the mitochondrial permeability transition 
pore (PTP) [169-171]. Under normal physiological conditions, the IMM is relatively impermeable, 
save for a few select metabolites and ions.  Under conditions of cellular stress, the PTP can open 
and allow the free passage of any molecule less than 1.5 kDA in size [172, 173].  The primary 
factor responsible for triggering PTP opening is mitochondrial calcium (Ca2+) overload, which 
occurs when the [Ca2+] within the mitochondrial matrix is excessively high [174]. Ca2+ is known 
as a “permissive” factor in PTP formation yet the threshold concentration required varies 
depending on in vivo conditions as Mg2+ and other divalent cations appear to compete for the same 
binding sites as Ca2+[26, 175].  
While the role of Ca2+ in PTP formation has been well established within the literature, much 
debate has remained over the structural components of the PTP and the mechanism by which Ca2+ 
can force the opening of this channel [169-171]. Indeed, Cyclophilin-D (CyPD), a peptidyl-prolil 
cis-trans isomerase, remains the best characterized protein involved in PTP opening yet acts as a 
modulator as opposed to a structural component of the pore.  ATP synthase has recently been 
identified as a channel matching the properties of the PTP. The b-subunit of ATP synthase contains 
a catalytic binding site for Mg2+-ATP which can be replaced with Ca2+-ATP, resulting in a 
conformational change of the enzyme [176]. Furthermore, CyPD was found to bind to oligomycin-
sensitivity conferring protein (OSCP), a component of the F1 subunit of ATP Synthase responsible 
for coupling H+ flux to ATP synthesis [26]. This left the working hypothesis that PTP opening 
occurs when Ca2+ replaces Mg2+ at the catalytic site, causing a conformational change that is 
transmitted through OSCP resulting in an opening of the pore through the IMM; a concept that has 
since been proven correct in multiple laboratories [176-178].  
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In addition to Ca2+ overload, there are several other cellular effectors that, while not required, 
increase the probability of PTP formation. Firstly, as previously mentioned in section 2.4.2, PTP 
opening is very sensitive to oxidative stress. Specifically, pore opening is promoted by the 
oxidation of matrix pyridine nucleotides (NADH/NADPH) and dithiols and can be prevented 
through the use of reducing agents and the reduction of glutathione [167]. Furthermore, ROS 
production at complex I is a key modulator of PTP opening and can be prevented through the use 
of rotenone, a complex I inhibitor [179]. In addition to elevated levels of oxidative stress, the PTP 
is also modulated through matrix pH, with 7.4 being optimal for opening and values above and 
below this acting as inhibitory conditions for opening. Finally, despite the fact that inorganic 
phosphate can decrease matrix [Ca2+], this metabolite acts as an inducer of PTP opening in 
mammalian mitochondria [175].     
The opening of the PTP results in two major consequences for the cell. Firstly, the increase in 
permeability of the IMM causes a rise in osmotic pressure and subsequent swelling of the 
mitochondria. The unfolding of the cristae allows the matrix to expand and prevents the IMM from 
rupturing but the OMM will break leading to the release of proteins in the intermembrane space, 
including cytochrome c, which plays an important role in the activation of apoptosis (see section 
2.4.3.3). Secondly, the IMM becomes completely permeable to protons which results in the 
uncoupling of OXPHOS and the hydrolyzation, as opposed to synthesis, of ATP [172]. The 
swelling of the mitochondria and OMM rupture are sufficient to activate the apoptotic cascade and 
unless pore closure occurs, irreversible damage to the cell will be caused, resulting in necrotic cell 
death.  
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2.4.4.3 Mitochondrial-Derived Apoptosis 
Apoptosis, known as “programmed” cell death, is a tightly regulated pathway that occurs in during 
both normal development as well as in response to cell damage or stress [180]. Indeed, apoptosis 
is used to remove unwanted and harmful cells during both embryonic development, and for the 
maintenance of tissue homeostasis and immune regulation [181]. This process can be triggered by 
external stimuli through cell surface death receptors or through intrinsic stimuli that activate the 
mitochondrial signaling pathway. For the purpose of this review, only mitochondrial derived 
apoptosis will be discussed.  
Apoptosis is predominately regulated by a group of cysteine proteases, called caspases, that cleave 
cellular substrates and dismantle cellular components [182]. Briefly, Bcl-2, an anti-apoptotic 
protein situated on the OMM is inactivated by BH3-only proteins which are activated in response 
to certain cellular stressors. The inactivation of Bcl-2 results in the activation of pro-apoptotic 
proteins BAX and BAK which promote the permeabilization of the OMM. This permeabilization 
promotes the release of cytochrome c, which binds with APAf-1 forming an apoptotosome. This 
apoptotosome then cleaves initiator caspase-9 which further cleaves executioner caspase-3, 
thereby inducing apoptosis [27, 183]. Apoptosis requires ATP as both the binding of cytochrome 
c to APAf-1 and the enzymatic activation of caspase 9 are ATP-dependent processes [183, 184]. 
Therefore, if PTP opening is prolonged and an energy crisis ensues, an ongoing apoptotic process 
can be converted into a less favourable necrotic process [184].   
The resulting cellular outcomes of the activation apoptosis include the condensation of chromatin 
followed by cell shrinkage to revoke contact with neighbouring cells. The membrane then blebs 
and forms vacuoles which are removed from phagocytic cells (macrophages) [185]. Apoptosis, 
which occurs in single cells, is seen as an efficient way to remove cellular “debris” without evoking 
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a full inflammatory response and as such, is considered the preferential form of cell death over 
necrosis (Table 2.4).  
2.4.4.4 Mitochondrial-Derived Necrosis 
While apoptosis is identified as an active, programmed process that plays a role in normal muscle 
development, necrosis is viewed as a more pathological process involving passive, unordered 
cellular explosion in response to a stress or trauma [27]. While apoptosis has established activation 
pathways in response to extrinsic stimuli (death receptors; TNF-a) and intrinsic stimuli 
(mitochondria), less is known about the precise signaling pathway that occurs following the 
initiation of mitochondrial-derived necrosis although TNF-a, which is activated by mitochondrial 
ROS [186],  is considered to be a key player [27]. Given TNF-a also induces apoptosis, two key 
steps in the signaling process distinguish the two processes from each other. The activation of 
necrosis includes the inhibition of caspases by a small peptide, zVAD as well as the activation of 
the poly(ADP-ribose)polymerase, PARP1, which reduces ATP levels – a hallmark feature of the 
necrotic process [27].  
Necrosis in an energy-independent process and affects large fields of cells, evoking an 
inflammatory response (Table 2.4). Morphologically, necrosis results in cell swelling and loss of 
membrane integrity. This results in the release of cytoplasmic contents into the surrounding tissues 
and the subsequent recruitment of inflammatory cells (neutrophils, dendritic cells, macrophages 
[180, 187, 188]. In turn, the field of affected cells are degenerated and remain in a necrotic state 
until regeneration occurs. Given this large scale, pathological response, necrosis is viewed as the 
less favored cell death pathway relative to apoptosis.  
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Table 2-4: Comparison of Mitochondrial-Derived Apoptosis and Necrosis. Adapted from 
[189, 185, 27].  
Apoptosis Necrosis 
Programmed cell death Un-programmed cell death 
Response to “physiologic” stimuli Response to “pathologic” stimuli 
Affects single cells Affects neighbouring cells 
Cells shrink in size Cells and organelles swell 
Membrane remains intact; blebbing occurs Loss of cell membrane integrity 
Caspase-dependent Caspase-independent 
Formation of Apoptotic Body à 
phagocytosis of apoptotic cells and fragments 
 
Leakage of cellular components 
No inflammatory response* Evokes an inflammatory response 
Requires ATP Passive process – no ATP required 
 
2.5 Mitochondrial Function in Duchenne Muscular Dystrophy 
2.5.1 Mitochondrial Oxidative phosphorylation 
DMD has long been considered a disease involving metabolic impairments with several reports of 
deficiencies in key systems and regulators. Specifically, decreases in enzymes comprising the 
glycolysis pathway [190-193] and Tricarboxylic Acid cycle (TCA) [193] as well as decreased 
protein content of the electron transport chain have consistently been reported [34, 30, 194, 195, 
23]. The physiological consequence of these deficiencies is a reduction in ATP production, as 
evidenced by the severely reduced ATP content (~50% reduction) present in both animal models 
and patients with DMD [20, 22-24].  
Research to date indicates that this reduction in ATP content is due to functional abnormalities 
within the mitochondria. Firstly, functional deficits in specific enzymes (succinic CoA synthetase, 
aconitase, malate dehydrogenase and IDH) of the TCA cycle have been reported which would 
result in a decrease in the quantity of reducing equivalents available for reduction by the ETC [21, 
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196, 197]. Secondly, decreased oxidation rates of substrates including glucose, pyruvate, malate 
and glutamate have been reported in both mdx muscle and muscle from patients with DMD [198, 
29, 194, 34]. These combined findings suggest there should be concomitant decreases in the rate 
of oxidative phosphorylation in dystrophic muscle yet the results to date are divergent in nature 
[23, 28-34, 199]. It should be noted, albeit in limited sample sizes, the two evaluations of oxidative 
phosphorylation in human muscle to date both reveal impairments in respiration rates [29, 30] 
indicating there is likely an intrinsic impairment in oxidative phosphorylation within the 
mitochondria in DMD although this remains to be conclusively determined.  
2.5.1.1 Creatine Impairments in DMD 
MtCK plays a vital role in maintaining cellular energy homeostasis  and as a result, diseases 
characterized by impairments in cell metabolism or oxidative phosphorylation are increasingly 
being identified with mtCK defects [152]. MtCK is extremely susceptible to the compensatory up-
regulation of its expression in response to dysfunction as well as alterations by oxidative stress 
resulting in functional impairments [200, 152, 153]. Only one study to date has assessed mtCK 
functionality in dystrophic muscle. In oxidative muscle (soleus and left ventricle), an insensitivity 
to creatine was evident in dystrophic mice based on the inability of exogenous creatine to increase 
mitochondrial sensitivity to ADP [201]. Specifically, in WT muscle, the addition of creatine results 
in a greater rate of oxygen consumption for a given [ADP] because creatine activates mtCK, which 
promotes the transfer of energy through the efficient creatine-dependent pathway. On the contrary, 
the addition of creatine had no effect on ADP sensitivity, indicating an impairment in mtCK 
functionality in oxidative dystrophic muscle which was not due to alterations in mtCK activity 
levels [201]. These findings may account for some of the divergent data surrounding mitochondrial 
oxidative phosphorylation as no other study has assessed the two energy systems separately and 
as a result, may have masked dysfunctions that exist in specific pathways in dystrophic muscle.  
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2.5.2 Mitochondrial Reactive Oxygen Species Production 
As previously discussed in section 2.3.2 Oxidative Stress in DMD, there is a plethora of evidence 
to suggest that mitochondrial ROS should be elevated and in turn, that mitochondrial ROS 
contributes to DMD disease pathology yet the literature to date remains is inconclusive. Work by 
Shkryl et al., found that in FDB single fibres from mdx mice aged 4-8 weeks of age, basal levels 
of mitochondrial ROS were not different from WT but following an osmotic shock, mimicking the 
conditions that occur in dystrophic muscle following stretch-induced contractions, mitochondrial 
ROS levels were significantly higher than WT controls [125]. While basal levels of mitochondrial 
ROS were not higher, this work implicates the mitochondria as a contributor to oxidative stress in 
response to Ca2+ overload within the fibre. Additionally, given the compensatory nature of the mdx 
mouse [52], a time frame of 4-8 weeks makes it difficult to draw conclusions on the bioenergetic 
status of the muscle. Indeed, the only study to date to directly measure mitochondrial ROS 
emission rates in skeletal muscle did so in the TA muscle of mdx mice at 6 weeks of age. This 
novel work by Godin et al., found no increases in H2O2 emission rates but found a significant 
increase in H2O2 scavenging capabilities in mdx muscle, indicative of compensation occurring at 
this early time point [33].  
A second study by Ascah et al., found no increases in H2O2 emission in cardiac muscle from 12 
week old mdx mice but did report decreased aconitase activity, indicative of a loss of function due 
to oxidative modifications [199]. Therefore, while basal levels of ROS production were not higher 
in cardiac or skeletal muscle, it does not rule out the possibility that this impairment is being 
masked by the high degree of compensation that occurs in the mdx mouse. Evidence to support 
this idea comes from an mdx mouse model with “humanized” telomere lengths. Recent work by 
Chang and colleagues suggests the hyper-regeneration that occurs in the mdx mouse [51, 52, 202] 
masks the ability to detect early attenuations in mitochondrial bioenergetics in dystrophic heart 
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[203, 204]. Indeed, shortening telomeres to a more “humanized” length, thereby lowering the stem 
cell pool, revealed an increase in mitochondrial superoxide production and impairments in 
respiration in cardiomyocytes relative to the classic mdx model [204]. Additionally, treatment with 
two antioxidants, butylated hydrooxyanisole (BHA), a global antioxidant and MnTBAP a 
mitochondrial targeted antioxidant, lowered oxidative stress and prolonged the onset of 
cardiomyopathy in dystrophic animals with shortened telomeres, with MnTBAP providing far 
more benefit than BHA [204]. To date, no study has confirmed whether mitochondrial ROS 
production is elevated in non-compensated, dystrophic tissue relative to healthy controls despite 
the evidence suggesting this may be the case and the potential implications of the identification of 
the mitochondria as a source of ROS in the context of DMD disease pathology.   
2.5.2.1 ADP as a Central Governor of Bioenergetics 
Defined impairments in creatine sensitivity in DMD [201] highlight the need for the careful design 
of in vitro assessments in order to capture the specific source and degree of bioenergetic 
dysfunction in a disease. Given the membrane potential dependency of superoxide production in 
the ETC, ADP plays an important role in not only stimulating OXPHOS, but lowering superoxide 
production and consequentially, the amount of H2O2 emitted from the mitochondria [230]. As 
such, it is possible that mitochondrial dysfunction could manifest as a loss of central control by 
ADP to govern both H2O2 emission and respiration during oxidative phosphorylation. 
Furthermore, mtCK is known to play an essential role in optimizing ADP-stimulation of oxidative 
phosphorylation and attenuation of H2O2 emission given its ability to accelerate mitochondrial 
matrix ADP cycling which ultimately reduces H2O2 emission and stimulates oxidative 
phosphorylation (Figure 2-6) [205, 157]. Overall, given the complexity of how bioenergetics are 
governed by ADP and creatine, it is plausible that re-designing in vitro protocols to mimic in vivo 
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conditions may uncover specific impairments in the governance of mitochondrial H2O2 emission 
during oxidative phosphorylation in DMD.  
2.5.2.2 Targeting Mitochondrial ROS in DMD 
Recent results from clinical trials (2011-2019) involving the compound Idebenone infer that 
mitochondria may be a source of oxidative stress in DMD. Idebenone, a synthetic analog to 
coenzyme Q10, is known for its ability to improve mitochondrial oxidative phosphorylation and 
reduce oxidative stress through its role as an electron shuttler [206, 207]. In recent years, idebenone 
has been tested in both mdx mice and in clinical trials involving patients with DMD where the 
primary focus of these studies was idebenone’s effect on cardiac and respiratory function. In mdx 
mice, long term treatment with Idebenone corrected cardiac diastolic dysfunction and prevented 
mortality from cardiac pump failure induced by dobutamine stress testing in vivo, significantly 
reduced inflammation and fibrosis in cardiac tissue, and significantly improved voluntary running 
performance [208]. Results from clinical trials were equally promising with reports of improved 
cardiac and respiratory function in patients with DMD [76, 209-211]. Specifically, in the clinical 
trial DELOS, which involved patients aged 10-18 not currently taking glucocorticoids, assessed 
peak expiratory flow as a percentage of expected as well as forced vital capacity and peak cough 
flow. All three parameters improved in the treatment group, yet there was no effect on arm strength 
or function [210, 211]. A separate clinical trial DELPHI assessed cardiac and respiratory function 
in boys with DMD aged 8-16 years comprised of both glucocorticoid users and glucocorticoid-
naïve participants.  Idebenone treatment resulted in a trend for increased peak systolic radial strain 
in the left ventricle and significantly improved peak expiratory flow [209]. Further post-hoc 
analysis revealed a greater improvement in peak expiratory flow following idebenone treatment in 
glucocorticoid-naïve patients, potentially indicative of a steroid-mediated suppression of 
idebenone or a maximal treatment effect reached by steroids [76].   
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Despite these beneficial effects, it remains unknown whether improvements following idebenone 
treatment are due to alterations in mitochondrial function. Firstly, idebenone is not a 
mitochondrial-targeted compound but a general antioxidant based on its structure. To date, the 
beneficial effects of idebenone on mitochondrial function in DMD have been inferred based on 
the structural similarity to coenzyme Q10,  yet the specific mechanism of action remains to be 
elucidated  Additionally, while promising at high doses, there are concerns over idebenone’s 
limited bioavailability [212]. Overall, these promising results highlight the need to directly 
evaluate whether the mitochondria are a secondary mechanism contributing to DMD disease 
pathology as the identification of the mitochondria as a therapeutic target would provide several 
therapeutic candidates to evaluate in the development of a portfolio of compounds to be considered 
for clinical trials.  
2.5.3 Mitochondrial Calcium Handling and Mitochondrial-Derived Cell Death 
In addition to oxidative phosphorylation, the mitochondria play a key role in the regulation of cell 
death pathways, which, by nature, are Ca2+ dependent. Dating back to 1987, TEM analysis of 
mitochondria in muscle fibres from patients with DMD revealed no differences in mitochondrial 
content but vast ultrastructural abnormalities ranging from “small and dense” mitochondria, 
indicative of apoptosis to “large and dilated” mitochondria, indicative of necrosis [213]. This is 
associated with evidence of excess Ca2+ uptake by the mitochondria dystrophic tissue. In fact, work 
by Robert et al., revealed that dystrophic mitochondria will take up excess calcium in response to 
increased cell membrane permeability, even before cytosolic Ca2+ overload is evident [214]. 
Further work by Ascah et al., revealed that in unstressed mitochondria, Ca2+ uptake velocity is 
significantly higher in mdx muscle relative to WT controls [199]. Together these findings indicate 
that the mitochondria may actually be a direct cause of impaired Ca2+ homeostasis in dystrophic 
tissue as opposed to an organelle simply responding to perturbations in cytosolic [Ca2+].  
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Surprisingly, direct assessment of mitochondrial susceptibility to Ca2+-induced PTP opening has 
led to divergent results. In permeabilized muscle fibre systems, whereby the cell membrane is 
removed but the mitochondrial membrane remains intact, mitochondrial susceptibility to Ca2+-
induced PTP opening is assessed using membrane impermeant fluorophores which bind Ca2+ in 
the cytoplasm, but not in the mitochondria. Following the addition of exogenous Ca2+ 
mitochondrial uptake and subsequent release of Ca2+, indicative of PTP opening can be assessed. 
When analyzing the time to PTP opening in response to a set [Ca2+], dystrophic tissue consistently 
demonstrates an increased susceptibility to PTP opening relative to WT [199, 33, 35] which is 
likely related to the previously mentioned increase in mitochondrial Ca2+ uptake velocity in 
dystrophic tissue. Alternatively, when Ca2+ is titrated into the system in small amounts, the [Ca2+] 
required to induce PTP opening is unchanged between mdx and WT animals [33, 215]. Perhaps, 
given the increased Ca2+ uptake velocity, a single large bolus of Ca2+ better reflects the in vivo Ca2+ 
influx experienced by dystrophic mitochondria while the small titrations allow the in vitro system 
to deal with the influx better. For example, when intact hearts from mdx mice are subjected to I/R 
injury, the number of mitochondria undergoing PTP opening is increased compared to normal 
hearts. However, this physiological stressor was required to unmask differences, as PTP opening 
was unchanged prior to the induction of I/R relative to WT controls [199, 32]. In essence, the 
mitochondria needed to be primed with Ca2+ in order to mimic in vivo conditions and to further 
unmask the increased susceptibility to PTP opening.     
While functional data remains perplexing, the most compelling evidence for the contribution of 
mitochondrial derived cell death to the DMD disease pathology stems from the use of PTP 
inhibitors in DMD. Millay et al., genetically modified mdx mice to delete the gene encoding 
Cyclophilin D, resulting in resistance to mitochondrial Ca2+overload-induced swelling and 
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decreased levels of necrosis in diaphragm and gastrocnemius muscle [36]. However, this was not 
associated with a recovery in muscle function [36]. A second study, conducted by Reutenauer et 
al., aimed to pharmacologically inhibit Cyclophillin D using a compound Debio 025. Treatment 
with this compound partially reduced necrosis in the diaphragm and soleus of mdx mice during the 
peak necrotic period as well as  provided a greater resistance to fatigue in the triceps muscle, 
despite maximal tetanic force being unchanged [215]. Finally, the use of sildenafil, which inhibits 
PTP opening through the activation of cGMP signaling, resulted in improvements in diaphragm 
strength and enhanced respiratory muscle contractility [216]. In a second study, sildenafil 
decreased PTP opening and caspase 9 activity [199] as well as necrosis [217] in dystrophic cardiac 
muscle prior to the onset of cardiomyopathy. Perhaps most striking, sildenafil also demonstrated 
the capability to improve cardiac function in aged mdx mice, after the onset of cardiomyopathy 
[218]. Unfortunately, the subsequent clinical trial in patients with DMD was unsuccessful with the 
trial being terminated early due to several patients worsening on sildenafil [219].  
While it is evident that mitochondrial-derived cell death is a contributing factor to DMD disease 
pathology, it appears that targeting the cell death itself provides minimal benefit at a clinical level. 
These findings highlight need to consider targeting the upstream causes of mitochondrial-derived 
cell death in order to prevent this pathological process from needing to occur.     
2.6 Mitochondrial Targeted Antioxidants 
It has been proposed that previously tested global antioxidants were ineffective at treating DMD 
because of their un-targeted nature and that targeting the specific source of ROS production may 
be more effective [82, 93, 208]. Over the past decade or so, extensive research has gone in to 
developing mitochondrial targeted antioxidants given the important role the mitochondria play in 
the control of cell life and death. There are three predominant ways that drugs can be targeted to 
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the mitochondria: 1. Targeting the biophysical properties of the mitochondria (ie. A negatively 
charged mitochondrial matrix), 2. Targeting based on the location of mitochondrial enzymes which 
catalyze the release of drugs from prodrugs and 3. Targeting based on transporter dependent 
prodrugs [220]. A wide range of general antioxidants have been targeted to the mitochondria 
through the conjugation with the lipophilic cation triphenylphosphonim (TPP). Lipophilic cations 
pass easily through lipid bilayers because their charge is dispersed over a large surface area and 
their positive charge allows the potential gradient to drive their accumulation into the 
mitochondrial matrix [221]. The most extensively used antioxidant, MitoQ (Figure 2-8a), sees 
Coenzyme Q conjugated to TPP and has been shown to scavenge superoxide and peroxynitrite as 
well as prevent lipid peroxidation [221, 220]. A second set of compounds, similar in structure and 
functionality to MitoQ are the Sk compounds with SKQ1 (Figure 2-8b) being most commonly 
used. SKQ1 is comprised of plastiquinone, a compound equivalent to ubiquinone found in 
chloroplasts which has been found to be a stronger antioxidant, conjugated to TPP [222]. Both 
MitoQ and SkQ1 act as antioxidants at low doses, yet are found to become pro-oxidants at high 
doses. Additionally, due to their dependence on membrane potential to accumulate within the 
mitochondria, diseases with dissipated mitochondrial membrane potential are likely not potential 
targets for this form of antioxidant. 
The SS peptides, which represent another group of mitochondrial targeted antioxidants, are 
aromatic–cationic peptides that bear alternating aromatic and basic amino acid residues with some 
compounds (SS-31, SS-02) also containing a 2′,6′-dimethyltyrosine (Dmt) residue (Figure 2-8c). 
These cell permeable compounds bind to cardiolipin on the IMM and are shown to improve 
oxidative phosphorylation, decrease ROS, prevent oxidative damage and prevent the dissociation 
of cytochrome c from cardiolipin, thereby preventing the activation of cell death pathways [223]. 
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SS-31 and SS-02 appear to have the strongest antioxidant capabilities which are attributed to the 
Dmt residue, which is a phenolic antioxidant [220]. While SS-20 does not act as a direct scavenger 
of ROS, it still has beneficial effects on mitochondrial function and the prevention of oxidative 
damage [224]. Unlike MitoQ and SKQ1, the uptake of SS peptides is only reduced by 
approximately 20% upon the depolarization of the mitochondria and therefore, may be an 
attractive alternative in diseases of dissipated membrane potential. The SS compounds have been 
shown to effectively protect against damage caused by ischemia-reperfusion injury and myocardial 
infarction in rats [224-226] while SS-31 (elamipretide) specifically is currently being used in 
clinical trials for Primary Mitochondrial Myopathy, Barth syndrome, Leber’s Hereditary Optic 
Neuropathy and Age-Related Macular Degeneration, diseases that are all characterized by elevated 
oxidative stress [227, 228].  
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Figure 2-8: Structures of commonly used mitochondrial targeted antioxidants.  MitoQ: 10-
(6′-ubiquinolyl)decyltriphenylphosphonium bromide. B. SKQ1: 10-(6’-
plastoquinolyl)decyltriphenylphosphonium. C. SS Peptides: SS-31, D-Arg–Dmt–Lys–Phe–NH2; 
Dmt, 2′,6′-dimethyltyrosine; SS-02, Dmt–D-Arg–Phe–Lys–NH2; SS-20, Phe–D–Arg–Phe–Lys–
NH.  
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3 Objectives and Hypothesis 
 
3.1 Overview of Thesis 
The overall purpose of this thesis was to determine whether the mitochondria represent a viable 
therapeutic target for the treatment and prevention of disease progression in Duchenne muscular 
dystrophy (DMD). The specific objectives and hypotheses for each study are outlined below. 
3.2 Objective and Hypotheses for Study 1 (CHAPTER 4) 
While the mitochondria have always been proposed to contribute to DMD disease pathology, the 
literature evaluating the actual contribution of the mitochondria remains controversial. The 
objective of this study was to determine the specific source(s) and degree of altered mitochondrial 
bioenergetics in diaphragm and skeletal muscle in young D2.mdx, a new mouse model that more 
closely mimics human disease progression and furthermore, to determine if these potential 
alterations in mitochondrial bioenergetics were associated with muscle wasting and weakness.  
Hypotheses: 
1. By modelling in vivo conditions in vitro, altered mitochondrial bioenergetics (oxidative 
phosphorylation, H2O2 emission, susceptibility to calcium-induced permeability transition 
pore opening) will be evident in dystrophic muscles exhibiting cell membrane damage. 
2. Corresponding muscle weakness as exhibited through muscle functional assessments will 
be present in dystrophic tissue displaying membrane damage. 
3. These impairments in mitochondrial and muscle function will be associated with muscle 
wasting. 
3.3 Objective and Hypotheses for Study 2 (CHAPTER 5) 
The heart represents a unique muscle in DMD given the late onset of muscle degeneration and 
subsequent cardiomyopathy within this tissue despite a lack of dystrophin akin to all other muscles 
in the body. Cardiomyopathy occurs in 98% of patients and develops into heart failure in 40% of 
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patients yet the underlying mechanisms causing this myopathy remain unknown. Literature to date 
suggests the mitochondria should be a contributing factor yet the compensatory nature of the 
animal models used appear to mask any bioenergetic defects that may be present. The objective of 
this study was to evaluate mitochondrial function in dystrophic heart muscle prior to the onset of 
cardiomyopathy in the D2.mdx mouse, a mouse model with impaired regenerative capabilities and 
subsequently, less compensation than classical models.  
Hypothesis: 
1. Mitochondrial bioenergetics (oxidative phosphorylation, H2O2 emission, susceptibility to 
calcium-induced permeability transition pore opening) will be altered in dystrophin 
deficient heart muscle at a time point prior to the onset of cardiomyopathy.  
3.4 Objective and Hypotheses for Study 3 (CHAPTER 6) 
Based on the findings from study 1, we then sought to determine if a mitochondrial-targeted 
peptide (SBT-20) could improve altered bioenergetics and subsequently improve DMD disease 
pathology in diaphragm and skeletal muscle of young D2.mdx mice. 
Hypotheses: 
1. 28 days of treatment with SBT-20 will improve mitochondrial bioenergetics in dystrophic 
diaphragm and quadriceps muscle 
2. Improved bioenergetics will be associated with improvements in mitochondrial quality 
(permeability transition pore induction, mitochondrial ultrastructure), muscle quality 
(specific force production, histopathology) and lean muscle volume relative to saline 
treated D2.mdx mice 
3.5 Objective and Hypotheses for Study 4 (CHAPTER 7) 
Study 4 can be divided into two parts and subsequently has two distinct objectives. While studies 
1-2 demonstrated impaired mitochondrial bioenergetics in young D2.mdx mice, the first objective 
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of study 4 was to determine if these impairments were still evident in the late stages of disease 
progression using aged (52 week old) D2.mdx mice. Objective 2 of this study was to determine if 
the mitochondrial-targeted peptide SBT-20 could improve impaired mitochondrial bioenergetics 
by preventing oxidation of the pathways that were identified as dysfunctional in part 1.  
Hypotheses: 
1. Mitochondrial bioenergetics (oxidative phosphorylation, H2O2 emission, susceptibility to 
permeability transition pore opening) will be altered in heart, diaphragm and skeletal 
muscle of aged animals with DMD. 
2. Longer term in vivo treatment with SBT-20 will prevent oxidative inhibition of 
mitochondrial bioenergetics 
3. After revealing creatine-specific impairments in bioenergetics, we hypothesized that In 
vitro treatment with SBT-20 will improve creatine-dependent energy exchange and protect 
mtCK from oxidative modification-induced dysfunction 
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3.6 Additional Contributions 
The following work encompasses the additional contributions made throughout my PhD that are 
not included in my dissertation. *Denotes equal contribution. 
Co-First Author - Published 
1. Monaco CMF*, Hughes MC*, Ramos SV, Varah NE, Lamberz C, Rahman FA et al. Altered 
mitochondrial bioenergetics and ultrastructure in the skeletal muscle of young adults with type 1 
diabetes. Diabetologia. 2018;61(6):1411-23. doi:10.1007/s00125-018-4602-6. 
 
2. Ramos SV*, Hughes MC*, Perry CGR. Altered skeletal muscle microtubule-mitochondrial 
VDAC2 binding is related to bioenergetic impairments after paclitaxel but not vinblastine 
chemotherapies. American Journal of Physiology-Cell Physiology. 2019. 
doi:10.1152/ajpcell.00384.2018. 
 
Co-Author - Published 
1. Edgett BA, Hughes MC, Matusiak JB, Perry CG, Simpson CA, Gurd BJ. SIRT3 gene 
expression but not SIRT3 subcellular localization is altered in response to fasting and exercise in 
human skeletal muscle. Exp Physiol. 2016;101(8):1101-13. doi:10.1113/EP085744. 
 
2. Smith BK, Ford RJ, Desjardins EM, Green AE, Hughes MC, Houde VP et al. Salsalate 
(Salicylate) Uncouples Mitochondria, Improves Glucose Homeostasis, and Reduces Liver Lipids 
Independent of AMPK-β1. Diabetes. 2016;65(11):3352.  
 
3. Bhattacharya D, Ydfors M, Hughes MC, Norrbom J, Perry CGR, Scimè A. Decreased 
transcriptional corepressor p107 is associated with exercise-induced mitochondrial biogenesis in 
human skeletal muscle. Physiological Reports. 2017;5(5).  
 
4. Pinho RA, Sepa-Kishi DM, Bikopoulos G, Wu MV, Uthayakumar A, Mohasses A, Hughes 
MC, Perry CGR and Ceddia RB. High-fat diet induces skeletal muscle oxidative stress in a fiber 
type-dependent manner in rats. Free Radical Biology and Medicine. 2017;110 (Supplement 
C):381-9. doi:https://doi.org/10.1016/j.freeradbiomed.2017.07.005. 
 
Co-First Author – In Progress 
1. Ramos SV*, Hughes MC*, Bellissimo CA and Perry CGR. Mitochondrial bioenergetic 
dysfunction in Duchenne muscular dystrophy is associated with microtubule disorganization in 
skeletal muscle. Submitted to PLoS One. March 2019.  
2. Ramos SV*, Hughes MC*and Perry CGR. The effects of microtubule-binding 
chemotherapies on cardiac mitochondrial bioenergetcs.  
 
3. Ramos SV*, Hughes MC*and Perry CGR. The role of mitochondrial function in 
chemotherapy induced muscle weakness.  
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Co- Author – In Progress 
1. Al-Sajee D, Molt S, Gingrich M, Au M, Coleman SK, Filler T, Provias J, DeBeer J, Hughes MC, 
Perry CGR, Chambers P, Tupling RA, Tarnopolsky MA, Fürst D and Hawke TJ. The Absence of 
Xin Results in Triadopathy; Evidence of Xin as a Novel Player in Skeletal Muscle Calcium 
Handling. 
2. Colon cancer specific cell death in response to palmitoylcarnitine is caused by elevated 
H2O2 and glutathione depletion. Turnbull PC, Hughes MC and Perry CGR.  
 
3. Decreasing Mitochondrial H2O2 Emission and Increased Glutathione Levels mediate a unique 
fatty Acid-Induced HepG2 Growth. Turnbull PC, Dehghani AC, Hughes MC, Theriau C, 
Connor M and Perry CGR. 
 
4. Auranofin coupled with serine and glycine depletion selectively targets p53-null cells for ROS 
induced cell death through antioxidant depletion. Turnbull PC, Dehghani AC, Deep B, Delfinis 
LJ, Hughes MC, Abdul-Sater A and Perry CGR. 
 
5. The mitochondrial-enhancing drug Olesoxime improves quadriceps mitochondrial function 
and force recovery but not diaphragm function in a mouse model of Duchenne muscular 
dystrophy. Belissimo CA, Delfinis LJ, Hughes MC, Tadi P, Amaral C, Dehghani A and Perry 
CGR.  
 
6. Collaboration with Dr. Robert Tsushima (York University) evaluating the alterations in 
mitochondrial bioenergetics in pancreatic β-cells following statin therapy. 
 
7. Collaboration with Drs. David MacLennan and Anthony Gramolini (University of Toronto) 
evaluating mitochondrial bioenergetics in the left atria and ventricle from phospholamban-mutated 
(R9C) mice.  
 
8. Collaboration with Dr. Keith Avin (Indiana University) evaluating the role of kidney 
dysfunction in mitochondrial-mediated cachexia 
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4 Early myopathy in Duchenne muscular dystrophy is associated 
with elevated mitochondrial H2O2 emission during impaired 
oxidative phosphorylation  
 
This chapter is an original published article. It is presented in its published form. 
 
Early myopathy in Duchenne muscular dystrophy is associated with elevated mitochondrial 
H2O2 emission during impaired oxidative phosphorylation. MC Hughes*, SV Ramos*, PC 
Turnbull, IA Rebalka, A Cao, CMF Monaco, NE Varah, BA Edgett, JS Huber, P Tadi, LJ 
Delfinis, U Schlattner, JA Simpson, TJ Hawke and CGR Perry. The Journal of Cachexia, 
Sarcopenia and Muscle Wasting. DOI:10.1001/jcsm.12405. 
*Co-first authors 
 
Assay Development Prior to the start of Project 1: 
1. Standardization of Whole Body In Vivo Muscle Function Measurements 
2. Hindlimb Plantarflexor Force Production 
3. Mouse µCT scanning and analysis SOP 
4. Calcium Retention Capacity  
5. Serum Creatine Kinase Evaluation 
6. Caspase Activity Assay 
7. Mitochondrial Membrane Potential 
a. The method I established to measure mitochondrial membrane potential was used 
to collect data for Chapters 4, 5 and 7. However, due to technical limitations related 
to signal artifacts specifically in permeabilized fibres, we deemed this data unusable 
and therefore it is not included in this thesis. However, the development of this 
method benefited the collaborative component of my PhD through my contribution 
to the publication by Smith et al., (2016) which employed this assay in isolated 
mitochondria, as classically performed. I also established a protocol to measure 
proton conductance for this publication. 
 
 
Author Contributions: The majority of experiments for this project were carried about by 
Meghan Hughes. MH established and maintained the breeding colony required for this project as 
well as all subsequent studies (Chapter 5-7). MH ran all in vivo whole body functional testing as 
well as hindlimb plantarflexor force production measurements. MH completed µCT scans while 
PT completed the analysis following training from MH. MH and SV Ramos performed all tissue 
harvests and mitochondrial bioenergetic assays (respiration, mH2O2 emission, calcium retention 
capacity) together. Due to the nature of these experiments, two people are required in order to 
 
 
59 
efficiently complete all bioenergetic assays on fresh, viable tissue. As such, MH and SVR 
completed surgeries and bioenergetics experiments for all projects contributing to both theses (see 
Appendix B - additional contributions). MH ran all serum creatine kinase experiments, caspase 
assays and western blotting experiments. JAS performed the in vivo respiratory occlusion 
experiments. PCT completed glutathione measurements. CMFM and NEV analyzed TEM images. 
IAR, AC, BAE and JSH performed all immunohistochemistry staining and analysis. MH and 
CGRP wrote and revised the manuscript.  
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Abstract 
Background: Muscle wasting and weakness in Duchenne muscular dystrophy (DMD) causes 
severe locomotor limitations and early death due in part to respiratory muscle failure. Given 
current clinical practice focuses on treating secondary complications in this genetic disease, there 
is a clear need to identify additional contributions in the etiology of this myopathy for knowledge-
guided therapy development. Here we address the unresolved question of whether the complex 
impairments observed in DMD are linked to elevated mitochondrial H2O2 emission in conjunction 
with impaired oxidative phosphorylation. This study performed a systematic evaluation of the 
nature and degree of mitochondrial-derived H2O2 emission and mitochondrial oxidative 
dysfunction in DMD by designing in vitro models that attempt to mimic in vivo conditions known 
to be critical for the regulation of mitochondrial bioenergetics.  
Methods: Mitochondrial bioenergetics were compared to functional and histopathological indices 
of myopathy early in DMD (4 weeks) in D2.B10-DMDmdx/2J mice – a model that demonstrates 
severe muscle weakness. ADP’s central effect of attenuating H2O2 emission while stimulating 
respiration was compared under two models of mitochondrial-cytoplasmic phosphate exchange 
(creatine-independent and dependent) in muscles that stained positive for membrane damage 
(diaphragm, quadriceps and white gastrocnemius).  
Results: Pathway-specific analyses revealed complex I-supported maximal H2O2 emission was 
elevated concurrent with a reduced ability of ADP to attenuate emission during respiration in all 
three muscles (mH2O2: +17 to +197% in DMD vs WT). This was associated with an impaired 
ability of ADP to stimulate respiration at sub-maximal and maximal kinetics (-17 to -72% in DMD 
vs WT), as well as a loss of creatine-dependent mitochondrial phosphate shuttling in diaphragm 
and quadriceps. These changes largely occurred independent of mitochondrial density or 
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abundance of respiratory chain complexes, except for quadriceps. This muscle was also the only 
one exhibiting decreased calcium retention capacity which indicates increased sensitivity to 
calcium-induced permeability transition pore. Increased H2O2 emission was accompanied by a 
compensatory increase in total glutathione, while oxidative stress markers were unchanged. The 
mitochondrial bioenergetic dysfunctions were associated with induction of mitochondrial-linked 
caspase 9, necrosis, and markers of atrophy in some muscles as well as reduced hindlimb torque 
and reduced respiratory muscle function.  
Conclusions: These results provide evidence that Complex I dysfunction and loss of central 
respiratory control by ADP and creatine cause elevated oxidant generation during impaired 
oxidative phosphorylation. These dysfunctions may contribute to early stage disease 
pathophysiology and support the growing notion that mitochondria are a potential therapeutic 
target in this disease.  
Keywords: bioenergetics, Duchenne muscular dystrophy, mitochondria, reactive oxygen species, 
respiration, oxidative stress 
  
 
 
63 
Introduction 
Duchenne muscular dystrophy (DMD) is a debilitating disease that causes progressive muscle 
atrophy and weakness. Immobility related to skeletal muscle weakness manifests in childhood 
while eventual respiratory muscle failure causes ~40% of deaths in early adulthood [45, 2]. 
Inherited mutations in the gene dystrophin causes a loss in the normal function of this 
sarcolemmal-cytoskeletal protein [229]. Subsequent disruptions to cell membrane stability and 
cytoskeletal organization are linked to increased cytosolic calcium, oxidative stress and cell death 
that are cellular hallmarks of this disease [93, 2]. Moreover, a highly pro-inflammatory 
environment worsens the myopathy [230]. In this light, it has been proposed that mitochondrial 
dysfunctions arise from these multiple cellular stressors and may even reciprocate as a direct 
influence on muscle fibre degeneration [34, 195, 33].  
Given there is no cure for DMD, identifying secondary contributions has been a major focus for 
guiding therapy development [46]. Indeed, current clinical practice targets inflammation rather 
than the genetic mutation itself [46]. To this end, compounds that target mitochondria have 
attenuated the myopathy in mouse models of this disease. For example, the quinone-based 
idebenone - an electron shuttler [207] -  improved cardiac function and exercise performance in 
mice [208] as well as cardiac and respiratory function in Patients with DMD [210, 211, 209]. These 
drugs were developed based in part on pre-clinical evidence of impaired mitochondrial respiratory 
function in skeletal muscle of mice with DMD [30, 33, 231] and humans [30, 29]. As such, 
identifying additional mitochondrial abnormalities could guide further therapy development. 
As mitochondria naturally emit H2O2 during oxidative phosphorylation, impairments to efficient 
electron transport through the electron transport system could contribute to excessive H2O2 
emission. To our knowledge, only one study to date has compared mitochondrial-specific H2O2 
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emission in DMD muscle to wildtype [33]. This well-designed investigation demonstrated the 
expected impairment in oxidative phosphorylation and calcium retention capacity (an index of 
permeability transition linked to apoptosis), but also reported a surprising decrease in 
mitochondrial H2O2 emission in C57bl/10-mdx mice. However, a concomitant increase in oxidant 
buffering capacity was noted and could represent a compensatory response in this mouse model, 
suggesting that mitochondrial H2O2 may indeed be elevated in vivo, particularly in relation to 
impaired oxidative phosphorylation [33]. Given these observations, it is uncertain if mitochondrial 
H2O2 is elevated in DMD. 
The design of in vitro assessments of both mitochondrial H2O2 emission and respiration can be 
essential for capturing the degree of bioenergetic dysfunction in a disease. It is well-established 
that ADP lowers mitochondrial H2O2 emission while stimulating oxidative phosphorylation by 
virtue of reduced premature electron slip from the electron transport system [232]. As such, it is 
possible that mitochondrial dysfunction could manifest as a loss of central control by ADP to 
govern both H2O2 emission and respiration during oxidative phosphorylation. Furthermore, it has 
also been proposed that creatine is essential for optimizing ADP-stimulation of oxidative 
phosphorylation and attenuation of H2O2 emission. This is believed to occur through a process of 
‘high energy phosphate shuttling’ facilitated by mitochondrial creatine kinase (mtCK) (Figure 2) 
[200, 146, 150, 147] whereby the rapidly diffusing phosphocreatine export ultimately accelerates 
mitochondrial matrix ADP cycling, reduces H2O2 emission and stimulates oxidative 
phosphorylation [205, 157]. Overall, given the complexity of how bioenergetics are governed by 
ADP and creatine, it follows that a re-design of in vitro protocols may reveal the extent to which 
DMD impairs the governance of mitochondrial H2O2 emission during oxidative phosphorylation. 
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In this investigation, we determined the precise mechanism and degree of mitochondrial 
dysfunction in dystrophic locomotor muscles as well as respiratory muscle. The ability of ADP to 
attenuate H2O2 emission during oxidative phosphorylation was determined in the D2.B10-
DMDmdx/2J (D2.mdx) mouse. This model demonstrates severe muscle atrophy and weakness that 
more closely mimics human disease progression compared to the classic C57bl/10-mdx mice due 
to attenuated muscle regeneration arising from a natural mutation in TGF-β4 binding protein 4 in 
the background D2A strain [60, 59]. By employing these methodological approaches, we provide 
new evidence that a central impairment in ADP and creatine’s control of bioenergetics is linked 
specifically to increased Complex I-supported H2O2 concurrent with impaired respiration. This 
observation is ubiquitous across locomotor and respiratory muscles and may be related to muscle 
weakness, atrophy and cellular pathology in very early stages of DMD.   
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Material and Methods 
Animal Care 
The 4-week old D2.mdx animals originated from a colony maintained at York University (Toronto, 
Canada) and sourced from Jackson Laboratories (Bar Harbor, United States). Post-weaning (28 
days) animals were housed with male littermates until they underwent functional testing, at which 
time they were singly housed. 4-week old DBA/2J wildtype (WT) mice were obtained directly 
from Jackson Laboratories due to breeding challenges with this strain. Upon arrival, DBA/2J mice 
were singly housed and given a minimum of 72 hours to acclimatize before experiments were 
performed. All animals were provided access to standard chow and water ad libitum. All 
experiments and procedures were approved by the Animal Care Committee at York University 
(AUP Approval Number 2016-18) in accordance with the Canadian Council on Animal Care. 
Body Composition and Functional Assays 
Timeline of measurements 
A variety of tests were performed on mice before surgical removal of muscle for in vitro analyses. 
Specifically, 2 days prior to surgery, whole body functional testing (Cage Hang Time, Forelimb 
Grip Strength and Voluntary Wheel Running) were performed. On the day of surgery, prior to 
muscle harvest, animals underwent a µCT scan for muscle volume (see below). Due to tissue 
limitation, a separate set of animals were used for histochemistry and TEM analysis. Finally, in 
order to avoid confounding influences of force/pressure measurements on mitochondrial 
bioenergetic analysis, a separate set of animals were used to assess esophageal pressure 
transduction and in vivo force production.  
In Vivo µCT Scans 
In vivo body scans were performed using µCT (SkyScan 1278, Bruker-microCT, Kontick, 
Belgium). Mice were anaesthetized and maintained with isoflurane anesthetic during the scans. 
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Mice were laid supine with hind limbs extended and secured in place. Body scans were completed 
with a 100 µm resolution using a 0.5 mm aluminum filter at 50 kV and 996 µA, with a 30 ms 
exposure time and a 0.75° rotation step. Following scans, lower limb muscle volume was analyzed 
by first reconstructing the image using NRecon (software version 1.7.0.4, Bruker-microCT, 
Kontick, Belgium). Reconstructed images were then imported into CTAn (software version 
1.15.4.0, Bruker-microCT, Kontick, Belgium) where the region of interest was selected and 
analyzed. The region of interest for hind-limb muscle volume was landmarked from the top of the 
patella to the ankle joint and was quantified by setting thresholds for fat free mass (76-102), 
expressed as volume (mm3) of lean mass/g body weight.  
Voluntary Wheel Running 
Animals were placed in individual cages equipped with a locked 14 cm diameter running wheel 
and rotation counter (VDO m3 bike computer, Mountain Equipment Co-Op, Vancouver, Canada). 
After 24 hours of acclimatization, wheels were unlocked and distance run over 24 hours was 
recorded. 
Cage Hang Time 
Animals were placed on top of a metal cage lid approximately 30 cm above soft bedding and 
positioned so that all four limbs grasped the cage. The cage lid was inverted so that the mouse was 
hanging, and a timer was started. Cage hang time was recorded for a maximum of 180 seconds. 
Animals that fell off prior to 180 seconds were given three minutes to recover before a second trial 
and third trial. The maximum hanging time for each animal was recorded [233]. 
Forelimb Grip Strength 
A metal grid was attached to a force transducer (Mark 10 Digital Force Gauge, Copiague, NY) set 
to peak tension mode. The force transducer was placed on the edge of a table top allowing the grid 
to extend past the table. Mice were removed from their cages by the tail and brought towards the 
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grid until such time that the mice grasped the grid with their forepaws. Upon grasping, animals 
were pulled away from the grid until their grasp was broken. Peak tension was recorded, and the 
trial was repeated twice more. If the animal did not show resistance to the experimenter, the trial 
was not recorded. Maximum peak tension from the best of 3 trials was used for analysis [233]. 
Esophageal Pressure Transduction 
Esophageal pressure measurements were performed as previously described [234]. Briefly, mice 
were anesthetized with an isoflurane/oxygen mix (2%:100%) and body temperature was 
maintained at 37°C. Mice were intubated using a 20-gauge angiocatheter (Becton, Dickinson and 
Company) to maintain an open/unobstructed airway. Compressible tubing was attached to the 
angiocatheter to facilitate inducible airway occlusions.  Esophageal pressure (Peses) was measured 
with a 1.2F catheter (Transonic) recorded on LabScribe2 software (iWorx) and analyzed with 
Spike2 software (Cambridge Electronic Design). Immediately after 2 min of baseline Pes 
recording, the trachea was occluded, and Pes was monitored for changes. Tracheal occlusions were 
initiated at end expiratory volume to ensure consistency of the Diaphragm length-tension 
relationship. Maximum inspiratory pressure (PIocc) was evaluated after 30s of occlusion when 
pressure generation reached a plateau. 
In Vivo Hind-limb Force Production 
In vivo force production of the hind-limb plantarflexor muscles was partially adapted from 
previous methods [235]. In brief, mice were anesthetized with isoflurane and placed on a platform 
maintained at 37° C. The left foot was secured to a footplate attached to an Aurora Scientific 305C 
muscle lever (Aurora, Ontario, Canada) so that the ankle’s axis of rotation coincided with that of 
the servomotor shaft. The knee was clamped in place such that the knee and ankle angles were 
both 90°. Contraction of the plantarflexors was controlled through percutaneous stimulation of the 
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sciatic nerve. Peak isometric torque was determined by varying the voltage delivered to the sciatic 
nerve at a frequency of 60 Hz and 0.2-ms square wave pulse. Torque as a function of stimulation 
frequency was measured during 7 isometric contractions at varying stimulation frequencies (40, 
60, 80, 100, 120, 140, 160 Hz). Maximum torque produced during the torque-frequency protocol 
was recorded and compared between groups. 
Serum Creatine Kinase 
Blood was collected through cardiac puncture and allowed to clot at room temperature for 30 
minutes. Following clotting, blood was spun at 1000g for 10 minutes and serum was collected. 
Creatine kinase activity was measured spectrofluorometrically (QuantaMaster 80, HORIBA 
Scientific, Edison, NJ, USA) based on the autofluorescence of NADPH (excitation – 340 nm, 
emission – 450 nm) using the Pointe Scientific Serum Creatine Kinase kit (Pointe Scientific, 
Canton, MI, USA). Creatine kinase activity (U/L) was calculated from the rate of NADPH 
production (F/min) applied to a standard curve produced under the same conditions and normalized 
to volume dilution. 
Selection of Muscles for Analyses 
A subset of mice (n=2) were injected i.p. with 1% Evans Blue Dye (Sigma, St Louis, MO, USA) 
(w/v) in phosphate-buffered saline (PBS, pH 7.5) sterilized by passage through a Millex®-GP 0.22 
µm filter (Millipore, Bedford, MA, USA). 16 hours post injection animals were sacrificed and 
muscles were harvested to allow for the visual inspection of dye uptake. We selected skeletal 
muscles that stained positive for Evans Blue Dye to ensure mitochondrial bioenergetics were 
assessed in muscle displaying a severe phenotype (Supplemental Figure 1). The vastus 
intermedius of the quadriceps (Quad), comprised of IIA, IIX and IIB fibres [236], and white 
gastrocnemius (WG), comprised of predominantly of IIB fibres [236]  were selected in addition to 
Diaphragm which also showed substantial membrane damage. 
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Mitochondrial Bioenergetic Assessments 
Preparation of Permeabilized Muscle Fibre Bundles (PmFB) 
This technique is partially adapted from previous methods and has been described elsewhere [237-
240]. Briefly, muscles were removed from mice during anaesthesia with isoflurane. We performed 
all tissue harvests in approximately half an hour to minimize the chance of negative effects of 
isoflurane on mitochondrial function as has been reported with longer 6 hour durations [241]. The 
Quad and WG from the non-stimulated leg as well as a strip of Diaphragm were removed and 
immediately placed in ice-cold BIOPS, containing (in mM): 50 MES Hydrate, 7.23 K2EGTA, 2.77 
CaK2EGTA, 20 imidazole, 0.5 dithiothreitol, 20 taurine, 5.77 ATP, 15 PCr, and 6.56 MgCl2·6 H2O 
(pH 7.1). Each muscle was trimmed of connective tissue and fat and divided into several small 
muscle bundles (~2–7 mm, 1.0–2.5 mg wet weight). Each bundle was gently separated along the 
longitudinal axis to form bundles that were treated with 40 µg/ml saponin in BIOPS on a rotor for 
30 minutes at 4° C. Bundles destined for Complex I and pyruvate dehydrogenase complex  
mitochondrial H2O2 emission (mH2O2) measurements (described below) were also treated with 35 
µM 2,4-dinitrochlorobenzene (CDNB) during the permeabilization step to deplete glutathione and 
allow for detectable rates of mH2O2 [242]. Following permeabilization, the PmFB were divided 
into three groups; 1) bundles intended for high resolution respirometry were placed in MiR05 
containing (in mM): 0.5 EGTA, 10 KH2PO4, 3 MgCl2·6 H2O, 60 K-lactobionate, 20 Hepes, 20 
Taurine, 110 sucrose and 1 mg/ml fatty acid free BSA (pH 7.1) while 2) bundles intended for 
mH2O2 were placed in Buffer Z containing (in mM): 105 K-MES, 30 KCl, 10 KH2PO4, 5 MgCl2·6 
H2O, 1 EGTA and 5mg/ml BSA (pH 7.4). PmFB were washed on a rotor at 4°C in MiR05 or 
Buffer Z until the measurements were initiated. 3) bundles intended for calcium retention capacity 
were placed in Buffer Y + 1 mM EGTA containing (in mM): 250 sucrose, 10 tris-HCl, 20 tris-
base, 10 KH2PO4 and 0.5mg/mL BSA and washed on a rotor at 4° C for 10 minutes. PmFB were 
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then transferred to a second wash of Buffer Y + 10 µM blebbistatin (BLEB, see below) and were 
washed on a rotor at 4°C until measurements were initiated. Following permeabilization and 
washing, all mitochondrial bioenergetic measurements were performed in the same order from one 
animal to another and between groups to ensure consistent durations of the wash step.  
Mitochondrial Respiration 
High-resolution O2 consumption measurements were conducted in 2 ml of respiration medium 
(MiR05) using the Oroboros Oxygraph-2k (Oroboros Instruments, Corp., Innsbruck, Austria) with 
stirring at 750 rpm at 37 °C [239, 240, 243-245]. Respiration medium contained 20mM Cr to 
saturate mitochondrial creatine kinase or no creatine to prevent the activation of mtCK [243, 246]. 
A third condition of 13.9mM PCr and 9.1mM Cr was used to provide an equilibrium across mtCK 
as occurs in skeletal muscle at rest in vivo [247]. For ADP-stimulated respiratory kinetics, standard 
procedures to determine Complex I and II-supported respiration were employed [245]. 5 mM 
pyruvate, accompanied by 2 mM malate, were added as Complex I-specific substrates (via 
generation of NADH to saturate electron entry into Complex I) followed by a titration of 
submaximal ADP (25 µM and 500 µM) and maximal ADP (5 mM). Cytochrome c was added to 
test for mitochondrial membrane integrity, with all experiments demonstrating <10% increase in 
respiration. Finally, succinate (20 mM) was then added to saturate electron entry into Complex II. 
All experiments were conducted in the presence of 5µM BLEB in the assay media to prevent 
spontaneous contraction of PmFB which has been shown to occur in response to ADP at 37 °C 
which alters respiration rates [243, 248, 244]. Each protocol was initiated with a starting [O2] of 
approximately 350 µM and was completed before the oxygraph chamber [O2] reached 150 µM as 
done previously [239, 240, 243-245]. Polarographic oxygen measurements were acquired in 2 s 
intervals with the rate of respiration derived from 40 data points and expressed as pmol/s/mg wet 
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weight. PmFB were weighed in ~1.5 ml of tared BIOPS (ATP-containing relaxing media) to ensure 
PmFB remained relaxed. 
Mitochondrial H2O2 Emission (mH2O2) 
mH2O2 was determined fluorometrically (QuantaMaster 40, HORIBA Scientific, Edison, NJ, 
USA) in a quartz cuvette with continuous stirring at 37°C, in 1 mL of Buffer Z supplemented with 
10 µM Amplex Ultra Red, 0.5 U/ml horseradish peroxidase, 1 mM EGTA, 40 U/ml Cu/Zn-SOD1,5 
µM BLEB and 20mM Cr. Site specific induction of mH2O2 was measured through the addition of 
either 10 mM pyruvate and 2 mM malate (NADH, Complex I), 10 mM succinate (FADH2, 
Complex I via reverse electron flux from Complex II) or 2.5 µM antimycin A (Complex III). 
Additionally, using 0.5 µM rotenone, a complex I inhibitor, plus 10 mM pyruvate, electron slip 
specific to pyruvate dehydrogenase complex was also measured in CDNB-treated fibres as noted 
above [242]. Following the induction of state II mH2O2 by Complex I and Complex II substrates, 
a titration of ADP was added to progressively attenuate mH2O2. Complexes I and II-supported 
mH2O2 were repeated with no creatine in the assay buffer to compare ADP’s effects without 
mtCK-mediated phosphate shuttling. All measurements were made in the presence of 1 µM BLEB 
to prevent ADP-induced rigor as described above. The rate of H2O2 emission was calculated from 
the slope (F/min), from a standard curve established with the same reaction conditions and 
normalized to fibre bundle wet weight as described above, or citrate synthase content determined 
by western blot in muscle sampled from the same mouse as bioenergetics.  
Mitochondrial Calcium Retention Capacity  
This assay is partially adapted from methods previously described [249]. Mitochondrial calcium 
retention capacity measurements were completed spectrofluorometrically (QuantaMaster 80, 
HORIBA Scientific, Edison, NJ, USA) in a cuvette with continuous stirring at 37° C, in 300 µL 
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of Buffer Y containing 1 µM Calcium Green-5N (Invitrogen), 2 µM tharpsigargin, 5 mM 2-
deoxyglucose, 2 U/mL hexokinase, 20mM creatine, 5 µM BLEB and 40 µM EGTA. Prior to the 
initiation of each experiment, the cuvette was placed on a stir plate with 500 µl water and 10 mM 
EGTA. The water was then aspirated from the cuvette but not rinsed, leaving the EGTA coating 
on the cuvette walls to chelate any residual Ca2+ in the assay buffer. Minimum fluorescence was 
obtained following the addition of the PmFB and 5 mM glutamate + 2 mM malate to the assay 
buffer. Calcium uptake was then initiated by a single 8 nmol pulse of CaCl2. Subsequent 4 nmol 
pulses of Ca2+ were added until mitochondrial permeability transition pore (PTP) opening was 
evident. Two 0.5 mM pulses of Ca2+ were then added to saturate the fluorophore and establish a 
fluorescent maximum. All experiments were conducted at 37 °C. Changes in free Ca2+ in the 
cuvette during mitochondrial Ca2+ uptake were then calculated using the known Kd for Calcium 
Green 5-N and the equations established for calculating free ion concentrations using ion-sensitive 
fluorophores [250]. After the experiments, the fibres were rinsed in double deionized H2O, 
lyophilized in a freeze-dryer (Labconco, Kansas City, MO, USA) for >4 h and weighed on a 
microbalance (Sartorius Cubis Microbalance, Gottingen, Germany). 
In Vitro Muscle and Blood Analyses 
Caspase Activity 
Enzymatic activities of caspase 3 and caspase 9 were measured fluorometrically using substrates 
Ac-DVED-AMC and Ac-LEHD-AMC (Enzo Life Sciences, Farmingdale, NY) as previously 
described [251, 252]. 
Transmission Electron Microscopy (TEM) 
Fresh plantaris tissue was immediately fixed in 2% (v/v) glutaraldehyde in 0.1 mol/l sodium 
cacodylate buffer and processed as described previously [253]. Eight representative micrographs 
from a unique fiber containing a portion of the subsarcolemmal region adjacent to the nucleus with 
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most of the image containing the intermyofibrillar area were acquired at x15000 magnification. 
Quantification was achieved using the Nikon Elements software by manually outlining 
mitochondria and converting these to actual size using a calibration grid [254]. 
Glutathione 
Glutathione was assessed as previously described [255]. GSH was assessed by UV-HPLC 
monitoring of NEM-GSH while GSSG was assessed by fluorescent-HPLC by tracking O-
pthalymide (OPA, Sigma-Aldrich, Oakville, Canada) tagged GSH through a flow-through cuvette 
following GSSG conversion to GSH (FireflySci 8830, NY, USA) in a QuantaMaster 40 
spectrofluorometer (HORIBA, NJ, USA). All values were referenced to protein concentration and 
reported in µmol/g protein. USA).  
Western Blotting 
An aliquot of frozen Quad, WG and Diaphragm (10–30 mg) from each animal was homogenized 
in a plastic microcentrifuge tube with a tapered teflon pestle in ice-cold buffer containing (mm): 
40 Hepes, 120 NaCl, 1 EDTA, 10 NaHP2O7·10H2O pyrophosphate, 10 β-glycerophosphate, 10 
NaF and 0.3% CHAPS detergent (pH 7.1 adjusted using KOH). Protein concentrations were 
determined using a BCA assay (Life Technologies, Carlsbad, CA, USA). Fifty µg of denatured 
and reduced protein was subjected to 6–12% gradient SDS-PAGE followed by transfer to low-
fluorescence polyvinylidene difluoride membrane. Membranes were blocked with LI-COR 
Odyssey Blocking Buffer (LI-COR, Lincoln NE, USA) and immunoblotted overnight (4°C) with 
antibodies specific for each protein. A commercially available monoclonal antibody was used to 
detect electron transport chain proteins (human OXPHOS Cocktail, ab110411; Abcam, 
Cambridge, UK, 1:250 dilution), including V-ATP5A (55 kDa), III-UQCRC2 (48 kDa), IV-
MTCO1 (40 kDa), II-SDHB (30 kDa) and I-NDUFB8 (20 kDa). Commercially available 
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polyclonal antibodies were used to detect voltage dependent anion carrier 2 (VDAC 2) (32059, 
32 kDa; Santa-Cruz, 1:1000), adenine nucleotide translocase 1 (ANT 1) (ab180715, 33 kDa; 
Abcam, 1:1000), citrate synthase (ab96600; Abcam, 1:3000), MnSOD (ab13534; Abcam, 1:2000), 
4-hydroxynoneonal (4-HNE) (ab46545; Abcam, 1:1000) and sarcomeric s-mtCK (Dr Uwe 
Schlattner, Grenoble, France; 42 kDa, 1:1000). The mtCK antibody has been validated previously 
to confirm specificity[256]. Protein carbonylation was detected using the OxyBlot Protein 
Oxidation Detection Kit (Millipore Sigma, Burlington, MA, USA). 
After overnight incubation in primary antibodies, membranes were washed three times, for 
5 minutes each time, in TBST and incubated for 1 hour at room temperature with the corresponding 
infrared fluorescent secondary antibody (LI-COR). Immunoreactive proteins were detected by 
infrared imaging (LI-COR CLx; LI-COR) and quantified by densitometry 
(ImageJ, http://imagej.nih.gov/ij/). All images were normalized to a whole membrane Amido 
Black total protein stain (A8181, Sigma, St Louis, MO, USA). A double band was detected at 
33 kDa for ANT 1 in skeletal muscle. Similar results were achieved when analyzing either band. 
As such, the bottom band closer to 33kDa has been reported.  
Histochemistry 
Immediately after removal from the animal, Quad and WG muscles were embedded in O.C.T 
compound (Tissue Tek), frozen in liquid nitrogen-cooled isopentane and stored at -80°C until 
analysis. Haematoxylin and eosin (H&E) staining was performed on hind-limb muscle sections 
(8 µm thickness) to determine average cross-sectional area (CSA) and the area of necrotic muscle 
fibres (i.e. fibres with fragmented sarcoplasm and/or areas of inflammatory cells). Three images 
spaced evenly throughout the muscle were used for analysis, and a total of 100 fibres per Quad 
and 100 fibres per WG were counted (n=3 per group). Necrotic area was expressed as a percentage 
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of the whole muscle section. To determine fibrotic area, skeletal muscle sections were stained with 
Masson’s Trichrome (fibrotic regions stain blue for collagen), and expressed as a percentage of 
the whole muscle section. Quad and WG sections were imaged Nikon 90i-eclipse microscope 
(Nikon Inc.; Melville, NY) and analyzed with the NIS Elements AR software (v 4.6; Nikon). 
For the Diaphragm, a piece attached to the rib cage was immediately placed in 10% neutral 
buffered formalin for 72 hours. After 72 hours, the Diaphragm was placed in 70% ethanol where 
it was preserved until processing using routine procedures. Processed Diaphragm was embedded 
in paraffin wax (Thermo Fisher Scientific, Burlington, Canada) prior to sectioning (5 µm 
thickness). Diaphragm sections were stained with H&E to measure CSA and necrotic area, and 
picrosirius red to measure fibrotic area (fibrotic regions stain red for collagen). Two to five images 
(4 on average) were used for Diaphragm analyses, and 200-250 fibres were used to determine CSA 
(n=7 per group). Diaphragm sections were imaged using an Olympus FSX100 light microscope 
(Olympus), Richmond Hill, Canada) and analyzed in cellSens software (Olympus) for necrosis 
and fibrosis analysis, or ImageJ (http://imagej.nih.gov/ij/) for CSA analysis. 
Statistics 
Results are expressed as means ± SEM. The level of significance was established as p<0.05 for all 
statistics. The D’Agostino – Pearson omnibus normality test was first performed to determine 
whether data resembled a Gaussian distribution. Given all data passed normality, parametric tests 
were then performed. For all data excluding state III respiration, state III mH2O2 emission and 
torque-frequency data, statistical differences were analyzed using unpaired t-tests between WT 
and DMD groups, within a given muscle where applicable. State III respiration, mH2O2 emission 
and torque-frequency curves were analysed within a given muscle (where applicable) using a 2-
 
 
77 
way ANOVA with a main effect for group being reported (GraphPad Prism Software, La Jolla, 
CA, USA).  
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Results 
Early onset of muscle wasting and weakness in D2.mdx mice 
Body weight was 20% lower in D2.mdx mice (p<0.05, Figure 1a).  Diaphragm fibre CSA was 
30% lower in D2.mdx which demonstrates muscle atrophy at this young age. (p<0.05, Figure 1c). 
In contrast, D2.mdx Quad CSA was increased by 42% (p<0.05, Figure 1c) while WG CSA was 
not different between groups (Figure 1c) despite a 15% reduction in lower limb muscle volume 
(p=0.07, Figure 1b) suggesting other lower limb muscles may have been atrophied. Serum 
creatine kinase activity was evaluated as a marker of net muscle damage with activity elevated by 
392% in D2.mdx mice (p<0.05, Figure 1d).    
In conjunction with muscle wasting, muscle weakness was also evaluated through several 
approaches. Four week old D2.mdx mice demonstrated reduced 24-hour voluntary wheel running 
(-98%, p<0.05, Figure 1e), cage hang time (-53%, p<0.05, Figure 1f) and forelimb grip strength 
(-32%, p<0.05, Figure 1g). Given the voluntary nature of these in vivo assays and the potential for 
neurological contributions to performance, muscle-specific measurements of force production 
were also performed. In vivo force production in the hind-limb plantarflexors revealed a main 
effect for decreases in D2.mdx torque production as a function of frequency (p<0.05, Figure 1h) 
as well as a 13% decrease in maximum isometric torque (p<0.05, Figure 1i) compared to WT. 
Diaphragm force production, measured through maximal inspiratory pressures produced during 
tracheal occlusion, revealed significant decreases in D2.mdx pressures from 15-30 seconds of 
tracheal occlusion (p<0.05) but there were no differences at the earlier time points (0-10 seconds) 
of the occlusion protocol (Figure 1j).  
 
 
79 
 
Figure 4-1: Evaluation of muscle wasting and weakness in DMD. Body weight (a, n=8-10), 
microCT analysis of lower limb muscle volume (b, n=6-7) and muscle-specific cross-sectional 
area (CSA) using wheat germ stain for Diaphragm (n=6) and H&E for Quad (n=3) and WG (n=3) 
(c). Whole body muscle damage was quantified by serum creatine kinase (CK) activity (d, n=5-7).  
Indices of muscle function were assessed by 24-hour voluntary wheel running (e, n=13-14), cage 
hang time (f, n=10-11) and forelimb grip strength (g, n=9-11). Lower hindlimb force production 
was assessed in vivo using through torque-frequency relationship (h) followed by a max-torque 
challenge (i, n=5-6). Respiratory function in vivo was assessed through esophageal pressure 
transduction to determine maximal inspiratory pressure (PIocc) (j, n=7). Results represent mean ± 
SEM;  # p<0.05 main effect compared to WT; * p<0.05 compared to WT. 
Elevated Complex I induced mH2O2 during oxidative phosphorylation in D2.mdx mice 
We first determined whether the central role of ADP in stimulating respiration and attenuating 
H2O2 emission was altered. Complex I-supported respiration and H2O2 emission was stimulated 
with NADH generated by pyruvate (5mM) and malate (2mM) in the presence of low/physiological 
(25µM), high sub-maximal (500µM) and saturating concentrations (5mM) of ADP. This titration 
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was repeated with (+Cr) and without (-Cr) 20mM creatine to drive energy transfer dependent or 
independent of mtCK, respectively (as depicted in Figure 2).  
 
Figure 4-2: Schematic representation of energy transfer between mitochondria and cytosol. 
The leading model for energy exchange involves a creatine-independent (-Cr) and creatine- 
dependent (+Cr) pathway. The left side depicts the –Cr pathway whereby ADP/ATP transfer 
occurs solely through diffusion across voltage dependent anion carrier (VDAC) on the outer 
mitochondrial membrane and adenosine nucleotide translocase (ANT) on the inner mitochondrial 
membrane. The right side depicts the +Cr pathway where, in the presence of Cr, energy transfer is 
facilitated by mitochondrial creatine kinase (mtCK) through the transfer of the phosphate group 
from ATP to Cr, producing phosphocreatine (PCr) and ADP in the inner membrane space. The 
PCr is exported via VDAC into the cytosol while the ADP is directly recycled back via ANT into 
the mitochondrial matrix. Figure adapted from Aliev et al., 2011, Guzun et al., 2012, Myer et al., 
1984 and Wallimann et al., 2011 [146, 150, 147, 157]. 
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In both -Cr and +Cr, ADP-stimulated respiration was decreased at various ADP concentrations in 
Diaphragm (-12 to -46%), Quad (-47 to -72%) and WG (-27 to -53%) in DMD vs WT (p<0.05, 
Figure 3). Similar impairments in respiration were seen when mtCK flux was maintained by both 
PCr and Cr (Supplemental Figure 2). mH2O2 was elevated during oxidative phosphorylation in 
both –Cr and +Cr across low and high [ADP] in DMD Diaphragm (+17 to 88%, p<0.05), Quad 
and (+19 to 197%, p<0.05) and WG (+18 to +74%, p<0.05) vs WT (Figure 4). 
We also determined the capacity for Complex I-supported H2O2 emission in the absence of ADP. 
This test promotes maximal electron slip and oxidant generation at Complex I given ADP is not 
present to attenuate membrane potential and promote forward electron flux. As such, the test 
reveals the capacity of oxidant generation by Complex I independent of the influence of ADP 
(State II). Respiration is driven by proton leak through uncoupling pathways independent of ATP 
synthase. Proton leak-dependent respiration trended lower in D2.mdx Diaphragm (-31%, p=0.06), 
and was significantly lower in D2.mdx Quad (-58%, p<0.05) and WG (-39%, p<0.05) vs WT 
(Supplemental Figure 3a). Concurrent pyruvate/malate-supported H2O2 in the absence of ADP 
was unchanged in Diaphragm, elevated by 110% in Quad (p<0.05) and tended to be higher in WG 
(+47%, p=0.09) vs WT (Supplemental Figure 3b).  
We then determined the degree to which other pathways support mH2O2. Complex III (2.5µM 
Antimycin A) and pyruvate dehydrogenase-supported mH2O2 (10mM pyruvate, 0.5µM Rotenone 
to inhibit Complex I) were decreased in the Quad (-53%, p=0.05) and WG (-60%, p<0.05), while 
the Diaphragm showed a trend for increased Complex III mH2O2 (+35%, p=0.11) and no 
differences in pyruvate dehydrogenase-supported mH2O2 between D2.mdx and WT 
(Supplemental Figure 4a and 4b). Normalizing mH2O2 to Complex III subunit content 
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(Supplemental Figure 4c) or pyruvate dehydrogenase E1α content (Supplemental Figure 4d) 
altered rates such that no differences existed in mH2O2 in any muscle vs WT.  
 
Figure 4-3: Complex I-supported respiration in DMD. State III respiration, supported by 
Complex-I substrates pyruvate (5mM) and malate (2mM), was assessed in the absence (Creatine 
Independent) and presence (Creatine Dependent) of 20mM creatine at physiological (25µM), sub-
maximal (500µM) and maximal (5000µM) [ADP]. Assessments of bioenergetic function were 
completed in Diaphragm (a-b), Quad (c-d) and WG (e-f) muscles. Results represent means ± SEM; 
n=8-14; * p<0.05 compared to WT.  
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Figure 4-4: mH2O2 emission during oxidative phosphorylation in DMD. State III mH2O2, 
supported by Complex-I substrates pyruvate (5mM) and malate (2mM), was assessed in the 
absence (Creatine Independent) and presence (Creatine Dependent) of creatine at physiological 
(25µM), sub-maximal (500µM) and maximal (5000µM) [ADP]. Assessments of bioenergetic 
function were completed in Diaphragm (a-b), Quad (c-d) and WG (e-f) muscles. Results represent 
means ± SEM; n=8-14; * p<0.05 compared to WT. 
Impaired creatine sensitivity in oxidative D2.mdx muscle 
Given impaired bioenergetics were seen in both creatine-independent and creatine-dependent 
models of phosphate shuttling, we also compared whether creatine insensitivity existed in D2.mdx 
to gain insight on the role of mtCK in this disease. As seen in Table 1, at 500µM ADP, creatine 
tended to increase respiration in both Diaphragm (+43%, p=0.06) and Quad (+57%, p=0.08), and 
decreased mH2O2 (Diaphragm: -37%, p<0.05; Quad: -56%, p<0.01) in WT consistent with its 
proposed role in facilitating phosphate shuttling (Figure 2). In contrast, +Cr had no effect on 
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respiration at 500µM in any D2.mdx muscle vs -Cr or on mH2O2 in Quad or WG, although it 
lowered mH2O2 in D2.mdx Diaphragm (-42%, p<0.05; Table 1) suggesting mtCK and phosphate 
shuttling are impaired in DMD in addition to loss of control by ADP (Figure 2). 
Table 4-1: Impairment in creatine sensitivity with 500µM ADP in DMD  
  
  
JO2 (pmol⋅sec-1⋅mg-1 wet wt) 
Wildtype   D2.mdx   
-Cr +Cr 
P Value  
(-Cr vs 
+Cr) -Cr +Cr 
P Value  
(-Cr vs 
+Cr) 
            
Diaphragm 67.2 ± 5.2 95.8 ± 10.2 P<0.05 57.6 ± 7.2 63.7 ± 6.4 P=0.94 
Quad 21.2 ± 2.2 33.2 ± 5.5 P=0.07 12.7 ± 2.1 12.9 ± 2.2 P=0.53 
WG 28.7 ± 3.5 28.1 ± 4.4 P=0.94 18.9 ± 3.0 16.7 ± 1.1 P=0.53 
mH2O2/O2 Consumed  
Diaphragm 0.73 ± 0.06 0.53 ± 0.07 P<0.05 1.25 ± 0.21 0.72 ± 0.10 P<0.05 
Quad 1.19 ± 0.11 0.52 ± 0.05 P<0.01 1.76 ± 0.26 1.54 ± 0.40 P=0.64 
WG 1.09 ± 0.19 0.72 ± 0.10 P=0.16 1.46 ± 0.28 1.11 ± 0.25 P=0.37 
Creatine Dependent (+Cr), Creatine Independent (-Cr), Quadriceps (Quad), White Gastrocnemius (WG).  
Values represent mean ± SEM, (n=8-14). 
 
Increased susceptibility to PTP opening and elevations in mitochondria-derived apoptosis in 
D2.mdx Quad 
Previous work has shown that calcium-overload leads to PTP opening more rapidly in DMD 
Diaphragm and Tibialis Anterior muscle from C57bl/10-mdx mice[35, 33]. We next determined 
whether reduced calcium retention capacity was related to the elevated mH2O2 during oxidative 
phosphorylation seen in the D2.mdx mice (Figure 5a,b). D2.mdx Diaphragm and WG muscle 
showed no differences in the [Ca2+] required to induce PTP opening vs WT (Figure 5b) whereas 
Quad required 62% less [Ca2+] vs WT (p<0.05, Figure 5b). Caspase 9 activity was also elevated 
in Quad (+25%, p<0.05) suggesting the reduced calcium retention capacity is related to 
mitochondrial-induced apoptosis in this muscle unlike WG (Figure 5c). Interestingly, despite no 
differences in calcium retention capacity, caspase 9 activity tended to be elevated in D2.mdx 
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Diaphragm (+43%, p=0.08; Figure 5c). These elevations in caspase 9 did not result in activation 
of its downstream target, caspase 3, in any muscle (Figure 5d).  
Given the decrease in D2.mdx Quad calcium retention capacity and subsequent increase in 
mitochondria-derived apoptotic signalling, further analysis of mitochondria structure and 
morphology was performed. Due to tissue limitations, the plantaris muscle, which displays a 
similar fibre type composition to the vastus intermedius component of the Quad used for calcium 
retention capacity [236], was used for TEM analysis. D2.mdx plantaris muscle was found to 
contain swollen mitochondria (Figure 5e), regardless of the mitochondrial location 
(subsarcolemmal vs intermyofibrillar). D2.mdx plantaris muscle also contained less mitochondria 
per unit area (Figure 5f) but due to their larger size, no differences in mitochondria density was 
evident (Figure 5g).
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Figure 4-5: Evaluation of mitochondrial calcium retention capacity, content and disbursement.  Calcium retention capacity, an 
index of susceptibility to permeability transition pore opening (a), was assessed in permeabilized fibres from Diaphragm, Quad and WG 
muscle (b); n=6-8. Mitochondrial-induction of apoptosis was evaluated through caspase 9 activity (c) followed by it’s down-stream 
target caspase 3 (d); n=7. Transmission electron micrographs were acquired in the plantaris muscle and analyzed for mitochondrial size 
(e, mean area, µm2), distribution (f, # per µm2) and density (g, µm2 x # per µm2 x 100) within the subsarcolemmal (SS) area and 
intermyofibrillar (IMF) area of the muscle. Representative images (h) demonstrate the large accumulation of swollen mitochondria (*) 
in DMD animals relative to the normal conformation of WT mitochondria (M); scale bar = 1 µm, n=2-3. Results represent mean ± SEM; 
* p<0.05 compared to WT.
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Increased redox buffering with no change in markers of cellular oxidative stress in D2.mdx 
mice  
Content of the reduced form of glutathione (GSH) content was increased in D2.mdx Quad (+55%, 
p<0.05) and WG (+38%, p<0.05), and tended to be higher in Diaphragm (+8%, p=0.09), indicative 
of a compensatory increase in redox buffering (Figure 6a) consistent with increased mH2O2 noted 
earlier. WG muscle demonstrated elevated levels of oxidized glutathione (GSSG) content (+50%, 
p<0.05) relative to WT, while no differences were found in Quad or Diaphragm (Figure 6b). 
However, total glutathione (GSH + 2xGSSG) was elevated or tended to be elevated in all muscles 
(Diaphragm: +8%, p=0.09; Quad: +54%, p<0.05; WG: +38%, p<0.05; Figure 6c) predominately 
due to increases in reduced GSH content. Importantly, the ratio of GSH:GSSG was unchanged in 
all muscles, suggesting the elevated mH2O2 was buffered to prevent cellular oxidation at this early 
time point (Figure 6d). Indeed, western blotting for lipid peroxidation (Figure 6e) and protein 
carbonylation (Figure 6f), indicators of whole cell oxidative stress, revealed no differences 
between D2.mdx and WT muscle. Mitochondrial matrix MnSOD was lower in Quad (-29%, 
p<0.05) and WG (-22%, p<0.05) with no change in diaphragm being observed (Figure 6g).
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Figure 4-6: Evaluation of redox buffering capacity and whole cell oxidative status. Glutathione was measured in muscle homogenate 
using HPLC-UV for the detection of GSH (a) and HPLC-Fluorescence for the detection of GSSG (b). The GSH:GSSG ratio (c) and 
total glutathione (d) were calculated from GSH and GSSG measurements; n=6. Whole muscle lysate was used for the quantification of 
proteins modified through lipid peroxidation (e) and carbonylation (f) as well as the quantification of protein content of MnSOD (g); 
n=6-8. Results represent mean ± SEM; * p<0.05 compared to WT
 
 
90 
Muscle-specific alterations in key regulators of energy shuttling 
Given the alterations in state III respiration and mH2O2 in D2.mdx muscle, we next quantified key 
regulators of energy shuttling. ANT 1 and VDAC 2, situated in the inner and outer mitochondrial 
membranes respectively (Figure 2), were unchanged in Diaphragm muscle but were significantly 
decreased in D2.mdx Quad (ANT 1: -48%, p<0.05; VDAC 2: -33%, p<0.05) and WG (ANT 1: -
53%, p<0.05; VDAC 2: -36%, p<0.05) relative to WT (Figure 7a and 7b). Similarly, mtCK 
content was unchanged in Diaphragm but significantly lower in D2.mdx Quad (-45%, p<0.05) and 
WG (-38%, p<0.05; Figure 7c). Citrate synthase protein content was reduced in Quad only (-23%, 
p<0.05; Figure 7d). Normalizing respiration to citrate synthase content (Supplemental Figure 5) 
as validated previously [257] generally did not explain the changes in respiration observed when 
normalized per mg weight seen in Figure 3. Quantification of the complexes comprising the ETC 
was also completed to provide an index of ETC content. ETC subunit contents were unchanged 
relative to WT in both Diaphragm (Figure 7e) and WG (Figure 7g) muscle apart from a decrease 
in Complex II subunit content in D2.mdx Diaphragm (-15%, p=0.06, Figure 7e). However, Quad 
demonstrated decreases or trends for decreases in subunit content of Complex I (-38%, p<0.05), II 
(-36%, p=0.08), III (-34%, p<0.05), IV (-55%, p<0.05) and V (-19%, p=0.09) as well as the sum 
of all 5 complex subunits (-37%, p<0.05) (Figure 7f). 
Bioenergetic impairments are associated with elevations in muscle damage in D2.mdx muscle 
Muscle specific membrane damage was evaluated though Evans Blue Dye staining in a separate 
subset of animals. 16 hours post injection of 1% Evans Blue Dye, animals were sacrificed, and 
muscle was visually inspected for dye uptake. Dye uptake, which occurs in muscles with damaged 
cell membranes[55], was evident in the Quad, WG and tricep brachii muscles with minimal uptake 
occurring in the soleus, plantaris, extensor digitorum longus and the tibialis anterior. A striated 
pattern of dye uptake was evident in the Diaphragm muscle (Supplemental Figure 1).  
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Necrotic area was elevated in Diaphragm (5.5% vs 0% of total area vs WT, p<0.05; Figure 8a), 
Quad (31.8% vs 0.6%, p<0.05; Figure 8b), and WG (48.2% vs 0.2%, p=0.06; Figure 8c). Fibrotic 
area was also elevated in Diaphragm (12.7% vs 8.4% of total area vs WT, p<0.05; Figure 8d), 
Quad: 17.0% vs 6.3%, p<0.05; Figure 8e) and WG: 22.0% vs 3.5%, p<0.05; Figure 8f). 
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Figure 4-7: Muscle-specific changes in essential regulators of bioenergetics in DMD. Protein content of adenine nucleotide 
translocase 1 (ANT 1) on the inner mitochondrial membrane (a), voltage dependent anion carrier 2 (VDAC 2) on the outer mitochondrial 
membrane (b), mitochondrial creatine kinase (mtCK) found in the inner membrane space (c) and citrate synthase which catalyses the 
first reaction in the citric acid cycle (d). Protein content of electron transport chain components were also quantified in Diaphragm (e), 
Quad (f) and WG (g). Results represent mean ± SEM; n=8-12; * p<0.05 compared to WT
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Figure 4-8: Quantification of muscle damage in DMD. Necrosis was evaluated in Diaphragm 
(a), Quad (b) and WG (c) using haemotoxylin and eosin (H&E) staining in all muscles. Fibrosis 
was evaluated in Diaphragm (d) using picrosirius red and in Quad (e) and WG (f) using Masson’s 
trichrome. Results represent mean ± SEM; n=3-6; * p<0.05 compared to WT. Representative 
images of Diaphragm (g, magnification, 40x), Quad (h, magnification, 20x) and WG (i, 
magnification, 20x). 
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Figure 4-9: Summary of the relationship between impaired mitochondrial bioenergetics and 
myopathy in DMD. Specific dysfunctions in Complex I and central respiratory control by ADP 
and creatine cause elevated oxidant generation during impaired oxidative phosphorylation in DMD 
in association with a loss of muscle force.     
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Discussion 
Oxidative stress has long been implicated as a contributor to the myopathy of Duchenne muscular 
dystrophy. However, identifying the precise source of elevated oxidants has remained 
controversial. In this study, we demonstrate that mH2O2 is elevated concurrent with impaired 
oxidative phosphorylation specific to Complex I-supported respiration. An impairment in the 
ability of ADP to both stimulate respiration and attenuate mH2O2 was central to these impairments. 
These bioenergetic deficits occurred early in the disease process (4 weeks of age) and were 
associated with severe myopathy in skeletal muscles and Diaphragm. By identifying a potential 
new relationship between elevated mH2O2, impaired oxidative phosphorylation and myopathy in 
Diaphragm (respiratory) and limb muscle (locomotor; see summary Figure 9), these findings 
suggest that DMD may be a candidate for therapeutics that attenuate mH2O2 [258] and improve 
mitochondrial respiratory control. 
Several factors warranted a re-evaluation of mH2O2 in DMD. First, an elegant study by Godin et 
al [33] demonstrated an unexpected decrease in mH2O2 in the tibialis anterior of the classic 
C57bl/10-mdx mouse, but this occurred concurrently with increased redox buffering capacity 
suggesting compensation occurred in response to an underlying redox stress [33]. Furthermore, 
the degree of mitochondrial dysfunction may differ across muscles in relation to the extent of 
myopathy which warrants comparisons of muscle types, particularly given the known regenerative 
capacities of the classic C57bl/10-mdx model [51, 52]. The design of in vitro protocols to measure 
mitochondrial respiration and mH2O2 must also be considered given 1) ADP governs both 
processes concurrently, 2) disease-related stressors may alter sensitivity to low ADP 
concentrations to a different extent than saturating conditions, 3) mitochondrial-cytosolic energy 
exchange is thought to occur through either direct ADP/ATP cycling or Cr/PCr shuttling via mtCK, 
and 4) there are multiple sources of oxidant generation that contribute to net mH2O2. By controlling 
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for these factors, a general pattern of impaired Complex I activity, creatine insensitivity and ADP 
insensitivity in the regulation of mH2O2 and respiration was identified in both dystrophic 
respiratory and locomotor muscles. 
Concurrent impairments in Complex I and governance by ADP  
At 4 weeks of age, D2.mdx Diaphragm, Quad and WG muscle exhibit elevated Complex I-
supported mH2O2 during oxidative phosphorylation. This pattern appeared to be due to several 
factors. First, the maximal rate of mH2O2 supported by Complex I was increased as seen in the 
absence of ADP’s influence on membrane potential (State II conditions). The impairments at 
Complex I were not explained by altered protein content of the NDUFB8 subunit. This suggests 
post-translational modifications may have occurred. Indeed, Complex I activity can be decreased 
by oxidation of specific cysteine residues [259] but the degree to which this occurs in DMD 
remains to be determined. Also, while superoxide production prior to dismutation to H2O2 was not 
assessed, the increases in H2O2 emission during respiration are suggestive of increased superoxide 
production particularly given MnSOD was lower in Quad and WG. It is also possible that the lower 
leak respiration in the absence of ADP reflects less uncoupling, which may contribute to elevated 
membrane potential-dependent Complex I superoxide production [232].  
Furthermore, low/physiological to high concentrations of ADP were unable to attenuate mH2O2 to 
the same extent as WT. The impaired control by ADP in skeletal muscle may not be related to 
changes in mitochondrial content given ETC markers were unchanged in Diaphragm and WG 
similar to what has been reported recently in C57bl/10-mdx mouse soleus and extensor digitorum 
longus [260]. Rather, this may be explained partially by limited ADP/ATP exchange due to 
decreased protein expression of VDAC 2 and ANT 1 in Quad and WG, or octameric mtCK, the 
regulator of high energy phosphate shuttling. There was no change in the content of these proteins 
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in Diaphragm which suggests that post-translational regulation of these proteins may have been 
altered. Indeed, all three proteins are redox sensitive [261-263]. ANT and VDAC also have known 
phosphorylation sites [264, 265] although the physiological relevance of this regulatory paradigm 
remains unknown. Furthermore, mtCK is highly susceptible to oxidative modifications, leading to 
enzymatic inactivation and octamer dissociation, as well as formation of crystalline mitochondrial 
inclusion bodies, all resulting in loss of function [153, 152]. The present findings suggest future 
examination of post-translational regulation of Complex I, isoforms of ANT 1 and VDAC 2, as 
well as mtCK may reveal how multiple cellular stressors in DMD lead to the observed 
mitochondrial dysfunctions. Lastly, while no other site of mitochondrial oxidant generation tested 
in this investigation demonstrated altered mH2O2 (reverse electron flux from complex II, complex 
III and pyruvate dehydrogenase), additional sites could be considered in future investigations at 
this early age [266, 267].  
To our knowledge, this is the first study to demonstrate impairments in ADP-stimulated respiration 
at both low and maximal kinetics in D2.mdx Diaphragm muscle. The respiratory impairments in 
Quad and WG are consistent with previous reports in humans [29, 30] and C57bl/10-mdx skeletal 
muscle [30, 33, 231, 268]. However, the role of creatine-dependent phosphate shuttling through 
mtCK was not assessed which means these earlier studies only report impairments in creatine-
independent ADP/ATP cycling similar to the present findings, albeit with one exception that also 
reported impaired creatine sensitivity in oxidative muscles [201]. Given the creatine-dependent 
model is predicted to be the dominant system of energy exchange [157], the lack of effect of 
creatine on respiration in DMD may be particularly detrimental to muscle function, in particular, 
at high workloads with repeated contractions (Table 1). As noted above, changes in ANT 1, VDAC 
2 and mtCK might contribute to this loss of control by ADP in Quad and WG but alternative 
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mechanisms are likely for Diaphragm, further highlighting the importance of considering post–
translational modifications.  
Possible relationships between mitochondrial bioenergetics and myopathy in DMD 
Mitochondrial induction of apoptosis and necrosis has been linked to several diseases that also 
exhibit elevated mitochondrial ROS and impaired oxidative phosphorylation [269, 270, 226, 271-
273]. It is thought that impairments in both processes can contribute to the induction of PTP 
formation as can occur under conditions of calcium overload [274]. Such PTP formation has 
already been implicated in DMD myopathy in response to calcium stress [33, 35]. However, the 
synergistic link with mH2O2 had not been demonstrated. Indeed, an increase in mitochondrial 
[Ca2+] alone is relatively ineffective at inducing PTP formation, but mitochondrial sensitivity to 
[Ca2+] can be drastically increased through elevated ROS [172]. Furthermore, the increases in 
caspase 9 seen in Quad are consistent with previous reports of greater cytochrome c release in 
dystrophic muscle [275] – a process that is known to be triggered in part by mitochondrial ROS 
during induction of the PTP [276]. Overall, the present findings suggest that elevated mH2O2 
contributes to this calcium-overload induction of PTP in Quad but not necessarily in Diaphragm 
or WG at this early stage of the disease (Figure 4). Surprisingly, Quad displayed hypertrophy based 
on fibre cross sectional area which may be compensation to caspase 9-mediated cell death. Indeed, 
this early hypertrophy is consistent with observations in Quad of young boys with DMD that was 
later followed by atrophy in advanced stages of the disease  [67].  
In contrast to the present study, previous work has shown heightened sensitivity to Ca2+-induced 
PTP in Diaphragm in C57bl/10-mdx mice. Methodological differences may contribute to these 
divergent findings as previous studies have produced divergent results depending on whether PTP 
opening was assessed in terms of elapsed time in response to a single bolus of Ca2+ [35] or 
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identifying the minimal concentration required to trigger PTP as in the present study [33, 35]. 
These discrepant findings suggest the approach used to determine PTP sensitivity to Ca2+ can 
change the conclusion, and that comparison to other proxies of PTP are warranted.  
It is possible that calcium-independent modulators of mitochondrial dysfunction and induction of 
cell death are present in DMD. While not assessed in this study, mH2O2 also activates necrosis in 
a PTP-independent manner by activating nuclear factor-kappa B (NF-kB) [137] and up-regulating 
the pro-inflammatory cytokine tumour necrosis factor-alpha (TNF-a) [277, 181]. Indeed, 
antioxidants that lower mH2O2 have been shown to prevent muscle wasting in a TNF-a induced 
model of cachexia [278], and an anti-TNF-a antibody (Remicade) reduces muscle necrosis and 
inflammation in C57bl/10-mdx mice [141]. Further examination of alternative mechanisms by 
which impaired mitochondrial bioenergetics contributes to cell death in DMD may be fruitful 
considering the necrosis observed in the present study (Diaphragm, WG, Quad) was not 
consistently linked to a calcium-induction of PTP, particularly in Diaphragm which displayed 
atrophy without caspase 9 activation.  
Perspectives on redox homeostasis in DMD: reconciling with previous literature 
While cytoskeletal-based NADPH oxidase activity is increased in DMD skeletal muscle [130], the 
contribution of mitochondrial-specific ROS across all muscle types has received surprisingly little 
attention. To our knowledge, only one previous study has directly measured mH2O2 in DMD 
skeletal muscle. Using Tibialis Anterior muscle from 6-week old C57bl/10-mdx mice, Godin et al 
demonstrated a surprising decrease in mH2O2 [33]. This decrease appeared to be due to increases 
in mH2O2 scavenging capacity which may be related to extensive muscle regeneration at this age 
in C57bl/10-mdx mice that occurs after an earlier period of peak necrosis at 3-4 weeks [51, 52]. 
This robust increase in scavenging capacity may reflect a compensation in response to an 
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underlying elevation in mH2O2. As such, we re-evaluated the relationship between mH2O2 and 
myopathy in a model with less regenerative capacity [59, 60] and in muscles displaying membrane 
damage (Supplemental Figure 1). While a direct comparison of mitochondrial bioenergetics in 
muscles with and without damaged cell membranes was not performed, heterogeneous rates and 
degrees of myopathy between muscles should be taken into consideration when evaluating the 
contribution of the mitochondria to DMD. It is also possible that the differences between these 
previous observations and the present investigation may be due to the age (6 weeks vs 4 weeks 
currently) or the muscle analysed (tibialis anterior previously), but this remains to be determined.   
Contrary to previous work in young C57bl/10-mdx mice which showed a more oxidized 
GSH:GSSG ratio [279, 21], the present investigation revealed no changes in the glutathione ratio 
in all muscles analyzed. Despite the differences in mH2O2 emission rates, both the present study 
and the work by Godin et al., demonstrate increases in redox buffering capacity. Similarly, in 
accordance with previous findings [21, 33], no differences in lipid peroxidation were detected 
through 4-HNE or protein carbonylation levels between WT and DMD muscles. These results 
suggest that the increases in buffering capacity are sufficient to tolerate the stress created by 
elevated mH2O2 and prevent detectable oxidative damage from occurring at this early time point. 
However, it is plausible that the buffering capacity of the cell will become overwhelmed and result 
in oxidative damage as the disease progresses. Furthermore, 4-HNE and carbonylation are 
measures of irreversible oxidative damage and therefore, the present investigation does not rule 
out H2O2 acting as a reversible redox signal within the cell. Future investigation into the time-
course of redox stress in the context of both reversible and irreversible modifications in this 
D2.mdx model of DMD are warranted.  
Conclusions 
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In summary, this investigation identified elevations in Complex I-supported mH2O2 during 
oxidative phosphorylation concurrent with impaired ADP and creatine control of respiration in 
DMD Diaphragm, Quad and WG muscle. These impairments were associated with a greater 
propensity for calcium-induced PTP and caspase 9 activation in Quad but the degree to which they 
are related to apoptosis in other muscles requires further investigation. The potential association 
between these mitochondrial impairments and myopathy at an early stage of DMD may guide the 
pre-clinical testing of mitochondrial-targeted therapeutics to restore normal mH2O2 and Complex 
I-supported oxidative phosphorylation, particularly by rescuing ADP and creatine control of 
bioenergetics. While such an approach would not target the primary cause of the disease, the 
addition of mitochondrial therapies warrants consideration given existing standards of care already 
focus on treating other secondary complications of DMD in the absence of genetic therapies. 
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Supplementary Data – Included in published manuscript 
 
Supplemental Figure 4-1: Evaluation of sarcolemmal damage by Evans Blue Dye staining in 
DMD. Representative images of Evans Blue Dye staining in WT and DMD skeletal muscles 16 
hours following an injection of 1% EBD solution at 5µl/g body weight. 
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Supplemental Figure 4-2: ADP-stimulated respiration in the presence of phosphocreatine 
and creatine. 13.9mM phosphocreatine (PCr) and 9.1mM creatine (Cr) were added to the assay 
media to assess state III respiration supported by Complex-I substrates pyruvate (5mM) and malate 
(2mM) in Diaphragm (A), Quad (B) and WG (C). Results represent mean ± SEM; n=10-12; * 
p<0.05 compared to WT. 
 
 
 
Supplemental Figure 4-3: Evaluation of state II respiration and mH2O2. State II (no ADP; 
proton leak) respiration (A) and mH2O2 emission (B) were initiated using Complex-I substrates 
pyruvate (5mM) and malate (2mM) in Diaphragm, Quad and WG muscles. Results represent mean 
± SEM; n=10-12; * p<0.05 compared to WT. 
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Supplemental Figure 4-4: Additional sites of state II mH2O2 emission. Complex-III derived 
mH2O2 was assessed using Complex-III inhibitor antimycin A (2.5µM). Data was expressed per 
mg muscle weight (A) as well as normalized to Complex-III content (B). Pyruvate dehydrogenase 
complex (PDC) derived mH2O2 was assessed using pyruvate (10mM) and Complex-I inhibitor 
rotenone (0.5µM). Data was expressed per mg muscle weight (C) as well as normalized to PDH-
E1a content (D).  Results represent mean ± SEM; n=8-12; * p<0.05 compared to WT. 
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Supplemental Figure 4-5: Intrinsic Respiratory Capacity. State III respiration, supported by 
Complex-I substrates pyruvate (5mM) and malate (2mM), was assessed in the absence (Creatine 
Independent) and presence (Creatine Dependent) of 20mM creatine at physiological (25µM), sub-
maximal (500µM) and maximal (5000µM) [ADP] and normalized to citrate synthase content. 
Assessments of bioenergetic function were completed in Diaphragm (a-b), Quad (c-d) and WG (e-
f) muscles. Results represent means ± SEM; n=5-8; * p<0.05 compared to WT.
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Supplemental Data – Not Included in Published Manuscript 
 
Supplemental Figure 4-6: Absolute rates of Complex-I supported mH2O2 emission. State II 
mH2O2 was supported by Complex-I substrates Pyruvate (5mM) and Malate (2mM) in the A. 
presence (Creatine Dependent) and B. absence (Creatine Independent) of 20mM creatine. ADP’s 
attenuation of maximal mH2O2 emission (state III) was evaluated in the same creatine-dependent 
(C-E) and independent conditions (G-I). Results represent mean ± SEM; n=10-12; * p<0.05, 
compared to WT. 
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5 Impairments in left ventricular mitochondrial bioenergetics 
precede overt cardiac dysfunction and remodelling in Duchenne 
muscular dystrophy  
 
This chapter is an original published article. It is presented in its published form. 
 
Impairments in left ventricular mitochondrial bioenergetics precede overt cardiac dysfunction 
and remodelling in Duchenne muscular dystrophy. MC Hughes*, SV Ramos*, PC Turnbull, BA 
Edgett, JS Huber, N Polidovitch, U Schlattner, PH Backx, JA Simpson and CGR Perry. The 
Journal of Physiology. doi.org/10.1113/JP277306.  
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Key Points Summary  
- 98% of patients with Duchenne muscular dystrophy (DMD) develop cardiomyopathy, with 
40% developing heart failure  
- While increased propensity for mitochondrial induction of cell death has been observed in 
left ventricle, it remains unknown whether this is linked to impaired mitochondrial 
respiratory control and elevated H2O2 emission prior to the onset of cardiomyopathy  
- Classic mouse models of DMD demonstrate hyper-regeneration in skeletal muscle which 
may mask mitochondrial abnormalities. Using a model with less regenerative capacities 
that is more akin to Patients with DMD, we observed elevated left ventricular 
mitochondrial H2O2 and impaired oxidative phosphorylation in the absence of cardiac 
remodelling or overt cardiac dysfunction at 4 weeks 
- These impairments were associated with dysfunctions at Complex I, governance by ADP 
and creatine-dependent phosphate shuttling which results in a less efficient response to 
energy demands 
- Mitochondria may be a therapeutic target for the treatment of cardiomyopathy in DMD  
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Abstract 
In Duchenne muscular dystrophy (DMD), mitochondrial dysfunction is predicted as a response to 
numerous cellular stressors yet the degree and contribution of mitochondria to the onset of 
cardiomyopathy remains unknown. To resolve this uncertainty, we designed in vitro assessments 
of mitochondrial bioenergetics to model mitochondrial control parameters that influence cardiac 
function. Both left ventricular mitochondrial responsiveness to the central bioenergetic controller 
ADP as well as the ability of creatine to facilitate mitochondrial-cytoplasmic phosphate shuttling 
were assessed. These measurements were performed in D2.B10-DMDmdx/2J mice – a model that 
demonstrates skeletal muscle atrophy and weakness due to limited regenerative capacities and 
cardiomyopathy more akin to people with DMD than classic models. At 4 weeks of age, there was 
no evidence of cardiac remodelling or cardiac dysfunction despite impairments in ADP-stimulated 
respiration and ADP- attenuation of H2O2 emission. These impairments were seen at both sub-
maximal and maximal ADP concentrations despite no reductions in mitochondrial content 
markers. The ability of creatine to enhance ADP’s control of mitochondrial bioenergetics was also 
impaired, suggesting an impairment in mitochondrial creatine kinase-dependent phosphate 
shuttling. Susceptibly to permeability transition pore opening and the subsequent activation of cell 
death pathways remained unchanged. Mitochondrial H2O2 emission was elevated despite no 
change in markers of irreversible oxidative damage, suggesting alternative redox signalling 
mechanisms should be explored. These findings demonstrate that selective mitochondrial 
dysfunction precedes the onset of overt cardiomyopathy in D2.mdx mice, suggesting that 
improving mitochondrial bioenergetics by restoring ADP, creatine-dependent phosphate shuttling 
and Complex I should be considered for treating Patients with DMD. 
Keywords: mitochondria, Duchenne muscular dystrophy, reactive oxygen species, respiration, 
cardiomyopathy  
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Introduction 
Duchenne muscular dystrophy (DMD) is a debilitating disease that causes progressive loss of 
skeletal and cardiac muscle fibres. Inherited mutations in the gene dystrophin located on 
chromosome Xp21 disrupts the normal function of this sarcolemmal-cytoskeletal protein in 
striated muscle. While initial clinical manifestations of DMD are related to skeletal muscle 
weakness, the development of dilated cardiomyopathy occurs progressively over time, resulting in 
heart failure and subsequent mortality in approximately 40% of patients [37, 43]. Currently, there 
are limited treatment approaches for patients with DMD and genetic-based therapies in preclinical 
models have yielded inconsistent results to date [46]. As such, there is a clear need for unravelling 
the underlying mechanisms leading to cardiomyopathy in order to identify putative therapeutic 
targets for the treatment and/or prevention of cardiomyopathy and subsequent heart failure.  
By disrupting sarcolemmal stability and cytoskeletal organization, the dystrophin mutation leads 
to a myriad of cellular stressors which have a significant impact on disease progression in DMD. 
Two identified contributors to the DMD myopathy include calcium dysregulation and oxidative 
stress [93, 82, 2]. As such, it is possible these stressors contribute to a mitochondrial dysfunction 
in DMD which may reciprocate on progression of the disease. However, direct assessments of 
mitochondrial respiratory function have found no impairments in left ventricle from 
C57BL10/ScSnmdx mice [199, 32, 30] or changes in mitochondrial H2O2 emission [199]. This is 
surprising given reductions in the activities of the redox-sensitive enzymes aconitase and NADP 
isocitrate dehydrogenase [280, 199] were reported, which suggests mitochodnrial H2O2 emission 
should be elevated consistent with the oxidative stress reported in dystrophic hearts [93, 82]. 
Furthermore, increased levels of calcium-induced permeability transition pore (PTP) opening as 
well as the activation of caspase 9/3, have been reported  at a young age prior to the onset of cardiac 
dysfunction, indicative of mitochondrial derived apoptosis [199]. As noted in an elegant review 
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by Burelle and colleagues [32], it is surprising that increased PTP susceptibility was not related to 
mitochondrial respiratory dysfunction or elevated H2O2 emission given these responses often occur 
in tandem in the presence of calcium stress [172, 173, 281, 282]. To date, this discrepancy between 
the mitochondrial PTP-cell death cascade and reports of normal mitochondrial respiration and 
H2O2 emission has not been resolved.  
Recent work by Chang and colleagues suggests the hyper-regeneration that occurs in the mdx 
mouse [51, 52, 202] masks the ability to detect early attenuations in mitochondrial bioenergetics 
in dystrophic heart [203, 204]. Indeed, shortening telomeres to a more “humanized” length, thereby 
lowering the stem cell pool, revealed an increase in mitochondrial superoxide production and 
impairments in respiration in cardiomyocytes relative to the classic mdx model [204]. These 
mitochondrial abnormalities were also related to a more severe cardiac dysfunction [203]. This 
inverse relationship between regenerative capacities and mitochondrial quality may explain why 
identifying mitochondrial dysfunction in mdx mice has been elusive given the high regenerative 
capacities demonstrated in this classic model. As such, it remains to be determined if 
mitochondrial dysfunction is observed in a model of DMD with natural reductions in regenerative 
capacity, more akin to people with DMD.  
The D2.B10-DMDmdx/2J (D2.mdx) exhibits attenuated muscle regeneration arising from a natural 
mutation in TGF-β binding protein 4 in the background D2A strain [60, 59]. In this investigation, 
we evaluated mitochondrial bioenergetics in dystrophic left ventricle (LV) muscle from the 
D2.mdx mouse relative to wildtype controls. At 4 weeks of age, D2.mdx mice exhibit increased 
Complex I-supported H2O2 concurrent with impaired respiration, revealing central impairments in 
the ability of ADP and creatine to control bioenergetics. These impairments were seen in the 
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absence of cardiac remodelling and cardiac dysfunction and before the previous reported indices 
of cardiomyopathy in this model [59].   
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Materials and Methods 
Ethical Approval  
All experiments and procedures were approved by the Animal Care Committee at York University 
(AUP Approval Number 2016-18) in accordance with the Canadian Council on Animal Care. 
Animal Care 
The 4-week old D2.mdx animals originated from a colony maintained at York University (Toronto, 
Canada) established with breeding pairs from Jackson Laboratories (Bar Harbor, United States). 
4-week old DBA/2J WT mice were obtained directly from Jackson Laboratories due to breeding 
challenges with this strain. Upon arrival, DBA/2J mice were given a minimum of 72 hours to 
acclimatize before experiments were performed. All animals were provided access to standard 
chow and water ad libitum.  
Study Design 
Immediately following weaning, D2.mdx and WT animals underwent transthoracic 
echocardiographic analysis (described in detail below) as well as the assessment of body weight. 
Animals were given minimum 2 days to equilibrate following this analysis. On the day of harvest, 
animals were maintained under isoflurane while skeletal muscles were harvested for other work 
as part of another investigation. Animals were then euthanized by exsanguination and a portion of 
the LV was immediately separated from the rest of the heart and placed in ice-cold BIOPS buffer 
(described below) for bioenergetic measurements. Remaining muscle was frozen in liquid nitrogen 
for western blotting and caspase activity measurements. Due to tissue limitation, a separate cohort 
of animals were used for glutathione and histochemical measurements.  
Animals were evaluated at 4 weeks of age to allow for the assessment of mitochondrial 
bioenergetics prior to the established onset of cardiomyopathy in this model [59].  
Echocardiography 
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All mice were subjected to transthoracic echocardiographic analysis (Vevo 2100, VisualSonics) 
to measure cardiac function and morphology 2-3 days prior to sacrifice for bioenergetic 
measurements. The animals were sedated using 3% isoflurane and maintained with 1–2% 
isoflurane. Mice were placed on a heating pad and body temperature was maintained between 36.9 
and 37.3 °C for the duration of the measurements. Left ventricular internal end diastolic diameters 
(LVDd), left ventricular internal end systolic diameters (LVDs) and left ventricular posterior wall 
thickness (LVPWTh) were measured in brightness mode (B-Mode) and motion mode (M-Mode) 
using the parasternal long axis view. Fractional shortening (FS) was calculated as FS(%) = (LVDd 
- LVDs)/LVDd x 100. Stroke volume (SV) was estimated as SV = Left ventricular diastolic 
volume (LVVol;d) - Left ventricular systolic volume (LVVol;s), where LVVol;d = ((7.0/(2.4 + 
LVDd)) x LVDd3 and LVVol;s = ((7.0/(2.4 + LVDs)) x LVDs3. Ejection fraction (EF) was 
estimated as EF = SV/LVVol;d and cardiac output (CO) was estimated as CO = SV x heart rate. 
All data analysis was performed using the Visual Sonic data analysis suite. 
Mitochondrial Bioenergetic Assessments 
Preparation of Permeabilized Muscle Fibre Bundles (PmFB) 
This technique is partially adapted from previous methods as described elsewhere [237-240]. 
Briefly, LV was removed from mice during anaesthesia with isoflurane and immediately placed 
in ice-cold BIOPS, containing (in mM): 50 MES Hydrate, 7.23 K2EGTA, 2.77 CaK2EGTA, 20 
imidazole, 0.5 dithiothreitol, 20 taurine, 5.77 ATP, 15 PCr, and 6.56 MgCl2·6 H2O (pH 7.1). The 
epicardium was trimmed away and the remaining muscle was divided into small bundles (~2–7 
mm long, 1.0–2.5 mg wet weight). Each bundle was gently separated along the longitudinal axis 
to form bundles that were treated with 40 µg/ml saponin in BIOPS on a rotor for 30 minutes at 4° 
C. Bundles for mitochondrial H2O2 emission (mH2O2) measurements (described below) were also 
treated with 35 µM 2,4-dinitrochlorobenzene (CDNB) during the permeabilization step to deplete 
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glutathione and allow for detectable rates of mH2O2 [242]. Following permeabilization, the PmFB 
were divided into three groups; 1) bundles intended for high resolution respirometry were placed 
in MiR05 containing (in mM): 0.5 EGTA, 10 KH2PO4, 3 MgCl2·6 H2O, 60 K-lactobionate, 20 
Hepes, 20 Taurine, 110 sucrose and 1 mg/ml fatty acid free BSA (pH 7.1) while 2) bundles 
intended for mH2O2 were placed in Buffer Z containing (in mM): 105 K-MES, 30 KCl, 10 
KH2PO4, 5 MgCl2·6 H2O, 1 EGTA and 5 mg/ml BSA (pH 7.4). PmFB were washed on a rotor at 
4°C in MiR05 or Buffer Z until the measurements were initiated. 3) bundles for calcium retention 
capacity were placed in Buffer Y + 1 mM EGTA containing (in mM): 250 sucrose, 10 tris-HCl, 
20 tris-base, 10 KH2PO4 and 0.5mg/mL BSA and washed on a rotor at 4° C for 10 minutes, then 
transferred to a second wash of Buffer Y + 10 µM blebbistatin (BLEB, see below) and washed on 
a rotor at 4°C until measurements were initiated. Following permeabilization and washing, all 
mitochondrial bioenergetic measurements were performed in the same order from one animal to 
another and between groups to ensure consistent durations of the wash step.  
Mitochondrial Respiration 
High-resolution O2 consumption measurements were conducted in 2 ml of respiration medium 
(MiR05) using the Oroboros Oxygraph-2k (Oroboros Instruments, Corp., Innsbruck, Austria) with 
stirring at 750 rpm at 37 °C [239, 240, 243-245]. Respiration medium contained 20mM creatine 
(Cr) to saturate mtCK or no Cr to prevent the activation of mtCK [283, 243]. For ADP-stimulated 
respiratory kinetics, 5 mM pyruvate, accompanied by 2 mM malate, were added as Complex I 
substrates (via generation of NADH to saturate electron entry into Complex I) followed by a 
titration of submaximal ADP (25 µM and 500 µM) and maximal ADP (5 mM). Cytochrome c was 
added to test for mitochondrial membrane integrity, with all experiments demonstrating <10% 
increase in respiration. Finally, succinate (20 mM) was then added to saturate electron entry into 
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Complex II. All experiments were conducted in the presence of 5µM BLEB in the assay media to 
prevent spontaneous contraction of PmFB [243, 244, 240]. Each protocol was initiated with a 
starting [O2] of approximately 350 µM and was completed before the oxygraph chamber [O2] 
reached 150 µM as done previously [239, 240, 243, 244]. Polarographic oxygen measurements 
were acquired in 2 s intervals with the rate of respiration derived from 40 data points and expressed 
as pmol/s/mg wet weight. PmFB were weighed in ~1.5 ml of tared BIOPS (ATP-containing 
relaxing media) to prevent rigor that occurs when weighing PmFB in open air (unpublished 
observations). 
Mitochondrial H2O2 Emission (mH2O2) 
mH2O2 was determined fluorometrically (QuantaMaster 40, HORIBA Scientific, Edison, NJ, 
USA) in a quartz cuvette with continuous stirring at 37°C, in 1 mL of Buffer Z supplemented with 
10 µM Amplex Ultra Red, 0.5 U/ml horseradish peroxidase, 1 mM EGTA, 40 U/ml Cu/Zn-SOD1, 
and 5 µM BLEB. Induction of state II mH2O2 was measured through the addition of 10 mM 
pyruvate and 2 mM malate followed by a titration of ADP which was added to progressively 
attenuate mH2O2. Complex I-supported mH2O2 was repeated with and without 20mM Cr in the 
assay buffer to compare ADP’s effects dependent or independent of mtCK-mediated phosphate 
shuttling. The rate of H2O2 emission was calculated from the slope (F/min), from a standard curve 
established with the same reaction conditions and normalized to fibre bundle wet weight as 
described above.  
Mitochondrial Calcium Retention Capacity  
This assay is partially adapted from methods previously described [249]. Mitochondrial calcium 
retention capacity measurements were completed spectrofluorometrically (QuantaMaster 80, 
HORIBA Scientific, Edison, NJ, USA) in a cuvette with continuous stirring at 37° C, in 300 µL 
of Buffer Y containing 1 µM Calcium Green-5N (Invitrogen), 2 µM thapsigargin, 5 mM 2-
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deoxyglucose, 2 U/mL hexokinase, 20 mM Cr, 5 µM BLEB and 40 µM EGTA. Prior each 
experiment, the cuvette was placed on a stir plate with 500 mL water and 10 mM EGTA. The 
water was then aspirated from the cuvette but not rinsed, leaving the EGTA coating on the cuvette 
walls to chelate any residual Ca2+ in the assay buffer. Minimum fluorescence was obtained 
following the addition of the PmFB plus 5 mM glutamate +2 mM malate to the assay buffer. 
Calcium uptake was then initiated by a single 8 nmol pulse of CaCl2. Subsequent 4 nmol pulses of 
Ca2+ were added until mitochondrial permeability transition pore (PTP) opening was evident. Two 
0.5 mM pulses of Ca2+ were then added to saturate the fluorophore and establish a fluorescent 
maximum. All experiments were conducted at 37 °C. Changes in free Ca2+ in the cuvette during 
mitochondrial Ca2+ uptake were then calculated using the known Kd for Calcium Green 5-N and 
the equations established for calculating free ion concentrations using ion-sensitive fluorophores 
[250]. After the experiments, the fibres were rinsed in double deionized H2O, lyophilized in a 
freeze-dryer for >4 h and weighed on a microbalance (Sartorius Cubis, Gottingen, Germany). 
In Vitro Muscle Analyses 
Western Blotting 
An aliquot of frozen heart (10–30 mg) from each animal was homogenized in a plastic 
microcentrifuge tube with a tapered teflon pestle in ice-cold buffer containing (mm): 40 Hepes, 
120 NaCl, 1 EDTA, 10 NaHP2O7·10H2O pyrophosphate, 10 β-glycerophosphate, 10 NaF and 
0.3% CHAPS detergent (pH 7.1 adjusted using KOH). Protein concentrations were determined 
using a BCA assay (Life Technologies, Carlsbad, CA, USA). 50 µg of denatured and reduced 
protein was subjected to 6–12% gradient SDS-PAGE followed by transfer to low-fluorescence 
polyvinylidene difluoride membrane. Membranes were blocked with LI-COR Odyssey Blocking 
Buffer (LI-COR, Lincoln NE, USA) and immunoblotted overnight (4°C) with antibodies specific 
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for each protein. A commercially available monoclonal antibody cocktail was used to detect 
electron transport chain proteins (human OXPHOS Cocktail, ab110411; Abcam, Cambridge, UK, 
1:250 dilution), including V-ATP5A (55 kDa), III-UQCRC2 (48 kDa), IV-MTCO1 (40 kDa), II-
SDHB (30 kDa) and I-NDUFB8 (20 kDa). Commercially available polyclonal antibodies were 
used to detect voltage dependent anion carrier 2 (VDAC 2) (32059, 33 kDa; Santa-Cruz, 1:1000), 
adenine nucleotide translocase 1 (ANT 1) (ab180715, 32 kDa; Abcam, 1:1000), 4-
hydroxynoneonal (4-HNE) (ab46545; Abcam, 1:1000) and sarcomeric s-mtCK (Dr Uwe 
Schlattner, Grenoble, France; 42 kDa, 1:1000). The mtCK antibody has been validated previously 
to confirm specificity [256]. Protein carbonylation was detected using the OxyBlot Protein 
Oxidation Detection Kit (Millipore Sigma, Burlington, MA, USA). 
After overnight incubation in primary antibodies, membranes were washed three times, for 
5 minutes each time, in TBST and incubated for 1 hour at room temperature with the corresponding 
infrared fluorescent secondary antibody (LI-COR). Immunoreactive proteins were detected by 
infrared imaging (LI-COR CLx; LI-COR) and quantified by densitometry 
(ImageJ, http://imagej.nih.gov/ij/). All images were normalized to a whole membrane Amido 
Black total protein stain (A8181, Sigma, St Louis, MO, USA). A double band was detected at 
33 kDa for ANT 1 and as such, both bands were analyzed and reported.  
Glutathione 
Glutathione was assessed as previously described [255]. GSH was assessed by UV-HPLC 
monitoring of NEM-GSH while GSSG was assessed by fluorescent-HPLC by tracking O-
pthalymide (OPA, Sigma-Aldrich, Oakville, Canada) tagged GSH through a flow-through cuvette 
following GSSG conversion to GSH (FireflySci 8830, NY, USA) in a QuantaMaster 40 
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spectrofluorometer (HORIBA, NJ, USA). All values were referenced to protein concentration and 
reported in µmol/g protein. USA).  
Caspase Activity 
Enzymatic activities of caspase 3 and caspase 9 were measured fluorometrically using substrates 
Ac-DVED-AMC and Ac-LEHD-AMC (Enzo Life Sciences, Farmingdale, NY) as previously 
described [251, 252]. 
Histochemistry 
In a subset of animals, not used for bioenergetic measurements, the lower third of the heart was 
immediately placed in 10% neutral buffered formalin for 72 hours. After 72 hours, the heart was 
placed in 70% ethanol where it was preserved until processing using routine procedures. Processed 
heart tissue was embedded in paraffin wax (Thermo Fisher Scientific, Burlington, Canada) prior 
to sectioning (5 µm thickness). Sections were stained with picrosirius red to measure fibrotic area 
(fibrotic regions stain red for extracellular matrix), areas of muscle damage and CSA (quantified 
only from cardiomyocytes with centralized nuclei). Two to five images (4 on average) were used 
for analyses (n=7 per group). Sections were imaged using an Olympus FSX100 light microscope 
(Olympus), Richmond Hill, Canada) and analyzed in cellSens software (Olympus) for necrosis 
and fibrosis analysis, or ImageJ (http://imagej.nih.gov/ij/) for CSA analysis.  
Statistics 
Results are expressed as means ± SEM. The level of significance was established as p<0.05 for all 
statistics. Outliers were omitted in accordance with the ROUT test GraphPad Prism Software, La 
Jolla, CA, USA). D’Agostino-Pearson omnibus normality test revealed that data resembled a 
Gaussian distribution which justified the application of parametric tests. For all data except the 
presence of muscle damage, statistical differences were analysed using unpaired t-tests between 
WT and D2.mdx. The design of ADP-titration protocols focused specifically on determining 
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separate questions regarding mitochondrial bioenergetic responses to low vs high ADP 
concentrations. As such, t-tests were used at each ADP concentration. Statistical differences in 
muscle damage in D2.mdx vs WT was analysed using Pearson’s chi-squared test.  
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Results 
 
Figure 5-1: Schematic representation of energy transfer between mitochondria and cytosol. 
The leading model for energy exchange involves a creatine-independent (-Cr) and creatine- 
dependent (+Cr) pathway. The left side depicts the –Cr pathway whereby the transfer of ADP/ATP 
occurs solely through diffusion across voltage dependent anion carrier (VDAC) on the outer 
mitochondrial membrane and adenosine nucleotide translocase (ANT) on the inner mitochondrial 
membrane. The right side depicts the +Cr ‘mitochondrial phosphate shuttling’ mechanism of 
energy transfer. In the presence of Cr, ATP produced during oxidative phosphorylation in the 
mitochondrial matrix diffuses through ANT into the inner membrane space where mitochondrial 
creatine kinase (mtCK) facilitates the transfer of the phosphate group from ATP to Cr, producing 
phosphocreatine (PCr) and ADP. The PCr is exported via VDAC into the cytosol while the ADP 
is directly recycled back via ANT into the mitochondrial matrix. This schematic has been partially 
adapted from Hughes et al. (paper in submission at the time of review) using concepts from [146, 
150, 147, 157]. 
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Physical Parameters and Echocardiography 
At 4 weeks of age, we first determined whether differences in whole body as well as cardiac-
specific physical parameters existed. D2.mdx animals demonstrate a significant decrease in body 
weight compared to WT controls (-21%, p=0.006, Figure 2A) and left ventricular diameter during 
both systole (-26%, p=0.00005; Figure 2B) and diastole (-14%, p=0.00006; Figure 2B) is 
unchanged when normalized to body weight (Figure 2B). Furthermore, cardiac output is driven in 
part by lean body mass and lean muscle mass has been shown to be lower in this model [60]. As 
such, stroke volume and cardiac output were normalized relative to body weight as a strong 
correlation between these measures has been established [284]. Accordingly, stroke volume per 
gram body weight was unchanged (Figure 2D) while cardiac output per gram body weight was 
significantly increased in D2.mdx animals vs WT controls (+13%, p=0.03, Figure 2E). However, 
heart rate was also significantly increased in D2.mdx mice relative to WT (+13%, p=0.02; Figure 
2C). Ejection fraction was significantly increased in D2.mdx mice relative to WT (+13%, 
p=0.0008; Figure 2F) as well as fractional shortening (+19%, p=0.001; Figure 2G), indicating 
overall that there was no overt cardiac dysfunction at 4 weeks of age in D2.mdx mice. 
Impaired respiration and elevated Complex I-supported mH2O2 during oxidative 
phosphorylation in left ventricle muscle of D2.mdx mice 
Key to this investigation is the design of in vitro assessments of mitochondrial bioenergetics that 
model in vivo critical parameters controlling respiratory and H2O2 emission kinetics. Specifically, 
we considered that mitochondrial responsiveness to ADP may be different at lower vs higher 
concentrations, as well as the substantial evidence demonstrating that creatine facilitates 
mitochondrial phosphate shuttling with the cytoplasm more efficiently than ATP/ADP cycling 
(Figure 1). Specifically, the stimulation of mitochondrial respiration and H2O2 emission in left 
ventricle muscle was initiated using pyruvate (5mM) and malate (2mM) which generates NADH 
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to stimulate Complex I. In the absence of ADP, state II respiration and mH2O2 were assessed in 
both the presence (+Cr) and absence (-Cr) of 20mM Cr to drive energy transfer dependent or 
independent of mtCK, respectively (Figure 1). In both +Cr and –Cr conditions, state II respiration 
was significantly decreased in D2.mdx mice (+Cr: -26%, p=0.045; -Cr: -16%, p=0.050; Figure 
3A,E), suggesting less uncoupling, while mH2O2 emission was significantly elevated in D2.mdx 
mice vs WT (+Cr: +75%, p=0.002; -Cr: +65%, p=0.003; Figure 3B,F).  
 
Figure 5-2: Physical parameters and echocardiography in D2.mdx mice. (A) Body weight. (B) 
Left ventricle (LV) diameter was calculated during both systole and diastole. (C) Heart rate (HR) 
during echocardiographic measurements. LV dimensions and volume along with HR were used to 
calculate (D) stroke volume and (E) cardiac output as well as (F) ejection fraction and (G) 
fractional shortening. Results represent means ± SEM; n=5-6; * p<0.05 compared to WT. 
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We then determined the ability of ADP to simulate coupled respiration and attenuate mH2O2 (state 
III conditions) while concurrently evaluating the function of mtCK by comparing +Cr and –Cr 
conditions. ADP was titrated beginning with low/physiological (25µM), followed by high sub-
maximal (500µM) and finally saturating concentrations (5mM) of ADP. +Cr, state III respiration 
was impaired at a range of [ADP] (25µM: -20%, p=0.08; 500µM: -37%, p=0.01; 5mM: -37%, 
p=0.003; Figure 3C) while mH2O2 during oxidative phosphorylation was elevated at all [ADP] 
(25µM: +133%, p=0.00002; 500µM: +131%, p=0.0004; 5mM: +133%, p=0.001; Figure 3D) in 
D2.mdx vs WT.  –Cr, ADP’s ability to simulate respiration and concurrently lower mH2O2 during 
oxidative phosphorylation was impaired at low [ADP] only (Respiration: -33%, p=0.007; Figure 
3G; mH2O2: +121%, p=0.0001; Figure 3H), indicating an impairment in ADP sensitivity that is 
not evident at high submaximal and saturating [ADP]. Overall, these findings suggest that there 
are impairments in ADP stimulated respiration and accompanied attenuation of mH2O2 at low 
[ADP] regardless of the degree of mtCK activation, yet high or saturating [ADP] demonstrates 
impaired control only in the +Cr pathway. Indeed, comparing sensitivity to Cr reveals an 
impairment in bioenergetics that is more specific to the predominant phosphate shuttling pathway 
that is dependent on mtCK (Table 1). 
Western blotting was performed on the key regulators of energy shuttling to determine if changes 
in mitochondrial bioenergetics could be attributed to alterations in protein content of these 
regulators. Adenine nucleotide translocator 1 (ANT 1), located on the inner mitochondrial 
membrane, was unchanged between D2.mdx and WT animals (Figure 4A). However, voltage 
dependent anion carrier 2 (VDAC 2) that is specific to the outer mitochondrial membrane, was 
significantly elevated in D2.mdx heart muscle (+50%, p=0.046; Figure 4B). Protein content of 
mtCK was unchanged in D2.mdx relative to WT (Figure 4C). Quantification of the proteins 
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comprising the electron transport chain was also performed. While subunits of Complexes I, III, 
IV and V as well as the sum of all 5 complexes were unchanged in D2.mdx mice, there was an 
increase in Complex II marker in D2.mdx mice (+22%, p=0.01; Figure 4D) relative to WT. This 
increase in Complex II marker content occurred concurrently impaired succinate-stimulated 
respiration, suggesting partial compensation may have been invoked (data not shown). Overall, 
alterations in protein content of key regulators of energy shuttling as well as markers of OXPHOS 
capacity do not explain the decreases seen in mitochondrial respiration and elevations in mH2O2 
in the left ventricle of D2.mdx mice at 4 weeks of age.  
 
 
Figure 5-3: Respiration and mH2O2 emission in left ventricle of D2.mdx mice. State II (no ADP) 
respiration (proton leak) and mH2O2 emission, supported by Complex-I substrates pyruvate (5mM) 
and malate (2mM), was assessed in the (A-B) presence (Creatine Dependent) and (E-F) absence 
(Creatine Independent) of 20mM creatine. State III (ADP) respiration and mH2O2 emission were 
evaluated at low (25µM), sub-maximal (500µM) and maximal (5000µM) [ADP] in the presence 
(C-D) and absence (G-H) of creatine. Results represent means ± SEM; n=12-17; * p<0.05 
compared to WT.  
 
  
 
 
128 
Table 5-1: Impairment in creatine sensitivity with 500µM ADP in dystrophic heart muscle 
  Wildtype   D2.mdx   
  -Cr +Cr 
P 
Value  
(-Cr vs 
+Cr) -Cr +Cr 
P 
Value  
(-Cr vs 
+Cr) 
             
JO2 (pmolsec-1mg-1 wet wt) 76.6 ± 4.6 128.8 ± 17.1 P<0.05 90.9 ± 11.7 76.3 ± 8.6 P=0.31 
             
mH2O2/O2 Consumed 0.55 ± 0.07 0.26 ± 0.04 P<0.01 0.62 ± 0.10 0.60 ± 0.07 P=0.37 
Creatine Dependent (+Cr), Creatine Independent (-Cr), Values represent mean ± SEM, (n=8-14). 
	
 
 
Figure 5-4: Evaluation of essential regulators of mitochondrial bioenergetics. Protein content 
of (A) adenine nucleotide translocase 1 (ANT 1) on the inner mitochondrial membrane, (B) voltage 
dependent anion carrier 2 (VDAC 2) on the outer mitochondrial membrane and (C) mitochondrial 
creatine kinase (mtCK) found in the inner membrane space. (D) Protein content of electron 
transport chain subunits. Results represent mean ± SEM; n=8-12; * p<0.05 compared to WT. 
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Elevated mH2O2 does not alter markers of irreversible oxidative damage in D2.mdx left ventricle 
Despite elevated mH2O2 emission in the left ventricle of D2.mdx mice, there were no changes in 
reduced glutathione (GSH, Figure 5A), oxidized glutathione (GSSG; Figure 5B), total glutathione 
(GSH + 2xGSSG; Figure 5C) or the ratio of GSH:GSSG (Figure 5D). Additionally, there was no 
evidence of changes in lipid peroxidation, as measured through the quantification of 4-
hydroxynoneal (Figure 5E) or evidence of protein carbonylation (Figure 5F) demonstrating that 
elevations in mH2O2 did not change whole cell oxidative status at this early time point.  
Bioenergetic impairments are not accompanied by changes in susceptibility to PTP opening or 
mitochondrial-derived apoptosis 
We next determined if elevated mH2O2 during impaired oxidative phosphorylation resulted in 
increased susceptibility to PTP opening at this early time point. D2.mdx left ventricle muscle 
showed no differences in the [Ca2+] required to induce PTP opening relative to WT (Figure 6A). 
Furthermore, there were no differences in mitochondrial-derived caspase 9 activity (Figure 6B) 
and subsequently, no elevations in caspase 3 activity (Figure 6C) indicating that elevated mH2O2 
and impaired mitochondrial respiration do not result in mitochondrial-derived apoptosis.   
Impaired mitochondrial bioenergetics precede muscle damage and atrophy in left ventricle of 
D2.mdx mice 
Interstitial fibrosis of the LV was quantified using picrosirius red stain and revealed no differences 
in degree of fibrosis between D2.mdx and WT (Figure 6D). Furthermore, quantification of fibre 
cross sectional area revealed no difference in D2.mdx relative to WT (Figure 6E) indicating that 
there is no fibre atrophy or hypertrophy in the LV at this early time point. The presence of muscle 
damage in the LV was also determined in D2.mdx and WT LV. While there were more instances 
of damage present in D2.mdx vs WT, this difference was not statistically significant (Figure 6F).   
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Figure 5-5: Evaluation of redox buffering capacity and whole cell oxidative status. 
Glutathione was measured in muscle homogenate using (A) HPLC-UV for the detection of GSH 
and (B) HPLC-Fluorescence for the detection of GSSG. (C) The GSH:GSSG ratio and (D) total 
glutathione were calculated from GSH and GSSG measurements; n=6. Quantification of proteins 
modified through (E) lipid peroxidation and (F) carbonylation; n=8. Results represent mean ± 
SEM; * p<0.05 compared to WT. 
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Figure 5-6: Quantification of mitochondrial-associated cell death pathways and overall 
muscle damage in left ventricle of D2.mdx mice. (A) Calcium retention capacity, an index of 
susceptibility to permeability transition pore opening, was assessed in permeabilized fibres from 
LV muscle; n=8-9. Mitochondrial-induction of apoptosis was evaluated through (B) caspase 9 
activity followed by it’s down-stream target (C) caspase 3; n=6-7. (D) Interstitial fibrosis of the 
LV was quantified using picrosirius red stain. (E) Cross-sectional area was quantified and 
represented as a relative frequency of fibre diameter with median ± SEM reported. (F) The 
presence or absence of muscle damage was also identified; n=7. Results represent mean ± SEM; 
* p<0.05 compared to WT. 
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Discussion 
While the early stages of DMD progression are characterized by severe skeletal muscle wasting 
and weakness, the development of cardiomyopathy occurs in 98% of Patients with DMD by the 
age of ~18 and progresses to heart failure in approximately 40% of Patients with DMD [77, 4, 37, 
43]. Given there is no cure for this condition, identifying secondary contributors to myopathy can 
guide the development of potential therapeutics in order to slow disease progression and improve 
quality of life. The present investigation provides evidence of elevated mitochondrial H2O2 
emission and impaired oxidative phosphorylation in LV muscle of D2.mdx mice. These findings 
also suggest that previous reports of altered substrate metabolism and decreased TCA cycle 
intermediates [280] may be related specifically to impaired respiratory sensitivity to ADP, loss of 
phosphate shuttling by creatine, and impaired Complex I activity. Of note, these mitochondrial 
dysfunctions occurred at a young age of 4 weeks, prior to the onset of overt cardiac dysfunction 
and remodelling in D2.mdx; abnormalities that present at 28 weeks of age in this mouse model 
[59]. These findings suggest a potential role for mitochondrial dysfunction as a contributing factor 
to the etiology of cardiomyopathy that manifests at later stages of the disease.  
Mitochondrial dysfunction occurs in the absence of overt cardiac dysfunction and remodelling 
Despite the clear changes in mitochondrial bioenergetics, D2.mdx mice showed no signs of overt 
cardiac dysfunction at this young age. Moreover, we found that the heart dimensions of D2.mdx 
mice were smaller than WT mice but these size differences were associated with decreased body 
weights. Thus, unlike most cardiac disease conditions that are typically associated with cardiac 
hypertrophy and increased interstitial fibrosis, at 4 weeks of age neither heart size nor the degree 
of interstitial collagen differed between D2.mdx and WT mice. In fact, a small increase in cardiac 
output was observed and this appeared to be related to increased heart rate, as there was no 
differences in normalized stroke volumes between the two groups of mice. The basis for the 
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increased heart rate is unclear, but may arise from increased demands for blood flow due to altered 
peripheral metabolic rate. There was also no difference in the number of animals presenting with 
muscle damage within the LV between D2.mdx and WT groups. While both groups demonstrated 
fibrosis and muscle damage to the same degree, this infiltration was limited to the epicardium of 
the heart. Given permeabilized fibres were separated strictly from the endocardium of the LV, all 
impairments in DMD mitochondrial bioenergetics were found in muscle that did not contain 
fibrotic or necrotic tissue. As such, the findings indicate that the impairments in mitochondrial 
bioenergetics occurred in the absence of overt cardiac dysfunction and/or cardiac remodelling.  
Specific mechanisms of impaired mitochondrial bioenergetics  
At 4 weeks of age D2.mdx LV muscle demonstrates elevated H2O2 emission as seen in ADP-free 
conditions. In this state, the absence of ADP results in a higher membrane potential  that promotes 
electron leak at various sites of the electron transport chain, including Complex I, which generates 
superoxide that is dismutated to H2O2 prior to its emission to the cytosolic compartment [232]. 
Respiration is driven by proton leak through uncoupling proteins, such that greater uncoupling 
lowers membrane potential and attenuates H2O2 emission without ATP synthesis. The observation 
that D2.mdx LV muscle had elevated maximal rates of H2O2 emission and lower uncoupled 
respiration supported by Complex I suggests compromised uncoupling mechanisms may 
contribute to the increased H2O2 emission. Furthermore, the impairments at Complex I were not 
explained by altered protein content of the NDUFB8 subunit, suggesting that post-translational 
modifications may also have occurred. Indeed, Complex I activity can be decreased by oxidation 
of specific cysteine residues [259] but the degree to which this occurs in DMD remains to be 
determined.  
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After supporting electron flux with Complex-I substrates, ADP was titrated to reflect an increased 
cellular energy demand in order to challenge oxidative phosphorylation and lower H2O2 emission. 
In the dystrophic left ventricle, mitochondrial insensitivity to ADP was seen in +Cr and -Cr 
conditions suggesting both mtCK-dependent PCr/Cr cycling and ADP/ATP cycling were 
compromised. Impaired ADP sensitivity is detrimental given ADP regulates both oxidative 
phosphorylation and H2O2 emission through governance of membrane potential as noted above 
[232]. These data suggest that mitochondria are less capable of responding to low and high states 
of energy demand in that less ATP synthesis would occur while H2O2 emission would be greater, 
and that mitochondrial-cytosolic phosphate shuttling through both PCr/Cr cycling and ATP/ADP 
cycling (-Cr condition) are compromised. 
It is thought that both PCr/Cr and ATP/ADP cycling occur through ANT and VDAC isoforms on 
the mitochondrial inner and outer membranes respectively (depicted in Figure 1). Given ANT 1 
(dominant ANT isoform in muscle) content was not different while VDAC 2 (mitochondrial-
specific isoform) content was increased despite impairments in ADP sensitivity in both +Cr and -
Cr conditions, it is possible that the ADP-insensitivities may be due to post-translational 
modifications of these proteins. Indeed, ANT and VDAC also have known phosphorylation sites 
[264, 265] and acetylation has been associated with ADP insensitivity [285], although the 
physiological relevance of this regulatory paradigm remains unknown.  
A robust impairment in the ability of creatine to govern mitochondrial bioenergetics was noted in 
D2.mdx LV. Specifically, in +Cr, ADP’s governance of bioenergetics was impaired across a range 
of low and high ADP concentrations which suggests a pronounced impairment in mtCK-dependent 
energy exchange. A study that compared both Cr-dependent and independent models of energy 
exchange [201] noted an impairment in LV Cr sensitivity, albeit in older C57BL10/ScSnmdx mice 
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(10-11 months). The present findings indicate this is an early event in the disease process. The 
cause of the creatine-insensitivity is uncertain as mtCK content was unchanged. However, mtCK 
is highly susceptible to oxidative modifications, leading to enzymatic inactivation and octamer 
dissociation, as well as formation of crystalline mitochondrial inclusion bodies, all resulting in loss 
of function [153, 152]. Future investigations could determine if the predominantly greater 
dysfunction seen in +Cr (Table 1) is driven by such modifications to mtCK. Finally, these 
impairments in both Cr conditions were not explained by changes in ETC marker contents which 
further suggests the dysfunctions are due to unknown post-translational modifications to mtCK 
and/or ANT and VDAC. Nevertheless, the importance of modelling mtCK equilibrium to capture 
the mitochondrial dysfunction is apparent given the Cr-dependent model is predicted to be the 
dominant system of energy exchange [157, 286]. 
Relationship between the DMD myopathy and impaired mitochondrial bioenergetics 
Inherited mutations in the gene dystrophin causes a loss in the normal function of this 
sarcolemmal-cytoskeletal protein [229]. Subsequent disruptions to cell membrane stability and 
cytoskeletal organization are linked to a myriad of cellular defects including increased cytosolic 
calcium, oxidative stress and cell death [93, 2]. Based on these hallmark features of DMD, it has 
been proposed that mitochondrial dysfunctions arise from these multiple cellular stressors and may 
ultimately contribute to muscle fibre degeneration [34, 195, 33]. It is thought that impairments in 
both mitochondrial respiration and H2O2 emission can contribute to the induction of PTP formation 
and subsequently activate mitochondrial derived cell death pathways. Indeed, mitochondrial 
induction of apoptosis and necrosis has been linked to several diseases that also exhibit elevated 
mitochondrial ROS and impaired oxidative phosphorylation [269, 270, 226, 271-273]. Such PTP 
formation has also already been implicated in DMD myopathy in response to calcium stress [33, 
35].  
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In contrast to the present findings of similar PTP sensitivities to calcium, previous work has shown 
increased susceptibility to PTP opening in both intact dystrophic hearts as well as LV muscle fibres 
from C57BL10/ScSnmdx mice [199, 32].  Differences in methodology may contribute to these 
divergent findings. For example, when intact hearts from C57BL10/ScSnmdx are subjected to I/R 
injury, the number of mitochondria undergoing PTP opening is increased compared to normal 
hearts. However, this physiological stressor was required to unmask differences, as PTP opening 
was unchanged prior to the induction of I/R relative to WT controls [199, 32]. Also, only one study 
to date has assessed PTP opening in permeabilized fibres but evaluated PTP opening in terms of 
elapsed time in response to a single bolus of Ca2+ [199], as opposed to determining the 
concentration of Ca2+ required to trigger PTP opening as was done in the present study. This 
difference in assessment approaches could alter conclusions, particularly given time to PTP 
opening was lower in mdx mouse Tibialis Anterior, yet the [Ca2+] required to induce PTP was 
unchanged [33]. This observation suggests that comparing methods of PTP assessment may be 
necessary to better understand PTP responses. Alternatively, our observations of increased H2O2 
emission and decreased respiration may be preceding compromised calcium sensitivity seen at 
later stages in DMD. 
In line with this speculation, elevated mH2O2 emission and impaired respiration at 4 weeks of age 
were not associated with changes in the redox status of the cell, as measured through glutathione, 
lipid peroxidation and protein carbonylation. This pattern suggests that the intrinsic buffering 
capacity of the muscle is sufficient to tolerate the stress induced by these bioenergetic impairments. 
As a result, no detectable oxidative damage is evident at this early time point. Furthermore, the 
lack of irreversible oxidative damage and activation of cell death pathways is consistent with the 
absence of an overt cardiomyopathy at this early time point. However, it is plausible to believe 
 
 
137 
that as the disease progresses, the buffering capacity of the cell will become overwhelmed, 
resulting in the documented oxidative damage of dystrophic cardiac muscle [93, 111] and the 
subsequent contribution of this damage to cardiomyopathy.  
The present findings implicate mitochondrial dysfunction as a potential contributor to cardiac 
dysfunction. Indeed, pre-clinical tests showed that Idebenone – a quinone based electron shuttler 
[206, 207] - improved cardiac function and exercise performance in mdx mice [208] as well as 
cardiac and respiratory function in persons with DMD during clinical trials [210, 211, 287, 209], 
directly implicating the mitochondria in cardiac dysfunction in DMD. While promising at high 
doses, there are concerns over idebenone’s limited bioavailability [212]. Given other 
mitochondrial-targeted therapeutics were shown to be effective at preventing mitochondrial 
dysfunction in conditions such as ischaemia-reperfusion injury [258, 224], the present findings 
suggest these compounds should be explored for their potential in preserving mitochondrial 
bioenergetics and muscle quality in DMD, particularly prior to the onset of cardiac dysfunction.   
Conclusions 
In summary, elevations in Complex I-supported mitochondrial H2O2 emission during impaired 
oxidative phosphorylation were identified in the LV of dystrophin-deficient mice. These 
mitochondrial abnormalities occur at any early age prior to the onset of overt cardiac dysfunction 
and remodelling [60, 59] given fibrosis and necrosis were unchanged, and cardiac functional 
indices were not impaired. Identifying these mitochondrial-specific impairments at this early age 
may guide the development of mitochondrial-targeted therapeutics that restore normal Complex I 
activity as well as bioenergetic control by ADP and creatine in order to delay the onset of 
cardiomyopathy and subsequent development of heart failure in DMD.   
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Supplemental Figure 5-1: Complex II supported mH2O2 emission and state III 
respiration in LV muscle. State II (no ADP) mH2O2 emission, supported by Complex-II 
substrate succinate (10mM), was assessed in the (A) presence (Creatine Dependent) and 
(B) absence (Creatine Independent) of 20mM creatine. State III (ADP) mH2O2 emission 
was evaluated at low (25µM), sub-maximal (500µM) and maximal (5000µM) [ADP] in 
the presence (C) and absence (D) of creatine; n=12-17. State III respiration, supported by 
complex-II substrate succinate (20mM) was evaluated in the presence (F) and absence (E) 
of 20mM creatine; n= 6-9. Results represent means ± SEM; * p<0.05 compared to WT.  
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Supplemental Figure 5-2: Absolute rates of Complex-I supported mH2O2 emission. State II 
mH2O2 was supported by Complex-I substrates Pyruvate (5mM) and Malate (2mM) in the A. 
presence (Creatine Dependent) and B. absence (Creatine Independent) of 20mM creatine. ADP’s 
attenuation of maximal H2O2 emission (state III) was evaluated in the same C. creatine-dependent 
and D. creatine-independent conditions. Results represent mean ± SEM; n=10-12; * p<0.05, 
compared to WT. 
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6 The mitochondrial targeted peptide SBT-20 improves diaphragm 
and skeletal muscle pathophysiology in dystrophin-deficient mice 
 
Assay Development Prior to the start of Project 3: 
1. In Situ Quadriceps Force Production – in collaboration with SVR 
2. In Vitro Diaphragm Force Production – in collaboration with CAB 
 
Author Contributions: The majority of experiments for this project were carried about by 
Meghan Hughes. MH maintained the breeding colony required for this project. As tissue from the 
animals in this project was being used for the theses of both MH and SVR, the following tasks 
were shared amongst the two students. MH and SVR completed daily drug injections. MH and 
SVR completed all whole body in vivo testing, in situ quadriceps force production experiments 
and all µCT scans. MH and SVR performed all tissue harvests and mitochondrial bioenergetic 
assays (respiration, mH2O2 emission, calcium retention capacity). PT completed the analysis of 
µCT data. CAB ran in vitro diaphragm force production while MH completed the analysis of this 
data and assisted with the method development. MH completed serum creatine kinase experiments. 
MH performed all caspase assays and western blotting experiments. PCT completed glutathione 
measurements. AD, ET and TH completed all immunohistochemistry and TEM imaging and 
analysis. 
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Abstract 
Duchenne muscular dystrophy (DMD) is a genetic-based disease which causes severe muscle 
wasting and weakness, resulting in loss of ambulation and premature death due to cardiac and/or 
respiratory failure. Current standard of care focuses on treating secondary contributors to the DMD 
myopathy and as such, there is a clear need to develop a portfolio of potential therapeutic 
candidates that target the underlying causes of muscle degeneration in this disease. Here we 
evaluate the efficacy of the mitochondrial-targeted peptide SBT-20 in improving DMD 
pathophysiology through the amelioration of impairments in mitochondrial bioenergetics.  
Beginning at 4 days of age, D2.B10-DMDmdx/2J (D2.mdx) mice received daily injections of 
5mg/kg SBT-20 or volume equivalent saline for 28 days. A WT group was also evaluated at this 
time point. Following treatment, mitochondrial bioenergetics (oxidative phosphorylation, 
mitochondrial H2O2 emission) were improved in diaphragm and quadriceps muscle. These 
improvements were associated with elevated force production in the diaphragm and decreased 
fibrosis in the quadriceps. The ultra-structure of quadriceps mitochondria was also improved 
following treatment, despite a surprising increase in susceptibility to calcium-induced permeability 
transition pore opening and mitochondrial-derived caspase activity. Furthermore, while body 
weight was unchanged, lower limb muscle volume improved, as did forelimb grip strength. These 
improvements were evident at a very early stage in disease progression. Collectively, these 
findings demonstrate that SBT-20 improved specific bioenergetic and muscle quality indices and 
should be considered further for its potential therapeutic efficacy.  
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Introduction 
Duchenne muscular dystrophy (DMD), caused by defective expression of the structural protein 
dystrophin, is the most common form of muscular dystrophy, affecting 1 in 3500 boys [45, 2]. 
Dystrophin acts as an anchor between the cytoskeleton and sarcolemma, providing structural 
stability to smooth, cardiac and skeletal muscle fibres [229]. While at a clinical level, a lack of 
dystrophin causes progressive muscle wasting and weakness, the cascade initiated by this loss of 
dystrophin, which culminates in robust muscle degeneration, is not fully understood. There is 
currently no cure for DMD and the progressive nature of the disease results in early loss of 
ambulation (mid-teenage years) followed by premature death due to cardiac and/or respiratory 
failure (early adulthood). To date, gene based therapies have had limited success in treating 
patients with DMD [47]. Indeed, current clinical practice involves the use of glucocorticoids for 
treatment, which target inflammation as opposed to the genetic defect itself [7]. Unfortunately, 
long term treatment with glucocorticoids is associated with several negative side effects [48]. As 
such, identifying the mechanisms underlying muscle degeneration has been a major focus for 
guiding therapy development [46]. 
Muscle lacking dystrophin is highly susceptible to tearing of the cell membrane, a process that has 
been linked to subsequent cytosolic calcium overload, oxidative stress and cell death [93, 2]. 
Additionally, a highly pro-inflammatory environment is believed to worsen the myopathy [230]. 
Recent work from our laboratory has identified the mitochondria as a source of ROS during 
impaired oxidative phosphorylation in respiratory and skeletal muscles from D2.B10-DMDmdx/2J 
(D2.mdx) mice [286, 155], a mouse model of DMD more closely mimicking human disease 
progression [59, 60]. These impairments were associated with heightened muscle wasting and 
weakness suggesting the mitochondria may be an important secondary contributor to disease 
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pathology. This notion is supported by previous work demonstrating that compounds inhibiting 
mitochondrial-derived cell death through the blocking of mitochondrial permeability transition 
pore opening have attenuated the DMD myopathy in mouse models [215, 199, 288], although 
subsequent clinical trials were less promising with reports of no changes or worsening of the DMD 
myopathy [219, 289].  
Recent clinical trials involving the quinone-based electron shuttler idebenone [207] suggest that 
targeting the bioenergetic deficits that activate mitochondrial-derived cell death may be more 
efficacious. Indeed, idebenone has been shown to improve cardiac and respiratory function in 
DMD patients, presenting some of the more promising outcomes of clinical trials in recent years 
[210, 211, 209]. However, whether this is related to improved mitochondrial bioenergetics remains 
unknown as these trials focused on clinical outcomes as opposed to mechanisms of action. 
Furthermore, as a synthetic analog to coenzyme Q10, structurally idebenone is not mitochondrial-
targeted and there are concerns over its limited bioavailability [212]. To date, while the 
mitochondria appear to be a potential therapeutic target, it remains unknown if a mitochondrial-
targeted compound can improve DMD pathophysiology through the attenuation of impaired 
mitochondrial bioenergetics.  
The mitochondrial-targeted peptide SBT-20, an aromatic-cationic compound that targets 
cardiolipin on the inner mitochondrial membrane, has been shown to increase mitochondrial 
oxidative phosphorylation [224], attenuate mitochondrial H2O2 emission [224] and prevent against 
the activation of cell death pathways [223] as well as oxidant-induced damage [225] in rodent 
models of ischemia reperfusion [224] and myocardial infarction [225]. Each of the aforementioned 
cellular dysfunctions have previously been identified in DMD [93, 2, 195, 156]. Furthermore, 
cardiolipin plays an important role in the control of mitochondrial bioenergetics through its binding 
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with key regulators of energy exchange (Figure 2C), forming a proteolipid complex that provides 
efficient energy exchange into and out of the mitochondria [200]. However, both cardiolipin and 
mtCK are highly redox sensitive whereby oxidative modifications render them dysfunctional 
[200]. Given the known elevations in mitochondrial ROS emission during impaired oxidative 
phosphorylation in DMD [156], SBT-20 may represent a viable therapeutic option for targeting 
mitochondrial bioenergetics to improve pathophysiology in DMD.   
In this investigation, we evaluated the efficacy of the cardiolipin-targeted peptide SBT-20 in 
improving muscle quality and function in respiratory and skeletal muscle from D2.mdx mice in 
the early stages of disease progression. 4 weeks of treatment with SBT-20 improved 
mitochondrial bioenergetics in both diaphragm and quadriceps muscle, which was associated 
with muscle specific improvements in pathophysiology as well as increases in lower limb muscle 
volume and forelimb grip strength. 
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Material and Methods 
Animal Care 
D2.mdx mice originated from a breeding colony maintained at York University (Toronto, Canada) 
and sourced from Jackson Laboratories (Bar Harbor, United States). Beginning at 4-days of age, 
all animals within a litter received a daily subcutaneous injection of SBT-20 (Stealth 
Biotherapeutics; Newton, MA, USA) at a dose of 5 mg/kg. At 10 days of age, pups were sexed 
and treatment commenced in male offspring. Age matched litters received the volume equivalent 
dose of vehicle (0.9% NaCl) through subcutaneous injection. Animals were treated for 28 days 
followed by functional testing and subsequent muscle harvest. 4-week old DBA/2J wildtype (WT) 
mice were obtained directly from Jackson Laboratories due to breeding challenges with this strain. 
Upon arrival, DBA/2J mice were given a minimum of 72 hours to acclimatize before experiments 
were performed. All animals were provided access to standard chow and water ad libitum. All 
experiments and procedures were approved by the Animal Care Committee at York University 
(AUP Approval Number 2016-18) in accordance with the Canadian Council on Animal Care. 
Body Composition and Functional Assays 
Timeline of measurements and muscle allocation 
Various functional assessments were performed on mice before surgical removal of muscle for in 
vitro analyses. Specifically, 2 days prior to surgery, whole body functional testing (Cage Hang 
Time, Forelimb Grip Strength and Voluntary Wheel Running) were performed. On the day of 
surgery, prior to muscle harvest, animals underwent a µCT scan for muscle volume followed by 
in situ assessment of quadriceps (Quad) force production. Immediately following tissue harvest, a 
portion of the Diaphragm from used for in vitro assessment of Diaphragm force production. Due 
to tissue limitations, a separate subset of animals was used for histochemistry, TEM, caspase 
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activity and glutathione measurements. Methods for these assessments are described in detail 
below.   
Voluntary Wheel Running 
Animals were placed in individual cages equipped with a locked 14 cm diameter running wheel 
and rotation counter (VDO m3 bike computer, Mountain Equipment Co-Op, Vancouver, Canada). 
After 24 hours of acclimatization, wheels were unlocked and distance run over 24 hours was 
recorded. 
Cage Hang Time 
Animals were placed on top of a metal cage lid and positioned so that all four limbs grasped the 
cage. The cage lid was inverted so that the mouse was hanging and cage hang time was recorded 
for a maximum of 180 seconds as previously described [156].  
Forelimb Grip Strength 
Forelimb grip strength was assessed using a force transducer (Mark 10 Digital Force Gauge, 
Copiague, NY) and has been described in detail previously [156]. Briefly, mice were removed 
from their cages by the tail and brought towards a grid attached to the force transducer until such 
time that the mice grasped the grid with their forepaws. Upon grasping, animals were pulled away 
from the grid until their grasp was broken. Peak tension was recorded, and the trial was repeated 
twice more. If the animal did not show resistance to the experimenter, the trial was not recorded. 
Maximum peak tension from the best of 3 trials was used for analysis [233]. 
In Vivo µCT Scans 
In vivo body scans were performed using µCT (SkyScan 1278, Bruker-microCT, Kontick, 
Belgium) as previously described [156]. Following scans, lower limb muscle volume was analyzed 
through reconstruction of the image using NRecon (software version 1.7.0.4, Bruker-microCT, 
 
 
149 
Kontick, Belgium) followed by the analysis of a selected region of interest using CTAn (software 
version 1.15.4.0, Bruker-microCT, Kontick, Belgium). The region of interest for hind-limb muscle 
volume was landmarked from the top of the patella to the ankle joint and was quantified by setting 
thresholds for fat free mass (76-102), expressed as volume (mm3) of lean mass/g body weight.  
In Situ Quadriceps Force Production 
In situ force production of the Quad muscle was partially adapted from previous methods [2]. In 
brief, mice were anesthetized with isoflurane and placed on a platform maintained at 37° C. Hair 
around the knee was removed and an incision was made above the patella to expose the femoral 
tendon which was then tightly secured with suture. Once the knot was in place, the tendon was 
carefully severed and the suture was attached to an Aurora Scientific 305C muscle lever arm with 
s hook (Aurora, Ontario, Canada). The knee was secured with a vertical knee clamp immobilizing 
the knee joint with a 27 G needle. Contraction of the Quad was controlled through percutaneous 
stimulation of the femoral nerve anterior to the hip joint. Optimal resting length (Lo) was 
determined using single twitches (pulse width = 0.2ms) at varying muscle lengths. Once Lo was 
established, force as a function of stimulation frequency was measured during 7 isometric 
contractions at varying stimulation frequencies (1, 40, 60, 80, 100, 120, 140, 160 Hz). Following 
the force-frequency protocol, a 5 minute recovery period was provided followed by a maximum 
torque test, performed at the frequency by which maximum force was achieved during the force-
frequency curve. The quadriceps muscle was then harvested and weighed to allow for 
normalization of force production to muscle weight in mg. 
In Vitro Diaphragm Force Production 
Assessment of contractile force in Diaphragm strips was partially adapted from previously 
described methods [290, 291]. The entire Diaphragm was removed and placed in a petri dish of 
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ice cold Ringer solution containing (in mM):121 NaCl, 5 KCl, 1.8 CaCl2, 0.5 MgCl2, 0.4 NaHPO4, 
24 NaHCO3, 5.5 glucose and 0.1 EDTA; pH 7.3 [292] oxygenated with 95% O2 and 5% CO2. 
Diaphragm strips were cut from the central region of the lateral costal hemidiaphragm. The strips 
included an adjacent section of rib on either side of the strip and part of a central tendon. Silk 
suture was tied to the central tendon as well the ribs, and the preparation was transferred to an 
oxygenated bath filled with Ringer solution, maintained at 25°C. The suture secured to the central 
tendon was then attached to a lever arm while the suture loop secured to the ribs was attached to a 
force transducer. The Diaphragm strip was situated between flanking platinum electrodes driven 
by a biphasic simulator (Model 305C; Aurora Scientific, Inc., Aurora, ON, Canada).  Optimal 
resting length (Lo) was determined using single twitches (pulse width = 0.2ms) at varying muscle 
lengths. Once Lo was established, force as a function of stimulation frequency was measured 
during 7 isometric contractions at varying stimulation frequencies (1, 10, 20, 40, 60, 80, 100, 120, 
140 Hz). Following the force-frequency protocol, a 5 minute recovery period was provided 
followed by a maximum torque test, performed at the frequency by which maximum force was 
achieved during the force-frequency curve. Force production was normalized to the calculated 
CSA of the muscle strip (m/l*d) where m is the muscle mass, l is the length, and d is mammalian 
skeletal muscle density (1.06 mg/mm3).  
 
Mitochondrial Bioenergetic Assessments 
Preparation of Permeabilized Muscle Fibre Bundles (PmFB) 
This technique is partially adapted from previous methods and has been described elsewhere [237-
240]. Briefly, muscles were removed from mice during anaesthesia with isoflurane. The Quad 
from the non-stimulated leg as well as a strip of Diaphragm were removed and immediately placed 
in ice-cold BIOPS, containing (in mM): 50 MES Hydrate, 7.23 K2EGTA, 2.77 CaK2EGTA, 20 
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imidazole, 0.5 dithiothreitol, 20 taurine, 5.77 ATP, 15 PCr, and 6.56 MgCl2·6 H2O (pH 7.1). Each 
muscle was trimmed of connective tissue and fat and divided into several small muscle bundles 
(~2–7 mm, 1.0–2.5 mg wet weight). Each bundle was gently separated along the longitudinal axis 
to form bundles that were treated with 40 µg/ml saponin in BIOPS on a rotor for 30 minutes at 4° 
C. Bundles destined for mitochondrial H2O2 emission (mH2O2) measurements (described below) 
were also treated with 35 µM 2,4-dinitrochlorobenzene (CDNB) during the permeabilization step 
to deplete glutathione and allow for detectable rates of mH2O2 [242]. Following permeabilization, 
the PmFB were divided into three groups; 1) bundles intended for high resolution respirometry 
were placed in MiR05 containing (in mM): 0.5 EGTA, 10 KH2PO4, 3 MgCl2·6 H2O, 60 K-
lactobionate, 20 Hepes, 20 Taurine, 110 sucrose and 1 mg/ml fatty acid free BSA (pH 7.1) while 
2) bundles intended for mH2O2 were placed in Buffer Z containing (in mM): 105 K-MES, 30 KCl, 
10 KH2PO4, 5 MgCl2·6 H2O, 1 EGTA and 5mg/ml BSA (pH 7.4) . PmFB were washed on a rotor 
at 4°C in MiR05 or Buffer Z until the measurements were initiated. 3) Bundles intended for 
calcium retention capacity were placed in Buffer Y + 1 mM EGTA containing (in mM): 250 
sucrose, 10 tris-HCl, 20 tris-base, 10 KH2PO4 and 0.5mg/mL BSA and washed on a rotor at 4° C 
for 10 minutes. PmFB were then transferred to a second wash of Buffer Y + 10 µM blebbistatin 
(BLEB, see below) and were washed on a rotor at 4°C until measurements were initiated. 
Following permeabilization and washing, all mitochondrial bioenergetic measurements were 
performed in the same order from one animal to another and between groups to ensure consistent 
durations of the wash step.  
Mitochondrial Respiration 
High-resolution O2 consumption measurements were conducted in 2 ml of respiration medium 
(MiR05) using the Oroboros Oxygraph-2k (Oroboros Instruments, Corp., Innsbruck, Austria) with 
 
 
152 
stirring at 750 rpm at 37 °C [239, 240, 243-245]. Respiration medium contained 20mM Cr to 
saturate mitochondrial creatine kinase or no creatine to prevent the activation of mtCK [283, 243]. 
A third condition of 13.9mM PCr and 9.1mM Cr was used to provide an equilibrium across mtCK 
as occurs in skeletal muscle at rest in vivo [247]. For ADP-stimulated respiratory kinetics, 5 mM 
pyruvate, accompanied by 2 mM malate, were added as Complex I substrates (via generation of 
NADH to saturate electron entry into Complex I) followed by a titration of submaximal ADP (25 
µM and 500 µM) and maximal ADP (5 mM). Cytochrome c was added to test for mitochondrial 
membrane integrity, with all experiments demonstrating <10% increase in respiration. Finally, 
succinate (20 mM) was then added to saturate electron entry into Complex II. All experiments 
were conducted in the presence of 5µM BLEB in the assay media to prevent spontaneous 
contraction of PmFB [243, 248, 244]. Each protocol was initiated with a starting [O2] of 
approximately 350 µM and was completed before the oxygraph chamber [O2] reached 150 µM as 
done previously [239, 240, 243-245]. Polarographic oxygen measurements were acquired in 2 s 
intervals with the rate of respiration derived from 40 data points and expressed as pmol/s/mg wet 
weight. PmFB were weighed in ~1.5 ml of tared BIOPS (ATP-containing relaxing media) to 
prevent rigor that occurs when weighing PmFB in open air (unpublished observations). 
Mitochondrial H2O2 Emission (mH2O2) 
mH2O2 was determined fluorometrically (QuantaMaster 40, HORIBA Scientific, Edison, NJ, 
USA) in a quartz cuvette with continuous stirring at 37°C, in 1 mL of Buffer Z supplemented with 
10 µM Amplex Ultra Red, 0.5 U/ml horseradish peroxidase, 1 mM EGTA, 40 U/ml Cu/Zn-SOD1,5 
µM BLEB and 20mM Cr. State II mH2O2 was induced using complex I substrates pyruvate 
(10mM) and malate (2mM) to assess maximal emission potential. Following the induction of state 
II mH2O2, a titration of ADP was added to progressively attenuate mH2O2. This assay was repeated 
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with no creatine in the assay buffer to compare ADP’s effects without mtCK-mediated phosphate 
shuttling. All measurements were made in the presence of 1 µM BLEB to prevent ADP-induced 
rigor as described above. After the experiments, the fibres were rinsed in double deionized H2O, 
lyophilized in a freeze-dryer (Labconco, Kansas City, MO, USA) for >4 h and weighed on a 
microbalance (Sartorius Cubis Microbalance, Gottingen, Germany). The rate of H2O2 emission 
was calculated from the slope (F/min), from a standard curve established with the same reaction 
conditions and normalized to fibre bundle dry weight.  
Mitochondrial Calcium Retention Capacity  
This assay is partially adapted from previous methods [249] and has been described in detail 
elsewhere [156]. Briefly, mitochondrial calcium retention capacity measurements were completed 
spectrofluorometrically (QuantaMaster 80, HORIBA Scientific, Edison, NJ, USA) in a cuvette 
with continuous stirring at 37° C, in 300 µL of Buffer Y containing 1 µM Calcium Green-5N 
(Invitrogen), 2 µM tharpsigargin, 5 mM 2-deoxyglucose, 2 U/mL hexokinase, 20mM creatine, 5 
µM BLEB and 40 µM EGTA. Minimum fluorescence was obtained following the addition of the 
PmFB, 5 mM glutamate + 2 mM malate and 5 mM ADP to the assay buffer. Calcium uptake was 
then initiated by a single 8 nmol pulse of CaCl2. Subsequent 4 nmol pulses of Ca2+ were added 
until mitochondrial permeability transition pore (PTP) opening was evident. Two 0.5 mM pulses 
of Ca2+ were then added to saturate the fluorophore and establish a fluorescent maximum. All 
experiments were conducted at 37 °C. Changes in free Ca2+ in the cuvette during mitochondrial 
Ca2+ uptake were then calculated using the known Kd for Calcium Green 5-N and the equations 
established for calculating free ion concentrations using ion-sensitive fluorophores [250]. After 
the experiments, the fibres were dried and weighed as described above. 
In Vitro Muscle and Blood Analyses 
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Caspase Activity 
Enzymatic activities of caspase 3 and caspase 9 were measured fluorometrically using substrates 
Ac-DVED-AMC and Ac-LEHD-AMC (Enzo Life Sciences, Farmingdale, NY) as previously 
described [251, 252]. 
Glutathione 
Glutathione was assessed as previously described [255]. GSH was assessed by UV-HPLC 
monitoring of NEM-GSH while GSSG was assessed by fluorescent-HPLC by tracking O-
pthalymide (OPA, Sigma-Aldrich, Oakville, Canada) tagged GSH through a flow-through cuvette 
following GSSG conversion to GSH (FireflySci 8830, NY, USA) in a QuantaMaster 40 
spectrofluorometer (HORIBA, NJ, USA). All values were normalized to protein concentration and 
reported in µmol/g protein.   
Western Blotting 
An aliquot of frozen Quad and Diaphragm (10–30 mg) from each animal was homogenized in a 
plastic microcentrifuge tube with a tapered teflon pestle in ice-cold buffer containing (mm): 40 
Hepes, 120 NaCl, 1 EDTA, 10 NaHP2O7·10H2O pyrophosphate, 10 β-glycerophosphate, 10 NaF 
and 0.3% CHAPS detergent (pH 7.1 adjusted using KOH). Protein concentrations were determined 
using a BCA assay (Life Technologies, Carlsbad, CA, USA). Fifty µg of denatured and reduced 
protein was subjected to 10–12% gradient SDS-PAGE followed by transfer to low- fluorescence 
polyvinylidene difluoride membrane. Membranes were blocked with LI-COR Odyssey Blocking 
Buffer (LI-COR, Lincoln NE, USA) and immunoblotted overnight (4°C) with antibodies specific 
for each protein. A commercially available monoclonal antibody was used to detect electron 
transport chain proteins (human OXPHOS Cocktail, ab110411; Abcam, Cambridge, UK, 1:250 
dilution), including V-ATP5A (55 kDa), III-UQCRC2 (48 kDa), IV-MTCO1 (40 kDa), II-SDHB 
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(30 kDa) and I-NDUFB8 (20 kDa). Commercially available polyclonal antibodies were used to 
detect voltage dependent anion carrier 2 (VDAC 2) (32059, 33 kDa; Santa-Cruz, 1:1000), adenine 
nucleotide translocase 1 (ANT 1) (ab180715, 32 kDa; Abcam, 1:1000) and sarcomeric s-mtCK 
(generous gift from Dr Uwe Schlattner, Grenoble, France; 42 kDa, 1:1000). The mtCK antibody 
has been validated previously to confirm specificity[256].  
After overnight incubation in primary antibodies, membranes were washed three times, for 
5 minutes each time, in TBST and incubated for 1 hour at room temperature with the corresponding 
infrared fluorescent secondary antibody (LI-COR Biotechnology, Lincoln, NE, USA). 
Immunoreactive proteins were detected by infrared imaging (LI-COR CLx; LI-COR) and 
quantified by densitometry (ImageJ, http://imagej.nih.gov/ij/). All images were normalized to a 
whole membrane Amido Black total protein stain (A8181, Sigma, St Louis, MO, USA).  
Histochemistry 
Immediately after removal from the animal, a strip of Quad and Diaphragm muscle was embedded 
in O.C.T compound (Tissue Tek), frozen in liquid nitrogen-cooled isopentane and stored at -80°C 
until analysis. To determine fibrotic area, skeletal muscle sections were stained with Picrosirius 
Red (fibrotic regions stain red for collagen). Diaphragm and quad sections were imaged on a Nikon 
90i-eclipse microscope (Nikon Inc.; Melville, NY) and analyzed with the NIS Elements AR 
software (v 4.6; Nikon).  All images were obtained with a ×20 objective. The operator was blinded 
with respect to the experimental group of each sample. Images were taken of the entire 8-µm 
section. To determine collagen content, one large region of interest (ROI) was created, 
representing the majority of the area of the section, with the exception of the periphery and any 
obvious artifact. A threshold was applied to create a binary layer to remove background 
fluorescence, and collagen content was expressed as a ratio of binary area / ROI area. To determine 
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muscle fiber size, 100 muscle fibers were manually circled per image, and minimum ferret 
diameter was measured using from NIS Elements software.  
Transmission Electron Microscopy (TEM) 
A thin strip of Quad and Diaphragm tissue was immediately fixed in 2% (v/v) glutaraldehyde in 
0.1 mol/l sodium cacodylate buffer and processed as described previously [253]. Seven unique 
fibers were represented by nine non-overlapping micrographs (3 subsarcolemmal, 6 
intramyofibrillar) each per animal. All images were acquired at x30,000 magnification. 
Quantification was achieved using object measurements in Nikon Elements software by manually 
outlining mitochondria and converting these to actual size using a calibration grid [254]. 
Serum Creatine Kinase 
Serum creatine kinase activity was quantified as described previously [156]. In brief, creatine 
kinase activity was measured spectrofluorometrically (QuantaMaster 80, HORIBA Scientific, 
Edison, NJ, USA) based on the autofluorescence of NADPH (excitation – 340 nm, emission – 450 
nm) using the Pointe Scientific Serum Creatine Kinase kit (Pointe Scientific, Canton, MI, USA). 
Creatine kinase activity (U/L) was calculated from the rate of NADPH production (F/min) applied 
to a standard curve produced under the same conditions and normalized to volume dilution. 
Statistics 
Results are expressed as means ± SEM. The level of significance was established as p<0.05 for all 
statistics. The D’Agostino – Pearson omnibus normality test was first performed to determine 
whether data resembled a Gaussian distribution. If data failed the normality test, a Kruskal-Wallis 
non-parametric test followed by a Dunn’s post-hoc test were performed (cage hang time, % body 
fat, seum CK, creatine-dependent state II mH2O2 emission in the Diaphragm and Quad, creatine-
independent state III mH2O2 emission in the Diaphragm, Diaphragm caspase 9, Quad ANT1 and 
VDAC 2 and Diaphragm GSH:GSSG). When data (all other data) passed normality, a 1-way 
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ANOVA followed by an LSD post-hoc test was performed for all data excluding state III 
respiration, state III mH2O2, force frequency curves and TEM. The aforementioned data sets 
underwent a 2-way ANOVA followed by an LSD post-hoc test (GraphPad Prism Software, La 
Jolla, CA, USA). 
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Results 
SBT-20 treatment improves Diaphragm force production and lowers fibrosis in D2.mdx mice 
Evaluation of force production in Diaphragm strips in vitro revealed an increase in specific force 
as a function of frequency in D2.mdx mice relative to saline treated D2.mdx mice (SAL) (main 
effect across frequencies, p<0.05) but remained lower than WT controls (main effect across 
frequencies, p<0.01; Figure 1A). Maximum force produced by SAL was significantly lower 
relative to WT (-53% vs WT, p<0.05). SBT-20 treatment improved maximum force production 
such that differences relative to WT were no longer evident (Figure 1B). Muscle fibre size, 
evaluated using minimum feret diameter, was not different among the three groups (Figure 1C). 
The degree of fibrosis in SAL animals was significantly higher relative to WT (+44%, p<0.05). 
SBT-20 did not alter degree of fibrosis in the Diaphragm as the degree of fibrosis was still elevated 
relative to WT (+63%, p<0.05; Figure 1D). 
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Figure 6-1:Evaluation of muscle quality in Diaphragm following treatment with SBT-20. 
Diaphragm specific force was evaluated (A) across a range of frequencies and through (B) 
maximal tetanic force. Fibre diameter was assessed using (C) minimum feret diameter. Degree of 
fibrosis (D) was quantified using picrosirius red staining. Results represent mean ± SEM; n=10-
12 (A-B) and n=6 (C-D); * p<0.05, DMD-Saline vs WT; # p<0.05, DMD-SBT-20 vs WT; $ 
p<0.05, DMD-SBT-20 vs DMD-Saline. 
 
Improvements in Diaphragm force and histopathology are associated with altered creatine-
independent mitochondrial bioenergetics  
An important consideration in this investigation is the design of in vitro assessments of 
mitochondrial bioenergetics that model in vivo critical parameters controlling respiratory and H2O2 
emission kinetics. Indeed, our previous work identified Complex I dysfunction and loss of central 
respiratory control by ADP and creatine as the cause of elevated oxidant generation during 
impaired oxidative phosphorylation. Based on these findings, we believe that a comprehensive 
assessment of mitochondrial responsiveness to ADP in the context of oxidative phosphorylation 
and mH2O2 emission may be necessary to fully elucidate the effects of SBT-20 on mitochondrial 
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bioenergetics. Specifically, the stimulation of mitochondrial respiration and mitochondrial H2O2 
(mH2O2) emission during oxidative phosphorylation in Diaphragm were initiated using pyruvate 
(5mM) and malate (2mM) which generates NADH to stimulate Complex I and were assessed in 
both the presence (+Cr) and absence (-Cr) of 20mM creatine to drive energy transfer dependent 
(Figure 2C) or independent of mtCK, respectively (Figure 2F). 
We first determined whether SBT-20 altered ADP-independent (state II) respiration and mH2O2 
emission during oxidative phosphorylation. State II respiration is driven by proton leak through 
uncoupling pathways independent of ATP synthase. Proton leak-dependent respiration both +Cr 
and -Cr was lower in SAL relative to WT (+Cr: -21%, p=0.07; –Cr: -26%, p<0.05). SBT-20 
treatment did not alter state II respiration rates such that respiration rates remained impaired 
relative to WT both +Cr (-28%, p<0.05; Supplemental Figure 1A) and -Cr (-33%, p<0.05; 
Supplemental Figure 1C). State II mH2O2 emission during oxidative phosphorylation reveals the 
capacity of oxidant generation by Complex I during oxidative phosphorylation, independent of the 
influence of ADP. State II mH2O2 emission was unchanged across all 3 groups +Cr (Supplemental 
Figure 1B) yet –Cr, SAL was significantly lower relative to WT (-26%, p<0.05) and SBT-20 
treatment tended to be lower relative to WT (-22%, p=0.06; Supplemental Figure 1D) while no 
difference between SBT-20 and SAL were evident. These findings highlight that any SBT-20-
derived changes in mitochondrial bioenergetics are ADP-dependent in nature.  
We then determined whether SBT-20 resulted in alterations to the central role of ADP in 
stimulating respiration and attenuating mH2O2 emission during oxidative phosphorylation. ADP-
supported (state III) respiration and mH2O2 emission was evaluated in the presence of 
low/physiological (25µM), high sub-maximal (500µM) and saturating concentrations (5mM) of 
ADP, creating a titration curve mimicking low and high metabolic stress. +Cr, SAL ADP-
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supported respiration was significantly impaired across all [ADP] relative to WT (-22 to -31%, 
main effect across ADP, p<0.05). SBT-20 did not rescue the impaired respiration such that rates 
across all [ADP] were no different from SAL and significantly lower relative to WT (-20 to -25%, 
main effect across ADP, p<0.05; Figure 2A). mH2O2 emission was no different between SAL and 
WT groups during oxidative phosphorylation +Cr, and no effect of SBT-20 was seen on mH2O2 
emission in the presence of creatine (Figure 2B).  
Alternatively, -Cr, SBT-20 treatment rescued both impaired ADP-dependent respiration and 
mH2O2 emission during oxidative phosphorylation. SAL respiration rates were significantly lower 
relative to WT (-10 to -36%, main effect across ADP, p<0.05) while SBT-20 treatment resulted in 
respiration rates higher relative to SAL (+9 to 21%, main effect across ADP, p<0.05) that were no 
different compaired to WT controls (Figure 2D). SAL mH2O2 emission was also significantly 
elevated relative to WT during oxidative phosphorylation (+31 to +47%, main effect across ADP, 
p<0.05) and SBT-20 treatment significantly decreased mH2O2 emission compared to SAL (-9 to -
10%, main effect across ADP, p<0.05), however emission rates remained significantly elevated 
relative to WT controls (+13 to +34%, main effect across ADP, p<0.05; Figure 2E).  
We also assessed state III respiration in the presence of 13.9mM PCr and 9.1mM Cr, 
concentrations found in vivo in resting skeletal muscle. State III respiration was impaired in SAL 
animals in Diaphragm (-5 to -17%, main effect across ADP, p<0.05; Supplemental Figure 2A). 
SBT-20 further impaired respiration in the Diaphragm such that respiration rates in SBT-20 treated 
muscle were significantly lower than SAL (-8 to -12%, main effect across ADP, p<0.05) and WT 
(-12 to -28%, main effect across ADP, p<0.05; Supplemental Figure 2A) indicating some form 
of heightened sensitivity to phosphocreatine following treatment with SBT-20.  
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Improvements in mitochondrial bioenergetics following treatment with SBT-20 are not due to 
changes in protein content of the regulators of energy exchange in Diaphragm 
Given the improvements in respiration and mH2O2 emission during oxidative phosphorylation that 
resulted from SBT-20 treatment, the protein content of key regulators of energy exchange was 
quantified in all 3 groups. Protein content of ANT 1 and VDAC 2, situated in the inner and outer 
mitochondrial membrane respectively, are significantly decreased in SAL Diaphragm (ANT 1: -
26%, p<0.05; VDAC 2: -36%, p<0.05) relative to WT. SBT-20 treatment did not alter ANT 1 or 
VDAC 2 content relative to SAL such that content remained reduced relative to WT (ANT 1: -
25%, p<0.05; VDAC 2: -28%, p<0.05; Figure 2G). MtCK content was no different among groups 
in Diaphragm muscle (Figure 2G). Quantification of the complexes comprising the electron 
transport chain (ETC) was also completed to provide an index of mitochondrial content. Individual 
ETC subunit content was unchanged across groups in the Diaphragm (Figure 2H). However, the 
sum of all 5 subunits was significantly decreased in SAL relative to WT (-13%, p<0.05; Figure 
2H). SBT-20 treatment did not alter the sum of 5 subunits relative to SAL such that total content 
was still reduced relative to WT (-16%, p<0.05; Figure 2H).  
SBT-20 reduces content of oxidized glutathione in Diaphragm muscle 
The content of the reduced form of glutathione (GSH) was unchanged across all groups in 
Diaphragm muscle (Figure 2I). However, content of the oxidized form of glutathione (GSSG) was 
significantly elevated in SAL relative to WT (+75%, p<0.05) (Figure 2J). SBT-20 treatment 
reduced the content of GSSG in Diaphragm to levels no different from WT controls (Figure 2J). 
Total glutathione (Figure 2K) and the ratio of GSH:GSSG (Figure 2L) were unchanged across 
all groups. 
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Figure 6-2: Evaluation of mitochondrial bioenergetics and regulators of energy exchange in Diaphragm muscle following 
treatment with SBT-20. The leading model for energy exchange involves a (C) creatine-dependent and (D) creatine-independent 
pathway. ADP stimulated respiration and mH2O2 emission during oxidative phosphorylation, supported by Complex-I substrates 
pyruvate (5mM) and malate (2mM), were assessed in the presence (Creatine Dependent, A-B) and absence (Creatine Independent, D-
E) of 20mM creatine across a range of low and high [ADP], n=10-12. Protein content of adenine nucleotide translocase 1 (ANT 1) on 
the inner mitochondrial membrane, voltage dependent anion carrier 2 (VDAC 2) on the outer mitochondrial membrane and 
mitochondrial creatine kinase (mtCK) found in the inner membrane space (G) n=8. Protein content of electron transport chain 
components were also quantified (H) n=8. Glutathione was measured in muscle homogenate using HPLC-UV for the detection of GSH 
(I) and HPLC-Fluorescence for the detection of GSSG (J). The GSH:GSSG ratio (K) and total glutathione (L) were calculated from 
GSH and GSSG measurements n=8. Results represent means ± SEM; * p<0.05, DMD-Saline vs WT; # p<0.05, DMD-SBT-20 vs WT; 
$ p<0.05, DMD-SBT-20 vs DMD-Saline.  
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SBT-20 reduces mitochondrial-derived caspase activity but does not alter mitochondrial ultra-
structure in Diaphragm  
We next determined whether alterations in respiration and mH2O2 emission following SBT-20 
treatment were associated with changes in markers of mitochondrial-derived cell death. In 
Diaphragm muscle, there was no difference in the [Ca2+] required to induce PTP opening across 
the 3 groups (Figure 3A). However, SBT-20 significantly decreased caspase 9, a marker of 
mitochondrial-derived apoptosis relative to both SAL (-23%, p<0.05) and WT (-14%, p<0.05; 
Figure 3B) yet there was a significant increase in caspase 3 activity in both SBT-20 (+64%, 
p<0.005) and SAL (+60%, p<0.005; Figure 3B) groups relative to WT and no difference between 
SBT-20 and SAL.  
We then evaluated mitochondrial structure and morphology following treatment with SBT-20. SS 
mitochondria were unaltered in SAL animals and as such, SBT-20 had no effect on SS ultra-
structure in Diaphragm muscle. IMF mitochondria were found to be swollen in SAL muscle and 
SBT-20 did not prevent this alteration in morphology (Figure 3C). SAL animals also 
demonstrated less IMF mitochondria per unit area than WT controls, however, this alteration was 
rescued by SBT-20 treatment (Figure 3D). Mitochondria density, likely driven by the enlarged 
mitochondria was elevated in SAL relative to WT and SBT-20 did not affect this marker (Figure 
3E).   
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Figure 6-3: Evaluation of mitochondrial quality in Diaphragm muscle following treatment 
with SBT-20. Calcium retention capacity, an index of susceptibility to permeability transition pore 
opening was assessed in permeabilized fibres from Diaphragm muscle (A); n=10-12. 
Mitochondrial-induction of apoptosis was evaluated through caspase 9 activity followed by it’s 
down-stream target caspase 3 (B); n=8. Transmission electron micrographs were acquired in the 
and analyzed for mitochondrial size (C), distribution (D) and density (E) within the 
intermyofibrillar (IMF) and subsarcolemmal (SS) area of the muscle; scale bar = 1 µm, n=3. 
Results represent mean ± SEM; * p<0.05, DMD-Saline vs WT; # p<0.05, DMD-SBT-20 vs WT; 
$ p<0.05, DMD-SBT-20 vs DMD-Saline. 
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SBT-20 decreases the degree of fibrosis in Quad muscle yet has no effect on force production  
Evaluation of Quad force production in situ revealed that SBT-20 did not increase force as a 
function of frequency relative to SAL such that both groups displayed significantly lower force 
production for a given frequency relative to WT controls (main effect across frequencies, p<0.05; 
Figure 4A). Based on the frequency at which maximum force was produced for a given animal, 
maximum tetanic force was then evaluated in each animal. SBT-20 treatment did not improve 
maximum tetanic force in Quad of D2.mdx mice (Figure 4B). Muscle fibre size, evaluated using 
minimum feret diameter, was no different among the three groups (Figure 4C) although 
qualitatively, there appeared to be a rightward shift in fibre distribution, seemingly normalizing 
fibre distribution following SBT-20 treatment. The degree of fibrosis in SAL animals was 
significantly higher relative to WT (+43%, p<0.05). SBT-20 decreased degree of fibrosis in 
relative to SAL (-66%, p=0.052) such that no differences were evident relative to WT controls 
(Figure 1D).  
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Figure 6-4: Evaluation of muscle quality in Quad following treatment with SBT-20. Quad 
specific force was evaluated (A). across a range of frequencies and through (B) maximal tetanic 
force, n=10-12. Fibre diameter was assessed using (C) minimum feret diameter, n=6. (D) Degree 
of fibrosis was quantified using picrosirius red staining, n=6. Results represent mean ± SEM; * 
p<0.05, DMD-Saline vs WT; # p<0.05, DMD-SBT-20 vs WT; $ p<0.05, DMD-SBT-20 vs DMD-
Saline.  
SBT-20 improves mitochondrial bioenergetics in a creatine-dependent manner in Quad 
muscle from D2.mdx mice 
The aforementioned bioenergetic experiments in Diaphragm muscle were repeated in Quad muscle 
across all three groups. +Cr, State II respiration and mH2O2 emission during oxidative 
phosphorylation were no different across the 3 groups (Supplemental Figure 1E and F) yet –Cr 
respiration was significantly lower in SAL vs WT (-41%, p<0.05) and SBT-20 did not rescue this 
impairment (-44% vs WT, p<0.05; Supplemental Figure 1G). –Cr mH2O2 emission during 
oxidative phosphorylation was no different across groups (Supplemental Figure 1F). These 
findings once again highlight the ADP-dependency of SBT-20’s effect.  
We then determined whether SBT-20 resulted in alterations to the central role of ADP in 
stimulating respiration and attenuating mH2O2 emission during oxidative phosphorylation in the 
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presence of varying [ADP]. +Cr, ADP-supported (state III) respiration was impaired in SAL 
relative to WT (-21 to -44%, main effect across ADP, p<0.05). SBT-20 treatment improved state 
III respiration relative to SAL (+18 to +25%, main effect across ADP, p<0.05) but rates remained 
lower than WT controls (-17 to -33%, main effect across ADP, p<0.05; Figure 5A). Similarly, 
+Cr ADP-stimulated mH2O2 emission is elevated during oxidative phosphorylation in SAL 
relative to WT (+42 to +82%, main effect across ADP, p<0.05) and SBT-20 treatment decreased 
mH2O2 emission relative to SAL (-10 to -25%, main effect across ADP, p<0.05) yet emission 
remained elevated compared to WT controls (+28 to +40%, main effect across ADP, p<0.05; 
Figure 5B). Alternatively, -Cr, while ADP-supported respiration was reduced in SAL relative to 
WT (-33 to -45%, main effect across ADP, p<0.05), SBT-20 had no effect on –Cr respiration 
relative to SAL with rates remaining significantly impaired relative to WT controls (-37 to -50%, 
main effect across ADP, p<0.05; Figure 5C). –Cr, mH2O2 emission was elevated in SAL relative 
to WT during oxidative phosphorylation (+23 to +31%, main effect across ADP, p<0.05). SBT-20 
treatment attenuated this impairment such that there were no differences in emission rates relative 
to WT (Figure 5D). 
Similar to Diaphragm, ADP-supported respiration in the presence of in vivo concentrations of PCr 
and Cr was impaired in SAL animals (-30 to -32%, main effect across ADP, p<0.05; 
Supplemental Figure 2B) relative to WT and SBT-20 further impaired this respiration in Quad 
muscle such that respiration rates in SBT-20 treated muscle were significantly lower than SAL (-
19 to -27%, main effect across ADP, p<0.05;) and WT (-43 to -50%, main effect across ADP, 
p<0.05; Supplemental Figure 2B).  
Improvements in mitochondrial bioenergetics following treatment with SBT-20 are not due to 
changes in protein content of the regulators of energy exchange in Quad 
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Protein content of ANT 1 and VDAC 2, were significantly decreased in SAL (ANT 1: -29%, 
p<0.05; VDAC 2: -29%, p<0.05) relative to WT. SBT-20 treatment did not alter ANT 1 or VDAC 
2 content relative to SAL such that content remained reduced relative to WT (ANT 1: -36%, 
p<0.001; VDAC 2-36%, p<0.001; Figure 5E). MtCK content was significantly decreased in SAL 
relative to WT (-41%, p<0.01) and SBT-20 did not alter MtCK relative to SAL such that content 
remained reduced relative to WT (-47%, p<0.01; Figure 5E). Individual ETC subunit content was 
unchanged however, the sum of all 5 subunits was significantly decreased in SAL relative to WT 
(-21%, p<0.001; Figure 5F). SBT-20 treatment did not alter the sum of 5 subunits relative to SAL 
such that total content was still reduced relative to WT (: -14%, p<0.05; Figure 5F).  
Glutathione (reduced, oxidized, total glutathione and ratio of reduced: oxidized) in Quad muscle 
was unaltered in SAL relative to WT (Figure 5G-J) and as such, SBT-20 did not alter the 
intercellular oxidative environment in this muscle.
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Figure 6-5: Evaluation of mitochondrial bioenergetics and regulators of energy exchange in Quad muscle following treatment 
with SBT-20. The leading model for energy exchange involves a (C) creatine-dependent and (D) creatine-independent pathway. ADP 
stimulated respiration and mH2O2 emission, supported by Complex-I substrates pyruvate (5mM) and malate (2mM), were assessed in 
the presence (Creatine Dependent, A-B) and absence (Creatine Independent, D-E) of 20mM creatine with low and high [ADP], n=10-
12. Protein content of adenine nucleotide translocase 1 (ANT 1) on the inner mitochondrial membrane, voltage dependent anion carrier 
2 (VDAC 2) on the outer mitochondrial membrane and mitochondrial creatine kinase (mtCK) found in the inner membrane space (G), 
n=8. Protein content of electron transport chain components were also quantified (H), n=8. Glutathione was measured in muscle 
homogenate using HPLC-UV for the detection of GSH (I) and HPLC-Fluorescence for the detection of GSSG (J). The GSH:GSSG 
ratio (K) and total glutathione (L) were calculated from GSH and GSSG measurements, n=8. Results represent means ± SEM; * p<0.05, 
DMD-Saline vs WT; # p<0.05, DMD-SBT-20 vs WT; $ p<0.05, DMD-SBT-20 vs DMD-Saline.
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SBT-20 increases mitochondrial-derived caspase activity yet improves mitochondrial ultra-
structure in Quad  
We next determined whether alterations in respiration and mH2O2 emission following SBT-20 
treatment were associated with changes in markers of mitochondrial-derived cell death. 
Surprisingly, the [Ca2+] required to induce PTP opening was lower in SAL relative to WT (+60%, 
p=0.06) and SBT-20 reduced the [Ca2+] required to induce PTP opening relative to SAL (-60%, 
p<0.01) such that there was no difference relative to WT (Figure 6A). SBT-20 tended to increase 
caspase 9 activity relative to SAL (+29%, p=0.09) and was no different relative to WT (Figure 
6B) while caspase 3 activity was significantly elevated relative to both SAL (+51%, p<0.05) and 
WT (+54%, p<0.05) despite no difference in activity between SAL and WT (Figure 6B). Overall 
these findings indicate that SBT-20 enhances mitochondrial-derived apoptosis in Quad muscle. 
We then evaluated mitochondria structure and morphology. IMF mitochondria from SAL Quad 
demonstrate a decrease in size (Figure 6C) and density (Figure 6E) relative to WT. SBT-20 has 
no effect on mitochondria size but significantly increases the number of mitochondria per unit area 
relative to both SAL and WT (Figure 6D) and density relative to SAL (Figure 6E). SS 
mitochondria also exhibit a decrease in size (Figure 6C) and density (Figure 6E) relative to WT. 
SBT-20 treatment increases SS mitochondria size, number of mitochondria per unit area and 
density relative to SAL.  
SBT-20 treatment improves limb muscle volume and specific markers of in vivo muscle 
function.  
Finally, we assessed the impact of SBT-20 treatment on body composition and whole body in vivo 
muscle function. Following 4 weeks of treatment with SBT-20, body weight was no different 
relative to saline treated SAL and both groups demonstrated significantly decreased body weight 
relative to WT controls (SAL: -9%, p<0.05; SBT-20: -12%, p<0.05; Figure 7A). Despite no 
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difference in muscle volume between SAL and WT controls, SBT-20 treatment resulted in a 
significant increase in lower limb muscle volume relative to SAL (+9%, p=0.08) and WT (+10%, 
p<0.05; Figure 7B). However, SBT-20 treatment did not have an effect on % fat mass such that 
there was no difference between SBT-20 and SAL and both groups were significantly lower than 
WT controls (SAL: -35%, p<0.001; SBT-20: -35%, p<0.05; Figure 7C). Additionally, SBT-20 
did not reduce serum creatine kinase levels relative to SAL and both SAL and SBT-20 rates were 
significantly elevated relative to WT (SAL: (+356%, p<0.05; SBT-20: +393%, p<0.05; Figure 
1D).  
We then evaluated muscle strength through a series of whole body in vivo measures. SBT-20 
treatment caused a significant increase in forelimb grip strength (+82% vs SAL, p<0.05) such that 
SBT-20 treated animals were no longer different than WT controls (Figure 1E). However, SBT-
20 did not result in increases in cage hang time relative to SAL and both DMD groups had 
significantly lower hang times relative to WT controls (SAL: -46%, p<0.05; SBT-20: -42%, 
p<0.05; Figure 1F). Distance covered during 24-hours of voluntary wheel running also did not 
increase following SBT-20 treatment relative to SAL and both groups ran significantly less than 
WT (SAL: -83%, p<0.05; SBT-20: -87%, p<0.05; Figure 1G).  
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Figure 6-6: Evaluation of mitochondrial quality in Quad muscle following treatment with 
SBT-20. Calcium retention capacity, an index of susceptibility to permeability transition pore 
opening was assessed in permeabilized fibres from Quad muscle (A); n=10-12. Mitochondrial-
induction of apoptosis was evaluated through caspase 9 activity followed by it’s down-stream 
target caspase 3 (B); n=8. Transmission electron micrographs were acquired in the and analyzed 
for mitochondrial size (C), distribution (D) and density (E) within the intermyofibrillar (IMF) and 
subsarcolemmal (SS) area of the muscle; scale bar = 1 µm, n=3. Results represent mean ± SEM; 
* p<0.05, DMD-Saline vs WT; # p<0.05, DMD-SBT-20 vs WT; $ p<0.05, DMD-SBT-20 vs 
DMD-Saline. 
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Figure 6-7: Evaluation of body composition and in vivo muscle function following treatment 
with SBT-20. Body weight (A), microCT analysis of lower limb muscle volume (B) and % fat 
mass (C). Whole body muscle damage was quantified by serum creatine kinase (CK) activity (D).  
Indices of muscle function were assessed by forelimb grip strength (E), cage hang time (F) and 
24-hour voluntary wheel running (G), Results represent mean ± SEM; n=12; * p<0.05, DMD-
Saline vs WT; # p<0.05, DMD-SBT-20 vs WT; $ p<0.05, DMD-SBT-20 vs DMD-Saline.  
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Discussion 
Despite the extensive evidence suggesting the mitochondria contribute to DMD myopathy, the 
direct implications of improving mitochondrial bioenergetics through the use of a mitochondrial-
targeted therapeutic for the treatment of this pathophysiology remains unknown. The present 
investigation presents data to support SBT-20 as a potential mitochondrial targeted therapy for the 
treatment of DMD myopathy through the improvement of mitochondrial bioenergetics. D2.mdx 
mice were injected daily with the mitochondrial-targeted peptide SBT-20, beginning at 4 days of 
age, for 28 days. Following treatment, SBT-20 improved mitochondrial bioenergetics in 
Diaphragm and Quad muscle and subsequently lowered mitochondrial-derived cell death in the 
Diaphragm while improving mitochondrial ultrastructure in the Quad, despite surprising increases 
in apoptosis in this muscle. These improvements in mitochondrial quality were associated with 
improved force production in the Diaphragm and decreased fibrosis in the Quad.  
Improvements in Diaphragm force production may be due to protection against fatigue-induced 
declines in contractility  
While beneficial overall to both the Diaphragm and Quad, SBT-20 had muscle-specific effects on 
certain indices of DMD myopathy. Firstly, force production was improved in Diaphragm muscle 
only. The Diaphragm presents a unique set of challenges in DMD as it is effected early and more 
severely than other skeletal muscles, however, the onset of respiratory failure in patients with 
DMD does not occur until the later stages of disease progression [293]. This is believed to be due 
to the compensatory recruitment of accessory respiratory muscles to carry the workload for the 
Diaphragm [53, 294]. Nevertheless, the Diaphragm undergoes progressive deterioration 
throughout lifespan in both rodent models and patients with DMD, likely due to its heavy use as a 
primary driver of ventilation at rest [294]. As such, even entirely inactive animals require the 
chronic contraction and relaxation of the Diaphragm, ultimately accelerating muscle degeneration. 
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Given the weakened state of the respiratory muscles in D2.mdx mice, even at this early time point 
[155], the Diaphragm is likely in a state of chronic fatigue by 4 weeks of age. Previous work using 
the general antioxidant n-acetylcysteine (NAC) demonstrated a protective effect against fatigue-
induced reductions in force production in the Diaphragm of rodents [295-297] as well as in humans 
following acute and chronic fatiguing protocols [298, 299].  However, the benefits of NAC were 
non-existent in un-fatigued muscle [295-297].  
While the Diaphragm muscle in D2.mdx mice is involuntarily chronically active, these animals 
exhibit little movement or activity from day to day. Therefore, it is plausible that the benefits of 
SBT-20 were evident in Diaphragm due to its underlying state of fatigue yet masked in Quad due 
the rested state of this muscle and that the induction of fatigue in Quad may have uncovered a 
protective effect of this peptide. Furthermore, SBT-20 lowered the intercellular content of oxidized 
glutathione (GSSG) in the Diaphragm only. It has been reported that inspiratory loading causes 
decreases in reduced glutathione and increases in GSSG content [300] while augmenting GSH and 
lowering GSSG pharmacologically increases respiratory muscle function [301]. Additionally, an 
oxidized intercellular environment has been positively correlated to disease pathology in patients 
with DMD [302]. Therefore, it is possible that the decrease in GSSG in Diaphragm muscle resulted 
in evident improvements in force production following SBT-20 treatment. 
On the contrary, the degree of fibrosis was unchanged in Diaphragm but decreased in Quad 
following treatment with SBT-20. While SBT-20 decreased the activation of mitochondrial-
derived apoptosis (decreased caspase 9 activity) in the Diaphragm, there was no effect on 
susceptibility to mitochondrial permeability transition pore (PTP) opening, which can trigger 
mitochondrial-derived necrosis. Additionally, caspase 3, the downstream effector caspase which 
is activated by both caspase 9 as well as non-mitochondrial targeted caspases [182], was still 
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significantly elevated relative to WT following treatment with SBT-20. As such, while SBT-20 
attenuated one cell death pathway, there were several other avenues through which cell death may 
have been occurring in Diaphragm muscle. Given the previously discussed fact that the diaphragm 
is in a constant state of activation, contraction-induced membrane tearing is likely heightened and 
it is possible that the mitochondria are not the only source of cellular dysfunction. While targeting 
the mitochondria proves partially beneficial, a combination of therapeutics targeting several 
dysfunctional pathways in the Diaphragm will likely provide greater benefits in this highly active 
muscle.   
SBT-20 treatment activates mitochondrial-derived apoptosis yet decreases fibrosis and improves 
mitochondria ultra-structure in Quad muscle 
As previously discussed, while no improvements in Quad force production were evident following 
SBT-20 treatment, improvements in muscle and mitochondria quality were robust. SBT-20 has a 
demonstrated ability to prevent mitochondrial-derived apoptosis through the stabilization of 
cytochrome c on the inner mitochondrial membrane. Based on this notion, we were surprised to 
find that SBT-20 increased mitochondrial derived apoptosis in Quad muscle which was 
accompanied by an increased susceptibility to mitochondrial PTP opening.  However, there were 
also subsequent improvements to mitochondria ultra-structure and decreased fibrosis. Taken 
together, these findings suggest that SBT-20 induced the preferential activation of mitochondrial-
derived apoptosis over necrosis which resulted in the removal of damaged mitochondria and an 
overall decrease in fibrosis. Indeed, previous work by Pauly and colleagues demonstrated that the 
pharmacological removal of defective mitochondria in mdx Diaphragm resulted in improved 
mitochondria morphology and histopathology, albeit through the induction of mitophagy as 
opposed to apoptosis [35].  
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Apoptosis has often been viewed as the preferential form of cell death over necrosis given it is a 
controlled process as it selectively targets individual damaged cells for degradation and 
furthermore, does not elicit an inflammatory response [180]. Early work by Tidball et al., proposed 
that apoptosis was the mode of cell death that occurred during the symptom free stage of disease 
progression (0-3 years) in patients with DMD. A notion that was confirmed in mdx mice whereby 
apoptosis was evident in the “pre-necrotic” phase of disease, and occurred in the absence of 
markers of muscle damage (ie. Fibrosis) [303]. Seemingly, it is possible that SBT-20 induced a 
switch to apoptosis, which has a somewhat protective effect, at least in the early stages of disease 
progression.  Given that apoptosis is an ATP-dependent process [183] and Quad from D2.mdx 
mice has evident impairments in oxidative phosphorylation, we propose that SBT-20 enhanced 
creatine-dependent exergy exchange (discussed below) which improved ADP’s ability to govern 
oxidative phosphorylation, allowing for the preferential selection of apoptosis over necrosis when 
cell death was induced within a cell.   
Modeling in vivo conditions in vitro reveal pathway specific alterations in mitochondrial 
bioenergetics 
Recent work from our laboratory has demonstrated the necessity of modeling in vivo conditions 
when designing in vitro assays in order to fully capture the source and degree of mitochondrial 
dysfunction that occurs in rodent models of DMD [304, 156]. Similarly, in the present 
investigation, treatment with SBT-20 revealed creatine-independent improvements in Diaphragm 
muscle and creatine-dependent improvements in Quad muscle with an underlying improvement in 
ADP’s ability to govern oxidative phosphorylation and attenuation of mH2O2 emission. SBT-20 
treatment had no effect on ADP-independent (state II) oxidative phosphorylation or mH2O2 
emission in either muscle. Given that SBT-20 binds to cardiolipin on the IMM, it is likely that this 
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peptide altered the regulation of energy exchange, thereby improving ADP’s provision of 
bioenergetics. 
Cardiolipin binds to ANT and mtCK as well as VDAC, forming a proteolipid complex across the 
mitochondrial membranes [200]. This complex creates stable contact sites between the IMM and 
OMM, and is shown to regulate energy exchange, reduce ROS formation and prevent permeability 
transition pore opening [200]. However, cardiolipin is highly susceptible to oxidative 
modifications and when oxidized, loses its binding affinity, resulting in the dissociation of the 
proteolipid complex [305, 261].  Given that SBT-20 did not alter protein content of the key 
regulators of energy exchange, improved bioenergetics are likely due to SBT-20’s effect on ANT 
and VDAC permeability and/or altered mtCK functionality. ANT, VDAC and mtCK are all known 
to be redox sensitive [261-263] and additionally, mtCK is highly susceptible to oxidative 
modifications, leading to enzymatic inactivation and octamer dissociation, as well as formation of 
crystalline mitochondrial inclusion bodies, all resulting in loss of function [153, 152]. Given the 
creatine-dependent improvements in Quad muscle, it is likely that SBT-20 stabilized this 
proteolipid complex through the prevention of oxidative modifications of these key regulators of 
energy exchange. 
It is somewhat perplexing that SBT-20 improved Diaphragm bioenergetics in a creatine-
independent manner given this muscle is highly oxidative and therefore, relies predominantly on 
creatine-dependent energy exchange [286]. Nevertheless, ANT and VDAC are also susceptible to 
several post-translational modifications including phosphorylation, acetylation [264, 265] and in 
ANT specifically, glutathionylation [306]. Spontaneous glutathionylation occurs when GSSG 
levels are elevated, a noted abnormality in D2.mdx Diaphragm tissue. It is possible that SBT-20 
lowered glutathionylation of ANT in Diaphragm muscle, thereby improving the cycling of 
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ADP/ATP into and out of the mitochondrial matrix respectively. While this is highly speculative, 
post translational modifications should be considered when trying to elucidate the mechanisms 
surrounding SBT-20 derived improvements in mitochondrial bioenergetics.   
Finally, in both Diaphragm and Quad muscle, SBT-20 treatment significantly impaired 
mitochondrial respiration in the presence of in vivo resting concentrations of PCr and Cr, 
suggesting that SBT-20 treatment results in a heightened sensitivity to PCr-induced inhibition of 
respiration. It has been demonstrated that Cr enhances mtCK-dependent ADP-stimulated 
respiration while PCr inhibits it [246]. Our results suggest that SBT-20 sensitized mtCK to PCr 
inhibition, a finding previously demonstrated following endurance training in humans [239]. While 
this is difficult to reconcile given the clear benefits of SBT-20 at the mitochondrial and 
pathological level, this finding certainly highlights a direct effect of SBT-20 on mtCK 
functionality, likely through the alteration of its redox status. Future work should consider 
exploring this mechanism further through the direct evaluation of the oxidative status of mtCK.   
Conclusions 
In summary, this investigation identified the mitochondrial-targeted peptide SBT-20 as a potential 
therapeutic candidate for the treatment and prevention of DMD disease pathology. Specifically, 4 
weeks of treatment with SBT-20 resulted in improved mitochondrial bioenergetics in Diaphragm 
and Quad muscle from D2.mdx mice. These improvements were associated with increased force 
production and decreased mitochondrial derived apoptosis in Diaphragm as well as decreased 
fibrosis and improved mitochondria morphology in Quad. This short-term treatment provides 
direct evidence that attenuating impaired mitochondrial bioenergetics improves DMD 
pathophysiology, an important finding given the need to develop additional therapies for this 
debilitating disease.   
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Supplemental Figures – Included in Manuscript 
 
 
Supplemental Figure 6-1: State II respiration and mH2O2 emission following SBT-20 
treatment.  State II (no ADP; proton leak) respiration and mH2O2 emission during oxidative 
phosphorylation were initiated using Complex-I substrates pyruvate (5mM) and malate (2mM) in 
Diaphragm (A-D) and Quad (E-H) in the presence and absence of 20mM Creatine. Results 
represent mean ± SEM; n=10-12; * p<0.05, DMD-Saline vs WT; # p<0.05, DMD-SBT-20 vs WT; 
$ p<0.05, DMD-SBT-20 vs DMD-Saline. 
 
 
Supplemental Figure 6-2: ADP-stimulated respiration in the presence of phosphocreatine 
and creatine. 13.9mM phosphocreatine (PCr) and 9.1mM creatine (Cr) were added to the assay 
media to assess state III respiration supported by Complex-I substrates pyruvate (5mM) and malate 
(2mM) in Diaphragm (A), Quad (B). Results represent mean ± SEM; n=10-12; * p<0.05, DMD-
Saline vs WT; # p<0.05, DMD-SBT-20 vs WT; $ p<0.05, DMD-SBT-20 vs DMD-Saline. 
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Supplemental Figures – not included in manuscript 
 
 
Supplemental Figure 6-3: Evaluation of mitochondrial bioenergetics in left ventricle muscle 
following SBT-20 treatment. ADP-supported respiration stimulated through Complex-I 
substrates pyruvate (5mM) and malate (2mM) was assessed in left ventricle muscle in the presence 
(A) and absence (B) of creatine. The ability of ADP to suppress mH2O2 emission during oxidative 
phosphorylation was evaluated under the same creatine-dependent (C) and independent (D) 
conditions. Mitochondrial susceptibly to permeability transition pore opening was evaluated 
through calcium retention capacity measurements (E). Results represent mean ± SEM; n=10-12; 
* p<0.05, DMD-Saline vs WT; # p<0.05, DMD-SBT-20 vs WT; $ p<0.05, DMD-SBT-20 vs 
DMD-Saline. 
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Supplemental Figure 6-4: Protein content of the key regulators of energy exchange in heart 
muscle following SBT-20 treatment. Protein content of adenine nucleotide translocase 1 (ANT 
1) on the inner mitochondrial membrane (A), voltage dependent anion carrier 2 (VDAC 2) on the 
outer mitochondrial membrane (B) and electron transport chain components were quantified (C). 
Results represent means ± SEM; n=8.  
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Supplemental Figure 6-5: Evaluation of glutathione in heart muscle following treatment with 
SBT-20. Glutathione was measured in muscle homogenate using HPLC-UV for the detection of 
GSH (A) and HPLC-Fluorescence for the detection of GSSG (B). The GSH:GSSG ratio (D) and 
total glutathione (C) were calculated from GSH and GSSG measurements. Results represent means 
± SEM; n=6-8.  
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Supplemental Figure 6-6: Absolute rates of complex-1 supported mH2O2 Emission. State II 
mH2O2 was supported by Complex-I substrates Pyruvate (5mM) and Malate (2mM) in Diaphragm 
and Quad muscle in the A. presence (Creatine Dependent) and B. absence (Creatine Independent) 
of 20mM creatine. ADP’s attenuation of maximal mH2O2 emission (state III) was evaluated in the 
Diaphragm (C – D) and Quad (E – F) in the same creatine-dependent and independent conditions. 
Results represent mean ± SEM; n=10-12; * p<0.05, DMD-Saline vs WT; # p<0.05, DMD-SBT-
20 vs WT; $ p<0.05, DMD-SBT-20 vs DMD-Saline. 
  
Di
ap
hr
ag
m
Qu
ad
0
75
150
250
375
500
m
H
2O
2 e
m
is
si
on
(p
m
ol
⋅m
in
-1
⋅m
g-
1 
dr
y 
w
t.)
25 10
0
50
0
0
20
40
60
80
ADP [µM]
m
H
2O
2 e
m
is
si
on
(%
 o
f 0
 µ
M
 A
D
P)
Diaphragm
*#
25 10
0
50
0
0
20
40
60
80
ADP [µM]
m
H
2O
2 e
m
is
si
on
(%
 o
f 0
 µ
M
 A
D
P)
Quad
Di
ap
hr
ag
m
Qu
ad
0
50
100
150
225
300
m
H
2O
2 e
m
is
si
on
(p
m
ol
⋅m
in
-1
⋅m
g-
1 
dr
y 
w
t.) WT
DMD-Saline
DMD-SBT-20* #
25 10
0
50
0
0
10
20
30
40
50
ADP [µM]
m
H
2O
2 e
m
is
si
on
(%
 o
f 0
 µ
M
 A
D
P)
Diaphragm
*#
25 10
0
50
0
0
10
20
30
40
50
ADP [µM]
m
H
2O
2 e
m
is
si
on
(%
 o
f 0
 µ
M
 A
D
P)
Quad
*
Creatine Dependent Creatine Independent
State II
State III
State III
A B
C D
E F
 
 
189 
7 Mitochondrial creatine kinase deficits evident in Duchenne 
muscular dystrophy are ameliorated through treatment with 
cardiolipin-targeting peptide SBT-20 
 
Assay Development Prior to the start of Project 4: 
1. Immunoprecipitation  
2. Licor 800CW Malemide IR Dye protein labelling methodology 
 
Author Contributions: Part 1: Aging work - MH maintained the breeding colony required for 
this project and monitored the animals on a bi-weekly basis from 4-52 weeks. Time-course analysis 
(4,8,12,16,24,32,40,52 weeks) of body weight, body composition (µCT scans) and whole-body 
function was completed by MH. Tissue harvest and mitochondrial bioenergetics experiments 
(respiration, mH2O2 emission, calcium retention capacity) were performed by MH with the 
assistance of TT. MH completed all western blotting and immunoprecipitation experiments. PT 
completed the analysis of µCT data. PCT completed glutathione measurements. Part 2: In Vitro 
work – MH performed all tissue harvest, bundle preparation and drug treatment for this work. MH 
completed all respiration experiments and analysis. Part 3: SBT-20 Treatment – MH maintained 
the breeding colony required for this project and performed all daily drug injections over the course 
of 12 weeks. Time-course analysis (4,6,8,10,12 weeks) of body weight, body composition (µCT 
scans) and whole-body function was completed by MH. MH and SVR performed all tissue harvests 
and mitochondrial bioenergetic assays (respiration, mH2O2 emission, calcium retention capacity). 
MH completed all western blotting and immunoprecipitation experiments. PT completed the 
analysis of µCT data.  
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Mitochondrial creatine kinase deficits evident in Duchenne muscular dystrophy are 
ameliorated through treatment with cardiolipin-targeting peptide SBT-20 
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Abstract 
In Duchenne muscular dystrophy (DMD), the mitochondria have been identified as a source of 
ROS during impaired oxidative phosphorylation in cardiac, respiratory and skeletal muscle. 
Furthermore, there is a specific impairment in mitochondrial creatine sensitivity, indicating a 
potential dysfunction in the enzyme mitochondrial creatine kinase (mtCK). MtCK is crucial in 
facilitating ADP’s ability to lower mitochondrial H2O2 emission while stimulating oxidative 
phosphorylation through the process of ‘high energy phosphate shuttling’. Additionally, mtCK is 
highly redox sensitive and susceptible to oxidant-induced dysfunction. The present study first 
sought to determine if altered mtCK functionality was the underlying cause of impaired 
mitochondrial bioenergetics in DMD. The second aim of this work was to determine whether the 
cardiolipin-binding peptide SBT-20, known for its ability to improve mitochondrial bioenergetics 
and protect against oxidative damage, could ameliorate these bioenergetic impairments, 
specifically through the protection of mtCK from oxidant-induced dysfunction. At late stages of 
disease progression (52 weeks) in D2.mdx mice, cardiac, respiratory and skeletal muscle exhibit 
creatine-dependent elevations in mitochondrial H2O2 emission during impaired oxidative 
phosphorylation which is associated with oxidized mtCK in cardiac muscle. In vitro treatment with 
SBT-20 improved creatine-dependent oxidative phosphorylation and protected against oxidant-
induced impairments in creatine-dependent respiration.  Similarly, in vivo treatment with SBT-20 
resulted in improvements in mitochondrial bioenergetics in a creatine-dependent manner, 
specifically in muscles that are sensitive to creatine. These findings demonstrate that DMD is a 
disease characterized by alterations in mtCK functionality and highlight a potential therapeutic 
target for the treatment and prevention of disease progression in DMD. 
Keywords: mitochondria, Duchenne muscular dystrophy, reactive oxygen species, respiration, 
mitochondrial creatine kinase, creatine 
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Introduction 
Affecting 1 in 3500 live male births, Duchenne muscular dystrophy (DMD) is a progressive muscle 
wasting disease resulting in early loss of ambulation and eventual premature death due to cardiac 
and/or respiratory complications [45, 2]. DMD is characterized by a lack of dystrophin due to 
mutations in the X-linked gene (Xp21) encoding for this structural protein [229]. At the cellular 
level, dystrophin acts as an anchoring protein between the cytoskeleton and the sarcolemma. In 
the absence of dystrophin, muscle becomes susceptible to membrane fragility and a myriad of 
cellular defects including disrupted calcium (Ca2+) homeostasis, oxidative stress, inflammation as 
well as the heightened activation of cell death pathways [93, 2]. Altogether, these impairments 
lead to chronic muscle degeneration causing the progressive replacement of muscle with fibrotic 
tissue and fat, resulting in an overall loss of muscle function.    
There is currently no cure for DMD. Given the genetic nature of this disease, extensive research 
has been conducted in attempts to establish gene based therapies to cure this condition. While 
recent reports have proved more promising [47], in general, gene based therapies have had limited 
impact on the treatment of DMD to date [45]. As such, there is a need to identify secondary 
therapeutic targets within the muscle in order to guide therapy development. Indeed, current 
standard of care targets inflammation rather than the genetic mutation itself [46].  
Recent work from our laboratory revealed the mitochondria are a source of ROS during impaired 
oxidative phosphorylation in cardiac, respiratory and skeletal muscles from young D2.B10-
DMDmdx/2J (D2.mdx) mice [156, 304]. These impairments in bioenergetics were associated with 
muscle damage and loss of function in respiratory and skeletal muscles and preceded the onset of 
cardiac dysfunction and remodelling. Furthermore, in oxidative muscles specifically, we identified 
an impairment in creatine sensitivity, as has previously been shown at later stages (10-11 months) 
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of disease progression [201], highlighting a potential dysfunction in the enzyme mitochondrial 
creatine kinase (mtCK) in dystrophic muscle (6, 7).  
The leading model of energy exchange involves a creatine-dependent (Figure 2A) and creatine-
independent (Figure 2B) pathway. Creatine-dependent energy exchange is facilitated by mtCK 
through the transfer of the phosphate group from ATP to Cr, producing phosphocreatine (PCr) and 
ADP in the inner membrane space. The PCr is exported via VDAC into the cytosol while the ADP 
is directly recycled back via ANT into the mitochondrial matrix (Figure 2A). Creatine-independent 
energy exchange involves ADP/ATP transfer through diffusion across voltage dependent anion 
carrier (VDAC) on the outer mitochondrial membrane and adenosine nucleotide translocase 
(ANT) on the inner mitochondrial membrane bypassing mtCK (Figure 2B) [200, 146, 150, 147].  
MtCK is believed to facilitate ADP’s role in lowering mitochondrial H2O2 emission while 
stimulating oxidative phosphorylation through this process of ‘high energy phosphate shuttling’ 
whereby the rapidly diffusing PCr export ultimately accelerates mitochondrial matrix ADP 
cycling, reduces H2O2 emission and stimulates oxidative phosphorylation [205, 157]. As such, 
diseases of altered mitochondrial bioenergetics are increasingly being identified as having a 
specific impairment in mtCK functionality [200, 152]. Furthermore, cardiolipin plays an important 
role in mtCK functionality through contact sites with mtCK and key regulators of energy exchange, 
forming a proteolipid complex that provides efficient energy exchange into and out of the 
mitochondria [200]. However, mtCK is extremely redox sensitive and therefore is susceptible to 
oxidative modifications, structural changes (crystallization) and the compensatory upregulation of 
its expression, all of which alter the enzyme’s functionality specifically through the dissociation 
from cardiolipin [200, 152, 153]. Given the elevated mitochondrial H2O2 emission during 
oxidative phosphorylation and impaired creatine sensitivity in young D2.mdx mice, it is plausible 
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that oxidant-induced impairments in mtCK functionality underlies mitochondrial dysfunction in 
dystrophic muscle, yet this remains to be elucidated. 
The mitochondrial-targeted peptide SBT-20, which binds to cardiolipin on the IMM, has been 
shown attenuate mH2O2 emission [224], prevent oxidative damage [225] increase mitochondrial 
oxidative phosphorylation [224] and prevent the dissociation of cytochrome c from cardiolipin, 
thereby preventing the activation of cell death pathways [223] in rodent models of ischemia 
reperfusion [224] and myocardial infarction [225]. Each of the aforementioned cellular 
dysfunctions have previously been identified in DMD [93, 2, 195, 156] suggesting that SBT-20 
may have beneficial effects on impaired mitochondrial bioenergetics in DMD, specifically through 
its improvement of mtCK functionality.  
The present study first determined whether alterations in mitochondrial bioenergetics were due to 
mtCK dysfunction at the late stages of disease progression in D2.mdx mice. We then assessed the 
efficacy of SBT-20 to alter mitochondrial bioenergetics following in vitro and in vivo treatment. 
Collectively, our findings demonstrate that mtCK is oxidized in dystrophic muscle, causing 
impairments in creatine-dependent mitochondrial bioenergetics and furthermore, that the 
cardiolipin-binding peptide SBT-20 improves mitochondrial bioenergetics in a creatine-dependent 
manner, potentially through the protection of mtCK from oxidant-induced dysfunction.  
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Material and Methods 
Animal Care and Timeline of measurements 
Part 1 – Aged Animals: D2.mdx and DBA/2J wildtype (WT) mice originated from breeding 
colonies maintained at York University (Toronto, Canada) and sourced from Jackson Laboratories 
(Bar Harbor, United States). At 4 weeks of age, body composition and whole body in vivo muscle 
function was evaluated. These assessments were repeated at 8, 16, 24, 32, 40 and 52 weeks 
respectively. At 52 weeks of age and two days following the last muscle function assessment, 
animals were sacrificed and tissue was harvested. Methods for the assessments completed with 
harvested tissue are described in detail below.   
Part 2 – In Vitro SBT-20 Treatment: D2.mdx mice originated from breeding colonies maintained 
at York University (Toronto, Canada) and sourced from Jackson Laboratories (Bar Harbor, United 
States). At 4 weeks of age, animals were sacrificed and quadriceps (Quad) muscle was harvested 
for the completed of in vitro SBT-20 assays. Methods for the assessments completed with 
harvested tissue are described in detail below.   
Part 3 – In Vivo SBT-20 Treatment: D2.mdx mice originated from breeding colonies maintained 
at York University (Toronto, Canada) and sourced from Jackson Laboratories (Bar Harbor, United 
States). Beginning at 4-days of age, all animals within a litter received a daily subcutaneous 
injection of SBT-20 (Stealth Biotherapeutics; Newton, MA, USA) at a dose of 5 mg/kg. At 10 
days of age, pups were sexed and treatment of only males within a litter continued. Age matched 
litters received the volume equivalent dose of vehicle (0.9% NaCl) through subcutaneous injection. 
Following 12 weeks of daily injections, all animals underwent whole body in vivo muscle 
functional analysis. Half of the animals were allocated for cardiac function analysis through 
echocardiography and the half of the animals were allocated for respiratory function analysis 
through esophageal pressure transduction. Animals were allowed to recover for 2 days following 
 
 
196 
their respective test. On the day of sacrifice, prior to tissue harvest, animals underwent a µCT scan 
for muscle volume in all animals followed by in vivo hindlimb plantar flexor force production 
measurements in a small subset of animals. These methods as well as methods for the assessments 
completed with harvested tissue are described in detail below.    
All animals were provided access to standard chow and water ad libitum. All experiments and 
procedures were approved by the Animal Care Committee at York University (AUP Approval 
Number 2016-18) in accordance with the Canadian Council on Animal Care. 
Body Composition and Functional Assays 
Voluntary Wheel Running 
Animals were placed in individual cages equipped with a locked 14 cm diameter running wheel 
and rotation counter (VDO m3 bike computer, Mountain Equipment Co-Op, Vancouver, Canada). 
After 24 hours of acclimatization, wheels were unlocked and distance run over 24 hours was 
recorded. 
Cage Hang Time 
Animals were placed on top of a metal cage lid and positioned so that all four limbs grasped the 
cage. The cage lid was inverted so that the mouse was hanging and cage hang time was recorded 
for a maximum of 180 seconds as previously described [156].  
Forelimb Grip Strength 
Forelimb grip strength was assessed using a force transducer (Mark 10 Digital Force Gauge, 
Copiague, NY) and has been described in detail previously [156]. Briefly, mice were removed 
from their cages by the tail and brought towards a grid attached to the force transducer until such 
time that the mice grasped the grid with their forepaws. Upon grasping, animals were pulled away 
from the grid until their grasp was broken. Peak tension was recorded, and the trial was repeated 
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twice more. If the animal did not show resistance to the experimenter, the trial was not recorded. 
Maximum peak tension from the best of 3 trials was used for analysis [233]. 
In Vivo µCT Scans 
In vivo body scans were performed using µCT (SkyScan 1278, Bruker-microCT, Kontick, 
Belgium) as previously described [156]. Following scans, lower limb muscle volume was analyzed 
through reconstruction of the image using NRecon (software version 1.7.0.4, Bruker-microCT, 
Kontick, Belgium) followed by the analysis of a selected region of interest using CTAn (software 
version 1.15.4.0, Bruker-microCT, Kontick, Belgium). The region of interest for hind-limb muscle 
volume was landmarked from the top of the patella to the ankle joint and was quantified by setting 
thresholds for fat free mass (76-102), expressed as volume (mm3) of lean mass/g body weight.  
Esophageal Pressure Transduction 
Esophageal pressure measurements were performed as previously described [234, 156]. Briefly, 
mice were anesthetized with an isoflurane/oxygen mix (2%:100%) and body temperature was 
maintained at 37°C. Mice were intubated using a 20-gauge angiocatheter (Becton, Dickinson and 
Company) to maintain an open/unobstructed airway. Compressible tubing was attached to the 
angiocatheter to facilitate inducible airway occlusions.  Esophageal pressure (Peses) was measured 
with a 1.2F catheter (Transonic) recorded on LabScribe2 software (iWorx) and analyzed with 
Spike2 software (Cambridge Electronic Design). Immediately after 2 min of baseline Pes 
recording, the trachea was occluded, and Pes was monitored for changes. Tracheal occlusions were 
initiated at end expiratory volume to ensure consistency of the Diaphragm length-tension 
relationship. Maximum inspiratory pressure (PIocc) was evaluated after 30s of occlusion when 
pressure generation reached a plateau. 
Echocardiography 
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All mice were subjected to transthoracic echocardiographic analysis (Vevo 2100, VisualSonics) 
to measure cardiac function and morphology 2-3 days prior to sacrifice for bioenergetic 
measurements as previously described [304]. The animals were sedated using 3% isoflurane and 
maintained with 1–2% isoflurane. Mice were placed on a heating pad and body temperature was 
maintained between 36.9 and 37.3 °C for the duration of the measurements. Left ventricular 
internal end diastolic diameters (LVDd), left ventricular internal end systolic diameters (LVDs) 
and left ventricular posterior wall thickness (LVPWTh) were measured in brightness mode (B-
Mode) and motion mode (M-Mode) using the parasternal long axis view. Fractional shortening 
(FS) was calculated as FS(%) = (LVDd - LVDs)/LVDd x 100. Stroke volume (SV) was estimated 
as SV = Left ventricular diastolic volume (LVVol;d) - Left ventricular systolic volume (LVVol;s), 
where LVVol;d = ((7.0/(2.4 + LVDd)) x LVDd3 and LVVol;s = ((7.0/(2.4 + LVDs)) x LVDs3. 
Ejection fraction (EF) was estimated as EF = SV/LVVol;d and cardiac output (CO) was estimated 
as CO = SV x heart rate. All data analysis was performed using the Visual Sonic data analysis 
suite. 
In Vivo Hind-limb Force Production 
In vivo force production of the hind-limb plantarflexor muscles was partially adapted from 
previous methods and has been described previously [235, 156]. In brief, mice were anesthetized 
with isoflurane and placed on a platform maintained at 37° C. Contraction of the plantarflexors 
was controlled through percutaneous stimulation of the sciatic nerve with left foot secured to a 
footplate attached to an Aurora Scientific 305C muscle lever (Aurora, Ontario, Canada) so that the 
ankle’s axis of rotation coincided with that of the servomotor shaft and the knee clamped in place 
such that the knee and ankle angles were both 90°. Peak isometric torque was determined by 
varying the voltage delivered to the sciatic nerve at a frequency of 60 Hz and 0.2-ms square wave 
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pulse. Torque as a function of stimulation frequency was measured during 9 isometric contractions 
at varying stimulation frequencies (40, 60, 80, 100, 120, 140, 160 180, 200 Hz). Maximum torque 
produced during the torque-frequency protocol was recorded and compared between groups. 
Animals then underwent a fatiguing protocol whereby the muscle was stimulated at a frequency 
of 60 Hz, every second for a total of 120 seconds. Animals were then allowed 10 minutes to recover 
before recovery from fatigue was assessed by stimulating maximum torque production at the same 
frequency used prior to fatigue [235]. Following a five-minute recovery period, animals then 
underwent eccentric contraction induced injury as previously described. Eccentric contractions 
were achieved by translating the footplate backward 30° at a velocity of 40mm/s after the first 
200ms of an isometric contraction. This was repeated 20 times with 45 seconds in between 
contractions.  Maximal torque production was assessed following the injury protocol to assess 
damage.  
Mitochondrial Bioenergetic Assessments 
Preparation of Permeabilized Muscle Fibre Bundles (PmFB) 
This technique is partially adapted from previous methods and has been described elsewhere [237-
240]. Briefly, muscles were removed from mice during anaesthesia with isoflurane. Heart, 
Diaphragm, quadriceps (Quad) and white gastrocnemius (WG) muscles were removed and 
immediately placed in ice-cold BIOPS, containing (in mM): 50 MES Hydrate, 7.23 K2EGTA, 2.77 
CaK2EGTA, 20 imidazole, 0.5 dithiothreitol, 20 taurine, 5.77 ATP, 15 PCr, and 6.56 MgCl2·6 H2O 
(pH 7.1). Each muscle was trimmed of connective tissue and fat and divided into several small 
muscle bundles (~2–7 mm, 1.0–2.5 mg wet weight). Each bundle was gently separated along the 
longitudinal axis to form bundles that were treated with 40 µg/ml saponin in BIOPS on a rotor for 
30 minutes at 4° C. Bundles destined for Complex I, Complex III or pyruvate dehydrogenase 
supported mitochondrial H2O2 emission (mH2O2) measurements (described below) were also 
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treated with 35 µM 2,4-dinitrochlorobenzene (CDNB) during the permeabilization step to deplete 
glutathione and allow for detectable rates of mH2O2 [242]. For Part 1 and Part 2, following 
permeabilization, the PmFB were divided into three groups; 1) bundles intended for high 
resolution respirometry were placed in MiR05 containing (in mM): 0.5 EGTA, 10 KH2PO4, 3 
MgCl2·6 H2O, 60 K-lactobionate, 20 Hepes, 20 Taurine, 110 sucrose and 1 mg/ml fatty acid free 
BSA (pH 7.1) while 2) bundles intended for mH2O2 were placed in Buffer Z containing (in mM): 
105 K-MES, 30 KCl, 10 KH2PO4, 5 MgCl2·6 H2O, 1 EGTA and 5mg/ml BSA (pH 7.4). PmFB 
were washed on a rotor at 4°C in MiR05 or Buffer Z until the measurements were initiated. 
Following permeabilization and washing, all mitochondrial bioenergetic measurements were 
performed in the same order from one animal to another and between groups to ensure consistent 
durations of the wash step.  
For assessment of mitochondrial bioenergetics following in vitro incubation with SBT-20, Quad 
muscle was separated in BIOPS buffer and permeabilized as described above. Following 
permeabilization with saponin, bundles were transferred to MiRO wash buffer supplemented with 
either 1 µM SBT-20 [224] or volume equivalent saline and were incubated at 4°C for two hours 
followed by the initiation of experiments.  
Mitochondrial Respiration in Aged Animals (Part 1) and in Animals following In Vivo Treatment 
with SBT-20 (Part 2) 
High-resolution O2 consumption measurements were conducted in 2 ml of respiration medium 
(MiR05) using the Oroboros Oxygraph-2k (Oroboros Instruments, Corp., Innsbruck, Austria) with 
stirring at 750 rpm at 37 °C [239, 240, 243-245]. Respiration medium contained 20mM Cr to 
saturate mitochondrial creatine kinase or no creatine to prevent the activation of mtCK [283, 243]. 
A third condition of 13.9mM PCr and 9.1mM Cr was used to provide an equilibrium across mtCK 
as occurs in skeletal muscle at rest in vivo [247]. For ADP-stimulated respiratory kinetics, 5 mM 
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pyruvate, accompanied by 2 mM malate, were added as Complex I substrates (via generation of 
NADH to saturate electron entry into Complex I) followed by a titration of physiological ADP (25 
µM) and supraphysiological (500 µM) ADP to mimic low and high metabolic stress respectively. 
Cytochrome c was added to test for mitochondrial membrane integrity, with all experiments 
demonstrating <10% increase in respiration. All experiments were conducted in the presence of 
5µM BLEB in the assay media to prevent spontaneous contraction of PmFB [243, 248, 244]. Each 
protocol was initiated with a starting [O2] of approximately 350 µM and was completed before the 
oxygraph chamber [O2] reached 150 µM as done previously [239, 240, 243-245]. Polarographic 
oxygen measurements were acquired in 2 s intervals with the rate of respiration derived from 40 
data points and expressed as pmol/s/mg wet weight. PmFB were weighed in ~1.5 ml of tared 
BIOPS (ATP-containing relaxing media) to prevent rigor that occurs when weighing PmFB in 
open air (unpublished observations). 
Mitochondrial Respiration Following In Vitro Treatment with SBT-20 
High-resolution O2 consumption measurements were conducted as described above with slight 
modifications. Following treatment with SBT-20 or volume equivalent saline, Quad muscle was 
placed in the Oroboros Oxygraph-2k (Oroboros Instruments, Corp., Innsbruck, Austria) in either 
20mM Cr to saturate mitochondrial creatine kinase or no creatine to prevent the activation of mtCK 
[283, 243]. State III respiration supported by Complex I substrates pyruvate (5 mM and malate 2 
mM) and 500 µM ADP was induced followed by the titration of 100 µM and 250 µM H2O2 to 
evaluate the % decrease in respiration following the addition of an oxidant. Cytochrome c was 
added to test for mitochondrial membrane integrity, with all experiments demonstrating <10% 
increase in respiration. After the experiments, the fibres were rinsed in double deionized H2O, 
lyophilized in a freeze-dryer (Labconco, Kansas City, MO, USA) for >4 h and weighed on a 
microbalance (Sartorius Cubis Microbalance, Gottingen, Germany). 
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Mitochondrial H2O2 Emission (mH2O2) 
mH2O2 was determined fluorometrically (QuantaMaster 40, HORIBA Scientific, Edison, NJ, 
USA) in a quartz cuvette with continuous stirring at 37°C, in 1 mL of Buffer Z supplemented with 
10 µM Amplex Ultra Red, 0.5 U/ml horseradish peroxidase, 1 mM EGTA, 40 U/ml Cu/Zn-SOD1,5 
µM BLEB and 20mM Cr. Site specific induction of mH2O2 was measured through the addition of 
either 10 mM pyruvate and 2 mM malate (NADH, Complex I), 10 mM succinate (FADH2, 
Complex I via reverse electron flux from Complex II) or 2.5 µM antimycin A (Complex III). 
Additionally, using 0.5 µM rotenone, a complex I inhibitor, plus 10 mM pyruvate, electron slip 
specific to pyruvate dehydrogenase complex was also measured in CDNB-treated fibres as noted 
above [242]. Following the induction of state II mH2O2 by Complex I and Complex II substrates, 
a titration of ADP was added to progressively attenuate mH2O2. Complexes I and II-supported 
mH2O2 were repeated with no creatine in the assay buffer to compare ADP’s effects without 
mtCK-mediated phosphate shuttling. All measurements were made in the presence of 1 µM BLEB 
to prevent ADP-induced rigor as described above. After the experiments, the fibres dried and 
weighed as described above. The rate of H2O2 emission was calculated from the slope (F/min), 
from a standard curve established with the same reaction conditions and normalized to fibre bundle 
dry weight.  
In Vitro Muscle and Blood Analyses 
Western Blotting 
An aliquot of frozen Heart, Diaphragm, Quad and WG (10–30 mg) from each aged animal was 
homogenized in a plastic microcentrifuge tube with a tapered teflon pestle in ice-cold buffer 
containing (mm): 40 Hepes, 120 NaCl, 1 EDTA, 10 NaHP2O7·10H2O pyrophosphate, 10 
β-glycerophosphate, 10 NaF and 0.3% CHAPS detergent (pH 7.1 adjusted using KOH). Protein 
concentrations were determined using a BCA assay (Life Technologies, Carlsbad, CA, USA). Fifty 
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µg of denatured and reduced protein was subjected to 10–12% gradient SDS-PAGE followed by 
transfer to low- fluorescence polyvinylidene difluoride membrane. Membranes were blocked with 
LI-COR Odyssey Blocking Buffer (LI-COR, Lincoln NE, USA) and immunoblotted overnight 
(4°C) with antibodies specific for each protein. A commercially available monoclonal antibody 
was used to detect electron transport chain proteins (human OXPHOS Cocktail, ab110411; 
Abcam, Cambridge, UK, 1:250 dilution), including V-ATP5A (55 kDa), III-UQCRC2 (48 kDa), 
IV-MTCO1 (40 kDa), II-SDHB (30 kDa) and I-NDUFB8 (20 kDa). Commercially available 
polyclonal antibodies were used to detect voltage dependent anion carrier 2 (VDAC 2) (32059, 
32 kDa; Santa-Cruz, 1:1000), adenine nucleotide translocase 1 (ANT 1) (ab180715, 33 kDa; 
Abcam, 1:1000) and sarcomeric s-mtCK (generous gift from Dr Uwe Schlattner, Grenoble, France; 
42 kDa, 1:1000). The mtCK antibody has been validated previously to confirm specificity [256].  
After overnight incubation in primary antibodies, membranes were washed three times, for 
5 minutes each time, in TBST and incubated for 1 hour at room temperature with the corresponding 
infrared fluorescent secondary antibody (LI-COR Biotechnology, Lincoln, NE, USA). 
Immunoreactive proteins were detected by infrared imaging (LI-COR CLx; LI-COR 
Biotechnology, Lincoln, NE, USA) and quantified by densitometry 
(ImageJ, http://imagej.nih.gov/ij/). All images were normalized to a whole membrane Amido 
Black total protein stain (A8181, Sigma, St Louis, MO, USA).  
Redox Status of MtCK 
Free reactive thiol (SH) groups on mtCK were labeled using IR-Dye 800CW-Maleimide (LiCor 
Biotechnology, Lincoln, NE, USA) by a modification of the technique previously described [307, 
308]. Heart tissue from animals from Part 1 was homogenized in CHAPS buffer plus inhibitors as 
described above. Samples were incubated overnight at 4°C with the IR-Dye at a concentration of 
 
 
204 
100nM/200µg total protein. Excess dye was removed from labeled proteins over Zeba Desalting 
Spin Columns (Thermo Fisher Scientific, Burlington, Canada) and protein concentration was 
determined using a BCA assay (Life Technologies, Carlsbad, CA, USA). MtCK was incubated at 
a ratio of 1:50 with 1mg of SureBead Protein G Magnetic Beads (Biorad, Mississauga, Canada) 
for 10 minutes at room temperature.  600µg of labeled proteins were then incubated with the 
SureBeads for 1 hour at room temperature. The bound proteins were eluted with 20mM Glyicine 
(pH 2.0) and were subjected to 10% SDS-PAGE. The gels were scanned using infrared imaging 
(LI-COR CLx; LI-COR Biotechnology, Lincoln, NE, USA) and quantified by densitometry 
(ImageJ, http://imagej.nih.gov/ij/).  
Statistics 
Results are expressed as means ± SEM. The level of significance was established as p<0.05 for all 
statistics. Outliers were omitted in accordance with the ROUT test GraphPad Prism Software, La 
Jolla, CA, USA). D’Agostino-Pearson omnibus normality test revealed that data resembled a 
Gaussian distribution which justified the application of parametric tests. In Part 1 and Part 3, all 
statistical differences were analyzed using unpaired t-tests between WT and D2.mdx (Part 1) or 
Saline and SBT-20 (Part 3) for all experiments except the time course functional data. Statistical 
differences in time course functional data were analyzed using a two-way ANOVA followed by 
an LSD post-hoc when an interaction was present (GraphPad Prism Software, La Jolla, CA, USA). 
All data from Part 2 underwent statistical analysis using a two-way ANOVA followed by an LSD 
post-hoc when an interaction was present (GraphPad Prism Software, La Jolla, CA, USA).  
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Results 
D2.mdx mice display muscle wasting and weakness across lifespan 
D2.mdx mice exhibit significantly lower body weights relative to WT controls at all time points 
from 4-52 weeks of age (-13 to -21%, main effect for group, p<0.05; Figure 1A). Lower limb 
muscle volume is reduced by 15% relative to WT at 4 weeks of age (p<0.05) but this reduction is 
restored from weeks 8-16 as no differences are evident between DMD and WT groups. Loss of 
muscle volume is once again apparent at 24 weeks of age (-15% vs WT, p<0.05) and muscle 
volume remains lower relative to WT at all subsequent time points (-28 to -35%, p<0.05; main 
effect for group, p<0.05; Figure 1B). Cage hang time (Figure 1C), forelimb grip strength (Figure 
1D) and distance covered during 24 hours of voluntary wheel running (Figure 1E) are all 
significantly lower relative to WT controls (main effect for group, p<0.05).  
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Figure 7-1: Evaluation of muscle wasting and weakness in D2.mdx mice throughout lifespan. Body weight (A, n=8-10) and µCT 
analysis of lower limb muscle volume (B, n=5-9) were used to evaluate body composition. Indices of muscle function were assessed by 
cage hang time (C, n=6-12), forelimb grip strength (G, n=6-12) and 24-hour voluntary wheel running (E, n=6-12). Results represent 
mean ± SEM;  # p<0.05 main effect for group compared to WT; * p<0.05 compared to WT.
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Alternations in mitochondrial bioenergetics are creatine-dependent in aged D2.mdx mice 
Previous work in our laboratory demonstrated elevated mitochondrial H2O2 (mH2O2) emission 
during impaired oxidative phosphorylation in young D2.mdx mice specifically highlighting an 
impairment in the central role of ADP in stimulating controlling bioenergetics [304, 156]. We first 
determined whether this impairment still exists in aged D2.mdx mice across a spectrum of 
oxidative and glycolytic muscles. Complex I-supported respiration and mH2O2 emission during 
oxidative phosphorylation were stimulated with NADH generated by pyruvate (5mM) and malate 
(2mM) in the presence of physiological (25µM) and supraphysiological (500µM) concentrations 
of ADP to mimic a low and high metabolic stress respectively. This titration was repeated with 
(+Cr) and without (-Cr) 20mM creatine to drive energy transfer dependent (Figure 2A) or 
independent of mtCK (Figure 2B), respectively. In the presence of a low (Figure 2C) or high 
(Figure 2G) metabolic stress, +Cr oxidative phosphorylation was impaired in D2.mdx Heart (-
35% to -36% vs WT, p<0.05), Diaphragm (-48% to -52% vs WT, p<0.05), Quad (-35% to - 41% 
vs WT, p<0.05) and WG (-31 to -50% vs WT, p<0.0) relative to WT controls. On the contrary -Cr 
oxidative phosphorylation was improved in D2.mdx Heart at both low (+102% vs WT, p<0.05; 
Figure 2D) and high (+90% vs WT, p<0.05l Figure 2H) [ADP] and unchanged between D2.mdx 
and WT Diaphragm, Quad and WG muscles, highlighting a creatine-dependent impairment and 
creatine-independent compensation in mitochondrial oxidative phosphorylation.  
During creatine-dependent oxidative phosphorylation, mH2O2 emission was elevated in D2.mdx 
muscle in the presence of either low metabolic stress (Heart: +43% vs WT, p=0.06; Figure 2E), 
high metabolic stress (WG: +117% vs WT, p<0.05; Figure 2I) or both (Diaphragm: +36 to +76% 
vs WT, p<0.05 and Quad: +54% to +57% vs WT, p=0.08 to p<0.05) relative to WT controls. 
However, during creatine-independent oxidative phosphorylation, mH2O2 emission was 
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unchanged in the Quad (Figure 2F and J), lower in D2.mdx Heart with supraphysiological ADP 
(-39% vs WT, p<0.05) and lower in D2.mdx Diaphragm muscle at both [ADP] (-30 to 51% vs WT, 
p<0.05) relative to WT controls. The WG from D2.mdx mice exhibited higher rates of creatine-
independent mH2O2 emission with low [ADP] (+55% vs WT, p<0.05; Figure 2F) but this 
impairment is no longer evident in the presence of a high metabolic stress (Figure 2J). Similar 
elevations in complex-II supported state III mH2O2 emission were present in a creatine-dependent 
manner across all D2.mdx muscles regardless of metabolic stress (Supplemental Figure 1A and 
C) while creatine-independent mH2O2 emission was unchanged (Diaphragm and WG) or lower 
(Heart, Quad) in D2.mdx muscle relative to WT controls (Supplemental Figure 1B and D).   
Complex III and pyruvate dehydrogenase complex (PDC)-supported mH2O2 emission were also 
assessed in the presence of 20mM creatine as a control given they are not regulated directly by 
ADP. Complex III-supported mH2O2 was unchanged in Heart, Diaphragm and Quad muscle and 
significantly lower in D2.mdx WG relative to WT (-37% vs WT, p<0.05; Supplemental Figure 
1E). PDC-supported mH2O2 emission was significantly lower in D2.mdx Heart (-26% vs WT, 
p<0.05), Diaphragm (-38% vs WT, p<0.05) and Quad (-52% vs WT, p<0.05) and unchanged in 
WG (Supplemental Figure 1F). These findings collectively suggest there is a creatine specific 
impairment in ADP’s control of bioenergetics in aged D2.mdx muscle. 
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Figure 7-2: Complex I supported respiration and mH2O2 emission in aged D2.mdx mice. The 
leading model for energy exchange involves a (A) creatine-dependent and (B) creatine-
independent pathway. ADP stimulated respiration and H2O2 emission, supported by Complex-I 
substrates pyruvate (5mM) and malate (2mM), was assessed in the presence (Creatine Dependent) 
and absence (Creatine Independent) of 20mM creatine. Assessments of bioenergetic function were 
completed in Heart, Diaphragm, Quad and WG muscles in the presence of physiological (25µM) 
[ADP] (C-F) and supraphysiological (500µM) [ADP] (G-J).  Results represent means ± SEM; 
n=6-10; * compared to WT, p<0.05. 
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Muscle specific alterations in key regulators of energy exchange in dystrophic tissue 
We next determined whether altered mitochondrial bioenergetics were related to changes in 
protein content of key regulators of energy exchange. In D2.mdx Heart and Quad muscle, protein 
content of ANT 1 (Figure 3A) and VDAC 2 (Figure 3B), situated in the inner and outer 
mitochondrial membranes respectively (Figure 2A and B),  mtCK (Figure 3C), the primary driver 
of creatine-dependent energy exchange and the components of the electron transport chain (Figure 
3D and F) were unchanged. In D2.mdx Diaphragm muscle, there was decreased protein content 
of all regulators of energy exchange (ANT 1: -33% vs WT, p<0.05; Figure 3A; VDAC 2: -33% 
vs WT, p<0.05; Figure 3B; MtCK: -28% vs WT, p<0.05; Figure 3C) and ETC components 
(Complex I: -16% vs WT, p=0.07; Complex II: -29% vs WT, p<0.05; Complex III: -25% vs WT, 
p<0.05; Complex IV: -28% vs WT, p<0.05; Complex V: -19% vs WT, p<0.05; Sum of Complexes: 
-25% vs WT, p<0.05; Figure 3E) suggesting an overall decrease in mitochondrial content in 
D2.mdx Diaphragm  relative to WT.  
On the contrary, in D2.mdx WG muscle, there were increased or tendencies for increased protein 
content of ANT 1 and VDAC 2 (ANT 1: +87% vs WT, p=0.08; Figure 3A; VDAC 2: +171% vs 
WT, p<0.05; Figure 3B) relative to WT but no differences in mtCK content. Additionally, there 
were increases in all complexes other than CIII of the ETC relative to WT (Complex I: +29% vs 
WT, p<0.05; Complex II: +122% vs WT, p<0.05; Complex IV: +113% vs WT, p<0.05; Complex 
V: +36% vs WT, p=0.08; Sum of Complexes: +46% vs WT, p<0.05; Figure 3G).  
MtCK is oxidized in D2.mdx mice 
Given that altered bioenergetics could not be explained by changes in protein content of key 
regulators of energy exchange, we next assessed the redox status of mtCK in Heart muscle of 
D2.mdx mice relative to WT controls. Heart was selected for analysis given it is established as the 
most creatine sensitive muscle [286]. IR-Dye 800CW-Maleimide binds to reduced thiols on 
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proteins. Whole Heart lysate from D2.mdx and WT animals was labeled with the IR-Dye and 
mtCK was immunoprecipitated from this lysate. Fluorescent maleimide labeling revealed mtCK 
is oxidized in D2.mdx Heart muscle as evidenced by a significant decrease in signal relative to WT 
controls (-57% vs WT, p<0.05; Figure 3H). Please see Supplemental Figure 7-2 for specific 
details about the methodological approach for this assay.  
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Figure 7-3: Muscle-specific changes in essential regulators of bioenergetics in DMD. Protein 
content of adenine nucleotide translocase 1 (ANT 1) on the inner mitochondrial membrane (A), 
voltage dependent anion carrier 2 (VDAC 2) on the outer mitochondrial membrane (B), and 
mitochondrial creatine kinase (mtCK) found in the inner membrane space (C) were quantified in 
Heart, Diaphragm, Quad and WG. Protein content of electron transport chain components were 
also quantified in Heart (D), Diaphragm (E), Quad (F) and WG (G). Results represent mean ± 
SEM; n=8; * p<0.05 compared to WT. Redox status of purified mtCK was evaluated in (H) Heart 
muscle. Results represent mean ± SEM; n=3; * p<0.05 compared to WT. 
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In vitro treatment with SBT-20 improves creatine-dependent oxidative phosphorylation and 
protects mtCK from oxidative modifications 
Cardiolipin, which binds to mtCK, is the binding site of the mitochondrial targeted peptide SBT-
20. Given the binding of cardiolipin to mtCK is known to affect mtCK function, we sought to 
determine if in vitro treatment with SBT-20 could improve creatine-dependent energy exchange 
through the stabilization of mtCK (Figure 4E). Complex I-supported state III respiration was 
stimulated with NADH generated by pyruvate (5mM) and malate (2mM) in the presence of 
physiological (25µM) supra-physiological (500µM) concentrations of ADP in Quad muscle 
(saline or SBT-20 treated) from 4-week old D2.mdx mice in the presence (+Cr) and absence (-Cr) 
20mM creatine to drive energy transfer dependent (Figure 2A) or independent of mtCK (Figure 
2B), respectively. Quad muscle was used given the established impairment in creatine sensitivity 
at this time point recently reported by our laboratory [156].  
Following treatment with SBT-20, there were no differences in oxidative phosphorylation between 
any of the groups in the presence of a low metabolic stress (25µM ADP) (Figure 4A). However, 
in the presence of a high metabolic stress, SBT-20 increased creatine-dependent respiration 
relative to saline treated fibres (+35% vs +Cr-Saline, p<0.05). However, SBT-20 did not increase 
creatine-independent respiration relative to saline treated fibres indicating that SBT-20 improved 
oxidative phosphorylation in a creatine-dependent manner. Finally, there were no differences in 
+Cr-Saline respiration relative to –Cr-Saline, reproducing our finding of an impairment in creatine 
sensitivity in this muscle. SBT-20 increased creatine-dependent respiration such that it was higher 
than –Cr-saline (+73% vs –Cr-Saline, p<0.05) and –Cr-SBT-20 (+44% vs –Cr-SBT-20, p<0.05) 
rates, indicating that SBT-20 rescued the impairment in creatine sensitivity in D2.mdx Quad 
muscle (Figure 4B).  
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Following the induction of state III respiration, H2O2 was titrated into the chamber to assess the 
ability of SBT-20 to protect against oxidant-induced decreases in respiration, believed to occur 
through the oxidation of mtCK [309, 310]. Following the addition of both 100 µM and 250 µM 
H2O2, +Cr-saline fibres saw the greatest drop in respiration (100 µM: -45%; Figure 4C; 250 µM: 
-83%; Figure 4D) which was a significantly greater drop than –Cr-saline (100 µM: -34%, p<0.05; 
250 µM: -65%, p<0.05) suggesting an oxidant-induced modification of mtCK activity. 
Furthermore, +Cr-SBT-20 respiration dropped to a similar degree as both –Cr-Saline and –Cr-
SBT-20 indicating that SBT-20 protected against the inactivation of mtCK.  
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Figure 7-4: Oxidative phosphorylation following in vitro treatment with cardiolipin-binding 
peptide SBT-20. ADP stimulated respiration, supported by Complex-I substrates pyruvate (5mM) 
and malate (2mM), was assessed following the in vitro incubation of Quad muscle from D2.mdx 
mice with 1µM SBT-20 or volume equivalent saline in the presence (Creatine) or absence (No 
Creatine) of 20mM Creatine. Assessments of oxidative phosphorylation were made in the presence 
of physiological (25µM) [ADP] (A) and supraphysiological (500µM) [ADP] (B). Results represent 
means ± SEM; n=9-10; * p<0.05 compared to Creatine-Saline; $ p<0.05 compared to Creatine-
SBT-20. (C) 100 µM and (D) 250 µM H2O2 were added to assess the oxidant-induced decrease in 
state III respiration. Results represent means ± SEM; n=6-8; * p<0.05 compared to Creatine-
Saline. SBT-20 binds to cardiolipin (E) and is believed to play a role in the stabilization of mtCK 
functionality.  
In vivo treatment with SBT-20 improves creatine-dependent mitochondrial bioenergetics 
Following 12 weeks of treatment with SBT-20, Complex I-supported respiration and H2O2 
emission during oxidative phosphorylation were stimulated in saline (SAL) and SBT-20 treated 
Heart, Diaphragm, Quad and WG muscle with NADH generated by pyruvate (5mM) and malate 
(2mM) in the presence of physiological (25µM) and supraphysiological (500µM) concentrations 
of ADP to mimic a low and high metabolic stress respectively. This titration was repeated with 
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(+Cr) and without (-Cr) 20mM creatine to drive energy transfer dependent (Figure 2A) or 
independent of mtCK (Figure 2B), respectively as well as a third condition of 13.9mM PCr and 
9.1mM Cr (+PCr/Cr) which provides an equilibrium across mtCK as occurs in skeletal muscle at 
rest in vivo [247].  
+Cr, SBT-20 treatment significantly increased oxidative phosphorylation in Heart muscle at both 
low (+33% vs SAL, p<0.05; Figure 5A) and high (+25% vs SAL, p<0.05; Figure 5F) ADP. 
Similarly, +Cr, SBT-20 lowered mH2O2 emission during oxidative phosphorylationin Heart 
muscle at low (-38% vs SAL, p=0.09; Figure 5D) and high (-49% vs SAL, p<0.05; Figure 5I) 
ADP relative to saline treated animals. However, SBT-20 treatment had no effect –Cr oxidative 
phosphorylation (Figure 5C) or mH2O2 emission (Figure 5E).  
In Diaphragm muscle, SBT-20 improved +PCr/Cr respiration (25µM: +97% vs SAL, p<0.05; 
Figure 5B; 500µM: +58% vs SAL, p=0.09; Figure 5G) and lowered +Cr mH2O2 emission during 
oxidative phosphorylation (25µM: -28% vs SAL, p=0.06; Figure 5D; 500µM: -32% vs SAL, 
p=0.11; Figure 5I) but had no effect on –Cr respiration (Figure 5C and H) or mH2O2 emission 
(Figure 5E and J).  
In Quad muscle, SBT-20 improved +PCr/Cr respiration (25µM: +53% vs SAL, p<0.05; Figure 
5B; 500µM: +157% vs SAL, p=0.09; Figure 5G) and tended to lower +Cr mH2O2 emission during 
oxidative phosphorylation at high [ADP] only (500µM: -26% vs SAL, p=0.08; Figure 5I. Similar 
to both Heart and Diaphragm, SBT-20 had no effect on –Cr respiration (Figure 5C and H) or 
mH2O2 emission (Figure 5E and J).  
WG muscle was used as a negative control given its established insensitivity to creatine due to the 
low degree of mtCK activity in this glycolytic tissue [286]. Indeed, SBT-20 treatment had no effect 
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on mitochondrial bioenergetics save for a decrease in +Cr respiration with 25µM ADP (-29% vs 
SAL, p<0.05; Figure 5A). Furthermore, Complex III and PDC-supported mH2O2 emission were 
also assessed in the presence of 20mM creatine as negative controls given they are not regulated 
directly by ADP. SBT-20 had no effect on Complex III or PDC supported mH2O2 emission in any 
muscle from D2.mdx mice (Supplemental Figure 2A and B). Overall, these results indicate that 
SBT-20 improves ADP’s control of creatine-dependent bioenergetics in D2.mdx muscles that are 
sensitive to mtCK functionality. 
The improvements in creatine-dependent mitochondrial bioenergetics were not associated with 
changes in muscle wasting or weakness following 12 weeks of treatment with SBT-20 
(Supplemental Figure 3) apart from improved hind-limb torque for a given frequency relative to 
saline (main effect for group, p<0.05; Supplemental Figure 3F).  
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Figure 7-5: Mitochondrial bioenergetics following 12 weeks of treatment with mitochondrial-
targeted peptide SBT-20. ADP-stimulated respiration and mH2O2 emission during oxidative 
phosphorylation, supported by Complex-I substrates pyruvate (5mM) and malate (2mM), was 
assessed in the presence of 20mM Creatine, 13.9PCr + 9.1 Cr or in the absence of creatine. 
Assessments of bioenergetic function were completed in Heart, Diaphragm, Quad and WG 
muscles in the presence of physiological (25µM) [ADP] (A-E) and supraphysiological (500µM) 
[ADP] (F-J).  Results represent means ± SEM; n=10-12; * p<0.05 compared to Saline. 
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Discussion 
Recent work from our laboratory has identified the mitochondrial as a source of ROS during 
impaired oxidative phosphorylation in cardiac, respiratory and skeletal muscles from D2.mdx mice 
[304, 156]. Pioneering work by Braun et al., identified an impairment in creatine sensitivity in 
oxidative muscle from 10-11 month old mdx mice [201], a finding that was replicated in young (4-
week) D2.mdx mice [304, 156]. These findings highlight a potential underlying defect in 
mitochondrial creatine kinase (mtCK) in dystrophic tissue yet the specific alteration in mtCK 
functionality and its subsequent contribution to impaired mitochondrial bioenergetics in DMD 
remains unknown. The present study identified oxidized mtCK as a source of creatine-dependent 
impairments in mitochondrial bioenergetics in the late stages of disease progression in D2.mdx 
muscle. In vitro and in vivo treatment with the cardiolipin-binding peptide SBT-20 improved 
mitochondrial bioenergetics in a creatine-dependent manner and protected against oxidant-induced 
decreases in creatine-dependent oxidative phosphorylation, highlighting mtCK as a therapeutic 
target of SBT-20.    
Impairments in mitochondrial bioenergetics are creatine and ADP-dependent in aged D2.mdx 
mice 
At 4 weeks of age D2.mdx mice exhibit elevated mH2O2 emission during impaired oxidative 
phosphorylation in cardiac, respiratory and skeletal muscle [304, 156]. While this is accompanied 
by an impairment in creatine sensitivity in oxidative muscles, impairments in bioenergetics were 
evident regardless of the energy exchange pathway activated (Figure 2A and B). At late stages of 
disease progression, the same muscles from D2.mdx mice exhibit divergent alterations in 
mitochondrial bioenergetics such that creatine-dependent function is impaired in all muscles while 
creatine-independent function is either unchanged (Quad and WG) or exhibits compensatory 
improvements (Heart and Diaphragm). While the creatine-dependent impairments in Diaphragm 
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may be explained by a decrease in mtCK content, alternative mechanisms are likely in Heart, Quad 
and WG muscle. mtCK is highly susceptible to oxidative modifications, leading to enzymatic 
inactivation and octamer dissociation, as well as formation of crystalline mitochondrial inclusion 
bodies, all resulting in loss of enzyme functionality [153, 152]. Evaluation of redox status of 
purified mtCK revealed that mtCK is oxidized in D2.mdx cardiac muscle, identifying a mechanism 
of dysfunction in creatine-dependent bioenergetics. Furthermore, creatine-dependent impairments 
appear to be ADP-dependent. Complex III and PDC are two membrane potential independent sites 
of mitochondrial ROS production and therefore, production rates are not governed by ADP. In the 
presence of creatine, mH2O2 emission rates were either unchanged or significantly lower in 
D2.mdx muscle signifying that there is a specific impairment in ADP’s control of bioenergetics. 
Given that mtCK facilitates ADP’s role in lowering mitochondrial H2O2 emission while 
stimulating oxidative phosphorylation, these findings collectively highlight oxidized mtCK as the 
underlying cause of impaired mitochondrial bioenergetics in aged D2.mdx mice [205, 157]. 
Improvements in creatine-independent bioenergetics in Heart and Diaphragm muscle can also not 
be explained by altered protein content of key regulators of energy exchange (ANT 1 and VDAC 
2) as protein content was unchanged in Heart and decreased in Diaphragm muscle. These findings 
suggest that post-translational regulation of these proteins may have been altered. Indeed, ANT 
and VDAC have known phosphorylation and acetylation sites [264, 265] although the 
physiological relevance of this regulatory paradigm remains unknown [200]. Furthermore, given 
the fact that these proteins are involved in both energy exchange pathways it is difficult to reconcile 
the divergent alterations in bioenergetics at the level of these regulators. It is possible that 
compensatory increases in ANT and VDAC permeability result in improvements in creatine-
independent bioenergetics yet this improved functionality is masked in creatine-dependent energy 
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exchange due to the overarching dysfunction in mtCK. The mechanisms surrounding the improved 
creatine-independent bioenergetics in Heart and Diaphragm muscle remain unknown but warrants 
consideration of post–translational modifications in the future.  
Targeting cardiolipin improves creatine and ADP-dependent bioenergetics in D2.mdx mice 
Cardiolipin is a unique phospholipid found almost exclusively on the inner mitochondrial 
membrane (IMM) that has been shown to interact with a variety of proteins on the IMM [200]. 
Notably, cardiolipin binds both ANT and mtCK, forming a proteolipid complex with VDAC on 
the OMM. This complex creates stable contact sites between the IMM and OMM, and is shown to 
regulate energy exchange, reduce ROS formation and prevent permeability transition pore opening 
[200]. However, both mtCK and cardiolipin are highly susceptible to oxidative modifications and 
when oxidized, lose their binding affinity resulting in the dissociation of the proteolipid complex 
[305, 261].   
SBT-20 is an aromatic–cationic peptide that bears alternating aromatic and basic amino acid 
residues targeting the mitochondria and binding specifically to cardiolipin [223]. In vitro treatment 
with this compound resulted in a significant increase in creatine-dependent oxidative 
phosphorylation while it had no effect on the creatine-independent dependent pathway. Similarly, 
in vivo treatment with SBT-20 improved creatine-dependent bioenergetics in oxidative muscle 
while it had no effect on the creatine-independent pathway. These findings suggest that SBT-20 is 
directly altering mtCK functionality, which was further supported by the lack of effect of SBT-20 
in WG, a highly glycolytic muscle that is insensitive to creatine [286]. Furthermore, SBT-20 
prevented an oxidant-induced decrease in creatine-dependent respiration, suggesting it protects 
mtCK from oxidative modifications. It is therefore likely that SBT-20 improves creatine-
dependent energy exchange through the stabilization of the proteolipid complex by preventing the 
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oxidation of mtCK, cardiolipin or both. Future work should examine the redox status of mtCK and 
cardiolipin to fully elucidate the mechanism by which SBT-20 is improving creatine-dependent 
bioenergetics in DMD.  
Creatine as a therapeutic strategy in DMD 
Creatine supplementation in DMD has been explored extensively in both animal models and 
human clinical trials with reports of improved strength and histopathology following treatment 
[311, 312]. The use of creatine has been shown to increase muscle mass as well as improve energy 
metabolism through the creatine-dependent energy exchange pathway. Furthermore, because of 
this effect on energy exchange, creatine has been shown to decrease apoptotic and necrotic cell 
death through its ability to influence rates ROS production and oxidative phosphorylation within 
the mitochondria [313]. Indeed, creatine supplementation has been shown to improve 
mitochondrial respiration and decrease necrosis in the mdx mouse [268]. The findings from this 
study demonstrate a drastic impairment in the ability of dystrophic tissue to use creatine efficiently, 
a cellular defect that was improved following treatment with SBT-20. While improvements in 
strength and histopathology have been demonstrated previously, it is conceivable that the 
enhancement of creatine sensitivity within dystrophic muscle would augment the beneficial effects 
of creatine in DMD. As such, an attractive therapeutic approach would involve a cocktail therapy 
of SBT-20 and creatine for the treatment and prevention of disease progression in DMD. 
D2.mdx mice exhibit compensation over lifespan 
A side observation from the present investigation was the establishment of a timeline of muscle 
function dynamics in the D2.mdx mouse. The D2.mdx mouse model (D2.B10-DMDmdx/2J ) 
exhibits attenuated muscle regeneration arising from a natural mutation in TGF-β binding protein 
4 in the background D2A strain. This mouse model has been shown to mimic human disease 
progression more closely than the classic mdx mouse (C57BL10/ScSnmdx) and furthermore, has a 
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more severe phenotype than the mdx mouse at any given stage of disease progression [60, 59]. 
However, minimal work to date has been done in this model of DMD. As such, we evaluated body 
composition and whole body functional parameters at various time points from 4 to 52 weeks of 
age to assess the degree of pathology from early to late stages of disease progression relative to 
WT controls (Figure 1). While muscle wasting was robust at 4 weeks of age, and in a fashion 
similar to the mdx mouse, D2.mdx animals recovered following this period of extensive 
degeneration [52]. A decrement in muscle volume was once again evident at 24 weeks of age and 
remained apparent at all remaining time points. While in vivo muscle function was impaired 
relative to WT controls at all time points, qualitatively an interesting pattern developed and is 
worth noting. From weeks 4 – 16, markers of muscle function improved in DMD animals relative 
to the previous time point yet by 24 weeks, the point at which muscle wasting is re-established, 
muscle function declined relative to 16 weeks and continued to decline across remaining time 
points. Evidently, while D2.mdx mice demonstrate impaired muscle function relative to WT 
controls throughout disease progression, muscle wasting and weakness is not a linear progression 
in this mouse model.  
This period of compensation may also contribute to the lack of functional benefit following in vivo 
treatment with SBT-20. 12 weeks of age falls directly in the period of peak muscle function in 
D2.mdx mice and as such, any improvements in muscle function resulting from drug treatment 
may be masked by the compensation occurring at this time. In order to truly elucidate the 
functional benefit of improved mitochondrial bioenergetics and mtCK functionality following 
SBT-20 treatment, a time point outside of the compensation window should be evaluated. 
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Conclusions 
In summary, oxidized mtCK contributes to impaired mitochondrial bioenergetics in the late stages 
of disease progression in D2.mdx mice. In vitro and in vivo treatment with the cardiolipin-binding 
peptide SBT-20 improves mitochondrial bioenergetics in a creatine-dependent manner and 
protects dystrophic muscle from oxidant-induced decreases in creatine-dependent oxidative 
phosphorylation. Collectively, these findings underscore mtCK as an underlying cause of 
dysfunction in dystrophic muscle and highlight a potential therapeutic target for the treatment and 
prevention of disease progression in DMD.  
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Supplemental Figures – Included in Manuscript 
 
 
 
 
 
 
 
 
  
Supplemental Figure 7-1: Complex II, Complex III and Pyruvate Dehydrogenase 
Complex supported mH2O2 emission in D2.mdx mice. Complex II (10mM 
Succinate)- supported mH2O2 emission was evaluated in the presence of physiological 
(25µM) (A+B) and supraphysilogical (500µM) (C+D) ADP in aged D2.mdx mice. In 
the absence of ADP, complex III-supported mH2O2 was assessed using Complex-III 
inhibitor antimycin A (2.5µM) (E) while Pyruvate dehydrogenase complex (PDC)- 
supported mH2O2 was assessed using pyruvate (10mM) and Complex-I inhibitor 
rotenone (0.5µM) (F). Results represent means ± SEM; n=6-10; * p<0.05 compared to 
WT.  
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Supplemental Figure 7-2: Representative images from mtCK immunoprecipitation and IR 
Dye methods development. Total mtCK content as measured by western blotting (A). Replicate 
examples of immunoprecipitated mtCK next to purified heart mtCK (B + C). Whole gel image of 
immunoprecipitated mtCK conjugated to the IR Dye Maelmide 800 CW (D). Limitations with this 
method are discussed in greater detail in Section 8.2 Limitations.  
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Supplemental Figure 7-3: Complex III and Pyruvate Dehydrogenase Complex 
supported H2O2 emission in D2.mdx mice following treatment with SBT-20.  In the 
absence of ADP, complex III-supported mH2O2 was assessed using Complex-III inhibitor 
antimycin A (2.5µM) (A) while Pyruvate dehydrogenase complex (PDC)-supported mH2O2 
was assessed using pyruvate (10mM) and Complex-I inhibitor rotenone (0.5µM) (B). 
Results represent means ± SEM; n=10-12; * p<0.05 compared to Saline. 
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Supplemental Figure 7-4: Evaluation of muscle wasting and weakness in DMD following 
treatment with SBT-20. Body weight (A, n=12) and microCT analysis of lower limb muscle 
volume (B, n=12) were used to assess body composition.  Indices of muscle function were assessed 
by 24-hour voluntary wheel running (C, n=12), cage hang time (F, n=12) and forelimb grip 
strength (G, n=12). Lower hindlimb force production was assessed in vivo using through torque-
frequency relationship (F) followed by a max-torque challenge (G, n=5). Recovery from fatigue 
(H, n=5) and recovery following eccentric contraction-induced injury (I, n=5) were evaluated. 
Cardiac function was evaluated through echocardiography including stroke volume (J, n=5), 
cardiac output (K, n=5), fractional shortening (L, n=5) and ejection fraction (M, n=5). Respiratory 
function in vivo was assessed through esophageal pressure transduction to determine maximal 
inspiratory pressure (PIocc) (N, n=4-5). Results represent mean ± SEM;  # p<0.05 main effect 
compared to WT; * p<0.05 compared to WT. 
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Supplemental Data – Not Included in Manuscript 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplemental Figure 7-5: Evaluation of glutathione levels in aged D2.mdx 
muscle. Glutathione was measured in muscle homogenate using HPLC-UV for the 
detection of GSH (A) and HPLC-Fluorescence for the detection of GSSG (B). The 
GSH:GSSG ratio (C) and total glutathione (D) were calculated from GSH and 
GSSG measurements. Results represent mean ± SEM; n=4-8; * p<0.05 compared 
to WT. 
Supplemental Figure 7-6: Susceptibility to permeability transition pore opening in D2.mdx 
mice. Calcium retention capacity, an index of susceptibility to permeability transition pore 
opening, was assessed in (A) aged D2.mdx muscle and (B) following 12 weeks of treatment with 
SBT-20. Results represent mean ± SEM; n=7-12; * p<0.05 compared to WT. 
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 Supplemental Figure 7-7: Absolute complex-I supported mH2O2 emission. State II mH2O2 was supported by Complex-I 
substrates Pyruvate (5mM) and Malate (2mM) in the A. presence (Creatine Dependent) and B. absence (Creatine Independent) 
of 20mM creatine.  ADP’s attenuation of maximal mH2O2 emission (state III) was evaluated in the same creatine dependent (C-
F) and independent conditions (G-J). Results represent mean ± SEM; n=7-10; * p<0.05 compared to WT. 
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Supplemental Figure 7-8: Absolute complex-I supported mH2O2 emission. State II mH2O2 was supported by Complex-I 
substrates Pyruvate (5mM) and Malate (2mM) in the A. presence (Creatine Dependent) and B. absence (Creatine Independent) 
of 20mM creatine. ADP’s attenuation of maximal mH2O2 emission (state III) was evaluated in the same creatine dependent (C-
F) and independent conditions (G-J). Results represent mean ± SEM; n=7-10; * p<0.05 compared to Saline 
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8 Summary of Findings 
 
8.1 General Discussion and Future Directions 
DMD is an X-linked muscle wasting disease resulting from a mutation in the gene encoding for 
the structural protein dystrophin. This debilitating disease targets limb muscles first, leading to 
loss of ambulation followed by premature death due to cardiac/respiratory failure [2]. Affecting 1 
in 3500 boys, there is currently no cure DMD. Given that gene based therapies have had minimal 
success to date and current standard of care involves the use of glucocorticoids, which have a 
several negative side effects associated with long-term treatment, extensive research has focused 
on identifying other therapeutics for the treatment and prevention of DMD [46]. The present thesis 
sought to first comprehensively evaluate the mitochondria across a spectrum of cardiac, respiratory 
and skeletal muscles to determine the precise mechanism and degree of mitochondrial dysfunction 
that occurs in DMD (Chapter 4 and 5). Based on these findings we then assessed the efficacy of 
the mitochondrial-targeted peptide SBT-20 in improving 1) the pathophysiology of DMD through 
the alteration of mitochondrial bioenergetics (Chapter 6) and 2) mitochondrial creatine kinase 
functionality in DMD, our proposed underlying mechanism of mitochondrial dysfunction (Chapter 
7). The findings from this thesis identify the mitochondria as a source of ROS during impaired 
oxidative phosphorylation in DMD and more specifically, that mtCK may be the underlying cause 
of mitochondrial dysfunction in oxidative muscle. Subsequently, the mitochondrial-targeted 
peptide SBT-20 presents promising therapeutic potential for the treatment of DMD myopathy, a 
direct result of its ability to improve mitochondrial bioenergetics in dystrophic muscle.   
Modeling in vivo conditions during in vitro assays reveals divergent alterations in mitochondrial 
bioenergetics in DMD 
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A consistent and major finding across the four projects of this thesis was the importance of 
designing in vitro protocols to mimic in vivo conditions in order to comprehensively evaluate 
mitochondrial bioenergetics. Firstly, in the absence of ADP, Complex-I stimulated mH2O2 
emission reveals the maximal capacity of oxidant generation by complex-I but does not reflect in 
vivo conditions whereby ROS production is a by-product of oxidative phosphorylation and is 
dependent on ADP’s ability to govern membrane potential through the stimulation of ATP 
synthesis [200]. Indeed, our conclusions surrounding mitochondrial mH2O2 emission in DMD 
would be entirely different had we just evaluated maximal capacity in the absence of ADP, 
particularly when considering the efficacy of SBT-20, which appears to be ADP-dependent in 
nature.  
Secondly, the opening of the mitochondrial permeability transition pore (PTP) is a membrane 
potential-dependent process and therefore, is also regulated by ADP [314]. Given our 
identification of specific impairments in ADP’s ability to govern bioenergetics in DMD, the design 
of our calcium retention capacity (CRC) assay warrants further discussion. In Chapter 4, Quad 
muscle from D2.mdx mice exhibit the suspected decrease in the [Ca2+] required to stimulate PTP 
opening. However, this assay was performed in the absence of ADP and as such, the effectiveness 
of ADP in lowering membrane potential is unidentified. Based on our findings from Chapter 4 and 
5, when evaluating CRC in Chapter 6, ADP was added to the assay media. We were surprised to 
find that CRC was actually elevated in D2.mdx Quad muscle, suggesting a decreased susceptibility 
to PTP opening but importantly, an entirely different conclusion in the presence of ADP. While 
the explanation of this seemingly counterintuitive result is somewhat speculative at this point, this 
suggests an impairment in the ability of dystrophic mitochondria to induce programmed cell death, 
likely due to limited ATP supply[184], a notion supported by the decrease in CRC following SBT-
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20 treatment.  Nevertheless, the divergent findings from Chapter 4 and 6 further highlight the 
necessity of modelling in vivo conditions in in vitro assays. 
Thirdly, and perhaps most strikingly, were the divergent responses in ADP-supported 
bioenergetics when modelling different pathways of energy-exchange. Leading models of energy 
exchange suggest that ADP and ATP can be cycled in and out of the mitochondria through a 
creatine-dependent pathway, whereby mtCK facilitates the transfer of high energy phosphate 
groups allowing for the efficient cycling of ADP/ATP or through a creatine-independent pathway 
whereby ADP and ATP bypass mtCK and rely solely on diffusion (Figure 2-6) [200]. The creatine-
dependent pathway is believed to make up about 80% of energy exchange in cardiac muscle and 
is heavily relied on by all other oxidative muscles as it is considerably more efficient. However, 
in the majority of literature to date, the role of creatine-dependent phosphate shuttling through 
mtCK was not assessed which means conclusions are limited to alterations in ATP/ADP diffusion, 
save for one study that reported an impairment in creatine sensitivity in oxidative muscles [201].  
Our findings from Chapter 7 highlight the potential discrepancy in findings that would be reported 
if bioenergetics were assessed in the absence of in vivo conditions. Specifically, in late stages of 
disease progression, there are severe impairments in creatine-dependent oxidative phosphorylation 
and ADP’s suppression of mH2O2 emission. However, there are also compensatory improvements 
in creatine-independent energy exchange, masking impairments in bioenergetics at this time point. 
If our assay conditions had followed experimental procedure from literature to date, we would 
have concluded that mitochondrial bioenergetics are improved in D2.mdx mice in the late stages 
of disease progression. Indeed, a recently published paper by Gaglianone et al., reported no 
impairments in mitochondrial respiration in mdx soleus muscle, a highly oxidative muscle, yet 
their assay conditions were devoid of creatine [315]. Additionally, SBT-20’s effects appear to not 
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only be ADP-dependent, but creatine-dependent in nature as well. We hypothesize this is through 
the protection again oxidant-induced damage of mtCK. Importantly, modeling creatine-dependent 
energy exchange in vitro allowed us to uncover this beneficial effect, a finding that would have 
been missed if the assays focused solely on creatine-independent pathways.   
Periods of compensation in the D2.mdx mouse may affect therapeutic windows 
The four projects in this thesis also implemented a relatively new and unstudied mouse model of 
DMD. The majority of work in rodent models of DMD to date has been done in the C57bl/10-mdx, 
a naturally occurring mouse model with a mutation in exon 23, resulting in the dystrophic 
phenotype [51]. Unfortunately, the mdx mouse represents a poor model relative to human disease 
progression given its highly compensatory nature [52]. We therefore employed a relatively new 
mouse model, the D2.B10-DMDmdx/2J (D2.mdx), which exhibits attenuated muscle regeneration 
arising from a natural mutation in TGF-β binding protein 4 in the background D2A strain [60, 59]. 
D2.mdx mice have a more severe phenotype relative to mdx mice and have demonstrated pathology 
relative to WT mice at all time points [59, 58]. However, a time course evaluation of D2.mdx mice 
reveal qualitative compensation within this strain as well.    
At 4 weeks of age, in a similar fashion to mdx mice, D2.mdx mice exhibit muscle wasting and 
weakness relative to WT controls. In mdx mice, this period of peak degeneration is followed by 
robust regeneration and compensation that results in a relatively mild dystrophic phenotype until 
15 months of age [51]. Based on our findings, D2.mdx mice also undergo a period of compensation, 
albeit less robust and lasting only until 24 weeks at which point the phenotype progressively 
worsens (Supplemental Figure 7-3). We believe that this compensatory window may help to guide 
therapeutic timelines in this animal model.  
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Firstly, work by Chang and colleagues demonstrated that the mdx mouse has lengthened telomeres 
which promote their regenerative capabilities [203]. Patients with DMD are identified as having 
shortened telomeres which limit the stem cell pool and ultimately inhibit the regeneration of 
damaged muscle, leading to muscle wasting. Through the shortening of mdx telomeres, not only 
were previously unidentified cellular impairments now evident, a more severe cardiomyopathy 
was apparent, highlighting the fact that heightened regeneration may be masking dysfunction in 
rodent models of DMD [203, 204]. This in turn may partially explain why we revealed bioenergetic 
dysfunctions in the D2.mdx mice at 4 weeks of age that were previously unidentified in mdx 
counterparts, but also identifies the need to evaluate therapeutics during periods of disease 
progression that are not underscored with heightened regeneration. It is possible that our time-
point dependent effects of SBT-20 on force production were due to the severity of the disease. At 
4 weeks of age, when SBT-20 was effective at improving muscle function, muscle wasting and 
weakness was also heightened. In contrast, at 12 weeks of age, when SBT-20 had no beneficial 
effects on muscle function, the animals were in a period of compensation. Future work should 
extend treatment past the compensatory window into the second phase of severe myopathy. 
Specifically, evaluating the ability of this compound to extend lifespan would provide great insight 
into potential clinical benefits, regardless of force production outcomes.  
Comparison of methods to measure muscle function in rodent models of DMD 
A third point of consideration that was an underlying topic throughout this thesis was the design 
of protocols to analyze muscle function. We employed both in vivo whole-body muscle function 
tests as well as in vitro isolated muscle function tests within Chapters 4,6 and 7 in order to 
comprehensively evaluate both clinical markers of myopathy as well as muscle specific force 
production. The findings from these evaluations led to divergent conclusions. All in vivo tests at 
4-weeks of age showed minimal effect of SBT-20, save for an increase in forelimb grip strength. 
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We speculate that this may be due to the voluntary nature of these experiments. While SBT-20 is 
beneficial to dystrophic muscle at a cellular level and improves specific force of individual 
muscles, this treatment is by no means a cure and it begs to question what impact this drug had on 
energy levels and perception of strength in these animals. For example, 24 hours of voluntary 
wheel running involves a 24-hour acclimation period with a locked running wheel followed by 24 
hours of recorded running distance. If the animals, despite having improvements at the cellular 
level, do not feel better overall, they are unlikely to choose to partake in voluntary exercise. On 
the contrary, when a strip of diaphragm muscle is evaluated in vitro, there is no neurological 
component to this assay, removing this confounding variable that exists in in vivo assessments.  
Similarly, in addition to the previously discussed compensation that occurs at 12 weeks of age, the 
neural component of muscle function may also partially explain the lack of effect of SBT-20 in 
the diaphragm, that was previously evident at 4 weeks of age. Specifically, following 12 weeks of 
treatment with SBT-20, diaphragm force production was evaluated using an in vivo assessment of 
esophageal pressure transduction. While mice were anesthetized, respiratory drive was still a 
confounding factor affecting the partial pressures produced in these animals and given that neural 
drive to breath is believed to be altered in patients with DMD [316, 294], this approach for the 
assessment of respiratory function may have masked the potential beneficial effects of SBT-20 
that would have been elucidated with an in vitro model. While in vivo measures of function are 
considered to be more clinically relevant, generalized interpretations about muscle strength should 
be made with caution given the neural component of these evaluations cannot be controlled for.  
Future Directions 
In Chapter 5, analysis of mitochondrial bioenergetics was limited to the left ventricle (LV) from 
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the LV and furthermore, that echocardiographic measures were performed on LV. Through 
histochemical analysis, a high degree of fibrosis was evident in the right ventricle (RV) at 4 weeks 
of age, a surprising finding we did not anticipate. Therefore, our conclusions regarding impaired 
mitochondrial bioenergetics preceding the onset of cardiac dysfunction and remodeling are limited 
specifically to the LV and it remains possible that evaluation of the RV would have revealed 
dysfunction and remodelling at this early age. An intriguing possibility for future investigation is 
to determine whether the well-characterized diaphragm weakness in this disease drives right 
ventricular failure through decreased pulmonary perfusion, and whether this contributes to a joint 
RV and LV mechanism for the progression of cardiomyopathy. Furthermore, to fully and 
comprehensively evaluate cardiac function, invasive hemodynamic measurements would have 
been required. Considered the gold standard for evaluating cardiac function in heart failure, using 
invasive hemodynamic techniques would have presented us with both systolic and diastolic 
functional data as well as right side function allowing for more in-depth conclusions about the 
development of cardiomyopathy at the time point in question.  
Secondly, while we identified the mitochondria as a source of oxidative stress in DMD in Chapters 
4 and 5, we did not identify alterations in the overall redox status of the cell when measured 
through markers of reversible oxidative stress (lipid peroxidation, protein carbonylation). 
However, the use of these markers do not rule out H2O2 acting as a reversible redox signal within 
the cell, as evidenced by the oxidized status of mtCK presented in Chapter 7. Future work should 
consider the redox status of ANT, VDAC and mtCK collectively to further understand the 
mechanistic causes of impaired mitochondrial bioenergetics in DMD.  
The collective findings from this thesis also suggest that a cocktail therapy may provide a more 
potent treatment option for the attenuation of disease progression in DMD. The first, and likely 
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most viable option, as was discussed in Chapter 7, is a combination therapy with creatine. Creatine 
supplementation in both animal models and human clinical trials has proven highly beneficial, 
particularly in the context of improved muscle strength [311, 312]. The use of creatine has been 
shown to increase muscle mass as well as improve energy metabolism through its effect on creatine 
dependent energy exchange. This involves decreasing apoptotic and necrotic cell death through 
creatine’s ability to influence the rates ROS production and oxidative phosphorylation within the 
mitochondria [313]. A key finding from this thesis was the underlying impairment in creatine 
dependent energy exchange in dystrophic muscle, specifically due to the oxidation of mtCK. Given 
that the DMD phenotype involves a shift from type II to type I fibres throughout lifespan and that 
mtCK activity is predominant in oxidative tissue, it stands to believe that the enhancement of 
creatine sensitivity within dystrophic muscle following SBT-20 would augment the beneficial 
effects of creatine in DMD. Secondly, SBT-20, aside from its evident benefits in DMD as a stand-
alone therapeutic, is also attractive because of its unique mitochondrial-targeting abilities. Unlike 
the majority of widely used mitochondrial-targeted antioxidants, SBT-20 is not membrane 
potential dependent [228]. This is an important distinction in diseases of impaired ADP 
governance, like DMD. Idebenone, a synthetic analog to coenzyme Q10, has provided positive 
results in clinical trials of DMD, specifically in its ability to improve cardiac and respiratory 
function [208, 209, 76, 210, 287]. However, there are concerns surrounding idebenone’s 
bioavailability. Conjugating idebenone to SBT-20 would increase the uptake of idebenone by the 
mitochondria and would conceivably heighten its benefits in dystrophic muscle. Indeed, using 
SBT-20 as a vehicle to target the mitochondria presents a promising and unexplored avenue for 
therapy development to date.  
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8.2 Limitations 
Although every effort was made in the design and execution of the studies in this dissertation to 
control for variables, it must be acknowledged that limitations do exist. Firstly, in Chapter 4, due 
to tissue limitations, TEM analysis was done in the plantaris as opposed to the Quad muscle. While 
plantaris and the vastus intermedius (the portion of the Quad used for bioenergetic assays) exhibit 
similar fibre type compositions [236], given the heterogeneity of disease progression across 
muscles in DMD, our conclusions about mitochondrial morphology in the Quad must remain 
speculative given we did not assess this marker in this specific muscle.  
In Chapter 6 there are two important limitations to discuss. Firstly, SBT-20 treatment was initiated 
at 4 days of age and continued for 28 days, taking animals at the age of sacrifice to 32 days at the 
youngest. While we controlled for age as best as possible, given the size of some litters and the 
fact that due to tissue viability and technical limitations, only one mouse could be sacrificed each 
day, animals ranged from 32-36 days at the time of sacrifice. While the groups all had an average 
age of sacrifice of 34 days, this brings animals closer to five weeks of age than four. Given that 
compensation occurs within this model sometime between 4 and 8 weeks of age, it is possible that 
the phenotype of these animals is less severe than animals that are sacrificed at 28 days, the time 
point used in Chapter 4. Therefore, comparisons between the two studies (Chapter 4 and 6) proved 
difficult as the underlying effect of compensation was unknown at the second-time point and may 
explain some divergent findings. In hindsight, a shorter treatment window and subsequent younger 
age of sacrifice may have decreased variability. However, this may not be feasible given the time 
requirements for the breadth of measures performed in this study. 
In Chapter 7, the in vivo SBT-20 study is lacking a WT control group. While our initial study 
design was more mechanistic in nature with a specific interest in looking at the impact of SBT-20 
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on mtCK function, a lack of WT control makes it hard to determine the overall efficacy of SBT-
20. Indeed, while our comparison to a saline group allows for the determination of SBT-20’s 
efficacy in DMD, we cannot determine the degree to which SBT-20 rescued myopathy in relation 
to WT.  Additionally, a critical finding from this study was the presence of oxidized mtCK in 
DMD muscle relative to WT. Additional time is required to resolve technical issues with the 
method (Supplemental Figure 7.2) which limit the strength of conclusions at this time. The 
antibody being used for mtCK immunoprecipitation (IP) is a polyclonal serum based antibody and 
as such, has non-specific biding that is evident on a standard western blot (Supplemental Figure 
7-2A) and becomes particularly evident when the contrast is increased on an image. While a 
regular IP of mtCK reveals high specificity for mtCK (Supplemental Figure 7-2B and C), the IR 
Dye appears to be much more sensitive and brings out several non-specific bands (Supplemental 
Figure 7-2D). Additionally, due to the oxidized state of mtCK in the DMD samples, the contrast 
must be increased significantly in order to bring out bands in the DMD lanes. This also brightens 
the WT lane causing an overabundance of bands around 42KDa. While we are comfortable in our 
conclusion that mtCK is oxidized given the conclusion is identical regardless of the band you 
quantify, samples will be re-run in the near future to try and decrease the non-specific binging that 
is evident when using the IR Dye 
A final limitation in Chapter 7, which has been touched on briefly through the discussion, is the 
choice of functional tests used following 12 weeks of treatment with SBT-20. Firstly, skeletal 
muscle function was evaluated through force production of the hind-limb plantarflexors (soleus 
and gastrocnemius). Given that SBT-20 provided no therapeutic benefit to the WG at the 
mitochondrial level, in hindsight it was not surprisingly that treatment elicited no functional benefit 
on this muscle. Unfortunately, force production assessments are done prior to bioenergetic assays 
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and as such, the lack of treatment effect in the WG was unknown at the time of measure. 
Furthermore, echocardiography was our only method of cardiac function and therefore, it remains 
to be seen if improvements in function would have been revealed through invasive hemodynamics. 
Based on literature in the D2.mdx mouse, cardiomyopathy does not manifest until approximately 
28 weeks of age so we did not expect to see functional deficits or subsequent drug-induced 
improvements at this time. Cardiac muscle was evaluated on a mechanistic level based on its 
known sensitivity to creatine [286].  
8.3 Conclusions 
 
The findings from this thesis highlight the mitochondria as a source of ROS during impaired 
oxidative phosphorylation in DMD and that mechanistically, mtCK underlies these bioenergetic 
impairments. Subsequently, impaired mitochondrial bioenergetics do indeed contribute to DMD 
pathophysiology, an influence that can be attenuated through the use of the mitochondrial-targeted 
peptide SBT-20, likely through its protection of mtCK from oxidant-induced dysfunction (Figure 
8-1). Overall, SBT-20 may be a promising therapeutic candidate for the improvement of DMD 
pathophysiology and should be considered further in both lifespan studies as well as a component 
in cocktail therapy approaches for the treatment and prevention of DMD myopathy.  
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Figure 8-1: Summary of the mechanisms of mitochondrial dysfunction in dystrophic muscle 
and the role of SBT-20 in attenuating their effect on DMD pathophysiology. A lack of 
dystrophin results in cell membrane fragility and contraction-induced tearing. This causes an influx 
of calcium (Ca2+) into the cytosol. The mitochondria uptake this Ca2+ causing Ca2+ overload within 
the mitochondria. Mitochondria exhibit impaired oxidative phosphorylation and elevated ROS 
emission during this impaired oxidative phosphorylation. Elevated Ca2+, impaired ATP production 
and elevated ROS form a pathological triad within the mitochondria leading to 1. H2O2-induced 
oxidative modifications on mitochondrial proteins (mitochondrial creatine kinase, mtCK) through 
the oxidation of exposed cysteines (SHàS-àS-R-), 2. H2O2 leaving the mitochondria and acting 
as a redox signal (oxidative modifications, S-R and macromolecular damage, lipid peroxidation) 
3. Permeability transition pore opening and the activation of mitochondrial-derived cell death 
pathways. Mitochondrial derived cell death can induce muscle wasting through apoptosis or 
necrosis and subsequent fibrosis. Muscle wasting causes muscle weakness in dystrophic muscle. 
Solid black arrows represent pathways directly assessed within this thesis. Dashed black arrows 
represent well characterized aspects of the DMD phenotype not directly measured in this thesis. 
Grey dashed arrows represent proposed cellular influences of elevated mitochondrial H2O2 
emission.  
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Appendix A - Detailed Experimental Methods 
 
A.1 - SkyScan 1278 – Scanning an Animal 
1. Open Skyscan 1278 
2. Click X-Ray button – if this is the first time the machine has been used in a while, it can 
take up to 10 minutes for the x-ray to warm up 
3. With nothing in the machine, you must update the bright and dark flat field 
a. Option: Update flat field for current mode 
b. Want background of mouse to be grey colour not white – want average to be 90% 
not 100%, 100% is saturated 
4. Set your parameters 
a. Resolution (# of pixels): 50, 100 or 200 microns 
b. Filter (energy, controls x-ray voltage): 0, 0.5mm, 1mm aluminum or low dose 
5. Load mouse, make sure mouse is centered and arms and legs are taped down 
6. Click the TV screen icon to turn on x-ray and bring up live image of mouse 
7. Right click to bring up transmission values 
a. Want a minimum value of 20-30%, if this is too high, lower the filter in the bottom 
right corner 
b. If you change any parameter values, you must update the flat field 
8. Click the green arrow to bring up scanning parameters 
a. For 50 + 100 microns – use step and shoot 
b. For 200 microns – use continuous acquisition 
c. For a mouse, use 180°. For a rat, use 360° 
** Make sure the parameters used are the same for entire study 
9. Click scan 
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A.2 - SkyScan 1278 µCT - % Body Fat 
 
Step 1) Open the reconstructed images made in NRecon software. They are saved in the folder 
containing the original scans. Click on the firs image and press open. 
 
Step 2) Click on the icon of square with magnifying glass. This opens the profile tab (sometimes 
the profile tab do not fully open and gets hidden on top of palette tab. You can open the profile tab 
by double clicking on it). Click on the icon of black square with snowflake on it (it is called 
maximum intensity projection). This opens the maximum intensity projection tab. Click on Ok 
button. This will generate a coronal view of the animal so that you can navigate better. Click on 
the icon of magnifying glass with the arrow next to it (called send image into projection window) 
and then click on the icon on the right (called close window). 
 
Step 3) This step is called “thresholding”. Click on the icon of black and white cactus (called 
binary selection preview) on the top. This will open the binary selection tab (next to raw images 
tab) in the top, and the histogram tab in the bottom. When you perform these steps, the transverse 
view of the animal turns into a black and white (binary) preview. This view is hard to highlight 
fat. Click on the colored cactus image with a red dot in background (called toggle half tone view) 
in the histogram tab. This will bring back the original transverse preview of the animal under a 
green filter. Open “from dataset” tab in the histogram tab. On the binary view, scroll down to the 
very bottom slice (or any slice that shows fat clearly). Highlight fat accurately using the selectors 
on top and bottom of the histogram (the highlighted area will be red in the transverse view).  
Sometimes, a part of the lung will stay in slices after reconstruction. To check for that, scroll to 
the top slices in binary selection. The lung usually appears in the top few slices. They have to be 
removed because they get highlighted as fat. To do so, find the first slice from the top in the binary 
selection that does not contain the lungs. Left click on that slice and select “set the top of the 
selection”. This will eliminate the slices that contain lungs. Then click on the icon of histogram 
with an arrow on top (called automatic thresholding). This will highlight the entire animal together 
with isoflurane tube and the mouse housing. 
 
Step 4) In this step, we separate the isoflurane tube and the housing from the animal. To do so, we 
need to create a region in space that only contains the animal called region of interest (ROI). Click 
on the hexagonal colored cactus icon (called regions of interest preview). This will open the 
regions of interest tab next to raw images tab. In this step, the transverse view is colored red. This 
makes it hard to visualize the animal. From the palette tab, select the filter that works best for you 
(from experience, “color” shows the fat better, but “color 2” shows the edges better than the 
“greyscale”).  
 
Step 5) In this step we create the ROI. To create the ROI we draw shapes around the mouse every 
few slides from bottom to top. Software will generate a 3D space by connecting these shapes along 
the longitudinal axis of the animal. This space separates the animal from the housing and the 
isoflurane tube. 
Shapes are drawn manually by mouse. You need to hold the right click while drawing the shapes. 
When drawing the shapes, make sure to avoid the tube and the housing. If you need to remove a 
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shape, click on the scissors icon (called cut ROI) on the top. Go up and down inslices to make 
sure ROI contains all of the animal and non of the tube and the housing. 
 
Step 6) Click on the icon of the face on the top (called custom processing preview). This will open 
the custom processing tab, next to binary selection tab, and the plug-ins tab on the bottom. Go to 
the internal tab in the plug-ins tab. Click on the thresholding section. This will open threshold tab. 
Leave the setting as global and check the default box. Then click ok.  
To run every step in internal tab, you need to press play and then press continue. 
This will highlight everything that you selected in the thresholding step and turn it into binary. 
 
Step 7) In this step, we remove the isoflurane tube and the housing from the animal. The internal 
tab has 4 views. You can navigate them using 4 icons on the right. These views, from left to 
right, are “Image”, “Image inside ROI”, “ROI”, and “Clipboard”.  
From the internal tab, click on the “Bitwise operations”. The way that bitwise operations works is 
similar to Venn diagrams with the same logical rules of “and”, “or”, “not” etc. Bitwise operations 
allow you to modify the “Image” using the shapes in other views. When you click on the bitwise 
operations, it will open bitwise operation tab. Put the settings in the following way: Image = Image 
AND Region of Interest. 
This will remove the isoflurane tube and housing. 
 
Step 8) In this step, you need to modify the image. Parts of the housing or the tube might still stay 
in the image that must be removed. Click on “Despeckle”. Select the settings according to the 
image (in the remove section, the largest object is the highlighted animal). Click on the play icon 
to run the despeckle. 
Some parts of the tube or the housing may still be attached to the animal. To remove them click 
on the “Morphological operations”. Select the settings according to the image and press ok.  
Always despckle after any morphological operation to remove any speckles that might be created. 
You need to save the image after the modifications. Software allows you to save the image only 
in the clipboard view. To do so, click on the “bitwise operations”. Set the setting as follow: 
Clipboard = Image AND Image. 
 
Step 9) In this step, we turn the image into a solid region. To do that, click on the “ROI shrink-
wrap”. Make sure that it is applied to 2D space. The default should be to keep “stretch over the 
holes” unchecked. But, if there are dips in the image you need to check that box. You also need to 
assign a diameter measured in pixels. The diameter should be set as the lowest number possible 
because this will increase the ROI volume. The right diameter is found through trial and error. 
Start with a high diameter (20 pixels) and work your way down. When you click on OK, a solid 
shape that has all the holes filled will be created in the ROI view in the internal tab. If the dip is 
covered, click on the bitwise operations and put the settings as follow: Image = clipboard AND 
clipboard. This will load the image again. Go back the “ROI shrink-wrap and put a lower diameter. 
Repeat these steps until you reach the lowest diameter that covers all the dips. 
Until now, we have created a space in ROI that consist of the entire mouse. This space will be 
the total volume which is the denominator in the percent body fat formula. Now we need to select 
the fat. 
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Step 10) Click on the bitwise operation and put the setting as follow: Image = region of interest 
AND region of interest. Then click OK.  
 
Step 11) In this step, we threshold the fat. Go back to the binary selection tab. Scroll down to the 
very bottom slice (or any slice that shows fat accurately). Use the selectors on top and bottom of 
the histogram and highlight fat (it should be the same thresholding values as you found in step 3). 
 
Step 12) Go back to the custom processing tab. Click on the internal tab. Click on the “Reload”. 
This will open the reload tab. Set apply to “Image” and then click OK. This will load the original 
image in the transverse view (make sure you are in the image view of the internal tab).  
Click on thresholding and then click OK. This will highlight the parts of the animal (fat) that 
was selected in step 11 and turn the entire image into binary. 
Click on the bitwise operations and put the settings as follow: Image = Image AND Region of 
Interest. This will remove the isoflurane tube and the housing from the selected area of the animal. 
 
Step 13) Click on the “3D Analysis” in the internal tab. This will open 3D analysis tab. Leave the 
settings as it is and click on OK. 
This step will perform the 3D calculations to measure the percent body fat. 
To see the results, go to the Output/Report tab and click on the first Open from the top. This will 
open a text file containing the results. Scroll down to the very bottom and you can find the results. 
Measurements are made in mm3. Total VOI volume is the volume of ROI. It is the total volume of 
the animal that was selected which is the denominator of the percent body fat formula. Object 
volume is the volume of fat, the numerator of the percent body fat formula. Percent object volume 
is the percent body fat which is calculated by dividing object volume by total VOI volume. 
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A.3 - SkyScan 1278 µCT - Analyzing Hind-Limb Muscle Volume 
 
Step 1) Open the reconstructed images made in NRecon software. They are saved in the folder 
containing the original scans. Click on the firs image and press open. 
 
Step 2) Click on the icon of square with magnifying glass. This opens the profile tab (sometimes 
the profile tab do not fully open and gets hidden on top of palette tab. You can open the profile tab 
by double clicking on it). Click on the icon of black square with snowflake on it (it is called 
maximum intensity projection). This opens the maximum intensity projection tab. Click on Ok 
button. This will generate a coronal view of the animal so that you can navigate better. Click on 
the icon of magnifying glass with the arrow next to it (called send image into projection window) 
and then click on the icon on the right (called close window). 
 
Step 3) Click on the image of black and white cactus (called binary selection preview). Click on 
the “from dataset” tab in histogram tab. Go to the top slices in the binary tab. Scroll up and down 
until you find the knee joint. In the transverse view (superior part of the tibia has a curved shape 
in coronal view; therefore, it will be shown like two parallel ovals in transverse view). Left click 
on the slice that it the top of the tibia and select “set the top of selection”. This will eliminate the 
higher slices from the selection. 
Use the selectors on top and bottom of the histogram to select muscle. Muscle is usually the 
second spike after on the right of the spike for fat. Use the top slices to highlight muscle. 
 
Step 4) In this step, we separate the isoflurane tube and the housing from the animal’s leg. To do 
so, we need to create a region in space that only contains the animal called region of interest (ROI). 
Click on the hexagonal colored cactus icon (called regions of interest preview). This will open the 
regions of interest tab next to raw images tab. In this step, the transverse view is colored red. This 
makes it hard to visualize the animal. From the palette tab, select the filter that works best for you 
(from experience, “color” shows the fat better, but “color 2” shows the edges better than the 
“greyscale”). 
 
Step 5) In this step we create the ROI. To create the ROI we draw shapes around the leg every few 
slides from bottom to top. Software will generate a 3D space by connecting these shapes along the 
longitudinal axis of the animal. This space separates the animal’s leg from the housing and the 
isoflurane tube. 
Shapes are drawn manually by mouse. You need to hold the right click while drawing the shapes. 
When drawing the shapes, make sure to avoid the tube and the housing. If you need to remove 
a shape, click on the scissors icon (called cut ROI) on the top. Go up and down in slices to make 
sure ROI contains all of the animal’s leg and non of the tube and the housing. 
 
Step 6) Click on the icon of the face on the top (called custom processing preview). This will open 
the custom processing tab, next to binary selection tab, and the plug-ins tab on the bottom. Go to 
the internal tab in the plug-ins tab. Click on the thresholding section. This will open threshold tab. 
Leave the setting as global and check the default box. Then click ok. 
To run every step in internal tab, you need to press play and then press continue. 
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This will highlight everything that you selected in the thresholding step and turn it into binary. 
 
Step 7) In this step, we remove the isoflurane tube and the housing from the animal’s leg. The 
internal tab has 4 views. You can navigate them using 4 icons on the right. These views, from left 
to right, are “Image”, “Image inside ROI”, “ROI”, and “Clipboard”. 
From the internal tab, click on the “Bitwise operations”. The way that bitwise operations works is 
similar to Venn diagrams with the same logical rules of “and”, “or”, “not” etc. Bitwise operations 
allow you to modify the “Image” using the shapes in other views. When you click on the bitwise 
operations, it will open bitwise operation tab. Put the settings in the following way: Image = Image 
AND Region of Interest. 
 
Step 8) Click on the “3D Analysis” in the internal tab. This will open 3D analysis tab. Leave the 
settings as it is and click on OK. 
To see the results, go to the Output/Report tab and click on the first Open from the top. This will 
open a text file containing the results. Scroll down to the very bottom and you can find the results. 
Measurements are made in mm3. Object Volume is the hind limb muscle volume.  
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A.4 - In Vivo Hind-limb Plantarflexor Force Production 
See attached video for step up procedure (1). 
In Vivo force is measuring Torque production (mN/m) 
 BEFORE STARTING ENSURE UNITS ARE CORRECT, IF NOT: 
 SETUP:CHANNEL SETUP:FORCE IN DEVICE – select mN/m 
 
Protocol 
1. Create a folder to save files for each animal -  Setup:Autosave Folder, open folder you 
created; click “current folder” 
2. Setup:Instant Stim 
a. Pulse Frequency: 1Hz 
b. Pulse Width: 0.2ms 
c. Number of Pulses: 1 
d. Train Frequency: 0.1Hz 
e. Run Time: 1 second 
3. Open Live Data monitor and set time to 10 minutes 
4. Optimize Current 
a. Range:100mA 
b. Run instant stim 
c. Adjust range to ensure all muscle fibres are being recruited – obtain 3 twitches in a 
row where force does not increase (run instant stim and increase current between 
twitches (wait about 30 seconds in between twitches) 
d. Set supramaximal current by increasing current by 15%  
5. Optimize Resting Length 
a. Increase/decrease length of quad until maximal twitch force is achieved, wait about 
30 seconds in between twitches to avoid fatigue 
Once optimal current and length have been set, protocol is ready to begin 
 
6. Load “In Vitro Torque Frequency” sequence 
a. Frequencies of 40Hz, 60Hz, 80Hz, 100Hz, 120Hz, 140Hz, 160Hz, 180 Hz, 200Hz 
i. Initial Delay: 200ms 
ii. Pulse Frequency: ____Hz 
iii. Pulse Width: 0.2ms 
iv. Duration: 300ms 
b. 30 seconds in between  
7. Allow 5 minutes of recovery 
8. Load the tetanic protocol at the frequency that produced the highest torque during step 6 
9. Perform Max Force Test – make sure to save this file! 
10. Allow 2 minutes recovery  
11. Load “In Vitro Fatigue” sequence 
a. 60 Hz, stim every second for 120 seconds 
b. 300ms stimulation, 700ms rest 
c. 119 repeats (total of 2 minutes) 
12. Allow 10 minute recovery from fatigue 
13. Perform a second max torque test at the same frequency used in step 8 – this assesses 
recovery from fatigue 
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14. Wait 5 minutes 
 
15. Load “Eccentric Contraction – Injury” protocol 
a.  Set offset on main DMC screen to -19, this allows for full range of motor of the 
foot plate 
b. 30° translation of the footplate at a velocity of 40mm/s after the first 200ms of the 
isometric contraction 
c. 20 times, 45 seconds in between 
d. Allow 10 minute recovery from injury 
e. Perform a third max torque test at the same frequency used in step 8 – this assesses 
recovery from injury 
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A.5 - In Situ Quadriceps Force Production 
 
See attached paper for step up procedure with videos (1). 
In Situ force is measuring force production (mN) 
 BEFORE STARTING ENSURE UNITS ARE CORRECT, IF NOT: 
 SETUP:CHANNEL SETUP:FORCE IN DEVICE – select mN 
 
Protocol 
1. Create a folder to save files for each animal -  Setup:Autosave Folder, open folder you 
created; click “current folder” 
2. Setup:Instant Stim 
a. Pulse Frequency: 1Hz 
b. Pulse Width: 0.2ms 
c. Number of Pulses: 1 
d. Train Frequency: 0.1Hz 
e. Run Time: 1 second 
3. Open Live Data monitor and set time to 10 minutes 
4. Optimize Current 
a. Range:100mA 
b. Run instant stim 
c. Adjust range to ensure all muscle fibres are being recruited – obtain 3 twitches in a 
row where force does not increase (run instant stim and increase current between 
twitches (wait about 30 seconds in between twitches) 
d. Set supramaximal current by increasing current by 15%  
5. Optimize Resting Length 
a. Increase/decrease length of quad until maximal twitch force is achieved, wait about 
30 seconds in between twitches to avoid fatigue 
Once optimal current and length have been set, protocol is ready to begin 
6. Load “Quad In Situ Force Frequency” sequence 
a. Frequencies of 40Hz, 60Hz, 80Hz, 100Hz, 120Hz, 140Hz, 160Hz 
i. Initial Delay: 0.2ms 
ii. Pulse Frequency: ____Hz 
iii. Pulse Width: 0.2ms 
iv. Duration: 300ms 
b. 45 seconds in between  
7. Allow 5 minutes of recovery 
8. Load the tetanic protocol at the frequency that produced the highest force during step 6 
9. Perform Max Force Test – make sure to save this file! 
10. Allow 2 minutes recovery  
11. Load “Quad In Situ Fatigue” sequence 
a. 60 Hz, stim every second for 120 seconds 
12. Allow 10 minute recovery from fatigue 
13. Perform a second max force test at the same frequency used in step 8 – this assesses 
recovery from fatigue 
14. Harvest muscle and before freezing MAKE SURE TO RECORD MUSCLE WEIGHT 
**Data will be normalized to muscle mass 
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A.6 - In vitro Diaphragm Strip Force Production 
 
See attached paper for protocol (1) and step up procedure with videos (2). 
In Vitro force is measuring force production (mN) 
 BEFORE STARTING ENSURE UNITS ARE CORRECT, IF NOT: 
 SETUP:CHANNEL SETUP:FORCE IN DEVICE – select mN 
 
Protocol 
1. Create a folder to save files for each animal -  Setup:Autosave Folder, open folder you 
created; click “current folder” 
2. Setup:Instant Stim 
a. Pulse Frequency: 1Hz 
b. Pulse Width: 0.2ms 
c. Number of Pulses: 1 
d. Train Frequency: 0.1Hz 
e. Run Time: 1 second 
3. Open Live Data monitor and set time to 10 minutes 
4. Optimize Current 
a. Range:100mA 
b. Run instant stim 
c. Adjust range to ensure all muscle fibres are being recruited – obtain 3 twitches in a 
row where force does not increase (run instant stim and increase current between 
twitches (wait about 30 seconds in between twitches) 
d. Set supramaximal current by increasing current by 15%  
5. Optimize Resting Length 
a. Increase/decrease length of diaphragm until maximal twitch force is achieved, wait 
about 30 seconds in between twitches to avoid fatigue 
6. Measure the length of the diaphragm and record, this is LO and can be input on the main 
DMC screen and will be used for analysis 
a. Setup:Normalization – enter reference length in mm 
Once optimal current and length have been set, protocol is ready to begin 
 
7. Load “Diaphragm In Vitro Force Frequency” sequence 
a. Frequencies of 1Hz, 10Hz, 20Hz, 40Hz, 60Hz, 80Hz, 100Hz, 120Hz, 140Hz 
i. Initial Delay: 0.2ms 
ii. Pulse Frequency: ____Hz 
iii. Pulse Width: 0.2ms 
iv. Duration: 400ms 
b. 60 seconds in between  
8. Allow 5 minutes recovery  
9. Load the tetanic protocol at the frequency that produced the highest force during step 7 
10. Perform Max Force Test – make sure to save this file! 
11. Allow 2 minutes recovery  
12. Load “Diaphragm In Vitro Fatigue” sequence 
a. 70 Hz (350ms stim, 0.2ms pulse width) every 2 second for 5 minutes 
13. Allow 10 minute recovery from fatigue 
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14. Perform a second max force test at the same frequency used in step 8 – this assesses 
recovery from fatigue 
15. Harvest muscle and before freezing MAKE SURE TO RECORD MUSCLE LENGTH 
AND MUSCLE WEIGHT (remove muscle from ribs/central tendon before weighing) 
**Data will be normalized to muscle cross sectional area: mass x length x density 
- Mammalian skeletal muscle density = 1.06 g/cm3(Mendez and Keys, 1960) 
 
Rodent Ringer’s Solution – Bombardier et al 2013 
 
Chemical Molecular 
Weight 
Weight (g) 
for 1L 
Final 
Concentration 
(mM) 
NaCl2 58.4 7.07 121 
KCl 74.6 0.373 5 
NaHCO3 84.0 2.016 24 
CaCl2 147.02 0.26 1.8 
NaH2PO4 119.98 0.05 0.4 
Glucose 180.16 0.99 5.5 
EDTA 292.24 0.029 0.1 
MgCl2  203.3 0.10 0.5 
pH to 7.3 
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A.7 - Serum Creatine Kinase 
Assay is done using Pointe Scientific Serum CK Kit (C7522) 
 
1. Set Excitation to 340 and Emission to 450 
2. Each sample will be run in duplicates and therefore requires 500ul of assay buffer 
a. # of samples x 2 x 250ul = total buffer volume 
b. Mix Buffer 1 and Buffer 2 in a 4:1 ratio to get the total buffer volume required 
3. Load 250ul of assay buffer into small cuvette and let background run for 3 minutes – this 
allows buffer to settle at 37 degrees 
4. Add 1ul of serum into buffer 
5. Record fluorescence for 5 more minutes 
6. Repeat once more with same sample (if duplicates appear variable, a 3rd assay can be run 
but the duplicates are usually very consistent) 
 
Standard Curve 
1. Make up a stock of 1.12mM NADPH (1mg in 1mL water) 
2. Load 250ul assay buffer into cuvette and obtain background for 3 minutes 
3. Follow the following step wise titration waiting 2 minutes between additions: 
 
Stock (mM) Volume (ul) Added to 
Cuvette 
Final [NADPH] in Cuvette 
(uM) (after dilution) 
1.12 2.22 9.858 
1.12 3.33 14.594 
1.12 5.56 23.849 
1.12 11.11 45.710 
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A.8 Measuring Mitochondrial Respiration 
 
BIOPS Buffer 
 
Chemical Stock Solution Molecular 
Weight 
Final 
Concentration 
Addition to 2 
Litre final 
volume 
CaK2EGTA* 100mM  2.77mM 55.4mL 
K2EGTA* 100mM  7.23mM 144.6mL 
Na2ATP  555.1 5.77mM 6.28g 
MgCl2 • 6H2O  203.3 6.56mM 2.67g 
Taurine  125.1 20mM 5.02g 
Na2Phosphocreatine  327.14 15mM 9.81g 
Imidazole  68.1 20mM 2.72g 
Dithiothreitol 
(DTT) 
 154.2 0.5mM 0.154g 
MES Hydrate  195.2 50mM 19.52g 
* prepare stock solutions (see instructions below) 
 
BIOPS contains the following ion concentrations: 
Ca2+ Free 0.1 uM 
Mg2+ Free 1mM 
MgATP 5mM 
Ionic Strength 160mM 
 
CaK2EGTA: Dissolve 2.002g CaCO3 in 100mM hot (80°C) solution of EGTA (7.608g of EGTA 
in 200mL ddH2O). Add 2.3g of KOH and adjust pH to 7.0 using KOH. Freeze unused portions 
 
K2EGTA: dissolve 7.608g EGTA and 2.3g KOH into 200mL ddH2O. Adjust pH to 7.0 using 
KOH. Freeze unused portions 
 
To make BIOPS: 
1. Add approximately 1500mL of ddH2O to 2000mL beaker 
2. While constantly stirring add stock solutions of CaK2EGTA and K2EGTA 
3. Weigh and add all powder chemicals 
4. Adjust pH to 7.1 using KOH pellets 
5. Using graduated cylinder, bring total volume to 2000mL 
6. Filter and then aliquot into 50mL falcon tubes 
7. Freeze falcon tubes 
 
MiRO Buffer 
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Chemical Stock Solution Molecular 
Weight 
Final 
Concentration 
Addition to 2 
Litre final 
volume 
EGTA  380.4 0.5mM 0.38g 
MgCl2 • 6H2O  203.3 3mM 1.22g 
K-
Lactobionate* 
0.5M 358.3 free acid 60mM 240mL 
Taurine  125.1 20mM 5.02g 
KH2PO4  136.1 10mM 2.72g 
HEPES  238.3 20mM 9.54g 
Sucrose  342.3 110mM 75.3g 
BSA  154.2 1g/L 2g 
* prepare stock solution (see instructions below) 
 
MiRO contains the following ion concentrations: 
Ca2+ Free 0.0 uM 
Mg2+ Free 2.1mM 
K+ 90mM 
Na+ 0 
EGTA free 0.46mM 
Osmolarity 330 mOsm 
Ionic Strength 95mM 
 
K-Lactobionate: Dissolve 71.6g lactobionic acid in 300mL ddH2O, adjust pH to 7.0, adjust 
final volume to 400mL with ddH2O 
 
To make MiRO: 
1. Add approximately 1500mL of ddH2O to 2000mL beaker 
8. While constantly stirring add stock solution of K-Lactobionate 
9. Weigh and add all powder chemicals 
10. Adjust pH to 7.1 using KOH pellets 
11. Using graduated cylinder, bring total volume to 2000mL 
12. Filter and then aliquot into 50mL falcon tubes 
13. Freeze falcon tubes 
 
Chemical Bank 
Chemical Stock Concentration 
 
Dissolved in: Storage after 
Removal 
Glutamate 500mM, 1M, 2M Water Fridge 
Malate 1M Water Fridge 
Succinate 500mM, 1M, 2M Water  Fridge 
ADP 5mM, 50mM, 500mM Water  Fridge 
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Permeabilized Fibre Preparation 
 
Pre-surgery 
1. For every fibre bundle you are going to make you will need one 0.5mL tube for wet weights 
one 1.5mL eppendorf tube for permeabilization and one 1.5mL tube for wash 
* Keep all tubes and buffers on ice 
2. In a 5mL tube, make 10mg/mL Saponin solution by dissolving a small amount of saponin 
in distilled water 
a. Vortex gently and place on rocker until ready for use 
3. Fill all permeabilization tubes with 1.5mL of freshly thawed BIOPS (or BIOPS from fridge 
with fresh EGTA…see “Other Things to Consider”) and *40ug/mL saponin (6uL in 1.5mL 
BIOPS). 
a. * different saponin concentrations may be used depending on species/tissue type 
but 40ug/mL is standard for rodent 
4. Fill all wash tubes with 1.5mL freshly thawed MiRO (or from fridge…same as above) 
5. Fill all 0.5mL tubes with 500uL of BIOPS 
6. Using a 50mL falcon tube, weigh out ~ 0.05g of creatine (this number will change based 
on the number of chambers you need with creatine), add the correct amount of MiRO to 
make a 20mM Creatine MiRO Solution 
a. Place on rocker as creatine takes some time to dissolve 
7. Label and fill a 5mL tube with 3.5mL BIOPS for every muscle that will be harvested during 
surgery 
8. Proceed to “O2k Setup” Section, after O2k’s are setup you are ready for surgery 
Post-Surgery  
1. Separate fibres in BIOPS as quickly and carefully as possible 
a. Remember to change ice block/ice pack frequently as buffer should never be 
allowed to warm up 
2. Place separated fibres in corresponding 0.5mL tube with BIOPS and proceed to wet weight 
procedure  
Bundle Wet Weights 
1. Fill a 1.5mL tube with BIOPS until a dome of liquid covers the top 
2. Place tube in holder on scale and tare the scale 
Oligomyocin 4mg/mL Ethanol  Freezer 
FCCP 1mM Ethanol Freezer 
Rotenone 1mM Ethanol  Freezer 
BLEB 10mM DMSO Fridge 
Cytochrome C 4mM Water Fridge 
P.Carn 10mM Water Fridge 
PCoA 10mM Water Fridge 
L-Carnitine 200mM Water  Fridge 
Antimycin A 5mM Ethanol Freezer 
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3. With fine forceps remove first bundle from eppendorf and using a kim wipe, blot the bundle 
to remove excess liquid 
a. Try to blot no more than 3 times and try to turn the bundle the same way each time 
to get consistent blotting 
4. Very carefully place bundle in liquid on scale, making sure the forceps to not draw up any 
liquid 
5. Wait for scale to stabilize and record weight 
6. Until accuracy is proven, do duplicates of each weight and take average if within 0.2mg, 
repeat weighing if weights are more variable 
7. When done weighing, place back in 0.5mL eppendorf tube until all bundles have been 
weighed 
 
Permeabilization 
1. Once all bundles are weighed, switch bundles to permeabilization tubes (the ones that have 
saponin) using forceps or a gel loading pipette tip 
2. Place on nutator in the fridge for 30 minutes 
a. Make sure all eppendorfs have the liquid mixing by ensuring that the air bubble is 
moving 
b. If air bubble appears stuck, invert eppendorf 1-2 times to allow for movement and 
place back on nutator 
3. After 30 minutes, transfer bundles to corresponding wash tubes using gel loading pipette 
tip  
4. Place bundles in wash back on nutator in the fridge for 15 minutes 
a. Permeabilized bundles can remain in fridge in wash for up to 2 hours but will start 
to lose viability after that point so use bundles ASAP 
5. After 15 minute wash proceed to “Running an Experiment” 
 
Using the O2k 
O2k Setup 
1. Using the switch on the back of the machine, turn machine on 
2. Open up DatLab and a connection box should pop up 
a. For O2k 1 and O2k 2 
i. O2k 1 – USB: E-0085 
ii. O2k 2 – Com 3: C-0024 
b. When connection box pops up ensure the top blue bar says E-0.0085 
c. If it does not, click the configuration tab, click “select communication port” and 
select USB 
d. Click the control tab and click “Connect to Oxygraph-2k” 
e. A screen will pop up asking you to change the file name, save file in location of 
choice 
f. An “Edit Experiment” screen will appear, click “Save” 
g. After O2k 1 is connected, open DatLab again and an error screen will appear, 
change the serial port to “Com 3” and click ok 
h. Follow steps d-f for O2k 2 
i. For O2k 3 and O2k 4 
i. O2k 3 – Com 3: D-0008 
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ii. O2k 4 – Com 4: D-0098 
j. Follow steps b-g for O2k 3 and O2k 4 
3. Remove stoppers and place with top down on top of the O2k 
4.  Turn on the aspirator and remove ethanol from chambers…keep aspirator AWAY from 
membrane inside the chamber 
a. the best way to ensure this is to only touch the bottom of the chamber on the wide 
opposite the membrane to avoid contact 
5. Fill chambers with water and aspirate out water 
a. When cleaning chambers be sure to not let chambers stay dry for very long, always 
replace liquid immediately 
6. Repeat rinse with ethanol 
7. Finish with 3 rounds of water rinses and leave spinning in water until ready to load buffers 
* If this is the first experiment of the day do Volume Calibration before loading buffers 
8. Load chambers with 2.1mL Creatine MiRO (or just regular MiRO if no creatine is wanted) 
9. Push stoppers down and adjust height with the plastic wrench so both stoppers are at the 
same height 
10. Wait for both O2 Concentration and O2 Slope to reach steady state and then proceed with 
“Air Calibration” 
 
Volume Calibration 
1. Volume calibrate chambers at the start of each day but it is not necessary to do in-between 
rounds of experiments 
2. Add 2.1mL of water to each chamber  
3. Using the allen wrench found in the O2k Accessory kit loosen the collar on the stopper and 
push it all the way to the top 
4. Slowly lower stopper into chamber until the first bit of liquid comes out the top of the 
capillary in the stopper 
5. Push the collar all the way to the bottom and tighten with allen wrench 
 
Air Calibration 
1. When a steady state has been achieved, click on the blue Y1 box in the top right corner of 
chamber A 
2. Holding down the shift button, use your mouse, click down and drag across the steady O2 
concentration line to create a “mark” 
3. Click “F5” 
4. Select 01 in the “Select Mark” box for the “Air Calibration” line 
If the sensors are working properly, your [O2] should be somewhere between 180 and 200 units 
during air phase. If this value is too high or too low: 
1. Confirm that O2 solubility is set to 0.92 for MiRO (F5 screen) 
2. Wash out chamber very well and re-do air phase – if this doesn’t fix the values, membrane 
likely needs to be changed and the sensor needs to be cleaned 
 
Running an Experiment 
1. When fibres are done washing and chambers have been air phased, remove stoppers and 
place on top of O2k 
2. Add 5uM BLEB and stop the stir bar pressing F11 for Chamber A and F12 for Chamber B 
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3. Add fibre and loosely place stopper in chamber (do not push down at all) 
4. Turn stir bar back on by clicking F11 and F12 
5. Add a very small amount of O2 with syringe through capillary in stopper 
6. Wait until O2 concentration reaches ~350 and remove stopper, O2 concentration will 
continue to rise, when the levels begin to fall push stopper in all the way so there is a tight 
seal between the chamber and stopper 
7. Ensure there is no air bubble in the chamber 
8. If no air bubble, press F10 to shut off lights 
9. If there is an air bubble, remove stopper, add more buffer and repeat steps 5-8 
10. Wait for background to reach a steady state…this usually takes 10+ minutes (see 
“Important Considerations, proceed with following protocol (remember to always achieve 
a steady state after the addition of a substrate) 
a. See “Important Considerations” for important tips on setting up syringes/beakers 
and substrates 
11. In order to record when you add each substrate, by clicking “Control” and Left Clicking 
your mouse on the spot on the graph that you added a substrate you can make an event 
a. A screen will pop up allowing you to name your event and you can pick whether it 
is for Chamber A, Chamber B or both 
b. Do this after the addition of each substrate 
12. At the end of the experiment, turn lights on clicking F10 and stop stir bars 
13. Remove tissue if being saved and place in labeled eppendorf 
14. Turn stir bars back on and proceed with cleaning 
a. 2 water washes 
b. 2 ethanol washes 
c. 1 water wash 
d. Add 70% ethanol and leave in chamber 
e. Rinse stoppers in sink with water and ethanol 
f. Place stoppers loosely in chamber with caps on and turn off machine 
 
Analyzing Data 
1. Open file you wish to analyze and click “F3” 
2. In the box labeled “background correction” click “Copy from File” 
3. Select the O2k file that contains your most recent background curve for that machine (See 
“Background Curve” section) 
a. Note you can also manually enter the slope and y-intercepts from your background 
curve in each file 
4. Click save 
5. In the top right corner of Chamber A, click on Y2 so the red box is highlighted 
6. Using the technique to “make a mark” like you did for air calibration, make marks for each 
of your steady states following a substrate addition as well as your background steady state 
a. If you make a mark and wish to delete it, hold shift and right click your mouse and 
drag over the mark you wish to delete, then let go and the mark will disappear 
7. Once all marks are made, click “layout” at the top of the screen and select “05 Flux per 
Volume Corrected” 
a. Your data is not corrected using the background curve you imported 
8. Click F2 and select copy to clipboard, your data can now be pasted into excel 
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9. Repeat steps 5-8 for Chamber B 
a. Note that while clicking F2 and pasting will export both Chamber A and Chamber 
B data…the data is not accurate unless you see the “X” beside that chamber in the 
pasted data (glitch in the system) 
 
POS Service and Membrane Mounting 
 ** Membranes should be changed and electrode should be cleaned when data appears excessively 
noisy or air calibration curves have dropped below normal** 
** See O2k Manual for detailed instructions and pictures 
POS Service 
1. IMORTANT: make sure to touch somewhere on the sides of the O2K to de-static yourself 
before removing the sensors 
2. Pull back the blue sheath and slowly remove sensor from inside the system 
3. Unplug the wire from the port on the O2K (should be plugged in to the port labeled O2) 
4. Remove the black cap from the sensor and keep in safe place as this may be reused 
5. Using the black “membrane mounting tool” use the open end of the smaller piece to 
squeeze and remove the membrane ring off the sensor head 
6. Using clean forceps remove the membrane from the top of the sensor and discard 
7. Using distilled water, rinse sensor 1-2 times with water but covering sensor until dome of 
water appears and then dump water off 
8. If gold cathode looks dirty (not shiny, dark grey colour) it must be cleaned with extreme 
care 
a. Using the “O2K Polishing Cloth” that is in the O2K accessory kit, add a small 
amount of  “polishing powder” to the top of the cloth and wet with distilled water 
b. Place the top of the centre face down on the cloth and very gently make small circles 
using the cloth and powder to clean the cathode, continue until cathode appears 
gold and shiny again 
9. Rinse sensor with distilled water 1-2 times 
10. The anode also becomes oxidized over time changing it from a cream colour to a dark grey 
colour, when this happens it must be cleaned with 25% ammonia 
11. Under fume hood, cover sensor with 25% ammonia until a dome appears, leave for 10 
minutes 
12. Repeat 1-2 times until grey colour disappears, if anode is very dark it may require overnight 
treatment with ammonia and/or a higher percentage solution of ammonia 
13. If leaving overnight in ammonia seal ammonia in with membrane (see below) and make 
sure sensor is protected from light 
14. After cleaning, rinse 1-2 times with water to make sure all traces of ammonia are removed 
 
Membrane Mounting 
1. If this is the first time mounting a membrane, fill “electrolyte solution” up to the 10mL 
mark with distilled water 
a. This is simply 1M KCl (you can also dissolve 1.49g KCl in 20mL water) 
2. Cover sensor with electrolyte until dome appears 
3. With forceps, remove a membrane from the membrane box avoiding contact with skin and 
making sure to remove the paper on either side of the membrane  
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4. Using the wider piece of “membrane mounting tool”, place membrane flat on the ledge 
inside the tool 
5. Pull down sheath on blue POS connector and place membrane mounting tool on top of 
sensor, letting go of sheath so it locks in place with the membrane lying flat on top of the 
electrolyte solution 
6. Place membrane ring around circle on the end of the smaller piece of the membrane 
mounting tool 
7. Using a good amount of force, going straight up and down push the smaller piece of the 
membrane mounting tool straight down on top of the membrane so the membrane ring 
locks in place 
8. Remove both pieces of the membrane mounting tool (pull back sheath to remove bigger 
piece) 
9. Check for air bubbles under the membrane, if there are considerable air bubbles you must 
restart at step 2 with a new membrane 
10. Once membrane is mounted with no air bubbles, cover the sensor with the black rubber 
cap and make sure the entire gold cathode is visible 
11. Plug connector wire into O2 port, pull back sheath on POS and place sensor back in place 
in the O2k 
12. Let Datlab run with the machine on for 24 hours to allow new membrane to equilibrate 
a. File will start off very noisy but by the end of 24 hours it should be a flat line, if 
file is still noisy, remove sensor and check membrane 
 
* over time the black caps get looser, if you notice the chamber leaking after replacing the 
membrane, replace the black cap so there is a tighter seal 
 
Background Curves 
1. Set up O2k as you would for normal experiment (see “O2k Setup”) loading chambers with 
2.1mL of MiRO Buffer 
2. When a steady state is achieved for the air phase, complete air calibration (see “Air 
Calibration”)  
3. Add O2 to chambers until O2 levels reach ~350, remove stoppers to ensure no air is trapped 
in stoppers 
4. When O2 levels start to drop, push stoppers in all the way and make sure there is no air 
bubble within the chamber 
5. Allow for a background steady state to be achieved 
6. Using the “zeroing powder” (dithionite) in the O2k accessory kit, mix a few grains of 
dithionite with distilled water and vortex 
7. Add 1uL of dithionite solution to each chamber once a steady state is achieved 
a. It is impossible to know how much dithionite to add, you want the oxygen 
concentration to drop 30-40 units with each addition so with your first addition add 
1uL, see how much it drops and add more if necessary 
b. Dithionite degrades over the course of the experiment so towards the end of the 
titration you will need a larger volume to get the same decrease in oxygen 
8. after each addition wait for a steady state to be achieved, continue with dithionite additions 
until O2 concentration reaches ~0. When O2 looks to be reaching zero add a large amount 
of dithionite (~20uL) to ensure O2 levels are at 0. 
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9. Once O2 has reached zero, create a mark measuring O2 concentration at the zero level in 
the same way you would make your air calibration mark 
10. Click F5 and insert “02” in the zero calibration “select mark” box 
a. Note, “01” should already be inserted in the “air calibration” select mark box” 
11. Click “Calibrate and Copy to Clipboard” 
12. Click on the red Y2 box in the upper right corner of each chamber to switch to “respiration 
mode”, using the method for making marks (see “Air Calibration”), make marks for each 
steady state that occurs after a dithionite addition (including the background steady state) 
13. With Chamber A highlighted (click anywhere on the chamber A box), select “F2” and then 
select “copy to clipboard” 
14. In excel paste the data you have just copied from DatLab 
15. Using the “O2 Concentration (A)” and “O2 Slope uncorr. (A)” data, create a graph with 
concentration on the y-axis and slope on the x-axis 
a. By having 7-10 points to use, you can drop outliers that do not fit the straight line 
model 
16. Repeat steps 13-15 for chamber B 
17. Record the slope and y intercept for each chamber 
18. Back in your DatLab file click “F3” In the section that says “background correction” insert 
your y intercept for each chamber in the a° boxes and the slopes in the b° boxes and click 
save 
 
 
 
Important Considerations 
Buffers 
Buffers must be thawed fresh each day for actual data collection. When thawed, write the date of 
thawing on the tube and place any left over in the fridge. For practice, buffers in the fridge can be 
reused…if it was thawed <2 days prior, it is fine to use as is. If it was thawed 3 days prior or more 
(up to 1 week….throw out buffers that are more than a week old) it must be topped up with EGTA. 
To do this, pour buffer into graduated cylinder to get accurate volume. Thaw a 0.5M EGTA from 
the freezer and add corresponding volume to get the following final concentrations: 
BIOPS: 10mM 
MiRO: 0.5mM 
y	=	0.0533x	- 9.1463
R²	=	0.99227
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Buffer Z: 1mM 
Substrates  
When making substrates, pH to 7.1 and aliquot into small volumes, enough for 6 chambers for 1 
protocol. When running experiments, thawed substrates cannot be put back in the freezer, they 
must be placed in fridge and can be used for up to 1 week after thawing (except for FCCP, 
Oligomyocin and Rotenone, see below). 
 ** ADP must be thawed fresh each day, do not reuse for actual data collection (ok for practice) 
Pyruvate must be made fresh each day, make 2M solution in a 1.5mL eppendorf by combining 
power and water, throw out pyruvate at the end of each day. 
Syringes and Beakers 
Each protocol being followed should have it’s own separate syringe and beaker filled with water. 
Syringes should be rinsed with water prior to use and should be wiped with a kim wipe after being 
put in the chamber to remove residual buffer. When switching substrates, syringes should be rinsed 
thoroughly with water. 
IMPORTANT: FCCP, Oligomyocin and Rotenone have THEIR OWN SYRINGES AND 
BEAKERS. Beakers should be filled with ethanol and these inhibitors should never be near other 
syringes. Only use these labeled syringes for their specific chemical and keep beakers labeled and 
separate from other beakers being used. Additionally, these inhibitors can be placed back in the 
freezer after use as they are dissolved in Ethanol 
Rotenone/Oligomyocin 
Rotenone and Oligomyocin stick to the chambers even after multiple water/ethanol washes. It is 
necessary to use yeast to remove all residual chemicals. After your experiment, rinse chambers 
with 2 water washes and 2 99% ethanol washes. Then add a small scoop of yeast to each chamber 
and fill chamber with water. Allow yeast to spin for 10 minutes. Aspirate out yeast solution using 
aspirator (if yeast clumps in tip use pipette tip to loosen). Repeat yeast wash 2 more times for a 
total of 30 minutes in yeast. Rinse chambers with water 2-3 times or until there is no residual yeast 
left. Complete 2 more 99% ethanol washes and leave in 70% ethanol over night. 
Steady States 
It is very important to make sure a steady state is achieved before each addition in order to get 
accurate data. When waiting for background steady state (after adding fibre but before adding any 
substrates) wait until respiration has leveled out ABOVE zero. If the background is below zero 
respiration will be a negative and all data will be corrected for a negative rate. This may take 10+ 
minutes to achieve proper steady state. 
After adding Glutamate/Pyruvate/Malate respiration often tends to slowly increase, again, make 
sure you have an accurate steady state so you do not end up over estimating this rate and getting a 
lower rate with your first substrate addition (may need to way 5+ minutes). 
If data is very noisy, make a large mark over steady state as opposed to trying to find a small flat 
line. Taking a larger area average will give a more accurate reading. 
Oxygen Levels 
Do not let oxygen levels drop below 150. If oxygen is below 200, make next addition and wait for 
steady state, once respiration has achieved steady state, loosen stopper and re-oxygenate up to 350. 
Push stopper back in and wait for steady state. Often when reoxygenating, respiration rates steady 
state higher than before reoxygenation, if this happens, take an average of the rate before 
reoxygenation and after reoxygenation and then proceed with adding next addition.  
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A.9 Measuring Mitochondrial H2O2 Emission 
 
Buffer Z 
 
Chemical Molecular Weight Final Concentration Addition to 500mL  
final volume 
K-MES 233.33 105mM 12.26g 
KCl 74.55 30mM 1.12g 
KH2PO4 136.08 10mM 0.7g 
MgCl2 • 6H2O 203.3 5mM 0.51g 
EGTA 380.35 1mM 0.19g 
BSA  5mg/ml 2.5g 
 
To make Buffer Z: 
14. Add approximately 400mL of ddH2O to 1000mL beaker 
15. Weigh and add all powder chemicals 
16. Adjust pH to 7.4 using KOH pellets 
17. Using graduated cylinder, bring total volume to 500mL 
18. Filter and then aliquot into 50mL falcon tubes 
19. Freeze falcon tubes 
 
Amplex Ultra Red – Preparation 
Total volume per experiment: 1000ul  
Total volume per black tube:  1050ul  
 
Stock A and B ingredients required:   
  Amplex Ultra-Red (Invitrogen A36006) 
  5000 IU/ml Cu/Zn Superoxide dismutase (SOD1; Sigma S9697) 
  10mM Blebbistatin (BLEB; Cayman) 
  DMSO 
  Buffer Z (5mg/ml BSA) 
  0.5M EGTA (aliquots in freezer) 
 
Stock B additional ingredients: 
  20mM Creatine hydrate 
 
Final concentrations for both AUR Stock A and AUR Stock B: 
  10uM AUR 
  5uM BLEB 
  25U/ml Cu/Zn SOD1 
  2mM EGTA 
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Work fairly quickly given AUR and BLEB should not be stored on ice.  Best to prepare with 
lights out in lab as AUR and BLEB are light sensitive. 
 
Preparation of AUR Stock A (No Creatine): 
 
Step 1: Prepare 5mM AUR.  Add 666.6ul of DMSO to 1mg AUR.  Vortex gently.  Prepare in 
black tube but do not place on ice (DMSO will freeze). 
 
Step 2:  Prepare 10mM BLEB.  Add 1.71 ml DMSO to 5mg bottle of BLEB.  Prepare in black 
tube but do not place on ice. 
 
Step 3:  Prepare 10uM AUR stock.  Mix the following: 
- 160.6 ml of Buffer Z (5mg/ml BSA).  Note:  sucrose buffers lower oxidant emission. 
- 325ul of 5mM AUR 
- 812.5ul of 5000 IU/ml SOD1 
- 80.3ul of 10mM BLEB 
- 325ul of 0.5M EGTA 
 
Aliquot 1.050 ul in black tubes.  Store @ -20◦C. 
 
Preparation of AUR Stock B (20mM Creatine): 
 
Prepare 10uM AUR stock as in Stock A but with 20mM creatine monohydrate.  Mix the 
following: 
 
- 160.6 ml of Buffer Z (5mg/ml BSA) 
- 484.74 mg creatine monohydrate 
- 325ul of 5mM AUR 
- 812.5ul of 5000 IU/ml SOD1 
- 80.3ul of 10mM BLEB 
- 325ul of 0.5M EGTA 
 
Aliquot 1.050 ul in black tubes.  Store @ -20◦C. 
(recommend 1050ul next time) 
 
H2O2 Protocols 
 
Treatment 
in Saponin 
Solution  
In Cuvette Prior 
to Experiment 
Volume to Add Substrate added 
to induce H2O2 
Volume to 
add 
NONE Amplex Red 
  
1U/mL HRP 
1mL 
 
2uL of 500U/ml 
10mM Succinate 5uL of 2M  
35uM 
CDNB 
Amplex Red 
  
 
1mL 
 
 
10mM Pyruvate 
 
2mM Malate 
5uL of 2M 
 
2uL of 1M 
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(5uL of 
10.5mM 
Stock) 
1U/mL HRP 2uL of 500U/ml 
35uM 
CDNB 
(5uL of 
10.5mM 
Stock) 
Amplex Red 
  
 
1U/mL HRP 
1mL 
 
 
2uL of 500U/ml 
20mM Glycerol-
3-Phosphate 
20uL of 1M 
35uM 
CDNB 
(5uL of 
10.5mM 
Stock) 
Amplex Red 
  
1U/mL HRP  
 
0.5uM 
Rotenone** 
1mL 
 
2uL of 500U/ml  
 
 
2uL of 250uM 
10mM Pyruvate 
 
5uL of 2M 
NONE Amplex Red 
  
1U/mL HRP 
1mL 
 
2uL of 500U/ml 
2.5uM Antimycin 
A 
5uL of 
0.5mM  
 
NONE Amplex Red 
  
1U/mL HRP 
1mL 
 
2uL of 500U/ml 
250uM Tyramine 5uL of 
50mM 
 
**Use Green Tape Cuvettes for Rotenone as it sticks to glass 
 
ADP Titration for: 
1. Succinate 
2. Pyruvate + Malate 
3. G3P 
 
Addition 1: 25uM ADP – 5uL of 5mM 
* Open lid prior to addition, wait 2 minutes before next addition 
 
Addition 2: 500uM ADP – 9.5uL of 50mM  
* Open lid prior to addition, wait 2 minutes before next addition 
 
Addition 3: 5mM ADP – 10uL of 500mM 
* Open lid prior to addition, wait 2 minutes before next addition 
 
CDNB for H2O2  
 
CDNB – Sigma 237329-10G 
** use gloves when handling…very toxic! 
 
Make a 1M Stock of CDNB – dissolve in 100% ethanol - will need to heat at 95° - needs to be made fresh daily 
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If working with RATS: 
Dilute 1M stock to make 20mM working solution 
- add 7.5 µL to your saponin tubes for a final concentration of 100 µM 
 
If working with MICE: 
Dilute 1M stock to make 10.5mM working solution 
- add 5 µL to your saponin tubes for a final concentration of 35 µM 
 
Use CDNB in your saponin tubes for the following H2O2 Protocols: 
1. 10mM Pyruvate + 2mM Malate 
2. 10mM Pyruvate + 0.5µM Rotenone 
3. 20mM Glycerol-3-Phosphate  
 
H2O2 Standard curve for Amplex Ultra Red 
 
1. H2O2 dilution  (serial dilution) 
• H2O2 is light sensitive. Keep in dark when possible. 
• Use H2O2 purchased within last 6 months (stored in fridge, wrapped in foil).  
• One standard curve per batch is acceptable, but re-make curve if batch approaches 6 
months of age. Discard if curve no longer consistent with original curve. 
• Good in -20C freezer up to 6 months or so. 
• Use stock 3% w/w H2O2 : 3 g H2O2 / 100 mL solution (1 mol H2O2 / 34.01 g) = 
0.0882 mol H2O2 / .100 L = .882 mol H2O2 / 1 L = 0.882 M H2O2 
(1) 4310ul ddH2O  +  100ul 3% w/w H2O2   >>>>  20mM H2O2. Use in dilution step 
2. 
(2) 3980ul ddH2O  +  20ul of 20mM H2O2   >>>>>>  100uM H2O2. Use in dilution 
step 3 for 20uM. 
(3) 3200ul ddH2O  +  800ul 100uM H2O2  >>>>>   20uM H2O2. Use in table below. 
(4) 2000ul ddH2O  + 2000ul 20uM H2O2  >>>>>>  10uM H2O2. Use in table below. 
(5) 2000ul ddH2O  + 2000ul 10uM H2O2  >>>>>>  5uM H2O2. Use in table below. 
NOTE: 
- H2O2 is light sensitive. 
- Prepare large volumes to minimize pipetting/dilution errors.  
- Do not vortex - H2O2is unstable and dismutates spontaneouslyover time. Agitation 
may worsen. Flip tube in hand several times. 
 
2. Add your Amplex UltraRed, HRP, (oligomycin) and other substrates (G/M/S/G-3-P……) 
into the cuvette as per your protocol.   
NOTE:  
- Each component of the protocol may affect background fluorescence so it is important 
to complete the standard curve in the conditions you will use in your experiments. The 
only exception is the absence of sample: while fibres/isolated mitochondria/cells could 
affect background fluorescence AND ‘scavenge’ H2O2 via cysteine/histidine 
reactions, it is difficult to include tissue in standard curves without a source of oxidants.  
- Another limitation is that we are not obtaining a separate standard curve in the presence 
of each substrate. Ie. H2O2 titrations with pyruvate alone, or pyrumate/malate, or 
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pyruvate/malate/ADP. In theory, this would be ideal to isolate the effect of each 
addition and apply a unique standard curve to each component of your experimental 
protocol. This is not feasible. Moreover, each substrate has negligible effect on 
fluorescence for amplex ultra red. The compromise is to simply add all components of 
a protocol during the H2O2 standard curve titration. 
 
3. H2O2 titration. NOTE: [final H2O2] depends on the final volume in the cuvette, which will vary 
depending on your protocol. 
 
Make sure to clean the pipette tip by pipetting up and down in a beaker of ddH2O after 
each addition, and wipe pipette tip with kim wipe. This avoids excess additions of H2O2 
as you progress. 
If for 1000 ul 
Titrate very fast, 45-60 sec 
If for 600ul 
Titrate very fast, 45-60 sec 
[H2O2] (µM) Add (µl)) [H2O2] (µM) Add (µl)) 
5 3.33 5 2.0 
5 3.33 5 2.0 
10 3.33 10 2.0 
10 5 10 3 
20 5 20 3 
20 5 20 3 
20 10 20 6 
4. Repeat 3 times. Average all 3 standard curves to make one equation for analyses in excel. See 
next page… 
NOTE: Prepare a standard curve for each protocol. For example, you may have a H2O2 
standard curve for PM-D-G-CytC-S protocols, and another for ROT-ADP-SUC protocols, 
etc.  
 
Generate Considerations:  
- You will have 7 points in the Standard Curve.  Consult experienced personnel on 
judgement for quantifying steady state fluorescence. In general, make an addition ever 3 
minutes. The key is to have at least 2 minutes of approximate steady state fluorescence 
(following <1 min equilibration of signal). Do not wait longer than 5 minutes as there is a 
positive drift over time that will inflate your standard curve.  
- During analyses, it is common to drop the 6th or 7th point given the relationship begins to 
form a curvilinear response. Check curve closely following analyses. Aim for at least 4 
data points in the final curve.  
- Finally, the accuracy of dilutions as an enormous effect on the lowest H2O2 points of the 
standard curve. It is not uncommon for new trainees to see scattered points at the low end. 
The stocks must be re-made with new curves prepared if this is the case. 
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A.10 Measuring Calcium Retention Capacity 
 
Buffers: 
1. BIOPS 
Chemical Stock Solution Molecular 
Weight 
Final 
Concentration 
Addition to 2 
Litre final 
volume 
CaK2EGTA* 100mM  2.77mM 55.4mL 
K2EGTA* 100mM  7.23mM 144.6mL 
Na2ATP  555.1 5.77mM 6.28g 
MgCl2 • 6H2O  203.3 6.56mM 2.67g 
Taurine  125.1 20mM 5.02g 
Na2Phosphocreatine  327.14 15mM 9.81g 
Imidazole  68.1 20mM 2.72g 
Dithiothreitol 
(DTT) 
 154.2 0.5mM 0.154g 
MES Hydrate  195.2 50mM 19.52g 
* prepare stock solutions (see full BIOPS recipe) 
 
2. Buffer Y – pH 7.1 
Chemical Final 
Concentration 
Addition to 500mL 
final volume 
Sucrose 250mM 42.78g 
Tris-HCl 10mM 0.788g 
Tris Base 20mM 1.21g 
KH2PO4 10mM 0.68g 
BSA 0.5mg/mL 0.25g 
• store in fridge at 4 C  
• may require heat to dissolve everything 
 
3. CRC Assay Buffer – 600uL aliquots 
Chemical Final 
Concentration 
Addition to 120mL 
final volume 
Buffer Y (freshly made)  120mL 
Creatine 20mM 0.358g 
EGTA 40uM 9.6uL of 0.5M 
2-Deoxyglucose 5mM 0.0984g 
Hexokinase 2U/mL 160uL of 1500U/mL 
BLEB 5uM 60uL of 10mM 
Calcium Green* 1uM 400uL of 0.3mM 
Tharpsigargin** 2uM 160uL of 1.5mM 
* Dissolve 0.5mg CG5N in 1.398mL water 
** 1mg vial, make 1mL, aliquot into 165uL stocks and freeze 
 
4. Create a stock of 50mM CaCl2 dissolved in water and store in 50uL aliquots in freezer 
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Procedure 
* place cuvettes on stir plate and fill with ddH2O and 10uL EGTA (0.5M stock) 
 
1. Harvest muscle and place in ice cold BIOPS 
2. Separate fibres into bundles (very small and overly separated).  
3. Permeabilize for 30 minutes in BIOPS with 40ug/mL saponin 
4. WASH 1: 10 minutes in 1.5mL Buffer Y + 1mM EGTA (3uL of 0.5M) 
5. Turn on fluorometer to allow lamp to heat up 
6. WASH 2: 10 minutes in 1.5mL Buffer Y + 5uM BLEB (0.75uL of 10mM BLEB) 
7. Aspirate out water from cuvette but DO NOT RINSE (keep cuvette lined with EGTA) 
8. Select Calcium Uptake Assay Protocol on PTI Software. Make sure the following 
parameters are set: 
a. Excitation: 506 
b. Emission: 532 
c. Duration – 3000 seconds 
d. Slit Widths:  Excitation 3nM  
Emission 3nM  
e. x-axis window: 2000 seconds 
f. y axis max and min: 500 000 and 800 000  
 
Substrate Stock 
Concentration 
Addition to cuvette Final Concentration in 
Cuvette 
CRC Assay Buffer  300uL  
Glutamate 2M 1.5uL 10mM 
Malate 1M 1.5uL 5mM 
ADP 500mM 3uL 5mM 
Fibre       ** make sure fibre is at the bottom of cuvette attached to stir bar** 
Collect 400 second background to establish “F-Min” 
CaCl2 5mM 2.5uL  8nmol 
Wait 5 minutes or until steady state 
CaCl2 5mM 1.25uL  12nmol (4nmol pulse) 
Wait 5 minutes in between pulses and continue pulsing until pore opens 
CaCl2 50mM 3uL 0.5mM Pulse (F-Max) 
Wait 3 minutes before final addition, this should establish F-Max but last addition is to 
make sure 
CaCl2 50mM 3uL 0.5mM Pulse (F-Max) 
* for each additions remove cuvette from holder and ensure fibre has not been disrupted 
**Make sure y axis is no more than 300 000 units or you will miss opening 
 
9. Remove bundle and save for freeze drying (if applicable) 
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A.11 Caspase Activity Assay 
 
Chemicals 
Homogenisation buffer: 500 ml 
 
Chemical Molecular Weight Concentration Amount added 
Sucrose 342.3 250 mM 42.8g 
Tris 121.14 50 mM 3.03g 
DTT 154.25 1 mM 0.077g 
EDTA 372.24 1 mM 0.186g 
MgCl2  203.3 5 mM 0.51g 
Glycerol  10% 50mL 
pH 7.5 
Incubation buffer:  100 ml 
 
Chemical Molecular Weight Concentration Amount added 
HEPES 283.3 100 mM 2.38g 
Sucrose  10% 10g 
DTT 154.25 1 mM 0.015g 
pH 7.5  
 
Fluorescent substrates for Caspase activities: 
 
Caspase 3: AC-DEVD-AMC (Enzo - ALX-260-031-M001) 
1mg into 1.48 mL DMSO for 1mM Stock 
 
Caspase 3 Inhibitor: AC-DEVD-CHO (Enzo - ALX-260-030-M001) 
1mg into 2mL DMSO for 1mM Stock 
 
Caspase 8: AC-IETD-AMC (Enzo - ALX-260-042-M001) 
1mg into 1.48 mL DMSO for 1mM Stock 
 
Caspase 8 Inhibitor: AC-IETD-CHO (Enzo - ALX-260-043-M001) 
1mg into 2mL DMSO for 1mM Stock 
 
Caspase 9: AC-LEHD-AMC (Enzo - ALX-260-080-M001) 
1mg into 1.45 mL DMSO for 1mM Stock **different MW from 3 and 8 
 
Caspase 9 Inhibitor: AC-LEHD-CHO (Enzo - ALX-260-079-M001) 
1mg into 1.86mL DMSO for 1mM Stock 
 
** Aliquot Substrates into 300uL, Aliquot inhibitors into 10uL. Store in black tubes at -20 
 
Experimental procedures 
 
Preparation of lysosome and proteasome fractions: 
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Homogenise muscle biopsy using tapered pestle with a muscle:homogenate ratio of 
10mg:100uL. 
 
Centrifugation steps: (P = pellet; S = supernatant) 
 
700×g 10 min at 4 degrees   P1 (nuclei, myofibrils) 
       S1 
16,300×g 20 min at 4 degrees  P2 (lysosomes, mitochondria) 
       S2 (bound and free proteasomes) 
 
S2: divide into 100 µl portions to be used for CASPASE AND CALPAIN ASSAYS 
 
Freeze all fractions at -80ºC 
 
Protein determination: 
 
Protein determination is done with the Bradford method USING THE REDUCING AGENT 
COMPATIABLE KIT. 
 
Caspase Activity: 
 
1. Dilute 1mM stock of each substrate into 100µM using incubation buffer – make up total 
volume needed for all samples plus 200µL extra (see loading table in excel) 
2.  Add 10uL of protein from S2 into the wells (total of 3 wells for each sample, unless 
running an inhibitor test) 
3.  Add 100 uL of diluted caspase 3 substrate to 1 well of sample  
4. Repeat step 3 using Caspase 8 and Caspase 9 substrate 
5. Add 3uL of Caspase 3 inhibitor to well if required 
6. Repeat step 5 for Caspase 8 and 9 inhibitor 
7. Read every 2 minutes for 1 hour 
**Do not need to run inhibitor well for every sample, just use as a check 
Fluorescence measurements (using Haas fluorescent plate reader in LSB: 
 
Prepare the plate reader settings before adding standards, muscle extracts and substrates into the 
micro plates. 
Temperature 37ºC; Excitation filter 360 nm; Emission filter 460 nm 
Gain 80 % of max value 
Read every 2 min for 1 hour 
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A.12 Western Blotting 
WESTERN BLOTTING – PREPARATION OF BUFFERS 
 
 Stacking Running 
5% 6% 8% 10% 12% 
dH2O 6.8 ml 11.4 10.6 ml 9.4 ml 8 ml 6.7 ml 
1.5M Tris-Base, pH 8.8 *** 5 ml 5 ml 5 ml 5 ml 5 ml 
1M Tris-Base, pH 6.8 1.25 ml *** *** *** *** *** 
30 % Acrylamide 1.70 ml 3.4 ml 4 ml 5.3 ml 6.7 ml 8 ml 
10 % SDS 100 µl 200 µl 200 µl 200 µl 200 µl 200 µl 
       
10 % APS 100 µl 200 µl 200 µl 200 µl 200 µl 200 µl 
Temed 20 µl 20 µl 20 µl 20 µl 20 µl 20 µl 
 
10 X Running Buffer: 
 
 500 ml 1 L 2 L 
Tris 15 g 30 g 60 g 
Glycine 72 g 144 g 288 g 
SDS 5 g 10 g 20 g 
 
1 X Running Buffer:  10 X Running buffer 100 ml 
    dH2O   900 ml 
 
 
10 X TBS (Tris Buffered Saline): 
 
 500 ml 1 L 
Tris 12.1 g 24.2 g 
NaCl 40 g 80 g 
Adjust to pH 7.6 with HCl 
 
1 X TBST: 
 1 L 2 L 
10 X TBS 100 ml 200 ml 
dH2O 900 ml 1800 ml 
Tween 20 1 ml 2 ml 
Note: Ensure solution is stirring when adding Tween 
 
Primary Antibody - Blocking Buffer - .1% Tween - .01% SDS 
Secondary Antibody - Blocking Buffer - .1% Tween - .01% SDS 
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CHAPS Buffer 
For 200mL solution at pH 7.5 
Amount Reagent Concentration Molecular Weight 
1.906g HEPES pH 7.5 40mM 238.3 
1.403g NaCl 120mM 58.44 
74.4mg EDTA Na2 1mM 372.2 
892mg NaHP2O7.10H2O 
pyrophosphate 
10mM 446.1 
432mg B-glycerophosphate 10mM 216.04 
420mg NaF 50mM 41.99 
0.6g CHAPS 0.30%  
 
Muscle Homogenization 
** Turn on centrifuge and cool to 4°C 
1. Place frozen muscle in corresponding eppendorf tube with Buffer/Inhibitors 
i. 10mg muscle = 100uL CHAPS Buffer  
ii. Fridge Protease Inhibitors = 1:100  
iii. Freezer Phosphatase Inhibitor = 1:200  
2. On ice, use small scissors to mince tissue until it is broken up into small pieces 
3. Rinse pestol with 70% ethanol followed by water, wipe pestol with kim wipe 
4. Place eppendorf with minced tissue in beaker of ice 
5. Push pestol to bottom of eppendorf 
6. Turn on homogenizer and allow to run for 10 seconds while pushing pestol against eppendorf 
7. Turn off for 10 seconds and scrape any muscle off of pestol 
8. Repeat step 6 and 7 two more time (total of 3x10 seconds homogenizing) 
9. Place sample back in ice box and repeat steps 1-9 for next sample 
 
10. Once all samples are homogenized, place in centrifuge and spin for 10min: 800g at 4 degrees 
11. Pipette off supernatant and place in new labeled tube 
12. Throw out remaining pellet 
13. Proceed with Bradford Protein Assay 
 
Protein Assay – BCA 
1. Create standards by diluting BSA in homogenization buffer 
Standards (BSA): 
0 mg/mL (buffer) 
0.0625 mg/mL 
0.125 mg/mL 
0.25 mg/mL 
0.50 mg/mL 
0.75mg/mL 
1.00 mg/mL 
2. Dilute 5 µL of each sample in 45 µL of homogenization buffer 
3. Using a 96 well plate load in triplicates each standard and each sample 
4. Add 190uL of mixed solution (50:1 Solution A:SolutionB) into each well of sample 
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* Amount needed: (# of standards + # of unknowns) x (3 replicates) x (200uL) 
5. Heat in over for 30 minutes at 37°C 
 
Running a Western 
1. In 50mL falcon tubes make running gel and stacking gel (1 column makes 2 gels) 
*DO NOT ADD TEMED UNTIL READY TO LOAD 
2. Take 1 short plate and one spacer plate and clean both sides of glass with methanol 
and kimwipe 
3. Place clean short plate on top of spacer place and place both in mounting apparatus, 
ensuring the edge of the plates are lined up against the bench top 
4. Place plates in apparatus on foam piece in gel stand 
5. Place 3 transfer pipettes and falcon tube with methanol close to gel stand 
6. Add TEMED to running gel and invert falcon tube 1-2 times 
7. Using transfer pipette, fill space between glass plates with running gel until solution 
reaches the top of the green doors 
1.  Using new transfer pipette add methanol to top of plate to create an even line along 
the top of the gel removing any bubbles 
2. Let sit until remaining running gel has hardened in the falcon tube 
3. Once gel has set, invert gel to remove any excess methanol 
4. Add TEMED to stacking gel and invert 1-2 times 
5. Using transfer pipette, add stacking gel to top of glass plates, use methanol transfer 
pipette to remove any bubbles 
6. Add comb to top of gel and allow to set 
 
7. Prepare diluted samples by combining sample, water and Laemmeli’s buffer + 2-
mercaptoehtanol (100 µl 2-mer: 900 µl Lam) 
a. Example of dilution to load 50µg protein at a concentration of 1µg/ µl 
Sample 
Corr Prot 
(ug/ul) 
Aliquot 
(ug) Sample (ul) H20 
4X Laem 
(1:9 2-
Mercap) 
Vol for 1 
Well 
    		   		 		 		
C7.5-A	 4.599	 50	 10.9 26.6	 12.5	 50	
8. Boil samples at 95 °C for 5 minutes 
9. Spin down samples for 5 seconds 
10. Make 1X running buffer in 1000mL graduated cylinder 
11. Remove combs from gels and place gels in gasket 
12. Place gasket with gels in tank and add 1X running buffer until it fills the top of gasket 
and tank 
13. Load wells with desired concentration of samples 
14. Run for desired time (40-75 minutes) at 160mV (or desired voltage) 
 
15. Fill 2 plastic “biorad” dishes, one with methanol and one with transfer buffer 
16. Place 2 transfer packs in dish of transfer buffer and place membrane in dish of 
methanol 
17. After 2-3 minutes place first transfer pack on bottom of transfer case 
18. Place membrane in transfer buffer for 10-15 seconds 
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19. Place membrane on top of transfer pack ensuring no air bubbles 
20. Remove short plate from gel and place gel face down on membrane 
21. Place second transfer pack on top of membrane 
22. Using roller, roll from one side of transfer pack to the other to remove air bubbles 
23. Hold firmly down in the middle of the transfer pack and remove excess liquid 
24. Put lid on transfer case and run transfer (standard setting is 1.5mm gel for 10 minutes) 
 
25. Following transfer remove membrane and place in dish with blocking buffer (50% 
Odyssey Blocking Buffer, 50% TBS) for 1 hour, rocking at room temperature 
26. After 1 hour pour blocking buffer back into falcon tube (it can be resused) and add 
primary antibody 
27. Place membrane in primary in fridge overnight, rocking 
28. In the morning remove primary and pour back into falcon tube (can be resued) 
29. Add TBST to dish and complete 3x5 minute TBST washes rocking at room 
temperature. 
30. Add secondary antibody and leave rocking at room temperature for 1 hour 
31. Remove secondary and place back in falcon tube (can be resused) 
32. Complete 3 more 3x5 minute TBST washes 
33. Detect using LiCOR Infrared Imager 
 
Antibody Optimization 
Antibody Company Concentration Animal Gel% Molecular Weight [Protein] 
ANT 1 Abcam – 180715 1-1000 Rabbit 12% 
33 
Cut gel at 25 and 
37 (right at 37 to 
get rid of thick 
band above 37) 
Heart: 50 
Diaphragm: 40 
Quad: 30 
WG: 50 
VDAC 2 Sigma – SAB2501096 1ug/ml Goat 12% 32 50 
OXPHOS Abcam 1:250 (6ug/mL) Mouse 12% 
20-50 
Cut gel at 15 and 
75 
Heart: 30 
Diaphragm: 40 
Quad: 15 
WG: 15 
MiCK - Uwe 1-1000 Rabbit 10% 42 15 
4-HNE Abcam – 46545 1-1000 Rabbit 12% <75 kda 50 
Oxyblot 
Millipore 
Sigma – 
S7150 
1-150 Rabbit 12% Above 100, Below 20 
Heart: 15 
Diaphragm: 15 
Quad: 40 
WG: 40 
PDH 
E1alpha 
Abcam - 
ab110330 1-1000 Mouse 10% 43 50 
 
 
307 
A.13 Evaluating Redox Status of Specific Protein 
Optimized for IP of MtCK 
Lysis Buffer: Chaps 
For 200mL solution at pH 7.5 
Amount Reagent Concentration Molecular Weight 
1.906g HEPES pH 7.5 40mM 238.3 
1.403g NaCl 120mM 58.44 
74.4mg EDTA Na2 1mM 372.2 
892mg NaHP2O7.10H2O 
pyrophosphate 
10mM 446.1 
432mg B-
glycerophosphate 
10mM 216.04 
420mg NaF 50mM 41.99 
0.6g CHAPS 0.30%  
 
Stock solutions 
 
 Catalog 
number 
Molecular 
Weight (g/mole) 
Amount  
(g) 
Volume of Solvent 
IR Dye – 8.4mM 
Licor, 929-80020 
1191 
0.5mg DMSO 50ul *5ul aliquots 
Dilute to 60uM Stock – freeze 60uM stock, can be reused several times 
1uL of 8.4mM Dye into 140uL DMSO 
 
H2O2 – 0.1M 
Fresh 
Sigma, 
95321-100ml 34.01 113ul (of 3%) 
WATER 
887ul 
 
 
 NaI – 100% 
Fresh 
Sigma 
217301-
100G 
185.92 0.1g WATER 100ul 
TCEP – 0.1M 
Fresh 
Fisher - 
20490 286.65 1mg 
WATER 
34.9ul 
Tissue Homogenization 
N.B: The IRDye-Maleimide should be protected from light at all time 
Day 1 
1. Weigh 2x 60 mg of left ventricular tissue (one will be labeled and the other one will be 
used for controls)  
2. Place 60mg of tissue into 0.6 ml ice cold CHAPS buffer + protease inhibitors (standard 
homogenization protocol) and homogenize for 3x10seconds 
3. Spin at 800g for 10 minutes (4°C) 
4. Transfer supernatant to new tube 
5. Determine protein concentration using standard BCA protein assay kit 
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6. Determine exact volume of lysate and calculate total protein in sample *Use prepared 
excel sheet 
7. Add 100nM dye/200ug protein (60uM stock) 
8. Mix gently on nutator overnight at 4°C 
Day 2 
9. Remove excess Dye by passing the lysate over 2 successive 2ml desalting Zeba columns. 
Use the same column twice. 
a. Remove bottom closure and place column in 15ml Eppendorf tube 
b. Unscrew red cap 
c. Spin down for 2 minutes at 1000g to remove storage 
d. Mark with sharpie the side of the column that has resin slanted upwards – always 
place this side facing outwards in the centrifuge 
e. Add 1ml of water to column and spin down again for 2min at 1000g 
f. Place zeba column in new 15ml Eppendorf 
g. Slowly load up to 700ul of sample onto filter bed 
h. Spin down for 2 minutes at 1000g 
 
10. Collect the cleaned sample 
11. Determine protein concentration using BCA 
12. Proceed to the IP 
 
Immunoprecipitation Protocol – based on BioRad SureBeads Protocol 
1. Vortex SureBeads in their solution and transfer 100ul (1mg of beads) of SureBeads to 
1.5ml tubes – 1 tube/sample 
2. Magnetize beads and aspirate off supernatant using pipette (aspirator is too aggressive 
and sucks up beads) 
3. Wash with 1ml PBS-T (PBS + 0.1% Tween 20) 
a. Add PBS to Eppendorf running liquid overtop of beads 
b. Rotate Eppendorf 180 degrees, let bead sit, rotate another 180 degrees and allow 
bead to gather 
4. Magnetize beads and aspirate off supernatant (always using pipette) 
5. Repeat steps 3 and 4 three times 
6. Remove tubes from magnet (should have no liquid) and add 200-volume of antibody ul 
of PBS-T over beads 
7. Add desired concentration of antibody (usually between 1 and 10ug) and vortex well 
a. Total volume in tube should be 200ul 
8. Rotate for 10 minutes at room temperature 
9. Spin down to remove liquid from the cap 
10. Wash with 1ml PBS-T (PBS + 0.1% Tween 20) 
a. Add PBS to Eppendorf running liquid overtop of beads 
b. Rotate Eppendorf 180 degrees, let bead sit, rotate another 180 degrees and allow 
bead to gather 
11. Magnetize beads and aspirate off supernatant 
12. Repeat steps 10 and 11 three times 
13. Remove tube from magnet (beads should have no liquid in tube) 
14. Add desired volume/concentration of lysate 
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15. Rotate for 1 hour at room temperature 
16. Spin down to remove liquid from lid 
17. Magnetize beads and discard supernatant 
18. Wash with 1ml PBS-T (PBS + 0.1% Tween 20) 
a. Add PBS to Eppendorf running liquid overtop of beads 
b. Rotate Eppendorf 180 degrees, let bead sit, rotate another 180 degrees and allow 
bead to gather 
19. Magnetize beads and aspirate off supernatant 
20. Repeat steps 18 and 19 three times 
a. Before last magnetization, transfer the re-suspended beads to a new tube 
21. Spin down tube for several seconds 
22. Magnetize beads and aspirate residual buffer from the tubes 
Elution: 
1. Add 20mM Glycine (pH 2.0) – 20ul and incubate for 5 minutes at room temperature 
2. Magnetize beads and move eluent to a new vial 
3. Neutralize eluent with 2ul (10% of total volume) with 1M PBS, pH 7.4 
** This elution strategy is used for IR Dye to avoid boiling and subsequent denaturing of 
proteins. If not using IR dye, standard Laemmli buffer plus boiling can be used to elute 
protein of interest 
4. Proceed to Western Blot Sample Preparation – do not boil 
a. 22ul total sample + 
b.  10ul of 4x Sample Buffer (1/10 2-Mercap, 9/10 4x Laemellis) + 
c. 8ul of H2O 
5. Spin samples down to remove bubbles 
6. Load 35ul of sample into lane 
Controls 
Day 1 
1. Homogenize in CHAPS buffer as above for samples.  
2. Run samples through zeba desalting column twice to remove any glutathione 
a. Use 0.5ml zeba column to reduce protein loss that occurs when sample is spun 
through the large 2ml column 
b. Remove bottom closure and place column in 1.5ml Eppendorf tube 
c. Unscrew red cap 
d. Spin down for 1 minute at 1500g to remove storage 
e. Mark with sharpie the side of the column that has resin slanted upwards – always 
place this side facing outwards in the centrifuge 
f. Place zeba column in new 1.5ml Eppendorf 
g. Slowly load up to 130ul of sample onto filter bed 
h. Spin down for 2 minutes at 1500g 
 
3. After spin, run protein assay with standard BCA kit 
4. Divide sample into 3 aliquots of 4.167ug/ul diluted in CHAPS (total volume 200ul) 
a. Use prepared excel sheet for calculations 
5. Add 5mM H2O2 + 0.5% NaI to oxidized sample – this sample should turn yellow! 
Make sure you added H2O2 and NaI at the same time! 
a. 5mM H2O2 = 10ul of 0.1M 
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b. 0.5% NaI = 1ul of 100% 
6. Add 1mM TCEP to control sample 
a. 1mM TCEP = 2ul of 0.1M 
7. Incubate at room temperature on nutator for 5 minutes along with non-treated control 
8. Spin all samples through zeba column to remove excess reagent - twice 
9. Run Protein Assay using reducing agent compatible BCA kit 
10. Determine volume of remaining lysates – calculate total protein in sample 
11. Add 100nM/200ug protein dye (60uM Stock) 
12.  Mix gently on nutator overnight at 4°C 
Day 2 
13. Remove excess Dye by passing the sample over 2 consecutive desalting Zeba columns 
(0.5mL columns). Use same column twice. 
14. Collect the cleaned sample  
15. Determine protein content using Reducing Agent Compatible BCA protein assay kit 
16. Prepare samples for western blot – will need 2.5ug Protein 
 
Western Sample Preparation 
** Do not boil 
**1/10 2-Mercaptoethanol; 9/10 4x Laemellis Buffer 
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A.14 Evan’s Blue Dye 
 
Evans Blue Dye Stock – 1% (0.01g/mL) 
Inject IP - 50µl/10g BW of mouse 
Wait 16-18 hours and harvest muscle 
 
Procedure 
1. 0.9% Saline 
a. 0.45g NaCl in 50mL ddH2O 
2. Dissolve EBD in Saline 
a. 0.1g in 10mL 0.9% Saline 
b. Run through sterile filter syringe 
c. Store in Fridge 
3. Inject mouse IP with 50µl/10g BW 
4. Wait 16-18 hours 
5. Harvest Tissue and weigh individual muscles – take photos for representative images 
6. Place in 1ml of formamide and incubate over night at 56 degrees on heat block 
7. Day 2: remove the tissues from the formamide and keep the “blue” solution  
8. Load 200µl from each tissue into a 96 well plate 
9. Load standard curve (see below) 
10. Read using spectophotometer set to A620 
Standard Curve 
a. Dissolve the 1% Evans Blue Solution 3:1000= 30mg/ml 
i. 3ul 1% EB in 1000ul formamide  
b. 12.9µg/ml: 430µl of 30mg/ml in 570ul formamaide  
c. 6.45µg/ml: 500ul of 12.9µg/ml in 500µl of formamide  
d. 3.225 µg/ml:  500ul of 6.45/ml in 500µl of formamide 
e. 1.6125 µg/ml: 500ul of 3.224/ml in 500µl of formamide 
f. 0.806 µg/ml: 500ul of 1.6125/ml in 500µl of formamide 
g. 0.403 µg/ml: 500ul of 0.806/ml in 500µl of formamide 
h. 0.2015 µg/ml: 500ul of 0.403/ml in 500µl of formamide 
i. 0.1 µg/ml: 500ul of 0.2015/ml in 500µl of formamide 
j. load 200ul per well, can do duplicates  
 
11. Convert amount of Evans blue to ng/mg of tissue 
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A.15 Glutathione 
Buffer - TRIS-BSA: homogenization buffer with Trizma Base + Boric Acid/Serine/Acivicin 
to inhibit γ-glutamyltranspeptidase from metabolizing GSH/GSSG.   
o 200mL HPLC grade water 
o 50mM Trizma Base: 1.212g -- (MW=121.14g) 
o 20mM Boric Acid: 0.248g – (MW=61.83g) 
o 2mM L-serine: 0.042g – (MW=105.69g) 
o 20uM Acivicin: (MW=178.57) 
o Acivicin inhibits y-glutamyltranspeptidase, a protein bound to the cell 
membrane which catabolizes glutathione upon contact 
o pH to 8 with HCL - DAY OF: 
o Add 25ul 0.2M NEM for every 1ml TRIS-BSA fresh day of use (some 
suggest NEM is light sensitive, freeze sensitive, not sure if this is true or not, 
but adding it same day allows for to decide whether you would want to or not 
add NEM, only time you wouldn’t add NEM is if you wanted to measure total 
glutathione) 
o NEM irreversibly binds to GSH creating a GS-NEM conjugate and inhibits 
glutathione reductase preventing the auto-oxidation GSH to GSSG 
Making Mobile phase solvents 
GSH mobile phase 
o Solvent A: 0.25% Glacial Acetic Acid in HPLC grade water 
§ 2.5mL glacial acetic acid into 997.5mL water 
• Or 1.25ml glacial acetic acid into 498.75mL water 
§ pH to 3.1 by adding in a couple drops of 2M NaOH to bring pH up or 
glacial acetic acid to bring pH down 
§ Prepare fresh every day 
o Solvent B: 100% Acetonitrile 
GSSG mobile phase 
- Solvent A: 25mM Na2HPO4 in HPLC grade water 
o Make 425ml 
§ pH to 6.0 using phosphoric acid 
o Add 75ml MeOH to get final 15% methanol mobile phase 
Sample preparation: 
- Make up 6 tubes: 
o Tube1 for homogenate/lysis 
o Tube2 for protein assay 
§ 5ul homogenate into 45ul buffer/RIPA buffer for cells 
§ Poke hole in top of tube 
o Tube3 with TCA 
§ 7ul TCA into tube 
o Tube4 PCA 
§ 70ul PCA into tube 
o Tube5 labeled GSH 
§ Poke hole in top of tube 
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o Tube6 labeled GSSG 
§ 500ul 0.5M NaOH 
For muscle: 
o Homogenize tissue in TRIS-BSAN at a 1mg-10ul ratio, leave on ice until all 
samples (I usually do about 10 samples at a time, do samples in random order). 
§ Try and get at least 145ul final volume, otherwise need to adjust volumes 
of TCA and PCA 
o Spin samples at  800g for 10 minutes at 4 degrees 
o Add supernatant to tube 1 
- Now have cells or muscle homogenate in tube 1 
- Take from tube 1: 
o 5ul tube 1 -> tube 2  (protein tube) 
§ Freeze in liquid nitrogen 
o 70ul tube 1 -> tube 3 (TCA tube, for GSH) 
§ Put onto rocker 
o 70ul tube 1 -> tube 4 (PCA tube, for GSSG) 
§ Put onto rocker 
o Vortex tubes 3 and 4 
- Spin TCA and PCA tubes at 20,000g for 5minutes at 4oC 
- Carefully take tubes out of centrifuge, be careful not to dislodge pellet 
- From tube 3: Take off supernatant, and transfer to tube 5 (GSH tube) 
- From tube 4: take 100ul of tube 4 ->  tube 6 (GSSG tube) 
- Freeze 
 
Determine protein from samples using tube 2 (protein tube) 
 
GSH determination (UV) 
- GSH flow rate at 1.25 ml/min (new HPLC down to 1.05ml/min) 
- Sample detected using VWD (UV detector) detector (on HPLC stack) at 265nm 
- 94% Mobile phase A, 6% acetonitrile 
o Protocol name on HPLC is TurnbullGSH 
- Take GSH tube, transfer total volume into HPLC vial. 
- Have machine insert 10ul of sample into machine 
o GSH elutes as two peaks right before NEM spike 
§ No idea why is elutes as two peaks, cant find answer (yet) but is reported 
as common – I think it is likely due to some of the amino acid residues 
being chimeric (maybe?) 
§ Found answer: it is because the configuration of GSH (3 amino acids) can 
be built in two ways depending on the specific amino acid configuration, I 
always use 2nd peak because 1st peak is sometimes influenced by other 
compounds depending on the tissue being analyzed 
GSH Standard 
o Every day, run a 4 point standard  
o 250uM GSH, 62.5uM GSH, 31.25uM GSH, 15.6uM GSH 
o Step 1: Make 50mM GSH in TRIS-BSAN 
o Step 2: Dilute 50mM GSH -> 5mM GSH in TRIS-BSAN 
 
 
314 
o Step 3: Dilute 5mM GSH -> 0.5mM GSH in TRIS-BSAN 
o Step 4: Do serial dilutions from 0.5mM (500uM GSH) 
§ 500uM GSH -> 250uM GSH -> 125uM GSH -> 62.5uM GSH -> 
31.25uM GSH -> 15.6uM GSH 
o Take 70ul of 250uM GSH, 62.5uM GSH, 31.25uM GSH, 15.6uM GSH tubes, and 
transfer to new tubes with 7ul TCA 
o Transfer GSH-TCA tube to HPLC vial, ready to load 
GSSG determination (fluorescent)  
- Excitation/Emission 350/420nm 
- Flow rate at 0.5 ml/min 
- Sample elutes as a single peak 
- Injection volume: 50ul 
- Protocol is set up as TurnbullGSSG 
- Take tube 6 out of freezer 
- When thawed, add in 37.5ul of 0.1% OPA (our fluorophore, which is stored in -20oC 
freezer) 
- Incubate samples in the dark for at least 15 minutes 
- After incubation, transfer to HPLC vial, ready for run.  
GSSG Standard 
o Every day, run a 4 point standard  
o 10uM GSH, 2.5uM GSH, 1.25uM GSH, 0.625uM GSH 
o Step 1: Make up 20mM GSSG in TRIS-BSAN 
o Step 2: Dilute 20mM GSSG -> 2mM GSSG in TRIS-BSAN 
o Step 3: Dilute 2mM GSSG -> 0.2mM GSSG in TRIS-BSAN 
o Step 4: Dilute 0.2mM GSSG -> 20uM GSSG in TRIS-BSAN 
o Step 5: Do serial dilutions starting from 20uM GSSG 
§ 20uM GSSG -> 10uM GSSG -> 5uM GSSG -> 2.5uM GSSG -> 1.25uM 
GSSG -> 0.625uM GSSG.  
o Step 6: Take 70ul of GSSG standard and mix with 70ul PCA 
o Take 100uL from GSSG standards and transfer to new tube with 500ul 0.5M 
NaOH 
o Add in 37.5ul of 0.1% OPA-MeOH (our fluorophore, which is stored in -20oC 
freezer) 
o Incubate standards in the dark for at least 15 minutes 
o After incubation, transfer to HPLC vial, ready for run.  
 
 
 
 
 
 
 
 
 
 
